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Abstract 
 
Dengue fever has emerged as one of the fastest growing health problems in recent 
years. Transmission of the mosquito-borne disease is widespread throughout the tropics, 
causing intriguing effects to the poorer populations with limited access to healthcare. 
At present, most vector control programmes have failed to contain the disease and no 
specific treatment is available yet. The existence of dengue virus as four distinct 
serotypes poses a significant threat as secondary infection is often manifested in a more 
severe form leading to hospitalisation and even death. Hence, this pushes the demand 
for a dengue vaccine as a long-term protective approach. Particularly for developing 
nations, cost is a major factor that needs to be meticulously addressed in order to provide 
a quick yet affordable medical relief. With that, this study aimed at producing a safe and 
cost-effective plant-based dengue subunit vaccine to protect against the febrile illness. 
A consensus sequence of the dengue envelope glycoprotein domain III (namely cEDIII) 
was selected as the antigenic determinant. cEDIII was expressed in two forms, i.e. as 
recombinant proteins with fusion to green fluorescent protein (sGFP) or cholera toxin 
B subunit (CTB), and as an epitope display on hepatitis B core antigen (HBcAg) virus-
like particles (VLPs). All the constructs were cloned into pEAQ-HT vector and transient 
expression was achieved via agroinfiltration of Nicotiana benthamiana plants. 
Following the successful detection of heterologous proteins in N. benthamiana, 
purification procedures were carried out to harvest the recombinant proteins and 
chimeric HBcAg VLPs-displaying cEDIII, correspondingly. The recombinant fusion of 
cEDIII to CTB was shown to preserve the ability to fold into its active pentamer and 
bind with native gangliosides. Meanwhile, assembly of the chimeric HBcAg VLPs-
displaying cEDIII was verified via transmission electron microscopy. These purified 
recombinant proteins and chimeric VLPs were then used for immunogenicity testing in 
BALB/c mice. Following vaccination with the recombinant protein, the results showed 
that successful production of anti-cEDIII specific response with neutralising potency 
ii 
 
against four dengue serotypes was obtained. T cell analyses suggested that the cEDIII 
induced a predominant T helper (Th) 1 response while the fusion with CTB could skew 
the response towards a mixed Th1/Th2. Immunisation with the chimeric VLPs-
displaying cEDIII also achieved induction of cEDIII-specific responses, however, 
further evaluations are needed to warrant the successful use of these VLPs-based 
vaccines. Overall, the findings in this study have provided solid evidence that the 
development of a plant-based dengue vaccine is feasible. This is of crucial importance 
to battle against the upsurge of disease burden, and the production of a local vaccine 
could complement with Malaysian government’s efforts in combating dengue disease. 
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1 General Introduction 
Dengue is a mosquito-borne disease predominantly found in the tropical and 
subtropical regions around the globe. It is caused by dengue virus (DENV) that co-
circulates in the form of four different serotypes, namely DENV 1-4. Classified as a 
member of the Flaviviridae family, DENV is an enveloped virus with 50 nm in size 
(Kuhn et al., 2002). Severity of dengue disease can vary from undifferentiated febrile 
illness, dengue fever (DF) to life-threatening conditions of dengue haemorrhagic fever 
(DHF) and dengue shock syndrome (DSS). The progression into DHF/DSS is 
commonly associated with a phenomenon termed as antibody-dependent enhancement 
(ADE). This is where the pre-existing, non-neutralising antibodies from a heterologous 
DENV infection can bind with the new infecting serotype and infect Fc gamma receptor 
(FcγR)-bearing cells to gain entry into host cells (Bäck and Lundkvist, 2013).  
Transmission of the disease has been reported in at least 128 countries to date, 
affecting over 50% of the world population (Brady et al., 2012). In fact, World Health 
Organization (WHO) has ranked dengue as one of most important tropical diseases due 
to the alarming rise of disease burden. Annual incidence rate has grown dramatically 
high in recent decades, in which 390 million cases are predicted per annum (Bhatt et al., 
2013). Out of these, it was reported that 500,000 people were hospitalised with severe 
dengue and approximately 2.5% of them would succumb to the disease (WHO, 2017). 
Various factors have led to the increased epidemiology including urbanisation, mobility 
of populations, poor sanitary practices and global warming. Experts believe that 
following climate change, dengue would continue to expand in low-income and middle-
income countries, whereby 4.86 billion people would be exposed to risk of dengue if 
socioeconomic development remains unchanged by year 2050 (Ebi and Nealon, 2016). 
Generally, groups of different age, gender and ethnic are all vulnerable to dengue 
infection. The severity of dengue in Malaysia can be reflected from an astonishingly 
high percentage (91.6%) of dengue immunoglobulin G (IgG) seropositivity among 
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randomly-selected adults (Muhammad Azami et al., 2011). The escalating trend of 
dengue infection is evident from approximately 7,000 cases reported every month, and 
it is a concern that the high seroprevalence of dengue antibodies can contribute to high 
fatality rate due to ADE (Pang and Loh, 2016). Moreover, the data might not represent 
an accurate figure due to under-reporting. Overall, these imply that the dengue episode 
in Malaysia is under an intense pressure of disease burden.  
 At present, no specific treatment nor anti-viral drug for dengue is available yet. 
In Malaysia, low public awareness in reducing mosquito breeding grounds is also partly 
responsible for the spread of disease-carrying Aedes mosquitoes. Thus, this has driven 
a major reliance on vector control programmes to suppress disease transmission. 
However, application of insecticides may not be a sustainable approach owing to high 
cost and development of chemical-resistance in Aedes mosquitoes (Packierisamy et al., 
2015). Following major investments on the plan to release genetically-modified (GM) 
mosquitoes, the project had been shelved in 2015 because the establishment of GM 
mosquitoes in the wild population was proven to be inefficient (Loh, 2015). 
Nevertheless, the latest strategy involves the use of Wolbachia as an intracellular 
bacterium that can help to reduce the ability of Aedes mosquitoes to transmit DENV. 
Although the field release of Wolbachia-infected mosquitoes has been initiated in Kuala 
Lumpur in March 2017 (Bernama, 2017), continuous monitoring is still needed to 
validate its efficacy in eradicating dengue.  
Considering the limitations as mentioned above, this pushes the demand for a 
dengue vaccine as a long-term protective approach. To account for the existence of four 
antigenically-distinct DENV serotypes, production of a vaccine that is able to provide 
solid neutralisation against all serotypes is essential. Although the world first dengue 
vaccine, namely Dengvaxia®, has been launched in December 2015, its adoption is low 
due to unconvincing safety and efficacy profiles (Whitehead, 2016). In fact, Philippine 
has recently withdrawn the use of Dengvaxia® following the adverse effects observed 
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among vaccinated children (Antiporda, 2018). Despite there are numerous vaccine 
candidates along the pipeline, it is still uncertain whether the demand for a reliable 
vaccine could be met. However, as the disease is progressing faster than it can be coped, 
more researches have embarked on the race to produce the first universal dengue 
vaccine. In this study, the production of a subunit dengue vaccine is explored. The 
envelope (E) glycoprotein of dengue virus has been the primary target in subunit vaccine 
development, and more specifically its domain III (EDIII) which harbours serotype-
specific neutralising epitopes. On top of that, Leng et al. (2009) had aligned the EDIII 
sequences of DENV 1-4 to obtain a consensus sequence (cEDIII) that could inhibit the 
infectivity of four serotypes simultaneously. Thus, cEDIII was chosen as the antigenic 
determinant for this study, with the hope that tetravalent protection could be provided 
and hence minimises the risk of ADE. 
The concept of molecular pharming has been initiated to explore plants as 
biofactories for pharmaceuticals production. Nowadays, plant system has drawn 
increasing attention to displace many existing systems based on its outstanding features 
of low production cost, rapid scalability, biocontainment warranty and eukaryotic 
processing machinery (Loh et al., 2017). Comparing to the classical stable 
transformation, various industrial and academia laboratories have opted the use of 
transient expression system for the benefits of speed and convenience. The emergence 
of agroinfiltration has significantly transformed the transient expression platform where 
rapid screening or production can be achieved within a matter of days (Thuenemann et 
al., 2013). Hence, plant-based system is opted to produce subunit dengue vaccine in this 
study, for which it has the potential to provide quick but affordable medical relief to 
developing nations. 
With the intention to express cEDIII as the antigen of interest in Nicotiana 
benthamiana, several expression cassettes had been designed as laid out in Chapter 3. 
In specific, the cassettes were used to express cEDIII in two main forms, which are 
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recombinant protein and epitope displayed on virus-like particles (VLPs). This is to 
explore the possibility of developing a vaccine candidate with strong immunogenicity 
profile. The expressions as recombinant proteins include cEDIII fusion to green 
fluorescent protein (sGFP) and cEDIII fusion to cholera toxin B subunit (CTB). 
Hepatitis B core antigen (HBcAg) that has the propensity to self-assemble into VLPs, 
is chosen as the carrier molecule to facilitate cEDIII epitopes presentation. Besides, 
several strategies have been applied to improve the transgene expression including 
codon optimisation, use of Kozak sequence, use of RNA silencing suppressor, 
subcellular localisation and integration of protein linkers. All the expression cassettes 
were cloned into a binary vector modified from cowpea Mosaic Virus (CPMV), which 
is well-known as pEAQ-HT vector. 
Following that, Chapter 4 presents the delivery of recombinant vectors into N. 
benthamiana via syringe agroinfiltration technique. Infiltrated leaves were harvested on 
the 6th day post-infiltration (dpi) and assessed by Western blotting analysis for the 
presence of heterologous proteins. Once confirmed, the expression kinetics of the 
recombinant cEDIII proteins and chimeric HBcAg VLPs-displaying cEDIII were 
evaluated in order to determine the optimal harvesting time. 
Chapter 5 then describes the purification of recombinant cEDIII proteins and 
chimeric HBcAg VLPs-displaying cEDIII. Immobilised metal affinity chromatography 
(IMAC) was adopted as the main purification procedure for recombinant cEDIII 
proteins. Then, tobacco etch virus (TEV) protease cleavage was used to remove those 
extra amino acids of 6X histidine (His) tag. Meanwhile, the purification of chimeric 
VLPs was achieved by density gradient ultracentrifugation.  
Lastly, Chapter 6 presents the immunogenicity studies of purified recombinant 
cEDIII proteins and chimeric HBcAg VLPs-displaying cEDIII. Immunisations of 
female BALB/c mice were carried out via intraperitoneal route, with a primary injection 
course and two booster doses. Then, the humoral immune responses were evaluated 
1-5 
 
based on the presence of cEDIII-specific antibodies and their neutralisation potencies. 
Cell-mediated immune responses were assessed via antigenic stimulation of immune 
cells and elucidating the secretion profiles of T helper (Th) 1 and/or Th2 cytokines. 
Worthwhile to mention, a significant finding has been achieved in this study 
whereby this is the first to demonstrate that plant-based dengue vaccine candidates are 
able to neutralise all four DENV serotypes simultaneously. Comparing to previous 
studies which expressed cEDIII using bacterial system, the cEDIII protein produced in 
this study has attained significantly higher neutralisation titres which potentiates its 
value to be developed into a dengue vaccine. Furthermore, the recombinant fusion of 
cEDIII to CTB has boosted its overall immunogenicity whereby the fusion protein is 
able to fold into its active pentameric form and behaves as self-adjuvanting molecule 
that can stimulate a balanced Th1/Th2 cellular response. Nevertheless, the successful 
presentation of cEDIII epitopes on chimeric HBcAg VLPs, in immunogenic context, 
also represents the first example in this field. 
Overall, the ultimate goal of this study aimed at developing a safe and cost-
effective plant-based dengue subunit vaccine candidate via agroinfiltration strategy to 
protect humans against the deadly dengue fever. To achieve this, the study was 
organised into different scopes which embarked on the following specific objectives:  
(i) To design and construct expression cassettes containing the cEDIII antigenic 
determinant;  
(ii) To deliver the cEDIII recombinant vectors into N. benthamiana via 
agroinfiltration and study the protein expression profiles;  
(iii)  To purify the plant-expressed recombinant cEDIII-sGFP and CTB-cEDIII fusion 
proteins, as well as chimeric HBcAg VLPs-expressing cEDIII; and  
(iv)  To evaluate the immunogenicity of purified vaccine candidates in BALB/c mice. 
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2.1 Flaviviridae family 
Taxonomically, Flaviviridae is classified as a family of positive and single-
stranded RNA viruses. This simply means that their genetic information can be utilised 
as messenger RNA (mRNA) and translated by host machinery. Such organisation 
enables RNA viruses to evolve million folds faster than the host chromosomal DNA 
(Holland et al., 1982); thus it is not surprising that they have the abilities to bypass 
subsets of host surveillance system. In the evolution context, single-strand molecules 
are prone to high rate of non-synonymous mutation that can result in amino acid 
replacement. Nucleotide shuffling in myriad ways and the poor proofreading capability 
lead to functional changes that allow RNA viruses to strategise their adaptation in new 
hosts. For instance, Domingo (1997) found that the emergence of mutants with altered 
pathogenicity were related to stress induced by nutritional deficiencies that extend to 
many deprived areas. 
The phylogeny of Flaviviridae branches into four distinctive genera, namely 
Flavivirus, Hepacivirus, Pegivirus and Pestivirus (Simmonds et al., 2017). Among 
them, the genus Flavivirus is responsible for the widespread of diseases that cause high 
morbidity and mortality across the globe. This genus constitutes more than 70 enveloped 
viruses, many of which pose substantial health threats including dengue virus (DENV) 
Japanese encephalitis virus (JEV), West Nile virus (WNV) and Zika virus (ZIKV). 
Albeit flaviviruses have similar genomic structure and replicative strategy, they can also 
manifest diseases in different clinical forms such as encephalitis or haemorrhage 
(Fernandez-Garcia et al., 2009). Besides, they are grouped into three major clusters 
according to the mode of transmission: mosquito-borne, tick-borne and non-vector 
borne (Kuno et al., 1998). In particular, the movement of vector-borne pathogens into 
new territories is increasing, thereby exposing more than half of the world population 
to risk of flavivirus diseases (World Health Organization (WHO), 2014). 
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2.2 Dengue virus (DENV) 
DENV inherently exists in the form of four distinct serotypes (DENV 1-4) that 
shares 65 – 70% of sequence homology (Rico-Hesse, 1990). The genome is 10.862 kilo-
base pairs (kbp) long, which encodes for a single polypeptide consisting of three 
structural proteins: (capsid (C), envelope (E), and precursor membrane (prM)), along 
with seven non-structural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and 
NS5) (Henchal and Putnak, 1990). An illustration of the virus genome arrangement is 
shown in Figure 2.1. DENV presents itself as a 50 nm spherical, enveloped virus, with 
the E glycoproteins arranged in pairs on the mature virion (Figure 2.2) (Whitehead et 
al., 2007). In fact, the three structural proteins exist in stoichiometric quantities (C, 100 
amino acids; E, 495 amino acids; prM, 75 amino acids) to give rise to the icosahedral 
symmetry (Kuhn et al., 2002). Similar to other flaviviruses, the 5’ end of DENV genome 
contains a type 1 cap (m7GpppAmp) structure and the 3’ terminus is lacking of 
polyadenylation signal (Gebhard et al., 2011). The untranslated region (UTR) is known 
to modulate roles such as synthesising negative strand template for viral replication, 
initiating translation and packaging of plus-strand RNA into progeny virions (Markoff, 
2003). In fact, there are two pairs of complementary sequences, namely 5’ – 3’ 
cyclisation sequence (CS) and 5’ – 3’ upstream AUG region (UAR), which are essential 
for long range RNA-RNA interactions (Alvarez et al., 2005). 
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Figure 2.1: Schematic representation of DENV genome organisation. Keywords: 
untranslated region (UTR); open reading frame (ORF); cyclisation 
sequence (CS); 5’ upstream AUG region (UAR); capsid (C); precursor 
membrane (prM); envelope (E); non-structural (NS). Image obtained 
from Gebhard et al. (2011). 
  
 
Figure 2.2: An illustration of the structural arrangement of E glycoproteins on a 
mature dengue virion. Distinct domains are shown in red (domain I), 
yellow (domain II) and blue (domain III), respectively. Image obtained 
from Whitehead et al. (2007). 
 
2-6 
 
During virus assembly, glycosylated prM will be specifically cleaved to yield the 
membrane-associated protein; whereas the arginine and lysine-rich residues on C 
protein have imparted it with highly-basic property to encapsidate RNA into the 
nucleocapsid particles (Henchal and Putnak, 1990). Besides, prM is known to prevent 
premature fusion of E proteins during the intracellular transport through acidic 
environment of trans-Golgi network (Allison et al., 1995). With much interest, the 55 
kilo-Dalton (kDa) E glycoprotein has been identified as the major antigenic determinant 
that interacts with host cellular receptors like heparin sulphate for virus entry (Faheem 
et al., 2011). Cryo-electron microscopy (cryo-EM) shows that DENV exists as an 
ordered icosahedral scaffold of 90 E dimers, comprising the centrally-localised domain 
I (EDI), dimerisation domain II (EDII) and the immunoglobulin-like domain III (EDIII) 
(Figure 2.2) (Kuhn et al., 2002).   
Dengue E protein is classified as a class II fusion protein, with tightly-arranged 
subunits that responds to endosomal low pH to form active porin from closed β-barrel 
structure (Kuhn et al., 2002). These proteins that arrange as dimers at neutral pH will 
recluster irreversibly into fusion-competent trimers upon acidification (Modis et al., 
2004). As shown in Figure 2.3 (Panel A), the three soluble ectodomains (residues 1 to 
392) are connected to viral membrane via a 53-residue stem segment, followed by two 
transmembrane (TM) domains (Nemésio et al., 2011). The TM in flaviviruses is known 
to harbour signals for endoplasmic reticulum (ER) localisation and budding to acquire 
the envelope structure (Op De Beeck et al., 2004). Based on Panels B and C in Figure 
2.3, the molecular architecture shows that dengue E protein comprises predominantly 
β-strands and there are only two N-linked glycosylation sites on each E monomer, 
specifically on the asparagine residues at position 67 of EDII and position 153 of EDI 
(Modis et al., 2003). 
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Figure 2.3: Schematic illustration of dengue E domains. Panel A: Residues 
arrangement of domain I (in red), domain II (in yellow), domain III (in 
blue) and the C-terminal transmembrane anchor is linked to folded E 
protein via a stem segment (in grey); Panel B: A pre-fusion conformation 
of dimeric E proteins along its two-fold symmetry axis; Panel C: 
Perpendicular view of E proteins to its two-fold axis, with the glycan on 
residues 67 and 153 labelled on each monomer of the dimeric E. Image 
reproduced with permission from Modis et al. (2005). 
 
EDI is the central region with non-neutralising epitopes, acting as a hinge point 
for pH-induced conformational change (Roehrig et al., 1998). EDII that exists as 
linearly discontinuous domain in E protein primary structure will make a head-to-tail 
contact to form dimer, but a hinge motion away from its partner is observed during the 
pH change to project fusion peptide at the tip (Modis et al., 2003). EDII comprises 
epitopes that are either non-specific or reactive only after conformational change 
2-8 
 
(Roehrig et al., 1998). EDIII, on the other hand, forms a highly stable structure with 
solvent-exposed buldge and receptor-binding motif that can elicit serotype-specific 
neutralisation response (Crill and Roehrig, 2001). This receptor binding loop (residues 
382 to 385) is indicated with  in Figure 2.3. A list of mammalian host cell receptors 
involved in binding had been explicitly described by Cruz-Oliveira et al. (2015). In fact, 
DENV EDIII is claimed to be highly antigenic (Figure 2.4) that can induce neutralising 
monoclonal antibodies and cellular immune responses (Chávez et al., 2010). For these 
reasons, EDIII has emerged as a promising antigen for subunit vaccine production. This 
is also due to the notion that other structural proteins, namely EDI/II and prM, may lead 
to adverse antibody-dependent enhancement (ADE) event. 
 
 
Figure 2.4: A tertiary structure of DENV EDIII, which shows the different amino 
acid residues involved in virus neutralisation as indicated by different 
colours. Image reproduced with permission from Chávez et al. (2010). 
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2.2.1 Prevalence and epidemiology 
Hitherto, dengue haunts about 50% of the world population where 3.97 billion 
people are living in areas prone to dengue transmission (Brady et al., 2012). Over the 
past 50 years, dengue incidence has expanded by 30 folds, spreading across the South 
East Asia, Americas and Western Pacific regions (WHO, 2009). In fact, the actual 
scenario could be worse than reported figures due to under-representation and an 
increasing trend of epidemiology has been predicted by many experts. Murray et al. 
(2013) had reviewed multi-factors that could drive dengue activity, including evolution 
of highly-virulent strain, proliferation of climate-dependent Aedes vectors, increased 
passenger travel and cargo trading, urban encroachment as well as socio-economic 
factors. To address the continued expansion, there is a need to devise active 
epidemiological surveillance systems with focused efforts on effective vector control. 
The transmission of DENV has been observed from two cycles: (i) sylvatic cycle 
of Aedes mosquitoes that infect non-human primates in rain forests of Asia and Africa; 
and (ii) urban transmission of A. aegypti and A. albopictus that feed on human hosts 
(Gubler, 1998a). Interestingly, DENV isolates in most urban regions are evolved from 
sylvatic progenitors approximately 100 – 1500 years ago (Wang et al., 2000). It is 
believed that the structural changes of dengue EDIII have prompted the adaptation of 
new peri-domestic vectors that led to resurgence of the arbovirus. According to Holmes 
and Twiddy (2003), the existence of DENV as four distinct serotypes could be reasoned 
from two hypotheses. Recent evidences were more in favour to the theory of 
independent lineage evolution among allopatric primate populations, instead of the 
sympatry evolution of antigenically-distinct serotypes to enhance transmission via ADE 
(Twiddy et al., 2002). The present encounter of co-circulating serotypes might have by 
chance aggravated ADE due to antigenic dissimilarity (Holmes and Twiddy, 2003).  
Dengue seems to have a longstanding history, as clinical description of a dengue-
like illness known as ‘water poison’ could be found in the Chinese medical 
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encyclopaedia of Jin Dynasty (Gubler, 2014). The first confirmed case was coined as 
‘break-bone fever’ in an epidemic that hit Philadelphia in 1780 (Rush, 1951). The term 
dengue which meant ‘cramp-like seizure’ in Swahili phrase only came into general use 
after 1827 (Rigau-Pérez, 1998). Although the earliest epidemic record could be traced 
back to 1780 – 1940, but it was the ecological disruptions during World War II that the 
intensified transmission in South East Asia and led to emergence of first dengue 
haemorrhagic fever (DHF) (Gubler, 1998a). Before the war, dengue outbreaks were 
only sporadic with one or two circulating serotypes in the tropics. It was not regarded 
as a major public health threat until the disease raged through Allied and Japanese forces, 
where movement of troops successively passed on DENV to new regions (Gubler, 2011). 
The first known DHF epidemic broke out in Manila within the period of 1953 – 1954, 
followed by Bangkok in 1975, which then expanded across South East Asia regions 
attributed to economic bloom and unprecedented urbanisation (WHO, 1980). In parts 
of Central and South American regions, the collapse of A. aegypti eradication campaign 
in early 1970s had set scene for re-infestation whereby hyperendemicity was seen 
following the increased circulation of new strains and serotypes (Gubler, 1998b). 
Ironically, the discovery of synthetic insecticides in 1940s could have led to a major 
breakthrough of disease eradication; however, it had failed miserably due to human 
negligence. Since then, disease transmission has followed the spread of its principal 
vector – A. aegypti. Continuous virus movement into new territories is mapped in 
Figure 2.5. The spread of different serotypes had accelerated in the last two decades, 
particularly in Asia and Latin America (Messina et al., 2014). Kyle and Harris (2008) 
mentioned that DENV could be maintained between epidemics by overwintering in 
vectors, transmitted vertically in mosquitoes or could persist though silent transmission 
given to the high number of asymptomatic cases. 
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Figure 2.5: An overview on the distribution changes of DENV from year 1943 to 2013. Co-circulating serotypes 1 to 4 were denoted with different colours. 
Images reproduced with permission from Messina et al. (2014). 
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The initial onset of dengue in Malaysia could be dated back to year 1901, 
following the transmission from Singapore to Penang (Skae, 1902). First epidemic 
outbreak was alarmed in 1973, recording a total of 969 dengue cases and 54 deaths 
(Wallace et al., 1980). The condition had continued to worsen thereafter, with increasing 
disease infestation among urban dwellers throughout the nation (Abubakar and Shafee, 
2002). All serotypes were found to be co-circulating in Malaysia, where national and 
states’ surveillance data had noted distribution of predominant serotypes that varied 
over time (Mohd-Zaki et al., 2014). Mudin (2015) claimed that surges of dengue cases 
and death tolls tend to follow 4 – 6 months after serotype shift, which may be attributed 
to the lack of immunity against disparate serotype. In addition, Lam (1993) suggested 
that the severity of disease outbreak could be predicted based on the predominant 
serotype at one point. Such correlation has been proven by various findings, as infection 
with DENV 1 or DENV 3 is more likely to occur in dengue-naïve individuals while 
DENV 2 appears to be associated with DHF in secondary infection (Fried et al., 2010; 
Nisalak et al., 2003; Vaughn et al., 2000). 
Generally, everyone is equally vulnerable to dengue infection irrespective of 
gender, ethic and age groups. In Malaysia, the mostly affected community are those 
aged between 13 – 35 years old (Sam et al., 2013). Astonishingly, 91.6% of dengue 
immunoglobulin G (IgG) seropositivity had been detected among randomly-selected 
Malaysian adults (Muhammad Azami et al., 2011). Over the years 2000 – 2010, the 
average number of dengue cases and death tolls had seen increment of 14% and 8%, 
respectively per annum (Mia et al., 2013). In fact, Malaysia had suffered a steep 
increment of 250% of number of reported cases in year 2014 alone (Figure 2.6). 
According to the latest record, a total number of 2,436 dengue cases and 2 deaths had 
been reported within the first two weeks of the year, as updated on 15th January 2018 
(Malaysian Remote Sensing Agency (ARSM) and the Ministry of Science, Technology 
and Innovation (MOSTI), 2018). Considering the passive surveillance system in 
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Malaysia, the data may not reflect an accurate figure due to under-reporting. It is 
presumed that the incidence of dengue will continue to escalate if no effective 
intervention programmes are enforced, and situation is likely to get worse when cases 
peak in the spell of wet weather during monsoon season. With more than 7,000 people 
contracting the disease every month, it can progress into more intense scenario as 
seroprevalence of dengue antibodies is contributing to high fatality rate when associated 
with ADE during secondary infection (Pang and Loh, 2016). 
 
 
Figure 2.6: Statistical number of dengue cases reported from 2000 to 2017. 
Information extracted from Malaysian Remote Sensing Agency (ARSM) 
and the Ministry of Science, Technology and Innovation (MOSTI) (2018), 
and World Health Organization Western Pacific Region (WPRO) (2018). 
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2.2.2 Pathogenesis and infection events 
Humans are infected through the bite of female Aedes mosquitoes that usually 
breed in domestic water containers. Abrupt fever accompanied by anorexia, headache, 
myalgia, retro-orbital pain and occasionally rashes are symptoms of classical dengue 
fever (DF) (Martina et al., 2009). DHF however, is aggravated with haemorrhagic 
bleeding, thrombocytopenia and increased fluid effusion; while dengue shock syndrome 
(DSS) is presented by weak pulse and pressure, where profound shock may set in and 
lead to death within 12 – 36 hours (Martina et al., 2009). Onset of DHF and DSS usually 
emerges during time of defervescence where physiological abnormalities of multiple 
organs are observed, including increased capillary permeability before hypovolemic 
shock (Halstead, 2015).  
As infecting virus is being circulated in the peripheral blood of patients, a 
mosquito’s bite during the febrile viraemic stage would result in disease being 
transmitted to another host after an extrinsic incubation period (Guzman et al., 2010). 
Upon feeding, DENV is introduced into the bloodstream where immature skin dendritic 
cells (DCs), such as Langerhans cells, are targeted and local virus replication will ensue 
(Wu et al., 2000). Then, infected DCs undergo maturation and migrate towards lymph 
nodes to target monocytes and macrophages (Marovich et al., 2001). Infection is often 
amplified through dissemination of virus in the lymphatic system (Martina et al., 2009).  
Principally, clathrin-mediated endocytosis is deployed as the cell entry 
mechanism during initial infection (Figure 2.7). Upon binding of viral particle to 
cellular receptor, clathrin-coated pit will capture the complex and pinches off to the cell 
cytoplasm (van der Schaar et al., 2008). However, during secondary infection, antigen-
antibody complexes are formed between the heterotypic viruses and non-neutralising 
antibodies acquired from primary infection or maternal antibodies (Wang et al., 2009). 
After internalisation, the vesicles will move through the endosomes until acidification 
triggers conformational change to release the uncoated single-stranded viral RNA into 
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cytoplasm (Green et al., 2014). Translation of ORF then proceeds in rough ER to 
produce the polyprotein. Besides, virus-induced hypertrophy facilitates invagination of 
membrane to form vesicles for RNA replication, where a complementary minus-strand 
RNA will be synthesised to serve as template (Gebhard et al., 2011). Newly-synthesised 
RNA then associates with the capsid, and the immature virions with prM and E proteins 
on surface will bud into the ER lumen (Villordo and Gamarnik, 2009). The prM is 
known to assist in the folding of surface-exposed E protein, and both are integrated into 
the lipid bilayer (Whitehead et al., 2007). Following budding, the progeny virions are 
transported to trans-Golgi complex for prM cleavage by cellular furin protease before 
being released from cell (Welsch et al., 2009).  
 
 
Figure 2.7: Overview of the infection events within a host cell, starting from (A) 
clathrin-mediated endocytosis, (B) pH-dependent conformational change, 
(C) uncoating, followed by (D) prM cleavage and virus maturation. 
Image obtained from Green et al. (2014). 
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In relation to virus pathogenesis, host immunity is often subverted by hijacking 
the host cellular machineries to promote infection. DENV adaption tricks are 
summarised as follow: (i) induction of autophagy via unfolded protein response (UPR) 
to trigger production of vesicles as viral replication platform; (ii) mobilisation of 
triglyceride by lipophagy to produce energy for replication; and (iii) sequestration of 
stress granules to prevent stalling of mRNA translation (Jain et al., 2014). Albeit the 
association of disease aggravation to ADE still remains elusive, compiling evidences 
indicate that severe illness is resulted from increased viraemia and alteration of local 
milieu for viral replication (Whitehorn and Simmons, 2011). It has been proven that 
ADE is the strongest risk factor of DHF/DSS development (Kliks et al., 1989). Jain et 
al. (2014) also emphasised that the risk of acquiring DHF in secondary infection was 
40 folds higher than primary case. In specific, ADE acts by facilitating the attachment 
of virus-antibody complexes to Fc gamma receptor (FcγR) of a permissive cell, 
including monocyte and macrophage (Stephenson, 2005). Since the heterotypic 
serotype is not recognised for neutralisation, the pathogen is free to replicate in the 
macrophages and secretes vasoactive mediators that increase vascular permeability 
leading to hypovolemia, haemorrhage and ultimately shock (Chaudhry et al., 2006). 
Stephenson (2005) stated that ADE could compromise disease recovery by promoting 
virus binding and destruction of cell-mediated immunity (CMI) components which also 
contain FcγR on their cell surfaces. Besides, the involvement of T cell activation in 
DHF/DSS has been proposed by Chaturvedi et al. (2000). According to Figure 2.8, a 
cascade of events is seen after the cluster of differentiation (CD)4+ T cells are trigged 
by DENV peptides presented on mononuclear cells. Then, a unique cytokine termed as 
human cytotoxic factor (hCF) is produced, which induces macrophages to generate free 
radicals and upregulate the production of proinflammatory cytokines. The balance of 
CMI response is also shifted from T helper (Th)1 to Th2-biased. As a result, increased 
plasma leakage follows with the exacerbation of disease. In addition to infection history, 
host genetic factors are associate with disease severity as well. For instance, the human 
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leucocyte antigen (HLA) allele profile is known to be unique in inducing distinct 
immune responses and patient with HLA-A*0207 allele is more frequently affected with 
DHF due to restricted antigen-binding and T cells presentation (Stephens et al., 2002). 
 
 
Figure 2.8: A cascade of cytokine events underlying the pathogenesis of DHF within 
an infected macrophage. Recruited T cells are found to release hCF and 
initiate a shift to Th2-type response that results in severe dengue. 
 
Furthermore, pathogenesis of dengue disease also involves an interplay of virus 
virulence factor. The fitness difference between genotypes was evident as the native 
American DENV 2 genotype had been associated with mild disease while the 
introduced South East Asian genotype was afflicted with severe dengue (Rico-Hesse et 
al., 1997). The same group then analysed the sequences of DENV 2 isolates from 
America and Thailand, and found that severe dengue might be related to amino acid 
substitutions within the polyprotein and UTRs, that led to altered antigenicity, cell 
attachment and viral replication (Leitmeyer et al., 1999). Cologna and Rico-Hesse 
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(2003) also showed that the replicative ability of infectious clone was profoundly 
hampered when the America genotype-specific mutations was substituted into the 
background of South East Asia genotype. This implies that the viral determinants have 
evolved to increase virus output per infected cell which leads to greater disease severity. 
 
2.2.3 Disease treatment 
Current clinical practices mainly rely on administration of paracetamol and 
intravenous fluid, together with close monitoring of the haematocrit and platelet levels 
(Anfasa et al., 2015). Intensive care is particularly important during the critical phase 
as plasma leakage could last for 24 – 48 hours and frequent fluid regime adjustments 
may be required throughout this period (Rajapakse et al., 2012). However, fluid 
overload can complicate situation and lead to circulatory failure in its most severe form. 
Concerns are raised as fluid overload is the cause of high death tolls in Malaysia (Cheah 
et al., 2014), which significantly reflects the incompetency in clinical management. 
Up to date, there is no anti-viral drug available against dengue. This has therefore, 
driven public’s reliance on traditional remedies that are mostly not scientifically proven. 
Common practices include decoction of tawa-tawa leaves and preparation of papaya 
leaf juice. Caution must be taken as over-dosage of certain plant extracts may be toxic. 
In fact, a few toxicological studies had found the genotoxic and cytotoxic properties of 
tawa-tawa extract (Kwan et al., 2013; Rajeh et al., 2012). Still, there are many on-going 
researches which aim to discover new drugs from the rich pool of biodiversity. For 
instance, a soft-gel capsule formulated with papaya leaves extract and virgin coconut 
oil had been introduced by the University Technology Malaysia that claimed to treat 
dengue (Musa, 2016). Nonetheless, it was disputed by the Ministry of Health (MOH) 
that the product must be clinically-tested and registered under the Drug Control 
Authority before releasing to the market (Mohd Shahar, 2016).  
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2.2.4 Vector control strategies 
For decades, the only available option to curb dengue disease relies on vector 
control due to the lack of effective treatment and vaccine. This mainly relies on source 
reduction, where interventions are aimed at minimising the oviposition sites to reduce 
dengue transmission. Ooi et al. (2006) highlighted that law enforcement and public 
education are also crucial in driving the success of vector control. However, prevention 
has become increasingly problematic as these mosquitoes are circulating in close 
contact with humans and most major cities are populated with 15 – 20 million people 
(Gubler, 2011). It can be an uphill task if community engagement is not strongly 
advocated. Preventive measures were often hampered by public’s underestimation of 
susceptibility to dengue infection and the lack of concerted community efforts (Wong 
and AbuBakar, 2013). Moreover, eradication programmes in most endemic countries 
have ambiguous goals with diluted commitments that are initiated only during time of 
epidemics (Morrison et al., 2008). For instance, Malaysia adopts a passive surveillance 
system, which relies on health-care practitioners to notify on suspected dengue cases 
before dispatching officers to investigate and arrange chemical fogging (Packierisamy 
et al., 2015). Nonetheless, WHO (2012) highlighted that successful vector control must 
be centred between vigilant monitoring and sustainable inventions in order to achieve 
significant impact. To date, disease containment comprises a number of methods 
ranging from chemical application, genetic control and the use of biocontrol agent. 
Application of these tools will be discussed in relevant to the strategies adopted in 
Malaysia. 
 
2.2.4.1 Application of insecticides 
Most of the regimes in practice such as insecticidal treatment and fogging have 
failed to produce expected disease containment due to high cost and limited 
effectiveness (Lacroix et al., 2012). In 2010 alone, Malaysia had spent US$73.5 million 
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on dengue vector control and 60% of the cost was channelled to chemical fogging and 
premise inspections (Packierisamy et al., 2015). Furthermore, extensive applications 
have adversely prompted the emergence of insecticide-resistant mosquitoes. Although 
malathion was the first insecticide to be used for fogging; however public acceptance 
was low due to the pungent and oily residues (Teng and Singh, 2001). For that reason, 
water-based pyrethroid was used as the primary insecticide since 1996. However, the 
effectiveness of permethrin, deltamethrin and malathion was deteriorating as chemical 
resistance had been detected from the field strains across major cities in Malaysia (Ishak 
et al., 2015; Shafie et al., 2012; Wan-Norafikah et al., 2010). In order to revamp vector 
control, a novel deltamethrin formulation was developed and used for outdoor residual 
spraying (Lee et al., 2015a). In the long run, this would not be a cost-effective approach 
due to the constant need to re-formulate chemical insecticide. 
 
2.2.4.2 Genetically-modified mosquitoes 
A new vector suppression technology known as Release of Insects with Dominant 
Lethality (RIDL) was also adopted by the Malaysian government as part of dengue 
control efforts. This transgenic approach is known to outweigh the conventional 
irradiation of mosquitoes, which can introduce random lethal mutations and cause 
significant reduction in field fitness (Benedict and Robinson, 2003). Sterile male A. 
aegypti (OX513A) was engineered to harbour a dominant, repressible and late-acting 
lethal transgene insertion, which can be differentiated through the expression of red 
fluorescence (Phuc et al., 2007). The study reported that, without tetracycline, high 
expression of the lethal factor in a positive feedback loop would limit the survival of 
transgenics by 95 – 97% at late-larval or early-pupal stage. Moreover, the mating 
competitiveness of RIDL male mosquitoes was not affected when compared to wild 
type strain under both laboratory and semi-field settings (Lee et al., 2013; Massonnet-
Bruneel et al., 2013). Hence, the first open field trial was conducted in December 2010, 
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where genetically-modified (GM) mosquitoes were released into the uninhabited forest 
of Bentong. Albeit the fitness of modified strain was not affected in open field settings, 
the data obtained was inconclusive to demonstrate vector suppression as the release site 
was far beyond their natural habitats in the urbans for mating (Lacroix et al., 2012). As 
a result, the project was shelved in 2015. Worthwhile to mention, lesson should be learnt 
from public backlash against the release of GM mosquitoes. This is because community 
engagement is indispensable to gauge support and promote sustainable implementation 
of a new programme. 
 
2.2.4.3 Biocontrol agents 
The use of Wolbachia transinfection in A. aegypti has gained increasing attention 
following the discovery of life-shortening property of Wolbachia in Drosophila 
melanogaster (Min and Benzer, 1997). According to Hoffmann et al. (2015), Wolbachia 
can supress the ability of mosquitoes to transmit disease by altering vector reproduction 
via cytoplasmic incompatibility (CI) and exhibiting virus blockage activities. Although 
early study with wMelPop-CLA strain showed that it could induce complete CI, but the 
high fitness costs was undesirable  (Yeap et al., 2011). Hence, most studies have 
established the use of wMel strain for Wolbachia interventions (Walker et al., 2011b); 
in which the infection could persist in the wild populations of mosquitoes for more than 
two years in Australia (Hoffmann et al., 2014). However, it was recently found that 
wMel strain may suffer from reduced establishment when mosquitoes were exposed to 
heat stress, and hence the heat-tolerant wALbB strain was preferred given to the higher 
chance of persisting in natural populations (Ross et al., 2017). In Malaysia, the field 
release of Wolbachia-infected mosquitoes had begun in Kuala Lumpur in March 2017. 
Nevertheless, the paradigm of Wolbachia release requires further monitoring on the 
direct test of efficacy. Predictions are made that dengue can mutate to acquire stronger 
virulence or partially escape transmission blockage; meanwhile, the evolution of 
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Wolbachia may be possible since life-shortening property is also limiting the bacterial 
establishment (Bull and Turelli, 2013).  
 
2.2.5 State of vaccine research 
The call for dengue vaccine development is an endless priority. This is not only 
driven by the lack of dengue-specific drugs and treatment, but also seeing that the 
efficacy of current vector control regimes is rather inconsistent. Waves of vaccine 
development have increased dramatically over the decade, with the competition to 
license an immunoprotective dengue vaccine has been progressing aggressively among 
Sanofi Pasteur, Walter Reed Army Institute of Research, Naval Medical Research 
Center and so on. Nonetheless, dengue vaccine development remains to be immensely 
challenging owing to: (i) the co-circulation of multiple serotypes with unpredictable 
predominance at different time points; (ii) knowledge gap in understanding DENV 
pathogenesis; (iii) lack of reliable animal model; and (iv) the complex interplay of host 
immunology (McArthur et al., 2013). In general, there are two types of vaccines: the 
traditional one based on live attenuated or inactivated virus, and the more recent 
development of recombinant subunit vaccine that expresses the primary antigenic 
determinant. Following literatures are focused on vaccine candidates that have been 
assessed in clinical trials (Table 2.1).  
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Table 2.1:  A list of dengue vaccine candidates in clinical development. 
Product Type 
ClinicalTrials.g
ov identifier 
Status Company 
CYD-
TDV 
Live 
attenuated 
virus (LAV) 
NCT01373281 
NCT01374516 
Phase 3 
(completion 
date revised to 
2017 and 
2018) * 
Sanofi Pasteur 
TV003/ 
TV005 
LAV 
 
TV003: 
NCT01696422 
NCT02332733 
NCT02406729 
 
TV005:  
NCT02873260 
NCT02879266 
NCT02678455 
 
TV003:  
Phase 2 and 3 
(on-going) 
 
 
TV005: 
Phase 1 and 2 
(on-going)  
National Institute 
of Allergy and 
Infectious 
Diseases and 
Butantan Institute 
TAK-003 LAV NCT02747927 
Phase 3  
(on-going) 
Takeda 
TDEN 
Inactivated 
whole virus 
NCT00468858 
Phase 2 
(completed in 
2010) 
Walter Reed Army 
Institute of 
Research and 
GlaxoSmithKline  
D1ME100 DNA NCT00290147 
Phase 1 
(completed in 
2009) 
Naval Medical 
Research Institute 
V180 
Subunit 
protein 
NCT01477580 
Phase 1 
(completed in 
2014) 
Hawaii Biotech 
 
Annotation: * Denotes that clinical trials should have been completed by 2014. 
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2.2.5.1 Live attenuated virus (LAV) chimeric vaccine 
Following 20 years of efforts, the world first dengue vaccine was licensed by 
Sanofi Pasteur in December 2015, branded as Dengvaxia®. The ChimeriVax 
Technology was first developed by St. Louis University to generate a molecular clone 
of yellow fever virus (YFV) 17D strain with JEV structural proteins (Chambers et al., 
1999). The C protein was excluded, or else the chimera would fail to recover due to 
inefficient protease processing on the JEV C/prM junction and defectiveness in viral 
replication and packaging. Subsequently, the chimeric virus was tested in mice and 
showed effective protection (Guirakhoo et al., 1999). With the successful prototype, 
Guirakhoo et al. (2000) then engineered the first YFV 17D/DENV 2 chimera with 
heterologous prM and E proteins. Continuous efforts led to generation of a tetravalent 
YF/DENV 1-4 using genes from human isolates of DENV, and the chimeras obtained 
from RNA-transfected Vero cells were tested in non-human primates as monovalent 
and tetravalent formulations (Guirakhoo et al., 2001). Despite tetravalency protection 
was displayed, the higher activity of YF/DENV 2 demanded further refinement, thus 
reconstruction of mutated viruses, plaque purification and dose adjustment were carried 
out (Guirakhoo et al., 2002; Guirakhoo et al., 2004). With that, the finalised tetravalent 
formulation consisting 5-log plaque forming units of each serotype was tested in a phase 
1 trial. Referred as chimeric-yellow fever-dengue (CYD), the vaccine was shown to be 
well-tolerated with full seroconversion among flavivirus-naïve adults; however, the first 
dose induced response mainly against DENV 2 and DENV 4, thus longer immunisation 
schedule was proposed to limit short-term viral interference (Morrison et al., 2010).  
Nevertheless, several reviews have condemned that serotype interferences 
represent a critical issue that needs to be addressed by Sanofi. In vivo competition of 
viral replication and epitopes-linked immunodominance had been observed when the 
vaccine was administrated as a tetravalent formulation (Guy et al., 2009). Essentially, 
imbalance viral replication among four monovalent serotypes can jeopardise the desired 
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level of immunoprotectivity (Imoto and Konishi, 2007). The phase 2b clinical trial 
conducted in Thailand revealed that CYD did not offer protection against DENV 2 
following three doses (Halstead, 2013). The possibility of antigenic mismatch between 
DENV 2 and CYD 2 vaccine design was perceived as a factor that could diminish the 
overall efficacy (Sabchareon et al., 2012). Looking at the phase 3 clinical trials, the 
vaccine had only conferred modest protection in Asia (56.5%) and Latin America 
(60.8%), and efficacy against DENV 2 still remained as the lowest (Capeding et al., 
2014; Villar et al., 2015). In the long run, more conclusive data on its safety and efficacy 
profiles are still needed. This is also considering that DENV 2 is often associated with 
outbreaks of severe dengue. Besides, the prolonged 12-month immunisation schedule 
and reduced efficacy for dengue-naïve subjects present major hiccups in CYD 
implementation (Whitehead, 2016). Though Dengvaxia® had been approved in 19 
countries, long-term safety assessment indicated that the risk of hospitalisation was 
higher among CYD paediatric recipients, as compared to placebo control in their third 
year post-vaccination (Hadinegoro et al., 2015). Thus, Dengvaxia® can only be 
administered to individuals aged between 9 – 45 years in endemic areas (Wilder-Smith 
and Massad, 2016); which signifies that a universal vaccine is still not available yet. To 
its worst, Sanofi had recently announced that Dengvaxia® could induce severe dengue 
in dengue-naïve subjects following vaccination (Sanofi, 2017); and this had spurred 
intense backlash, particularly in the Philippines following the deaths of 8 children 
(Antiporda, 2018). Overall, one of the key lessons learnt is the impact of partial 
protection that not only fails to prevent infection but may also contribute to risk of 
acquiring severe dengue. 
Meanwhile, another LAV vaccine candidate in the pipeline was co-developed by 
the National Institute of Allergy and Infectious Diseases (NIAID) and Instituto Butantan. 
Its preliminary work started with virus attenuation, that was achieved by nucleotide 
deletions in 3’ UTR or chimerisation with other serotype, and the most favourable 
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monovalent vaccines had been selected (Durbin et al., 2011). Different admixtures of 
the pre-selected monovalent components were then tested in a phase 1 trial, of which 
TV003 had been identified as the best tetravalent candidate given to the 90% 
seropositivity after a single dose (Durbin et al., 2013). Yet, it also showed a weaker 
seroconversion against DENV 2 like CYD. Thus, optimisation was performed and the 
resulting TV005, with increased DENV 2 dose, seemed to afford higher 
immunogenicity as compared to TV003 (Kirkpatrick et al., 2015). Nevertheless, the 
efficacy of TV003 was re-assessed in a DENV 2-challenge model (Kirkpatrick et al., 
2016), and complete protection were observed among the volunteers without signs of 
rash, neutropenia and thrombocytopenia. Another phase 1 trial with TV003 also showed 
that the candidate had performed well with 87% tetravalent response in flavivirus-
experienced subjects (Whitehead et al., 2017). Currently, TV003 has progressed into 
phase 2 and 3 clinical trials and while TV005 is being evaluated in phase 1 and 2 trials. 
 
Takeda to which had acquired Inviragen, is also evaluating its tetravalent vaccine 
candidate registered as TAK-003 (also known as TDV). The vaccine virus was 
developed based on the genetic background of an attenuated DENV 2 strain designated 
as PDK-53; which was then formulated into three chimeric viruses by having the prM 
and E replaced from wild-type DENV 1, DENV 3 and DENV 4 correspondingly (Osorio 
et al., 2011). Albeit phase 1 trials revealed that TDV did induce neutralising antibody 
response against all serotypes, but the percentage of subjects who acquired tetravalent 
protection varied between 44% – 80% and it was very likely attributed to lower anti-
DENV 4 titres (Osorio et al., 2015). Hence, the dosage of TDV-4 was increased by 
three-fold to boost the immunogenicity against DENV 4 (Rupp et al., 2015). A recent 
phase 2 data showed that TAK-003 was able to sustain immune responses against four 
DENV serotypes in individuals aged 2 – 17 years living in dengue-endemic areas, 
irrespective of dosing schedule or pre-exposure to dengue infection (Sáez-Llorens et al., 
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2017). From that, TAK-003 had presented superior safety profile that might surpass 
Dengvaxia® performance. A phase 3 clinical trial is currently on-going in 8 dengue-
endemic countries and results are expected to be released by late 2018. 
 
2.2.5.2 Purified inactivated whole virus vaccine 
One of the earliest vaccine developments came from the attenuation of DENV 
through intracerebral inoculation in mice (Sabin and Schlesinger, 1945). At first, the 
United States Army had focused on production of mouse brain vaccines; but later on it 
was replaced with the safer propagation in cell cultures (Innis and Eckels, 2003). This 
project led by Walter Reed Army Institute of Research (WRAIR), did not yield success 
due to varying levels of attenuation and immunogenicity exhibited by each serotype. 
The adoption of serial passage in primary dog kidney cells then offered a better 
alternative, whereby candidates had been selected for phase 1 human trials after 
assessing infectivity in rhesus monkeys (Eckels et al., 2003). These monovalent 
candidates were assessed in a series of trial runs to develop potential tetravalent 
formulation (Kanesa-Thasan et al., 2003; Sun et al., 2003). All of the studies mentioned 
thus far were completed in 2000 and since then, further clinical assessment was 
conducted in collaboration with GlaxoSmithKline (Innis and Eckels, 2003). Phase 2 
trials had an expanded evaluation of selected formulations and the best candidate was 
identified, conferring 63% tetravalent neutralisation after administration of two dosages 
at 6-month apart (Sun et al., 2009). Subsequent paediatric study with flavivirus-naïve 
children indicated that the vaccine was well-tolerated with 100% tetravalent protection 
acquired one month after second dose (Simasathien et al., 2008). Similar testing on 
seronegative Thai infants recorded no adverse events, but with a lower tetravalent 
seroconversion of 53.5% (Watanaveeradej et al., 2011). Thomas et al. (2013) then re-
derived a new candidate known as TDEN, by subjecting the precursor strain to 
additional passages in fetal rhesus lung cells, formulating the monovalent components 
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with carbohydrate stabiliser and lyophilising the final product in tetravalent form. 
Clinical profile of the new candidate was shown to be safe for administration in healthy 
adults, despite not much differences were observed when compared to its precursor. A 
phase I/II trial indicated that two doses of TDEN were able to prime tetravalent 
protection in DENV-naïve subjects aged between 1 – 50 years old (Bauer et al., 2015). 
Nevertheless, no information on follow-up clinical trial can be found. 
 
2.2.5.3 DNA vaccine 
On the other hand, Naval Medical Research Institute has ventured into the less-
adopted DNA vaccine technology. They started off with the construction of several 
recombinant plasmids expressing different structural segments of DENV 1 and each 
construct was then injected into mice to test for optimal neutralising response 
(Raviprakash et al., 2000). The ME100 construct that harboured the prM along with full 
length E sequence was chosen for further testing based on the best neutralisation activity. 
Partial to complete protection was observed when immunised rhesus macaques were 
subjected to viral challenge (Raviprakash et al., 2000). Following a series of pre-clinical 
trials, a prototype testing of DENV 1 vaccine candidate (D1ME100) was conducted 
among flavivirus-naïve adults in a phase 1 clinical trial (Beckett et al., 2011). 
Unexpectedly, only those who received high dosage developed anti-dengue response 
but it was merely less than 50% of the subjects. A breakthrough was achieved when the 
tetravalent dengue DNA vaccine, consisting equal mixture of serotype-specific plasmid 
DNAs formulated with Vaxfectin®, which was able to boost the anti-dengue neutralising 
response in primates (Porter et al., 2012). A concurrent testing in New Zealand white 
rabbits also indicated that the DNA vaccine was well-tolerated with 100% neutralisation 
against all serotypes (Raviprakash et al., 2012). As attractive as it may sound, though 
DNA vaccine is comparably stable, easy to modify and scale-up, but the ability to 
stimulate robust immunogenicity remains to be verified. 
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2.2.5.4 Subunit protein vaccine 
Hawaii Biotech initially attempted to express dengue recombinant E in both yeast 
and mammalian cells; however, it did not yield success until the Drosophila Schneider-
2 (S2) cell expression system was adopted (Coller et al., 2011). The S2 cells were 
transformed to secrete full length prM sequence along with 80% N-terminal of E 
molecule, designated as DEN-80E (Clements et al., 2010). The purified 80E subunits 
of each serotype were then combined and adjuvanted with ISCOMATRIX® for 
immunogenicity testing in animal models. Although neutralisation against all serotypes 
was obtained, but seroconversion was lower against DENV 4. Further attempts were 
explored by Govindarajan et al. (2015) to improve the immunogenicity of the tetravalent 
vaccine, particularly on DEN4-80E. A phase 1 clinical study of ISCOMATRIX®-
adjuvanted V180 demonstrated that high seroconversion rates of 85.7% – 100% was 
obtained following administration of three doses at 1-month intervals (Lim, et al., 2016). 
The findings thus far attested the superiority of subunit protein vaccine as immunisation 
of low dosage with short dosing schedule was sufficient to confer desired immune 
protection. 
  
2-30 
 
2.3 Plants as biofactories in molecular pharming 
In recent years, the pressure from growing clinical demands and limitations of 
established systems have spurred intense interest of utilising plants as ‘green factories’ 
for bioproduction. With the advent of modern biotechnology, molecular techniques can 
now be applied to synthesise commercially valuable products using plant system, either 
by manipulation of biosynthetic pathway or alteration to desired-feature (Slater et al., 
2003). This has essentially sparked the idea of ‘Molecular Pharming’, which harnesses 
the power of agriculture to produce recombinant pharmaceutical proteins such as 
antibodies, vaccines and therapeutic enzymes. In fact, Barta et al. (1986) was the first 
to demonstrate the feasibility of using tobacco to express human-growth hormone. Since 
then, in planta production of recombinant therapeutics has gained increasing adoption 
until it is successfully used to produce the ZMapp monoclonal antibody cocktail as a 
therapeutic for Ebola treatment (Davidson et al., 2015). To date, there are more than 25 
plant-made pharmaceuticals that have been assessed in clinical trials (Loh et al., 2017). 
Considering that there is only a handful of good manufacturing practice (GMP)-
compliance plant manufacturing facilities around the world, the achievement attained 
thus far is significant and an optimistic future is foreseen from the increasing industrial 
engagement (Sack et al., 2015). 
 
2.3.1 Merits of plant-based expression system 
Conventionally, the production of pharmaceutical proteins has mainly relied on 
bacteria and mammalian cells.  The use of E. coli is essentially favoured for the 
simplicity and rapid growth rate which makes it possible to produce recombinant 
pharmaceutics within a few hours. However, the expression of poorly-soluble or 
misfolded proteins has become a major drawback that limits the adoption of bacterial 
system (Gecchele et al., 2015). The use of mammalian cell-system, on the other hand, 
is hindered by heavy operational costs, limited scalability and risk of contamination 
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with human-transmissible pathogens (Chen and Lai, 2014). Although yeast and insect 
cell can be used as alternative expression systems, however their propensity to 
mannosylate protein may lead to undesirable antigenicity (Demain and Vaishnav, 2009). 
As a result, plant system has emerged as a more convenient, economical and safer 
alternative that cannot be matched by many existing production systems. 
As summarised in Table 2.2, plant generally outweighs other systems in terms of 
low cost, high scalability, capacity to perform protein post-translational modifications, 
increased safety as well as the ease of storage and distribution. Firstly, the start-up and 
operation costs for plant-based system are comparably lower than others since neither 
expensive reactor or reagent is required. In fact, the production cost of plant-made 
pharmaceuticals is only 2 – 10% of microbial systems and 0.1% of mammalian cell 
cultures (Yao et al., 2015). Plants are fascinating in the sense that they are 
photoautotrophs that are inexpensive to grow, and production can be easily scaled-up 
by using established planting infrastructure. Besides, plants are able to produce complex 
proteins that resemble native conformation such as secretory immunoglobulin A (IgA), 
collagen and spider silk (Tschofen et al., 2016). It is a general consensus that plants do 
not harbour mammalian pathogen, endotoxin or oncogene, which eliminates regulatory 
concerns and the cost associated with product screening and purification. Plants also 
offer added feature of product stability where long-term storage of protein is feasibile 
via accumulation in cereal seeds (Ramessar et al., 2008). The expression of protein in 
edible fruits might even exclude the need for downstream processing and cold chain 
shipment (Twyman, 2004).  
 
 
  
2-32 
 
Table 2.2: A comparison of merits offered by different expression systems. The scoring (+) was interpretatively made based on the following review papers: 
Demain and Vaishnav (2009); Loh et al. (2017); Ma et al. (2003). 
System Production coat Lead time Scalability Post-translational processing Purity Storage and distribution 
Bacterium +++++ ++++ ++++ + ++ +++ 
Yeast ++++ +++ ++++ ++ ++++ +++ 
Insect cell culture +++ ++ +++ +++ ++ ++ 
Plant cell culture +++ +++ +++ ++++ ++++ +++ 
Plant +++++ 
+ a 
+++ b 
+++++ ++++ ++++ +++++ 
Mammalian cell culture ++ ++ + +++++ + + 
Animal + + ++ +++++ + + 
 
Annotation: a Refers to stable gene integration into plant nucleus or chloroplast; b Refers to transient expression of whole plant.
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2.3.2 Plant transformation strategies 
The history of plant transformation began in 1983, after several research groups 
had demonstrated the potential of introducing bacterial genes into plant genome (Bevan 
et al., 1983; Fraley et al., 1983; Herrera-Estrella et al., 1983). Following that, genetic 
engineering of plants has been applied for fundamental study of plant physiology, 
genetic improvement of crop varieties and molecular pharming. To date, plant 
transformation is achieved via (i) stable integration of foreign gene into the plant nuclear 
or chloroplast genome, and (ii) transient expression of foreign gene without integration 
into host genetic constituent.  
 
2.3.2.1 Stable integration versus transient expression 
Stable transformation facilitates the establishment of transgenic lines with 
inheritable traits, which offers the reproducibility of long-term production of a biologics 
using master seed banks (Chen and Lai, 2014). Technically, stable gene integration can 
be achieved via a range of methods including Agrobacterium-mediated gene transfer, 
biolistic, polyethylene glycol treatment, microinjection and electroporation. However, 
the adoption of stable transformation is often held back by the long developmental time 
involving plant regeneration procedures, along with issues like gene silencing and 
potential outcrossing to food crops (Rybicki, 2009). In the 1980s, Janssen and Gardner 
(1989) already discovered that the frequency of gene transfer achieved by transiently-
expressed β-glucuronidase (GUS) was 1,000-fold higher than stable integration. At that 
time, transient expression was not popular and was merely used for testing efficiency of 
constructs before undertaking stable transformation. Kapila et al. (1997) then 
demonstrated the feasibility of using Agrobacterium-mediated infiltration to achieve 
high level of GUS expression, and since then, transient assay has been widely adopted 
to produce recombinant proteins within a matter of days. Technically, it eliminates the 
tedious works on plant tissue culture and regeneration, and introduces biocontainment 
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since the transgene is not integrated into host genome. Particularly for vaccine 
production, transient expression enables fast screening of candidates in prompt response 
to emerging outbreak. Industrial processes have been deliberately optimised for scaling-
up production to commercial level that can outcompete the stable transformation 
(D’Aoust et al., 2010). Nowadays, transient expression is mostly achieved via 
recombinant virus infection or Agrobacterium infiltration system, that combines the 
benefits of speed and convenience as compared to transgenic expression (Thuenemann 
et al., 2013).  
 
2.3.2.2 Agroinfiltration strategy 
To date, agroinfiltration is generally the method of choice used to deliver binary 
vector and plant virus-based vector into host plant. For binary vector, the transgene is 
inserted to the transfer-DNA (T-DNA) region and will be delivered into plant nucleus 
upon infiltration. Meanwhile, the initial strategy of exploiting ‘full virus’ as viral vector 
had failed due to the instability of virus genome resulting from large insertion (Gleba et 
al., 2007). Thus, ‘deconstructed’ vector has been re-built to retain only elements 
required to drive high transgene expression and locomotion is resolved by 
Agrobacterium-mediated gene transfer. The merger of plant virus vector and 
Agrobacterium was first demonstrated by Grimsley et al. (1987), whereby viral 
infection could still be initiated upon infiltrating a construct with cauliflower mosaic 
virus (CaMV) genome inserted to the T-DNA. This approach does not only ensure 
efficient systemic spread, but also extends to the use of plant viruses that in nature are 
not mechanically transmissible (Peyret and Lomonossoff, 2015). At present, most viral 
vectors have been integrated into binary vectors such that the genetic components of 
viral origin are placed within the T-DNA and will be transferred into host upon 
infiltration (Lico et al., 2008).  
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Agroinfiltration is mostly performed using either syringe or application of 
vacuum. Syringe infiltration was first described by Schöb et al. (1997), that involves 
manual injection of infiltration media using a needleless syringe. As adopted in this 
study, the simplicity of syringe technique has made it convenient to assess different 
constructs in laboratory setting, either by infiltrating the entire leaf with a specific 
construct or perform multiple assays as distinct spots. Adoption of vacuum infiltration 
however, is often primed for its automated scalability which is more suitable for 
industrial application (Chen et al., 2013b). Recently, a new air-brush technique has been 
introduced to allow direct spraying of bacterial suspension onto plant (Jin et al., 2015). 
This approach might have the potential to be mechanised into a high-throughput system 
since hundreds of plants could be infiltrated within 20 minutes. 
Specifically, a non-replicative system is opted in this study with the use of pEAQ-
HT binary vector. In relation to vector development, initial efforts were focused on 
modifying the smaller genomic RNA of cowpea mosaic virus (CPMV) to yield a 
replication-competent deleted RNA-2 construct (delRNA-2), which was replicated by 
RNA-1 (Cañizares et al., 2006). Later then, it was found that high expression could be 
achieved with the co-inoculation of P19 silencing suppressor (Sainsbury et al., 2008); 
whereby the transcribed mRNA was stable enough that made RNA-1 no longer required 
to achieve high expression. The removal of replicase had therefore led to the 
development of a non-replicative system. As Sainsbury and Lomonossoff (2008) 
continued to work on delRNA-2 design, they discovered that removal of two upstream 
AUG codons had boosted protein expression up to 10 folds, possibly due to enhanced 
translational efficiency. Since then, the new expression system based on mutated 5’ 
UTR of delRNA-2 was termed as CPMV-hypertranslational (HT) system. Overall, the 
non-replicative nature of CPMV-HT makes it more attractive than replicon system, 
whereby it is not affected by transgene size limitation, virus exclusion nor transcript 
mutation issue (Peyret and Lomonossoff, 2013). Subsequent efforts give rise to the 
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development of pEAQ series vectors (Sainsbury et al., 2009), which is now widely 
adopted by the Plant Production of Vaccines (PLAPROVA) consortium. In fact, various 
organisations have explored the use of pEAQ-HT system to express plant-based 
vaccines including Medicago’s seasonal influenza plant-based quadrivalent virus-like 
particle (QVLP) vaccine (Pillet et al., 2016), in addition to WHO-funded development 
of plant-based poliovirus vaccine (Marsian et al., 2017).   
  
2-37 
 
2.4 Strategies adopted in current study to enhance vaccine presentation 
Ideally, the development of vaccine products that can induce strong humoral and 
cell-mediated immune responses is highly desired. As purified subunit proteins may be 
less immunogenic than whole virus preparations, adjuvant is often formulated to boost 
the immunogenicity of subunit vaccines. Besides, adjuvant also improves the durability 
of a vaccine via reduced antigen dosage and immunisation, improves vaccine efficacy 
in immuno-compromised individuals and improves the quality of immune responses by 
guiding appropriate Th1/Th2 response (Coffman et al., 2010). Aside from the 
conventional use of aluminium salts and oil-in-water emulsions, new strategies have 
focused on using alternative adjuvants such as protein conjugation partners, 
nanoparticles and virus-like particles (VLPs) (Gerdts et al., 2013). By doing so, this 
would obviate the need to mix components as in conventional vaccination. In fact, WHO 
also prefers the development of ‘ready-to-use’ vaccines that can enhance the efficiency, 
convenience and safety of immunisation programmes, and are particularly beneficial for 
developing nations with limited medical settings (Mansoor et al., 2013). 
 
2.4.1 Protein conjugation  
To date, several types of modified bacterial toxins have been used for the design 
of conjugate vaccine including the non-toxic mutant of diphtheria toxin known as 
CRM197 (Micoli et al., 2011), Pseudomonas aeruginosa exotoxin A (rEPA) (Ho et al., 
2006), heat-labile enterotoxin (LT) from Escherichia coli (Martin and Nashar, 2013) 
and cholera toxin (CT) from Vibrio cholerae (Xue et al., 2016). However, there was a 
controversy raised regarding the effectiveness of rEPA as a booster following four failed 
clinical trials (Pier, 2007), and the fact that it was yet to be approved for human use 
made it less clinically-relevant. Comparatively, LT and CT have been extensively-used 
and are among the strongest adjuvants for both mucosal and parental immunisations 
(Mattsson et al., 2015). Although CT and LT share about 80% of sequence homology 
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(Dallas and Falkow, 1980), the use of CT is favoured for the ability to skew towards 
Th2 response to acquire sterilising immunity (Connell, 2010). 
 
2.4.1.1 Cholera toxin B subunit (CTB) 
The gram-negative V. cholerae causes cholera disease by secreting CT that binds 
to mucosal cells and activates the adenylate cyclase system (van Heyningen, 1976). 
Structurally, the toxin is made up of two subunits: the single ‘heavy’ 28 kDa toxic 
subunit A (CTA) and the 56 kDa aggregate of ‘light’ subunits B (CTB) (Holmgren, 
1981). In specific, CTA is proteolytically split to two parts upon host entry, into the 
toxic-active globular CTA1 and CTA2 that protrude into the tunnel formed by CTB 
(Gill, 1976). As illustrated in Figure 2.9, five monomers of CTB will interact via 130 
hydrogen bonds and 20 salt bridges to assemble as a homopentamer that embeds the 
CTA (Sanchez and Holmgren, 2011). The authors also highlighted that the tight packing 
of CTB might have contributed to its outstanding stability in intestinal milieu.  
Nevertheless, the use of CT must be rendered safe as it is proven to be too toxic 
for clinical use. For instance, oral administration of a mere 5 μg purified CT caused 
diarrhoea in volunteers while those received 25 μg suffered from 20-litre cholera purge 
(Levine et al., 1983). To avoid toxicity, CTB can be exploited as the non-toxic 
derivative that has the ability to induce intracellular signalling events to activate murine 
B cells and macrophages (Schnitzler et al., 2007). This may essentially correlate to CTB 
affinity for monosialotetrahexosylganglioside (GM1) distributed on the surface of most 
nucleated cells, including leucocytes (Freytag and Clements, 2015). By conjugating 
antigen with CTB, enhanced antigen uptake and presentation are thus anticipated. 
Stratmann (2015) even stated that the total B cell repertoire can be effectively converted 
into antigen presenters as mediated by CTB selective binding to GM1. Nevertheless, 
there are a few considerations that need to be taken while designing a CTB-fusion 
construct. Genetic coupling to a N-terminal partner is known to hamper the pentamer 
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assembly (Liljeqvist et al., 1997), whereas for C-terminal fusion, it is case-dependent 
as pentamerisation could be impaired by bulky partner that has larger molecular mass 
(Harakuni et al., 2005). Since cEDIII is a relatively short polypeptide with 103 amino 
acids, it is presumed that C-terminal fusion to CTB would not affect the conformational 
folding. 
 
 
Figure 2.9: Crystallographic structure of CTB. Panel A: Conformation of CTB 
pentameric ring; Panel B: Conformation of CTB with embedded CTA (in 
red). Image obtained from Sanchez and Holmgren (2011). 
 
2.4.2 Virus-like particles (VLPs) 
In general, VLPs are made of viral capsid proteins that self-assemble into 
structures that strongly resemble native viral particles. The absence of genetic materials 
makes them inherently safer to use, without intrigued by concerns of reversion to 
virulence as in live attenuated or killed virus vaccine. The repetitive array of protein 
subunits on VLPs surface allows effective cross-linking with B cell receptors to induce 
activation of B cells (Zabel et al., 2013). In addition, the size of VLPs is typically less 
than 100 nm, which allows it to passively traffic through the lymphatic system or 
directly internalised by antigen-presenting cells (APCs) and processed for presentation 
on major histocompatibility complex (MHC) to stimulate cellular immune response 
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(Kanekiyo and Buck, 2017). These advantages thereby promote the use of VLPs as 
vaccines, which are gaining wider attention following the successful use of 
Gardasil®/Cervarix® as human papillomavirus (HPV) vaccine, and Recombivax 
HB®/Energix-B®vaccine as hepatitis B virus (HBV) vaccine. For antigen presentation, 
VLPs can be used to display the epitopes derived from parental virus or extraneous 
origin (Tagliamonte et al., 2017).  
Nevertheless, surface display of a foreign antigen can be a significant challenge 
as steric constraint can interfere with particles assembly with a consequent loss of 
immunogenic property. Apart from the epitope size, successful antigen display also 
depends on the insertion site of particle carriers and the resulting geometrical 
architecture (Tissot et al., 2010). Thus, selection of an appropriate, assembly-competent 
carrier is vital and utilising those that have been widely-studied could be less risky. In 
this context, VLPs derived from HBV are the most studied chimeric VLPs for epitope 
display (Pushko et al., 2013). For instance, MosquirixTM malaria vaccine is developed 
based on hepatitis B surface glycoprotein (HBsAg) VLPs and has progressed far to 
phase III trial  (Kaslow and Biernaux, 2015). Alternatively, the hepatitis B core antigen 
(HBcAg) also has the intrinsic to form subviral capsid-like structures. The potency of 
HBcAg was quite evident, in which as low as 0.006 µg non-adjuvanted HBcAg could 
induce antibody production (Milich et al., 1997b). In fact, HBcAg VLPs are claimed to 
be more superior than those of HBsAg. This is not only due to higher array of HBcAg 
protein subunits, but also based on the unique ability of HBcAg to induce co-stimulatory 
molecules on naïve B cells and elicit efficient APCs function (Milich et al., 1997a). 
 
2.4.2.1 Hepatitis B core antigen (HBcAg) as antigenic carrier 
Depending on HBV strain, HBcAg is a 20 kDa protein made up from 183 amino 
acids. Two monomers of HBcAg can dimerise to form a hairpin structure bridged by 
the c/e1 loop of each monomer, which gives rise to the protruding spike (Figure 2.10, 
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Panel A) (Karpenko et al., 2000). In certain literatures, the c/e1 loop may be inter-
changeably referred as major immunodominant region (MIR). These dimers would self-
assemble to form the icosahedral particles (Figure 2.10, Panel B), with symmetry of 
either triangulation number (T)=3 from 90 dimers (particle diameter: 30 nm) or forming 
T=4 from 120 dimers  (particle diameter: 34 nm) (Crowther et al., 1994). Through cryo-
EM and image reconstruction, HBcAg particle is visualised as a large α-helical structure 
with the dimer appears as a hammer-like structure (Pumpens and Grens, 1999). 
 
 
Figure 2.10: Structural folding of HBcAg VLPs. Panel A illustrates the association of 
two HBcAg monomers to form the dimeric interface, with Cys61-Cys61 
disulphide bridge shown in green; Panel B presents the arrangement of 
subunits on capsid. Images reproduced with permission from Wynne et 
al. (1999).  
 
The C-terminal end of HBcAg features a protamine-like domain at residues 150 
– 183 which mediates RNA binding (Bottcher et al., 1997). Though Gallina et al. (1989) 
found that deletion of the protamine-like domain would not hinder particle assembly; 
but it had vital role of stabilising the capsid via disulphide linkage with neighbouring 
dimers. Hence, this explains for the reduced stability of HBc∆149 truncated particles as 
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compared to the full-length counterpart (Thuenemann et al., 2013). A full length HBcAg 
basically contains four cysteine (Cys) residues at positions 48, 61, 107 and 183. The 
connection between HBcAg dimer mainly depends on the Cys61-Cys61 intermolecular 
bonds, and sometimes Cys48-Cys48 (Zheng et al., 1992). Wynne et al. (1999) reported 
that the Cys48 interaction however, was not found in HBcΔ149 particles, together with 
Cys183 linkage which was also absence in HBcΔ149. As a matter of fact, the instability 
issue would impose a product shelf-life problem if HBcΔ149 were to be used for vaccine 
design. Besides, Seifer and Standring (1995) discovered that deletion of the protamine-
like domain would raise the concentration threshold required for dimers to trigger capsid 
assembly. These findings imply that the RNA-binding domain has crucial role in 
mediating particle assembly and stability; and hence, this domain was also included in 
the HBcAg expression cassettes in this study. 
Early use of HBcAg was demonstrated by Clarke et al. (1987), by fusing the 
immunogen of foot and mouth disease virus (FMDV) to the N-terminal end of HBcAg. 
Stahl and Murray (1989), on the other hand, successfully attempted HBcAg C-terminal 
fusion to HBsAg and another fusion to human immunodeficiency virus (HIV) envelope 
protein. Nevertheless, it was later discovered that epitope insertion into the c/e1 loop 
could stimulate stronger immune response by more than 10 folds (Brown et al., 1991). 
In fact, a Schödel et al. (1992) proved that potent immunogenicity was most efficiently 
achieved by c/e1 insertion as compared to fusion to N- and C- termini. Since then, many 
studies have preferentially introduced foreign epitopes to c/e1 loop for the better surface 
exposure (Roose et al., 2013).  
 
2.4.2.2 Emerging ‘Tandem Core’ technology 
Despite increasing interest has been devoted towards utilising HBcAg-based 
platform, it has yet to be fully developed as a vaccine vector. This is hindered by several 
factors that can abolish VLPs assembly. Firstly, the size of insert has a significant impact 
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as long peptide is prone to steric clashes since the two c/e1 loops at the dimer interface 
are positioned in close proximity (Pumpens and Grens, 2001). Next, the nature of insert 
also can affect VLPs formation, which includes hydrophobicity (Karpenko et al., 2000), 
the propensity of inserts to homo-oligomerise (Vogel et al., 2005) or form disulphide 
bonding with Cys residues in the inserts (Janssens et al., 2010). Worthwhile to mention, 
insertion of the green fluorescent protein is an exceptional case where the entire 238 
amino acids protein could be displayed on HBcAg particle (Kratz et al., 1999). Aside 
from compact structure of the fluorescent protein, it seemed that flanking the insert with 
linkers had alleviated steric hindrance around the c/e1 loop (Nassal et al., 2008). 
Therefore, the design of flexible linkers could be strategised to provide flexibility 
between the insert and carrier molecule. 
Hence, several techniques have been developed over the years to address possible 
limitation, including: (i) in vitro co-expression of native HBcAg protein with modified 
HBcAg to generate mosaics VLPs (Vogel et al., 2005); (ii) using SplitCore system to 
express distinct portions of HBcAg N- and C-termini that later assemble as structural 
dimers (Walker et al., 2011a); or (iii) adopting the ‘Tandem Core’ technology that 
covalently joins two HBcAg monomers to give a single dimeric protein (Gehin et al., 
2004). Among these approaches, the latter offers the versatility of rapid genetic 
modification of c/e1 loop without being compromised by extensive screening or 
assembly procedures. According to Peyret et al. (2015), the tandem core approach can 
help to minimise steric clashes since the assembly of dimer (Figure 2.11, Panel A) is 
no longer determined by random association of individual subunit. With that, this 
approach offers the flexibility of incorporating a wider selection of inserts. Besides, the 
formation of tandem core protein allows epitope display on either of the c/e1 loop 
(Figure 2.11, Panel B). As a result, only half of the particle will be decorated with 
antigen of interest, and such flexibility also permits insertion of larger sequence. 
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Alternatively, these tandem core particles can be used to develop a multivalent vaccine 
where presentation of different antigens on the two c/e1 loops is feasible.  
 
 
Figure 2.11: The formation of HBcAg VLPs via ‘Tandem Core’ technology. Panel A: 
An illustration of the tandem core protein, with two monomers (coloured 
in green and yellow, respectively) covalently linked by a flexible linker; 
Panel B: A surface representation of the tandem core protein on 
assembled particle. Images reproduced with permission from Peyret et al. 
(2015).  
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2.5 Pre-clinical examples of plant-based dengue vaccine 
Since the pioneer work done on plant-based vaccine (Mason et al., 1992), there 
is now wide adoption as proven by a number of human vaccines which are undergoing 
clinical trials and close to be marketed within this decade (Yusibov et al., 2011). 
Nevertheless, research on plant-based dengue vaccine is considered relatively new in 
the field, with less than 20 papers reported thus far (see Table 2.3). The candidate 
antigens that have been studied are the dengue structural proteins, namely prM and E. 
Among all, EDIII has been the most extensively used for heterologous expression. In 
relative to that, this project has ventured towards production of EDIII in its consensus 
form, which are further elaborated in the next few chapters.  
Among the studies, only four had reached until the stage of animal testing, and 
all of them had selected dengue EDIII as the immunogen subject (Huy and Kim, 2017; 
Kim et al., 2016a; Kim et al., 2017; Saejung et al., 2007). Though virus neutralising 
activity had been demonstrated by Kim et al. (2017) and Saejung et al. (2007), but the 
two candidates were only tested against DENV 2. In the long run, only vaccine that is 
proven to confer momentous protection against all infecting serotypes would be 
harnessed for product development. Hence, more efforts are still needed to fill up the 
gap towards achieving an effective dengue vaccination. Based on the on-going 
researches listed in Table 2.3, it is postulated that majority of the stable transformation 
systems have suffered from low product yield and/or long lead time, which hauled their 
progression towards preclinical trial. Nonetheless, the immunogenicity of these 
candidates still remains to be testified; in which these would eventually pave way 
towards the production of a plant-based dengue vaccine with global significance. 
Overall, it is no doubt that molecular pharming is likely to benefit the less developed 
regions, in view that modern medicine and technology are scarce in most dengue-
endemic areas (Ma et al., 2013). 
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Table 2.3: A compiled list of on-going researches on plant-based dengue vaccine development. 
Host plant Transformation strategy Expressed antigen Tested in animal Reference 
N. benthamiana 
Transient expression 
- Virus infection 
DENV 2-specific EDIII Yes (Saejung et al., 2007) 
Transient expression 
- Agroinfiltration 
(i) DENV 2-specific truncated E 
(ii) DENV 2-specific truncated C/prM/E 
(iii) DENV 2-specific EDIII fusion to HBcAg 
No (Martinez et al., 2010) 
Transient expression 
- Agroinfiltration 
(i) cEDIII 
(ii) cEDIII fusion to M-cell targeting ligand (Co1) 
No (Kim et al., 2015) 
Transient expression 
- Agroinfiltration 
(i) cEDIII 
(ii) cEDIII fusion to CTB 
Yes (Huy and Kim, 2017) 
Transient expression 
- Agroinfiltration 
cEDIII fusion to polymeric immunoglobulin G 
scaffold (PIGS) 
Yes (Kim et al., 2017) 
N. tabacum 
Stable transformation 
- Agrobacterium 
DENV 2-specific EDIII No (Kim et al., 2009) 
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N. tabacum 
Stable transformation 
Agrobacterium 
DENV 2-specific EDIII fusion to CTB No (Kim et al., 2010) 
Stable transformation 
- Biolistic 
Tetravalent fusion of EDIII No 
(Gottschamel et al., 
2016) 
Oryza sativa 
Stable transformation 
- Biolistic 
cEDIII  No (Kim et al., 2012) 
Stable transformation 
- Biolistic 
cEDIII fusion to Co1 No (Kim et al., 2013b) 
Stable transformation 
- Biolistic 
cEDIII fusion to CTB No (Kim et al., 2013a) 
Stable transformation 
- Biolistic 
DENV 2-specific E No (Kim et al., 2014b) 
Stable transformation 
- Biolistic 
(i) cEDIII 
(ii) cEDIII fusion to CTB 
Yes (Kim et al., 2016a) 
Zea mays 
Stable transformation 
- Agrobacterium 
(i) DENV 2-specific EDIII 
(ii) DENV 2-specific EDIII fusion to CTB 
No (Kim et al., 2014a) 
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Solanum 
tuberosum 
Stable transformation 
- Agrobacterium 
DENV 2-specific EDIII fusion to CTB No (Kim et al., 2016b) 
Lactuca sativa 
Stable transformation 
- Biolistic 
DENV 3-specific prM/E No (Kanagaraj et al., 2011) 
Cucumis melo 
Transient expression 
- Virus infection 
DENV 2-specific truncated E No (Teoh et al., 2009) 
Cucurbita pepo 
Transient expression 
- Virus infection 
DENV 2-specific EDIII No (Libsittikul et al., 2015) 
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3 Construction of Dengue cEDIII Expression Cassettes and the Corresponding 
Recombinant Vectors 
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3.1 Introduction 
The advent of recombinant DNA technology has rapidly revolutionised 
vaccinology research where specific antigenic epitope can now be selectively produced. 
Recombinant subunit vaccine offers added advantages in terms of: (i) improved safety 
without concerns of viral interference, genetic recombination or reversion to virulence; 
(ii) easier formulation of multivalent component; and (iii) accelerated immunisation 
schedule is possible, which suits to military personnel and traveller’s use (Coller et al., 
2011). Numerous expression systems have been established to date, ranging from 
bacterial, fungal, mammalian and plant system. Notably, a plant-based expression 
system has attracted increasing adoption for the benefits of low manufacturing cost, 
easy and scalable production and reduced risk to mammalian pathogens (Tschofen et 
al., 2016). Therefore, if a highly immunogenic subunit vaccine can be manufactured 
using a high-yielding system, it does have the potential to deliver a world-changing 
impact to the field of vaccinology. 
To explore the prospects of a plant-based vaccine, the antigenic component of 
dengue virus (DENV) was designed for gene delivery into N. benthamiana. As reviewed 
in Section 2.5, transient system has seemed to overshadow stable transformation in the 
efforts of deriving a dengue vaccine candidate. Agroinfiltration is generally the method 
of choice, as the simple and straightforward procedure has made it possible to harvest 
milligrams of target protein within a matter of days. For that, binary vectors and plant 
viral vectors are commonly used to carry the transgene to be delivered into host plants. 
These vectors have been developed to facilitate gene cloning works and maximise the 
transformation efficiency. In brief, binary vectors are engineered to harbour the transfer 
DNA (T-DNA) and virulence regions separately; while viral vectors are often 
‘deconstructed’ to retain only elements required for high transgene expression. In this 
study, a modified binary vector based on cowpea mosaic virus (CPMV) was used 
accredited to its hypertranslational (HT) feature, known as pEAQ-HT vector. The non-
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replicative nature of this vector has made it more attractive than viral vector since issues 
like virus exclusion and mutation of transcripts could be avoided (Peyret and 
Lomonossoff, 2013).  
As DENV neutralising epitopes are identified on the envelope glycoprotein 
domain III (EDIII), it has now emerged as the prime candidate for vaccine development. 
More recently, EDIII was expressed as a consensus sequence (cEDIII) aligned between 
four DENV serotypes (DENV 1-4) (Huy and Kim, 2017; Kim et al., 2015; Kim et al., 
2016a; Kim et al., 2017). So far, only recombinant cEDIII produced in E. coli had 
demonstrated neutralising activities against DENV 1-4 following vaccine delivery with 
adjuvant (Leng et al., 2009). However, E. coli has limited post-translational machinery 
function, and improper disulphide bond formation is known to affect the proper folding 
of antibody epitopes on EDIII structure (Roehrig et al., 2004). Hence, this leads to idea 
of producing the cEDIII protein in plant system, which is more likely to mimic its native 
configuration. It is believed that cEDIII has the potential to be developed as a single 
component vaccine that can protect against the four co-circulating serotypes. Since 
cEDIII is considered as a novel molecule, the characteristics of the protein is not well-
understood yet. Therefore, fusion to green fluorescent protein (sGFP) is strategised to 
monitor the localisation and expression level of the heterologous protein. 
Concurrently with the study of cEDIII antigen, efforts are also focused on 
developing a vaccine candidate with strong immunogenic profile. Principally, one of 
the challenges in vaccine development is the need to generate and sustain strong 
immune responses, and subunit vaccine can be less immunogenic due to the defined 
amount of antigenic determinant. Hence, they require administration with adjuvant to 
potentiate the immune response against a specific antigen. Cholera toxin B subunit 
(CTB), a non-toxic derivative of V. cholerae toxin has been widely used as an adjuvant 
(Section 2.4.1.1). CTB has specific affinity for monosialotetrahexosylganglioside 
(GM1) distributed on leucocytes (Holmgren et al., 1973), by which it can facilitate 
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optimal access to the immune system. As the CTB carrier can impart its 
immunostimulatory properties to bystander antigen, genetically-linked CTB-cEDIII 
constructs were designed here with the hope to boost the vaccine efficacy.   
Besides, virus-like particles (VLPs) have gradually emerged as vaccine delivery 
vehicles that are spontaneously assembled from viral structural proteins (Section 2.4.2). 
These are multimeric structures that can directly stimulate immune cells by mimicking 
the three-dimensional conformation of native viruses. Moreover, VLPs are devoid of 
infectious genetic material which makes them inherently safer than attenuated or 
inactivated virus preparations. In this study, hepatitis B core antigen (HBcAg) was 
exploited for cEDIII epitope display. The resulting chimeric HBcAg VLPs are favoured 
for the high density of cEDIII displays on 180 – 240 copies of core protein per particle. 
Alternatively, ‘Tandem Core’ technology was also adopted to produce the chimeric 
HBcAg VLPs. Tandem core indicates a tandem fusion of two HBcAg monomers in 
order to produce HBcAg dimer as a single polypeptide (Peyret et al., 2015). It is 
believed that the expression as tandem core particles can increase the chance of chimeric 
VLPs assembly. To enable differentiation of the variants of HBcAg VLPs, monomeric 
core HBcAg (mHBcAg) is used to refer a single open reading frame (ORF) of HBcAg, 
whereas tandem core HBcAg (tHBcAg) refers to the tandem repeat of HBcAg ORFs. 
Focusing on the design and construction of cEDIII recombinant vectors, several 
strategies had been applied to achieve a higher expression. Firstly, codon optimisation 
was performed to boost translation by re-coding the rare codon in foreign gene with the 
synonymous codon preferred by the expression host (Angov, 2011). Kozak sequence 
was also added as another strategy to enhance translation efficiency. Next, subcellular 
targeting was used to modulate the trafficking of heterologous protein. Since proteins 
expressed in cytosol tend to suffer from proteolytic degradation (Benchabane et al., 
2008),  transgene can be targeted to specific organelle such as apoplast, chloroplast, 
endoplasmic reticulum (ER) and mitochondria. Nonetheless, localisation also depends 
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on whether the protein requires specialised folding or modifications to acquire its 
biological function. In this study, ER retention was opted considering the benefits of 
protein processing and sequestration. To ensure protein retrieval to ER, a signal peptide 
from tobacco pathogenesis-related 1a protein (PR1a) was also added to direct the 
protein through the secretion pathway (Cornelissen et al., 1987). Lastly, protein linker 
was used to improve the interactions between connecting domains in fusion proteins as 
well as chimeric HBcAg VLPs. 
Overall, the specific objectives of this chapter are:  
(i) To design cEDIII fusion expression cassettes with sGFP; 
(ii) To design cEDIII fusion expression cassettes with CTB; 
(iii) To optimise gene sequences based on N. benthamiana codon usage; 
(iv) To incorporate subcellular targeting signals comprising PR1a signal peptide 
and/or ER retention signal (KDEL), into the cassettes of recombinant cEDIII-
sGFP and CTB-cEDIII fusion proteins;  
(v) To construct chimeric mHBcAg VLPs expression cassette with cEDIII gene 
insertion at the c/e1 loop; 
(vi) To construct chimeric tHBcAg VLPs expression cassette with cEDIII gene 
inserted into the c/e1 loop of Core II region; and 
(vii) To integrate the cEDIII expression cassettes into pEAQ-HT vector to generate 
the respective recombinant vectors;  
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3.2 Materials and methods 
3.2.1 Vector 
The plant-based expression vector, namely pEAQ-HT (Accession Number: 
GQ497234) was used throughout the study. A detailed illustration of the pEAQ-HT 
vector map is provided as shown in Figure 3.1.  
For the construction of recombinant vectors of mHBcAg VLPs, a cloning vector 
designated as pEAQ-HT::mEL was used (Appendix A3.1). This vector was previously 
designed to produce monomeric core particles with empty c/e1 loop (mEL). In other 
words, the c/e1 region had not been modified to carry any foreign gene. 
For the construction of recombinant vectors of tHBcAg VLPs, pEAQ-
HT::tHBcAg-VHH2 was used as the cloning vector (Appendix A3.2). This vector was 
previously designed to harbour VHH2 epitopes on the c/e1 loop of the Core II region of 
tHBcAg VLPs. 
All the vectors used in this study were kindly provided by John Innes Centre (JIC) 
in the United Kingdom (UK). 
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Panel A: Plasmid map of pEAQ-HT 
 
 
 
Feature 
LB : Left border 
OriV : pRK2 replication origin for A. tumefaciens 
TrfA : Replication-essential locus 
NPTIII : Prokaryotic neomycin phosphotransferase III 
ColE1 : pBR322 replication origin for E. coli 
RB : Right border 
35S promoter : Cauliflower mosaic virus (CaMV) 35S promoter 
CPMV RNA-2 5’ UTR : 5’ untranslated region from CPMV RNA-2 
MCS : Multiple cloning site 
CPMV RNA-2 3’ UTR : 3’ untranslated region from CPMV RNA-2 
Nos terminator : Nopaline synthase terminator 
P19 : 19 kDa silencing suppressor protein 
35S terminator : CaMV 35S terminator 
NPTII : Eukaryotic neomycin phosphotransferase II 
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Panel B:  Illustration of the MCS within pEAQ-HT T-DNA region  
 
 
 
Feature 
RB : Right border 
35S promoter : CaMV 35S promoter 
CPMV RNA-2 5’ UTR : 5’ untranslated region from CPMV RNA-2 
MCS : Multiple cloning site 
CPMV RNA-2 3’ UTR : 3’ untranslated region from CPMV RNA-2 
Nos terminator : Nopaline synthase terminator 
P19 : 19 kDa silencing suppressor protein 
35S terminator : CaMV 35S terminator 
NPTII : Eukaryotic neomycin phosphotransferase II 
Left border : Left border 
NruI/AgeI + XmaI/SmaI : Restriction sites that generate C-terminal 6X 
histidine (His) tag 
XmaI/SmaI + XhoI/StuI : Restriction sites that generate N-terminal 6X His 
tag 
NruI/AgeI + XhoI/StuI : Restriction sites that do not yield 6X His tag 
 
 
Figure 3.1:  Schematic illustrations of the pEAQ-HT vector used in this study. Panel 
A: An overview of the vector; Panel B: A detailed illustration of the 
pEAQ-HT T-DNA region. Image reproduced with permission from 
Sainsbury et al. (2009). 
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3.2.2 Synthetic genes 
All the cEDIII genes used for recombinant vector construction were synthesised 
by GeneScript (United States of America, USA) and GeneArt (USA) as stated in Table 
3.1. In specific, these synthetic genes were codon-optimised for expression in N. 
benthamiana. 
Firstly, cEDIII-sGFP-KDEL was designed as cEDIII fusion to sGFP (Accession 
Number: ABL09837.1), followed by ER retention signal (Appendix A3.3). A variant 
named as PR1a-cEDIII-sGFP-H-KDEL, comprising of cEDIII fusion to sGFP along 
with N-terminal PR1a signal peptide (Accession Number: ABV21361.1), 6X His tag 
and a KDEL signal (Appendix A3.4). These two synthetic genes were provided in 
pUC57 vectors. 
Next, CTB-cEDIII-KDEL was synthesised as cEDIII fusion to CTB (Accession 
Number: U25679), followed by ER retention signal (Appendix A3.5). A variant 
labelled as PR1a-CTB-cEDIII-H-KDEL comprising of cEDIII fusion to CTB along 
with N-terminal PR1a signal peptide, 6X His tag and a KDEL signal (Appendix A3.6). 
These two synthetic genes were held in pUC57 vectors.  
Lastly, cEDIII (L) was designed as cEDIII flanked by long glycine-glycine-serine 
(GGS)n linkers (Appendix A3.7), which was provided in pMA-RQ vector.   
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Table 3.1:  List of synthesised sequences. 
No. Synthesised sequence Holding vector Source Appendix 
1 cEDIII-sGFP-KDEL pUC57 
GeneScript, 
USA 
A3.3 
2 
PR1a-cEDIII-sGFP-H-
KDEL 
pUC57 
GeneScript, 
USA 
A3.4 
3 CTB-cEDIII-KDEL pUC57 
GeneScript, 
USA 
A3.5 
4 
PR1a-CTB-cEDIII-H-
KDEL 
pUC57 
GeneScript, 
USA 
A3.6 
5 cEDIII (L) pMA-RQ 
GeneArt, 
USA 
A3.7 
 
 
3.2.3 Overview of construction of cEDIII recombinant vectors 
The cEDIII-sGFP-KDEL and CTB-cEDIII-KDEL used for gene cloning were 
obtained from pUC57 holding vectors. The first represents cEDIII fusion with sGFP; 
while the second represents cEDIII fusion with CTB (Table 3.2). Both gene sequences 
were designed with the tobacco etch virus (TEV) protease cleavage site and C-terminal 
KDEL signal. After the genes were isolated via polymerase chain reaction (PCR) using 
corresponding primers (Table 3.3), they were cloned into the AgeI and XmaI sites of 
pEAQ-HT vector to fuse in-frame with the C-terminal 6X His tag from the mutiple 
cloning site (MCS) (see Figure 3.1, Panel B). This hence gave rise to pEAQ-
HT::cEDIII-sGFP-KDEL-H and pEAQ-HT::CTB-cEDIII-KDEL-H, correspondingly. 
Meanwhile, the PR1a-cEDIII-sGFP-H-KDEL and PR1a-CTB-cEDIII-H-KDEL 
were released from pUC57 holding vectors via restriction enzyme (RE) digestion. The 
former denotes cEDIII fusion with sGFP; while the latter denotes cEDIII fusion with 
CTB, with a glycine-proline-glycine-proline (GPGP) linker between the fusion protein 
to reduce potential steric constraint (Table 3.2). Both cassettes contain the Kozak 
sequence, PR1a signal peptide, TEV cleavage site, 6X His tag and KDEL signal. They 
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were cloned into the AgeI and XhoI sites of pEAQ-HT vector (see Figure 3.1, Panel B). 
The change of restriction sites allowed the KDEL signal to be placed at the very end of 
C-terminus upon ligation into pEAQ-HT vector. 
The PR1a-CTB-cEDIII-KDEL (xTH) represents a variant of PR1a-CTB-cEDIII-
H-KDEL, in which the TEV protease cleavage site and 6X His tag had been removed 
(Table 3.2; Figure 3.2), and hence it was labelled as ‘xTH’. The new insert, PR1a-
CTB-cEDIII-KDEL (xTH) was generated via a two-step PCR amplification using the 
recombinant vector pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL and specific primers 
(Table 3.3). Nonetheless, the PR1a-CTB-cEDIII-KDEL (xTH) still harbours PR1a and 
KDEL signals, which was then cloned into the AgeI and XhoI sites of pEAQ-HT vector. 
The mHBcAg-cEDIII and mHBcAg-cEDIII (L) were constructed by inserting the 
cEDIII gene into the c/e1 loop of mHBcAg (Table 3.2). The cEDIII inserts, designated 
as cEDIII_mono and cEDIII (L)_mono, were amplified from pMA-RQ::cEDIII (L) 
holding vector using specific primers (Table 3.3). The only difference between the 
amplicons of cEDIII_mono and cEDIII (L)_mono is the presence of (GGS)n linkers that 
flank the cEDIII; in which presence of linkers is denoted with ‘(L)’. Both cEDIII_mono 
and cEDIII (L)_mono were then inserted to pEAQ-HT::mEL vector through the SalI 
and AseI restriction sites (Table 3.2). 
The expression cassette for tHBcAg-cEDIII was constructed by inserting cEDIII 
gene into the c/e1 loop of tHBcAg Core II region (Table 3.2). In this case, the cEDIII 
insert was amplified from pUC57::cEDIII-sGFP-KDEL vector using specific primers 
(Table 3.3). The resulting amplicon, cEDIII_tandem was then cloned into the AvrII and 
SbfI restriction sites of pEAQ-HT::tHBcAg-VHH2 vector. 
A schematic illustration of the procedures involved in the construction of all 
recombinant vectors is depicted in Figure 3.3. 
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Table 3.2:  List of cEDIII expression cassettes and cloning vectors used in this study. 
No. Schematic representation of cEDIII expression cassette  Cloning vector 
1 
cEDIII-sGFP-KDEL-H 
 
 
Note: The C-terminal 6X His tag was generated from in frame fusion with pEAQ-HT MCS region. 
 
2 
PR1a-cEDIII-sGFP-H-KDEL 
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3 
CTB-cEDIII-KDEL-H 
 
 
Note: The C-terminal 6X His tag was generated from in frame fusion with pEAQ-HT MCS region. 
 
4 
PR1a-CTB-cEDIII-H-KDEL 
  
5 
PR1a-CTB-cEDIII-KDEL (xTH) 
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6 
mHBcAg-cEDIII 
  
7 
mHBcAg-cEDIII (L) 
 
 
8 
tHBcAg-cEDIII  
  
Annotation: TEV indicates TEV protease recognition site;  Represents GPGP linker;  Represents (GGS)n linker;  Represents nucleic acid binding 
domain. 
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Table 3.3:  Details of PCR amplification of cEDIII inserts using Phusion® polymerase. 
No. Insert Template 
Primers 
Ta 
Expected 
amplicon size 
Forward Reverse 
1 cEDIII-sGFP-KDEL pUC57::cEDIII-sGFP-KDEL PFGS (sGFP) PRGS 70℃ 1.089 kbp 
2 CTB-cEDIII-KDEL pUC57::CTB-cEDIII-KDEL PFGS (CTB) PRGS 66℃ 0.753 kbp 
3 
Intermediate PR1a-CTB-cEDIII-
KDEL (xTH) amplicon 
pEAQ-HT::PR1a-CTB-cEDIII-H-
KDEL 
CTBcED3F CTBcED3R (1st) 70℃ 0.798 kbp 
4 PR1a-CTB-cEDIII-KDEL (xTH) 
Intermediate PR1a-CTB-cEDIII-
KDEL (xTH) amplicon 
CTBcED3F CTBcED3R (2nd) 70℃ 0.824 kbp 
5 cEDIII_mono pMA-RQ::cEDIII (L)_mono cED3F (mono) cED3R (mono) 69℃ 0.332 kbp 
6 cEDIII (L)_mono pMA-RQ::cEDIII (L)_mono cED3F (monoL) cED3R (monoL) 70℃ 0.432 kbp 
7 cEDIII_tandem pUC57::cEDIII-sGFP-KDEL cED3F cED3R 70℃ 0.333 kbp 
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Figure 3.2: A two-step PCR amplification process using pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL as template to generate the new insert, PR1a-CTB-cEDIII-
KDEL (xTH).
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Figure 3.3:  A methodology flow chart illustrating the steps used for the construction 
of recombinant vectors in this study. 
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3.2.4 Specialised equipment 
Polymerase chain reaction (PCR) was performed using Mastercycler Nexus 
Thermal Cycler (Eppendorf, Germany). Centrifugation of 10 ml sample was carried out 
using 5810R Refrigerated Centrifuge (Eppendorf, Germany) while MiniSpin® 
Microcentrifuge (Eppendorf, Germany) was used for ≤ 2.0 ml sample. The purity and 
concentration of DNA were determined using a NanoDrop 1000 spectrophotometer 
(Thermo Scientific, USA). DNA gel electrophoresis was conducted using Mini-Sub® 
Cell GT System (Bio-Rad, USA), followed by imaging using GBOX F3 Gel Imaging 
System (Syngene, UK) or AlphaImage Gel Imaging System (Alpha Innotech, USA). 
Sample incubation at controlled temperature was performed using Thermomixer 
comfort (Eppendorf, Germany) or water bath system (Memmert, Germany). Incubation 
of bacterial culture was carried out using Innova 42 incubator shaker (Eppendorf, 
Germany) and BINDER Microbiological Incubator (Binder, Germany). Measurement 
of the bacterial optical density was performed using BioPhotometer Plus (Eppendorf, 
Germany).  
 
3.2.5 Polymerase chain reaction (PCR) 
The amplification of insert for DNA ligation was performed using Phusion® 
High-Fidelity DNA Polymerase (New England Biolabs, USA). All the PCR mixtures 
were prepared according to manufacturer’s recommendation: 1X Phusion HF buffer 
containing 1.5 mM magnesium chloride, 10 mM deoxynucleotides (dNTPs), forward 
and reverse primers at 10 µM each, 100 ng template DNA, 1 unit of polymerase and 
topped up to 50 µl with distilled water. The PCR programme was set as follows: initial 
denaturation at 98℃ for 30 seconds, followed by 25 cycles of denaturation at 98℃ for 
10 seconds, annealing at 66-70℃  for 20 seconds and extension at 72℃  for 30 
seconds/kilo-base pair (kbp). A final elongation step was held at 72℃ for 5 minutes. 
Lastly, collected amplicons were analysed via DNA gel electrophoresis (Section 3.2.8). 
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The annealing temperature (Ta) used for the amplification of corresponding insert is 
stated in Table 3.3. Details of the primer sequences are provided in Appendix A3.8. 
 
3.2.6 Plasmid DNA isolation 
Plasmid isolation was conducted according to manufacturers’ instructions, using 
QIAprep Spin MiniPrep Kit (Qiagen, Germany) and Hybrid-QTM Plasmid Rapidprep 
(GeneAll, Korea). In brief, 10 ml of overnight bacterial culture was pelleted at 4000 x 
g for 10 minutes at room temperature (RT). The pellet was then resuspended in 250 µl 
of cell suspension buffer (50 mM Tris base, pH 8.0; 10 mM ethylenediaminetetraacetic 
acid; 100 μg/ml ribonuclease A) and transferred to a new microcentrifuge tube. Next, 
250 µl of lysis buffer (200 mM sodium hydroxide; 1% (w/v) sodium dodecyl sulphate) 
was added and the tube was inverted for 4 – 6 times. After 3 minutes, 250 µl of 
neutralisation buffer (4.2 M guanidine hydrochloride; 0.9 M potassium acetate) was 
added and mixed immediately by inverting 4 – 6 times. The mixture was centrifuged 
for 10 minutes at 15,000 x g. The supernatant was transferred to spin column and 
centrifuged at 15,000 x g for 30 seconds. After discarding the flow through, 750 µl of 
wash buffer (10 mM Tris base, pH 7.5; 80% (v/v) ethanol) was applied to the spin 
column and centrifuged at 15,000 x g for 30 seconds. The spin column was subjected to 
additional centrifugation for 1 minute to remove residual wash buffer. Lastly, the spin 
column was placed in a new microcentrifuge tube and 30 µl of elution buffer (10 mM 
Tris base; pH 8.5) was added to the centre of the column. The column was incubated at 
RT for 1 minute before centrifuging at 15,000 x g for 1 minute.  
 
3.2.7 Restriction enzyme (RE) digestion 
The RE double digestion (New England Biolabs, USA) was prepared as follows: 
1X CutSmart buffer (20 mM Tris-acetate, pH 7.9; 10 mM magnesium acetate; 50 mM 
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potassium acetate; 100 µg/ml BSA) or 1X NEBuffer 3.1 (50 mM Tris-hydrochloride 
(Tris-HCl), pH 7.9; 10 mM magnesium chloride; 100 mM sodium chloride; 100 µg/ml 
BSA), 500 ng of DNA, 5 units of enzymes and topped up to 25 µl with distilled water. 
All the reactions were incubated at 37℃ using water bath. Specific details of the double 
digestion set up for each insert and vector are stated in Table 3.4. 
 
Table 3.4: Details of the REs used for digestion of cEDIII inserts and pEAQ-HT 
variant vectors. 
No. Template 
RE Incubation 
time 1 2 
1 
Insert 
cEDIII-sGFP-KDEL 
CTB-cEDIII-KDEL 
 
Vector 
pEAQ-HT 
AgeI XmaI 4 hours 
2 
Insert 
PR1a-cEDIII-sGFP-H-KDEL 
PR1a-CTB-cEDIII-H-KDEL 
PR1a-CTB-cEDIII-KDEL (xTH) 
 
Vector 
pEAQ-HT 
AgeI XhoI 4 hours 
3 
Insert 
mHBcAg-cEDIII 
mHBcAg-cEDIII (L) 
 
Vector 
pEAQ-HT::mEL 
SalI AseI 4 hours 
4 
Insert 
tHBcAg-cEDIII 
 
Vector 
pEAQ-HT::tHBcAg-VHH2 
AvrII SbfI 4 hours 
  
3-22 
 
3.2.8 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to analyse DNA fragments of PCR 
amplicons, RE-digested products and integrity of plasmids. Gel containing 1% (w/v) 
agarose was pre-stained with 0.5 mg/ml ethidium bromide (Thermo Scientific, USA) or 
SYBR Safe (Thermo Scientific, USA) at 1:10,000 dilution in TBE buffer (89 mM Tris; 
89 mM boric acid; 2 mM ethylenediaminetetraacetic acid). DNA separation was 
conducted at 90 V for 45 – 60 minutes, using either HyperladderTM 1 kbp DNA Ladder 
(Bioline, UK) or GeneRulerTM 1 kbp DNA Ladder (Thermo Scientific, USA) as 
reference marker.  
 
3.2.9 DNA purification strategies 
Purification of PCR amplicons was performed using QIAquick PCR purification 
kit (Qiagen, Germany) and ExpinTM Combo GP (GeneAll, Korea). In brief, 5 volumes 
(µl) of DNA binding buffer (5 M guanidine hydrochloride; 30% (v/v) isopropanol) were 
mixed with 1 volume (µl) of DNA sample and mixed by vortexing. The mixture was 
transferred to a spin column with collection tube, and centrifuged at 15,000 x g for 30 
seconds. The flow through was discarded before adding 750 µl of wash buffer (10 mM 
Tris base, pH 7.5; 80% (v/v) ethanol) and centrifuged at 15,000 x g for 30 seconds. 
Centrifugation was repeated for another 1 minute to remove residual liquid. Lastly, the 
column was placed in a clean microcentrifuge tube and 30 µl of elution buffer (10 mM 
Tris base; pH 8.5) was applied. The column was incubated at RT for 5 minutes before 
centrifuging at 15,000 x g for 1 minute.  
RE-digested products were purified from agarose gel using QIAquick PCR 
purification kit (Qiagen, Germany) and ExpinTM Combo GP (GeneAll, Korea). Firstly, 
the DNA band of interest was excised using a razor blade. Following that, 3 volumes 
(µl) of neutralisation and binding buffer (20 mM Tris base, pH 6.6; 5.5 M guanidine 
thiocyanate) was added to each volume (mg) of excised gel. The mixture was incubated 
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at 50℃ for 10 minutes until the gel had completely dissolved. Then, 1 gel volume of 
100% (v/v) isopropanol was added and vortexed to mix. The mixture was transferred to 
a spin column with collection tube and centrifuged at 15,000 x g for 1 minute. The flow 
through was discarded and 700 µl of wash buffer (10 mM Tris base, pH 7.5; 80% (v/v) 
ethanol) was added, followed by centrifugation at 15,000 x g for 1 minute. Residual 
buffer was removed by an additional 1-minute centrifugation. Lastly, 30 µl of elution 
buffer (10 mM Tris base; pH 8.5) was applied to the column for 5 minutes, followed by 
centrifugation at 15,000 x g for 1 minute. 
The purity and concentration of purified DNA products were determined using a 
NanoDrop 1000 spectrophotometer before further use. 
 
3.2.10 Ligation of vector and insert 
All the RE-digested inserts were ligated into pEAQ-HT vector at the molar ratio 
of 3:1 using T4 DNA ligase (New England Biolabs, USA). The reaction mixture was 
prepared as follows: 1X T4 DNA ligase buffer (50 mM Tris-HCl, pH 7.5; 10 mM 
magnesium chloride; 10 mM dithiothreitol; 1 mM adenosine triphosphate), 50 ng of 
vector, 150 ng of insert, 200 units of T4 ligase and topped up to 10 µl with distilled 
water. Then, ligation was performed overnight at 4℃. 
 
3.2.11 Preparation of competent cells 
TOP10 competent Escherichia coli was prepared according to the method 
described by Nishimura et al. (1990). Firstly, glycerol stock of TOP10 cells was revived 
by streaking on Luria-Bertani (LB) agar plate (10 g/l tryptone; 5 g/l yeast extract; 10 g/l 
sodium chloride; 15 g/l agar). A single colony was picked on the next day and inoculated 
in LB broth culture (10 g/l tryptone; 5 g/l yeast extract; 10 g/l sodium chloride). After 
overnight incubation, the bacterial cells were sub-cultured into a conical flask 
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containing 50 ml of super optimal broth with catabolite repressor (SOC) media (20 g/l 
tryptone; 5 g/l yeast extract; 0.5 g/l sodium chloride; 5 g/l magnesium sulphate 
heptahydrate; 20 mM glucose) and transferred to an incubator shaker set at 37℃. The 
optical density at 600 nm wavelength (OD600) was checked at every 15-minute intervals. 
Once OD600 = 0.5 was reached, the cells were stored on ice for 10 minutes and then 
centrifuged at 1,500 x g at 4℃ for 10 minutes. Lastly, pellet was recovered in 0.5 ml of 
SOC and 2.5 ml of storage medium containing 36% (v/v) glycerin, 12% (w/v) 
polyethylene glycol and 12 mM magnesium sulphate heptahydrate dissolved in LB 
broth. The competent cells were then stored at -80℃. 
 
3.2.12 Transformation of TOP10 competent Escherichia coli 
All the ligated mixtures were introduced into TOP10 competent cells using heat-
shock method. Briefly, the cells were thawed on ice before mixing with 100 ng of DNA. 
After the 30-minute incubation on ice, the cells were heat-shocked in 42℃ water bath 
for 45 seconds and then chilled immediately on ice for 2 minutes. SOC media was 
aseptically added and the cells were left to recover with shaking at 37℃ for 1 hour. 
Lastly, transformed cells were spread on LB agar plate supplemented with 50 μg/ml of 
kanamycin. The plate was incubated at 37℃  for 16 hours and the colonies were 
subjected to PCR screening. 
 
3.2.13 Verification of recombinant vector 
For PCR screening of bacterial colony, GoTaq® Green Master Mix (Promega, 
USA) and Recombinant Taq DNA polymerase (Thermo Scientific, USA) were used. 
PCR reaction mixtures were prepared as described in Section 3.2.5; except for the 
template that was substituted with transformed clone picked from selective agar plate. 
For colony screening use, C1 and C3 primers had been specifically designed to span 
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from CPMV RNA-2 5’UTR to CPMV RNA-2 3’ UTR of the pEAQ-HT vector (Figure 
3.4, as highlighted in yellow). All the thermocycling conditions were set as follows: 
initial denaturation at 95℃ for 5 minutes, followed by 30 cycles of denaturation at 95℃ 
for 1 minute, annealing at 58℃ for 45 seconds and extension at 72℃ for 1 minute/kbp. 
A final elongation step was held at 72℃ for 5 minutes. The expected size of PCR 
product amplified from transformed clone is summarised in Table 3.5.  
 
 
Figure 3.4:  C1 and C3 primers used for all PCR screening works in this study.  
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Table 3.5:   The expected size of amplicon from PCR colony screening, using C1 and 
C3 primers. 
No. Transformed clone  
Expected amplicon 
size 
1 pEAQ-HT:: cEDIII-sGFP-KDEL-H 1.644 kbp 
2 pEAQ-HT:: PR1a-cEDIII-sGFP-H-KDEL 1.729 kbp 
3 pEAQ-HT:: CTB-cEDIII-KDEL-H 1.308 kbp 
4 pEAQ-HT:: PR1a-CTB-cEDIII-H-KDEL 1.396 kbp 
5 pEAQ-HT:: PR1a-CTB-cEDIII-KDEL (xTH) 1.357 kbp 
6 pEAQ-HT:: mHBcAg-cEDIII 1.435 kbp 
7 pEAQ-HT:: mHBcAg-cEDIII (L) 1.534 kbp 
8 pEAQ-HT:: tHBcAg-cEDIII 2.087 kbp 
9 pEAQ-HT 0.603 kbp 
10 pEAQ-HT::mEL 1.156 kbp 
11 pEAQ-HT::tHBcAg-VHH2 2.162 kbp 
 
 
Upon PCR confirmation of putative clones, the recombinant vectors were 
extracted (described in Section 3.2.6) and subsequently sent for sequencing. At least 
four primers were used to map each cassette (Table 3.6), so that these sequenced 
fragments could cover greater read length of the pEAQ-HT MCS region (Figure 3.1, 
Panel B). The Sanger sequencing results obtained from Eurofins Genomics (Germany) 
and First Base Laboratories (Singapore) were assembled using Sequence Scanner 
Software 2, followed by analyses with nucleotide Basic Local Alignment Search Tool 
(BLAST) and Vector NTI Software (Thermo Scientific, USA) for further verification. 
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Table 3.6:  List of primers used for the sequencing of specific recombinant vector. 
No. Recombinant vector Sequencing primer 
1 pEAQ-HT:: cEDIII-sGFP-KDEL-H 
 C1 
 C3 
 cED3F 
 cED3R 
2 pEAQ-HT:: PR1a-cEDIII-sGFP-H-KDEL 
 C1 
 C3 
 cED3F 
 cED3R 
3 pEAQ-HT:: CTB-cEDIII-KDEL-H 
 C1 
 C3 
 cED3F 
 cED3R 
4 pEAQ-HT:: PR1a-CTB-cEDIII-H-KDEL 
 C1 
 C3 
 cED3F 
 cED3R 
5 pEAQ-HT:: PR1a-CTB-cEDIII-KDEL (xTH) 
 C1 
 C3 
 cED3F 
 CTBcED3F 
 CTBcED3R (2nd) 
6 pEAQ-HT:: mHBcAg-cEDIII 
 C1 
 C3 
 5’ MCS 
 3’ MCS 
 5’ core c/e1 
 3’ core c/e1 
7 pEAQ-HT:: mHBcAg-cEDIII (L) 
 C1 
 C3 
 5’ MCS 
 3’ MCS 
 5’ core c/e1 
 3’ core c/e1 
8 pEAQ-HT:: tHBcAg-cEDIII 
 C1 
 C3 
 5’ MCS 
 3’ MCS 
 5’ core c/e1 
 3’ core c/e1 
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3.3 Results 
3.3.1 Codon optimisation of cEDIII genes 
The codon preference of cEDIII genes had been adjusted according to N. 
benthamiana codon usage in order to enhance heterologous gene expression. As shown 
in Table 3.7, successful codon optimisation was reflected from the higher codon 
adaptation index (CAI) obtained for all synthesised sequences. The index is used to 
assess how well the codon usage of a gene matches to the reference set in the expression 
host, and an ideal CAI of 1.0 would indicate that the frequency of synonymous codon 
used is the same. In this case, the optimised indexes were considered as satisfactory with 
values ≥ 0.85. 
 
Table 3.7:  The adjustment of codon usage for synthesised sequences. 
No. Synthesised sequences 
Codon adaptation index (CAI) 
Before optimisation After optimisation 
1 cEDIII-sGFP-KDEL 0.64 0.86 
2 
PR1a-cEDIII-sGFP-H-
KDEL 
0.65 0.87 
3 CTB-cEDIII-KDEL 0.78 0.86 
4 
PR1a-CTB-cEDIII-H-
KDEL 
0.77 0.85 
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3.3.2 Polymerase chain reaction (PCR) amplification of cEDIII inserts 
Specific cEDIII inserts were amplified using high fidelity Phusion® Taq to isolate 
inserts for cloning into expression vectors, pEAQ-HT, pEAQ-HT::mEL and pEAQ-
HT::tHBcAg-VHH2.  
Expression cassettes that were designed to express cEDIII recombinant fusion 
proteins, namely cEDIII-sGFP-KDEL, CTB-cEDIII-KDEL and PR1a-CTB-cEDIII-
KDEL (xTH), were successfully isolated by PCR as shown in Figure 3.5.   
For cEDIII inserts that were designed for presentation on the c/e1 loop of 
mHBcAg and tHBcAg VLPs, namely cEDIII_mono, cEDIII (L)_mono and 
cEDIII_tandem, successful amplification was achieved as presented in Figure 3.6. 
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Lane Amplified product  Estimated size 
L(A) GeneRulerTM 1 kbp DNA Ladder  
L (B) HyperladderTM 1 kbp DNA Ladder  
1-3 cEDIII-sGFP-KDEL  ~ 1.089 kbp 
4-6 CTB-cEDIII-KDEL  ~ 0.753 kbp 
7-9 
Intermediate PR1a-CTB-cEDIII-KDEL (xTH) 
amplicon 
~ 0.798 kbp 
10-12 PR1a-CTB-cEDIII-KDEL (xTH)  ~ 0.824 kbp 
 
 
Figure 3.5:  PCR amplification profiles of inserts used for vector construction of 
cEDIII recombinant fusion proteins, namely cEDIII-sGFP-KDEL, CTB-
cEDIII-KDEL, intermediate PR1a-CTB-cEDIII-KDEL (xTH) amplicon 
and PR1a-CTB-cEDIII-KDEL (xTH). 
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Lane Amplified product  Estimated size 
L(A) GeneRulerTM 1 kbp DNA Ladder  
L (B) HyperladderTM 1 kbp DNA Ladder  
1-3 cEDIII_mono ~ 0.332 kbp 
4-6 cEDIII (L)_mono ~ 0.432 kbp 
7-9 cEDIII_tandem ~ 0.333 kbp 
 
 
Figure 3.6: PCR amplification profiles of inserts used for vector construction of 
chimeric mHBcAg and tHBcAg VLPs, namely cEDIII_mono, cEDIII 
(L)_mono and cEDIII_tandem. 
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3.3.3 Restriction enzyme (RE) digestion of cEDIII expression cassettes 
Two cEDIII expression cassettes that were designed to produce cEDIII 
recombinant fusion proteins, namely PR1a-cEDIII-sGFP-H-KDEL and PR1a-CTB-
cEDIII-H-KDEL, were directly isolated from the pUC57 holding vectors as illustrated 
in Figure 3.7. Digested fragments were then purified from DNA gel and cloned into 
pEAQ-HT vector. 
 
  
 
Lane Vector Digested product  Estimated size 
L(A)  GeneRulerTM 1 kbp DNA Ladder  
1 pUC57 PR1a-cEDIII-sGFP-H-KDEL  ~ 1.089 kbp 
2 pUC57 PR1a-CTB-cEDIII-H-KDEL ~ 0.853 kbp 
 
 
Figure 3.7:  RE digestion profiles of inserts used to design the expression cassettes 
for cEDIII recombinant fusion proteins, namely PR1a-cEDIII-sGFP-H-
KDEL and PR1a-CTB-cEDIII-H-KDEL. Successful isolation of desired 
products was indicated by red box.  
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3.3.4 Screening of transformed clones 
All the transformed clones were analysed by PCR screening to confirm the 
presence of transgene. Colony screening profiles for the following recombinant vectors 
were obtained after amplification with C1 and C3 primers: pEAQ-HT::cEDIII-sGFP-
KDEL-H (Figure 3.8); pEAQ-HT::PR1a-cEDIII-sGFP-H-KDEL (Figure 3.9); pEAQ-
HT::CTB-cEDIII-KDEL-H (Figure 3.10); pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL 
(Figure 3.11); pEAQ-HT::PR1a-CTB-cEDIII-KDEL (xTH) (Figure 3.12); pEAQ-
HT::mHBcAg-cEDIII (Figure 3.13); pEAQ-HT::mHBcAg-cEDIII (L) (Figure 3.14) 
and pEAQ-HT::tHBcAg-cEDIII (Figure 3.15). Verified clones harbouring the expected 
amplicon size (as highlighted in red box) were selected for sequencing confirmation. 
 
Panel A: Colony screening profiles 
 
 
 
Lane Template Estimated size 
L (B) HyperladderTM 1 kbp DNA Ladder  
1-3 
pEAQ-HT::cEDIII-sGFP-KDEL-H transformed 
clones (red box) 
~ 1.644 kbp 
4 Positive control: pEAQ-HT  ~ 0.603 kbp 
5 Negative control: Distilled water  
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Panel B: Schematic diagram of recombinant vector 
 
 
 
Figure 3.8:  Verification of TOP10 cells transformed with pEAQ-HT::cEDIII-sGFP-
KDEL-H. Panel A: PCR colony screening profiles using C1 and C3 
primers, by which the pEAQ-HT::cEDIII-sGFP-KDEL-H vector was 
successfully detected in putative clones (red box). The pEAQ-HT vector 
served as a positive control for the PCR. Panel B: Schematic illustration 
of the recombinant vector with cEDIII-sGFP-KDEL-H expression 
cassette. 
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Panel A: Colony screening profiles 
 
 
 
Lane Template Estimated size 
L (B) HyperladderTM 1 kbp DNA Ladder  
1-3 
pEAQ-HT::PR1a-cEDIII-sGFP-H-KDEL 
transformed clones (red box) 
~ 1.729 kbp 
4 Positive control: pEAQ-HT ~ 0.603 kbp 
5 Negative control: Distilled water  
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Panel B: Schematic diagram of recombinant vector 
 
 
 
Figure 3.9:  Verification of TOP10 cells transformed with pEAQ-HT::PR1a-cEDIII-
sGFP-H-KDEL. Panel A: PCR screening profiles using C1 and C3 
primers, by which the pEAQ-HT::PR1a-cEDIII-sGFP-H-KDEL vector 
was successfully detected in putative clones (red box). The pEAQ-HT 
vector served as a positive control for the PCR. Panel B: Schematic 
illustration of the recombinant vector with PR1a-cEDIII-sGFP-H-KDEL 
expression cassette. 
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Panel A: Colony screening profiles 
 
 
 
Lane Template Estimated size 
L (B) HyperladderTM 1 kbp DNA Ladder  
1-3 
pEAQ-HT::CTB-cEDIII-KDEL-H transformed 
clones (red box) 
~ 1.308 kbp 
4 Positive control: pEAQ-HT ~ 0.603 kbp 
5 Negative control: Distilled water  
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Panel B: Schematic diagram of recombinant vector 
 
 
 
Figure 3.10:  Verification of TOP10 cells transformed with pEAQ-HT::CTB-cEDIII-
KDEL-H. Panel A: PCR screening profiles using C1 and C3 primers, by 
which the pEAQ-HT::CTB-cEDIII-KDEL-H vector was successfully 
detected in putative clones (red box). The pEAQ-HT vector served as a 
positive control for the PCR. Panel B: Schematic illustration of the 
recombinant vector with CTB-cEDIII-KDEL-H expression cassette. 
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Panel A: Colony screening profiles 
 
 
 
Lane Template Estimated size 
L (B) HyperladderTM 1 kbp DNA Ladder  
1-3 
pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL 
transformed clones (red box) 
~ 1.396 kbp 
4 Positive control: pEAQ-HT ~ 0.603 kbp 
5 Negative control: Distilled water  
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Panel B: Schematic diagram of recombinant vector 
 
 
 
Figure 3.11:  Verification of TOP10 cells transformed with pEAQ-HT::PR1a-CTB-
cEDIII-H-KDEL. Panel A: PCR screening profiles using C1 and C3 
primers, by which the pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL vector 
was successfully detected in putative clones (red box). The pEAQ-HT 
vector served as a positive control for the PCR. Panel B: Schematic 
illustration of the recombinant vector with PR1a-CTB-cEDIII-H-KDEL 
expression cassette. 
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Panel A: Colony screening profiles 
 
 
 
Lane Template Estimated size 
L (B) HyperladderTM 1 kbp DNA Ladder  
1-3 
pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL (xTH) 
transformed clones (red box) 
~ 1.357 kbp 
4 
Positive control: pEAQ-HT::PR1a-CTB-cEDIII-H-
KDEL 
~ 1.396 kbp 
5 Negative control: Distilled water  
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Panel B: Schematic diagram of recombinant vector 
 
 
 
Figure 3.12:  Verification of TOP10 cells transformed with pEAQ-HT::PR1a-CTB-
cEDIII-KDEL (xTH). Panel A: PCR screening profiles using C1 and C3 
primers, by which the pEAQ-HT::PR1a-CTB-cEDIII-KDEL (xTH) 
vector was successfully detected in putative clones (red box). The pEAQ-
HT:: PR1a-CTB-cEDIII-H-KDEL vector served as a positive control for 
the PCR. Panel B: Schematic illustration of the recombinant vector with 
PR1a-CTB-cEDIII-KDEL (xTH) cassette. 
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Panel A: Colony screening profiles 
 
 
 
Lane Template Estimated size 
L (B) HyperladderTM 1 kbp DNA Ladder  
1-3 
pEAQ-HT::mHBcAg-cEDIII transformed clones 
(red box) 
~ 1.435 kbp 
4 Positive control: pEAQ-HT::mEL ~ 1.156 kbp 
5 Negative control: Distilled water  
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Panel B: Schematic diagram of recombinant vector 
 
 
 
Figure 3.13: Verification of TOP10 cells transformed with pEAQ-HT::mHBcAg-
cEDIII. Panel A: PCR colony screening profiles using C1 and C3 primers, 
by which the pEAQ-HT::mHBcAg-cEDIII vector was successfully 
detected in putative clones (red box). The pEAQ-HT::mEL vector served 
as a positive control for the PCR. Panel B: Schematic illustration of the 
recombinant vector with mHBcAg-cEDIII expression cassette. 
3-45 
 
 
Panel A: Colony screening profiles 
 
 
 
Lane Template Estimated size 
L (B) HyperladderTM 1 kbp DNA Ladder  
1-3 
pEAQ-HT::mHBcAg-cEDIII (L) transformed clones 
(red box) 
~ 1.534 kbp 
4 Positive control: pEAQ-HT::mEL ~ 1.156 kbp 
5 Negative control: Distilled water  
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Panel B: Schematic diagram of recombinant vector 
 
 
 
Figure 3.14: Verification of TOP10 cells transformed with pEAQ-HT::mHBcAg-
cEDIII (L). Panel A: PCR colony screening profiles using C1 and C3 
primers, by which the pEAQ-HT::mHBcAg-cEDIII (L) vector was 
successfully detected in putative clone (red box). The pEAQ-HT::mEL 
vector served as a positive control for the PCR. Panel B: Schematic 
illustration of the recombinant vector with mHBcAg-cEDIII (L) 
expression cassette. 
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Panel A: Colony screening profiles 
 
 
 
Lane Template Estimated size 
L (B) HyperladderTM 1 kbp DNA Ladder  
1-3 
pEAQ-HT::tHBcAg-cEDIII transformed clones (red 
box) 
~ 2.087 kbp 
4 Positive control: pEAQ-HT::tHBcAg-VHH2 ~ 2.162 kbp 
5 Negative control: Distilled water  
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Panel B: Schematic diagram of recombinant vector 
 
 
 
Figure 3.15: Verification of TOP10 cells transformed with pEAQ-HT::tHBcAg-
cEDIII. Panel A: PCR colony screening profiles using C1 and C3 primers, 
by which the pEAQ-HT::tHBcAg-cEDIII vector was successfully 
detected in putative clones (red box). The pEAQ-HT::tHBcAg-VHH2 
vector served as a positive control for the PCR. Panel B: Schematic 
illustration of the recombinant vector with tHBcAg-cEDIII expression 
cassette. 
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3.3.5 Verification by DNA sequencing 
Following analyses of the sequencing results, all the recombinant vectors were 
confirmed to harbour expected expression cassettes without mismatched or frame shift 
mutation. An example of the stepwise alignment of sequencing results with the expected 
DNA sequence is shown in Appendix A3.9. These verified recombinant vectors were 
then delivered into N. benthamiana plants through agroinfiltration, which is discussed 
in Chapter 4. 
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3.4 Discussion 
This chapter essentially describes the construction process of recombinant 
vectors used to achieve plant-based cEDIII production in N. benthamiana. As 
mentioned, cEDIII represents a novel vaccine candidate that is generated from the 
alignment of EDIII sequence from different strains of the four DENV serotypes. As 
illustrated in Appendix A3.10, a consensus sequence of serotype-specific EDIII was 
individually obtained before these four sequences were re-aligned to generate the 
cEDIII that is representative of DENV serotypes 1 to 4. The use of cEDIII for vaccine 
development is justified by the need to confer a simultaneous protection against all 
DENV serotypes to avoid immune interference. Moreover, considering that virus 
mutation is likely to happen, a vaccine that can provide consistent protection in the long 
run will be more highly valued. In fact, DENV clade replacements had been detected in 
recent years which was correlated to recurrences of disease outbreaks  (Teoh et al., 
2013). Although some researchers might argue that a tetravalent vaccine also can be 
derived by combining the monovalent component of each serotype (Block et al., 2010), 
however this demands for a series of empirical trials in order to determine the best 
formulation. Therefore, from a production standpoint, generating a single cEDIII 
protein as the principal component should be able to reduce the underlying costs.  
With the aim to achieve high transgene expression, codon optimisation of the 
cEDIII gene, along with its fusion partner including sGFP gene and CTB gene was 
performed based on N. benthamiana codon usage bias. Codon bias is inherently unique 
to each species, as it defines specific preference over synonymous codon due to 
degeneracy of the genetic code.  In most cases, the transgene donor and host species are 
likely to show divergence in their codon usage due to the difference in cognate transfer-
RNA (Ikemura, 1985). As a result, this would have a profound impact on the protein 
expression level as rare codons can reduce the efficiency of translation by tuning the 
elongation rates (Quax et al., 2015). Besides, re-coding the codons of foreign insert had 
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been shown to favour soluble protein production on top of boosting gene expression by 
4 – 1000 folds (Angov et al., 2008). This suggests that formation of insoluble aggregates 
can be minimised, thereby yielding a soluble functional protein that is more likely to 
assume native conformation. Codon optimisation is usually achieved by maximising the 
CAI to match the synonymous codon used by the expression host. Ranging from 0 to 1, 
all the synthesised sequences had been optimised to a high CAI of ≥ 0.85, as compared 
to the native sequences with values between 0.6 – 0.7 (Table 3.7). Since CAI also serves 
as a predictive tool to characterise gene expression (Sharp and Li, 1987), it is foreseen 
that relatively high cEDIII gene expression can be achieved in N. benthamiana host 
plants. 
The pEAQ-HT expression vector has been designed to allow direct gene insertion 
by restriction enzyme-based cloning, and inclusion of 6X His tag also can be tailored as 
desired (Figure 3.1, Panel B). In this study, the insertion of cEDIII fusion construct at 
(i) AgeI + XmaI sites and (ii) AgeI + XhoI sites, has facilitated the production of (i) C-
terminal His-tagged protein and (ii) the unfused variant to study the optimal positioning 
of ER retention signal (Table 3.2). In fact, it is presumed that shuffling of KDEL signal 
would influence the protein accumulation level. Besides, the use of non-replicative 
pEAQ-HT system can omit concerns of biocontainment and potential genetic drift that 
have been described in Section 2.3.2.2. Another outstanding feature of pEAQ-HT is 
that, the vector has been designed to harbour P19 cassette on the same T-DNA region. 
Hence, this obviates the need to co-infiltrate another bacterial suspension to deliver the 
P19 construct, which is routinely done for most transient expression vectors such as 
MagnICON, pBY030 and pPZP. Post-translational gene silencing (PTGS) is often 
manifested by plant to defend against foreign materials including viruses and transgenes 
(Ratcliff et al., 1997). To counter against PTGS, P19 helps to sequester the small double 
stranded RNAs generated by Dicer-Like enzyme from being incorporated into the RNA-
induced silencing complex (RISC) (Silhavy et al., 2002). This is because RISC can use 
3-52 
 
these effector molecules to initiate sequence-specific knockdown via mRNA 
degradation and inhibition of translation (Burgyán and Havelda, 2011). The P19 protein 
from tomato bushy stunt virus (TBSV) is preferred over other silencing suppressors 
such as cucumber mosaic virus 2b protein and potato virus Y P1-HC-protease, as  the 
tombusvirus-encoded P19 is also able to boost the amount of co-expressed protein by 
50 folds (Voinnet et al., 2003). Therefore, it is useful to have the P19 concurrently 
expressed by pEAQ-HT to inhibit PTGS from stalling desired gene expression. 
Hitherto, pEAQ-HT vector has been used to express a variety of products in plants 
ranging from recombinant proteins, active enzymes to VLPs. The versatility of pEAQ-
HT vector has made it an excellent choice for in planta production of cEDIII as 
recombinant proteins and VLPs, in which their immunogenic potential can be relatively 
compared. Recombinant protein subunit vaccines are favoured for the defined 
production of specific antigen that is sufficient to evoke a protective immune response. 
In this case, cEDIII proved to be suitable as it can induce anamnestic antibody response 
following a challenge study with DENV (Leng et al., 2009). On the other hand, VLPs-
based vaccines can be regarded as a more highly-organised form of subunit vaccines. 
The repetitive array of protein subunits seems to offer VLPs the superiority as stand-
alone vaccine, as compared to recombinant proteins that may be poorly presented to the 
immune system (Noad and Roy, 2003). Thus, the potential of VLPs development with 
enhanced cEDIII presentation is explored. 
Since clear knowledge on the expression profile of cEDIII is imperative for 
downstream application, it is tagged with a sGFP partner to enable detection of the 
fluorescent fusion protein during expression and purification. sGFP is a non-destructive 
reporter that also allows in situ monitoring of the protein localisation under ultraviolet 
(UV) light. As protein translation starts from the 5’ end, sGFP is preferentially fused to 
the C-terminus of cEDIII so that the expression of an intact cEDIII can be ascertained. 
A TEV protease recognition site was engineered between the cEDIII and sGFP (Table 
3-53 
 
3.2), in order to facilitate separation of cEDIII from the downstream sGFP and 6X His 
tag during purification. The cleavage using TEV protease was selected based on 
ExPASy Peptide Cutter software analysis. 
Albeit the cholera toxin (CT) produced by V. cholerae has been described as one 
of strongest adjuvants (Section 2.4.1.1), the use of whole CT has been proven to be too 
toxic (Levine et al., 1983). Therefore, with the aim of exploiting CT adjuvanticity, 
cEDIII fusion with the non-toxic component CTB is opted. The tight packing of CTB 
monomers into its pentasaccharide structure would make an excellent carrier for cEDIII 
antigen presentation to the immune system. Moreover, it is foreseen that formation of 
pentamer can help to stabilise the fusion protein in place. In this study, cEDIII was 
designed to fuse at the C-terminus of CTB partner. Liljeqvist et al. (1997) reported that 
this way of CTB C-terminal fusion had the most efficient binding to GM1 due to 
reduced steric hindrance, as the GM1 binding pocket was found near to the N-terminus 
of CTB. Following the successful vector construction, the adjuvanticity of CTB-cEDIII 
fusion protein can be explored later in this study. The efficacy of CTB had been proven 
to be so robust that it could boost the survival rate of immunised mice to 100% when 
the administration of antigen alone could not rescue the animals at all (Lee et al., 2015b). 
In this study, recombinant fusion proteins were targeted to ER to regulate protein 
glycosylation and accumulation. KDEL signal primarily helps to direct the retrograde 
transport of protein back to ER lumen upon recognition by KDEL receptor in cis-Golgi 
(Pelham, 1996). Due to the fact that plant and mammalian have different N-glycan 
processing in late Golgi apparatus, ER localisation is integrated with the hope to avoid 
improper glycosylation of cEDIII protein which may lead to inactivation of epitope 
reactivity or even elicit adverse immunogenicity (Lisowska, 2002). Plants generally 
produce β(1, 2)-xylose and α(1, 3)-fucose residues instead of mammalian core α(1,6)-
linked fucose and terminal sialic acids (Faye et al., 2005). Besides, localisation to ER is 
expected to improve the yield of heterologous protein. This was supported by He et al. 
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(2014) findings, where ER retention had led to high accumulation of West Nile virus 
recombinant EDIII at 73 μg/g fresh weight tissue (FWT), while no yields were detected 
from cytosol- and chloroplast-targeted constructs. Given that the redox environment is 
highly regulated in ER (Ellgaard, 2004), optimal oxidoreductase activity can be 
achieved to form the disulphide bonds in cEDIII. This issue is highlighted because the 
correct folding of antibody recognition epitope on DENV EDIII lies upon the disulphide 
linkage between cysteine (Cys)28 and Cys59 (Suzarte et al., 2014). For the 103 amino 
acids long cEDIII, these Cys residues are identified at positions 8 and 39 instead. The 
difference in Cys positions can be explained by the consensus sequence alignment of 
cEDIII (Appendix A3.10). For the reasons above, ER retention seems to be 
indispensable for the sequestration of correctly folded cEDIII protein in a stable cellular 
compartment. Since KDEL is the crucial mediator in regulating protein retrieval, several 
improvements were initiated such as (i) combinatory design with PR1a signal to 
improve protein trafficking across the secretory pathway and (ii) shuffling KDEL signal 
to the C-terminal end of expression cassette to avoid hindrance for receptor recognition. 
In terms of VLPs-based vaccine development, albeit production of dengue VLPs 
had been explored by several studies (Liu et al., 2010; Mani et al., 2013; Sugrue et al., 
1997; Zhang et al., 2011), these previous initiatives do not sound practical due to the 
following reasons: (i) the neutralising antibody responses acquired by mice were 
generally weak; (ii) co-expressing the DENV precursor membrane (prM) and envelope 
domain I/II (EDI/EDII) can trigger adverse antibody-dependent enhancement (ADE); 
and (iii) the need to express four monovalent VLPs and adjust the tetravalent 
formulation. Hence, it would be more sensible to produce chimeric VLPs, whereby 
these VLPs are able to self-assemble while presenting the foreign DENV antigens on 
their viral surfaces. In this study, the VLPs derived from hepatitis B core antigen 
(HBcAg) have been utilised for cEDIII epitope display. As the stand-alone stability of 
DENV domain III has made it intrinsically different from other parts of the E protein 
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(Soares and Caliri, 2013), it is believed that cEDIII can behave as an independent entity 
and would not interrupt the assembly of viral particles.  
Technically, cEDIII gene was incorporated into the c/e1 loop to maximise 
exposure on the protruding spikes of assembled VLPs. There are supporting evidences 
whereby c/e1 insertion can induce stronger immunogenicity than N- and C-terminal 
fusions as reviewed in Section 2.4.2.1. Besides, a full length mHBcAg sequence was 
used for gene construction including the nucleic acid binding domain (Table 3.2). This 
is because the RNA-binding domain can help to stabilise the particle via disulphide 
linkage with neighbouring dimers and modulate cell-mediated immune response 
(Section 2.4.2.1). One of the issues encountered during the construction of mHBcAg-
based recombinant vectors was the high frequency of self-ligation events (Figures 3.13 
and 3.14). This can be prevented in future by dephosphorylating the linearised vector 
using alkaline phosphatase prior ligation. As a result, vector DNA without the 5’ 
phosphate group would not be able to self-ligate but still contains the 3’-hydroxyl group 
to form phosphodiester bond with the insert. 
The tandem core HBcAg design had been adopted due to the concern that the two 
copies of cEDIII inserts at HBcAg dimer interface might suffer from steric clashes 
which could abrogate particle assembly (Section 2.4.2.2). Thus, tandem core strategy is 
used to alleviate the steric constraints as VLPs are now assembled from the dimers of 
HBcAg protein, expressed from the two ORFs of HBcAg that have been covalently 
linked (Peyret et al., 2015). The cEDIII gene was inserted into the c/e1 loop of Core II, 
so that this would minimise disruption to VLPs assembly as the translation moved in 5’ 
 3’ direction from the unmodified Core I (Table 3.2). With this, the tandem core 
would have greater flexibility as only half of each particle was decorated with cEDIII 
antigens. Worthwhile to mention, this work signifies the first report on developing a 
HBcAg-based dengue vaccine using plant system. 
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Besides, Kozak sequence was included in most of the cEDIII expression cassettes 
(Table 3.2) as an additional strategy to achieve optimal gene expression. Basically, 
Kozak sequence refers to nucleotide sequences that surround the ATG initiation codon. 
Kozak plays a key role in initiating protein translation as it serves as the binding site for 
small (40S) ribosomal subunit that moves from the 5' 7-methyl-guanylate cap of 
eukaryotes mRNA (Kozak, 1999). In specific, AACA had been identified as the general 
Kozak sequence for plant (Lütcke et al., 1987); therefore, this sequence was inserted 
preceding the start codon of cEDIII expression cassettes. 
With the interest of facilitating interactions between protein domains, two 
different types of linkers have been used in this study. First of all, a rigid linker is used 
for the spatial separation of CTB and cEDIII proteins so that their independent 
functionality can be maintained (Zhao et al., 2008). For that, proline is the most 
preferred amino acid as it does not have amide hydrogen to donate and the stiffness 
makes it a good ‘breaker’ of secondary structure (George and Heringa, 2003). 
Meanwhile, a flexible linker of (GGS)n has been designed to facilitate interaction 
between the cEDIII inserts and core protein subdomains (expression cassettes: 
mHBcAg-cEDIII (L) and tHBcAg-cEDIII, Table 3.2). As this approach has been 
proven useful in Kratz et al. (1999) findings, it is hoped that the (GGS)n linkers can 
help to minimise the steric constraints and stabilise the chimeric HBcAg VLPs-
expressing cEDIII epitopes.   
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3.5 Conclusion 
In summary, all the cEDIII expression cassettes that were designed had been 
successfully cloned into pEAQ-HT binary vector. Recombinant vectors that were 
constructed for expression of recombinant proteins include: (i) cEDIII fusion to sGFP 
protein, namely pEAQ-HT::cEDIII-sGFP-KDEL-H and pEAQ-HT::PR1a-cEDIII-
sGFP-H-KDEL; as well as (ii) cEDIII fusion to CTB partner, namely pEAQ-HT::CTB-
cEDIII-KDEL-H, pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL and pEAQ-HT::PR1a-
CTB-cEDIII-KDEL (xTH). Meanwhile, recombinant vectors that were constructed to 
express chimeric HBcAg VLPs based on (i) monomeric core were pEAQ-
HT::mHBcAg-cEDIII and pEAQ-HT::mHBcAg-cEDIII (L), whereas the construct 
developed based on tandem core was pEAQ-HT::tHBcAg-cEDIII. Furthermore, 
improvement strategies such as codon optimisation, incorporation of ER trafficking 
signal along with design of protein linkers had been integrated to aim for high transgene 
expression. These recombinant vectors are now ready for expression studies in N. 
benthamiana by which details are presented in the Chapter 4.  
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4.1 Introduction 
The era of molecular pharming has driven the production of various plant-based 
biologics by which many are now being assessed in clinical trials. The delivery of 
transgene into host plant can be achieved via several strategies that either involve stable 
transformation or transient expression. In the early days, transient expression is mainly 
used to assess the activity of gene constructs prior stable integration. However, the 
establishment of stable production system can be cumbersome due to the time-
consuming process of selection and regeneration of stable lines, potential genetic drift 
and vulnerability to epigenetic factors (Menassa et al., 2012). Therefore, various 
academic and industrial laboratories have switched to transient expression technology 
as it enables efficient delivery of products within a timescale of days. In fact, there is a 
notion that the ‘classical’ stable transformation might soon be displaced by the transient 
expression system that shows promise of high competitiveness (Rybicki, 2010). 
The introduction of agroinfiltration has rapidly revolutionised the manner where 
transient expression is achieved to date. This Agrobacterium-mediated transformation 
for transient gene expression is favoured for the speed and simplicity of procedures, by 
which leaves of potted plant can be easily infiltrated using a needless syringe, via 
vacuum application or air-brushing. Upon infiltration, the intercellular spaces within the 
leaf of host plant will be replaced by agrobacterial suspension harbouring the desired 
transgene. As discussed, both binary and viral vectors can be used for gene delivery via 
agroinfiltration (Section 2.3.2.2). In relation to this study, the pEAQ-HT vector 
developed from cowpea mosaic virus (CPMV) is used. It is a binary vector that relies 
on the integration of transfer DNA (T-DNA) into plant nucleus for the transgene to be 
transcribed and expressed. Essentially, the best of three biological systems is combined 
here: the plant eukaryotic expression system, the hypertranslational (HT) features of 
CPMV and the high transfection efficiency of Agrobacterium. 
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In this study, cEDIII recombinant vectors were designed to exploit the expression 
system of N. benthamiana. These vectors were differentiated into two main types, to 
express as (i) recombinant fusion proteins with either green fluorescent protein (sGFP) 
or cholera toxin B subunit (CTB); and (ii) chimeric hepatitis B core antigen (HBcAg) 
virus-like particles (VLPs) displaying cEDIII epitopes. As mentioned, these represent 
different variants of cEDIII vaccine candidates that would be assessed for their 
corresponding immunogenic potential. So, with the aim of recovering a satisfactory 
amount of heterologous proteins, several strategies had been applied during the 
construction of cEDIII recombinant vectors (Chapter 3). These include synthesising 
cEDIII genes with optimised N. benthamiana codons and adding the Kozak sequence 
to improve efficiency of translation. The use of pEAQ-HT vector offers the co-
expression of P19 gene silencing suppressor to prevent adverse turnover of transgene 
products. Besides, signal peptides were used to target the cEDIII recombinant fusion 
proteins to endoplasmic reticulum (ER) for high protein accumulation, which comprised 
of tobacco pathogenesis related protein 1a (PR1a) signal peptide and ER retention signal 
(KDEL). Protein linkers were also used to alleviate potential steric hindrance between 
the neighbouring domains in cEDIII fusion proteins and chimeric HBcAg VLPs. 
Following the successful construction of cEDIII recombinant vectors, this chapter 
presents the delivery of desired transgene into N. benthamiana. Upon transformation 
into Agrobacterium tumefaciens, syringe infiltration was used to inoculate the bacterial 
suspension harbouring recombinant vectors into the host plants. Firstly, the infiltrated 
leaves were harvested on 6th day post-infiltration (dpi) to verify the expression of 
delivered cEDIII transgenes. The localisation of recombinant cEDIII-sGFP fusion 
protein was determined via confocal microscopy. Then, time-course analyses were used 
to evaluate the expression kinetics of different cEDIII constructs. Owing to the poorly-
soluble monomeric core HBcAg (mHBcAg) and tandem core HBcAg (tHBcAg) VLPs, 
buffer optimisation was used to enhance the recovery of sample. 
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Overall, the specific objectives for this chapter are set as follows:  
(i) To deliver all the constructed recombinant vectors into N. benthamiana via 
syringe infiltration; 
(ii) To verify the ability of the recombinant vectors to express cEDIII fusion proteins 
and chimeric HBcAg VLPs with cEDIII epitopes; 
(iii) To examine the effect of subcellular localisation on the expression of 
recombinant cEDIII fusion proteins; and 
(iv) To study the expression kinetics of cEDIII fusion proteins and chimeric HBcAg 
VLPs with cEDIII epitopes in N. benthamiana. 
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4.2 Materials and methods 
4.2.1 Plant growth 
In this study, 5 – 6 weeks old N. benthamiana plants grown in glasshouse and 
plant growth chamber were used for agroinfiltration. To grow the plants, a controlled 
environment was set at 25℃, 70% humidity, with 16 hours of daylight period. These 
plants were watered on alternate days and fertiliser was applied on a weekly basis.  
 
4.2.2 Specialised equipment 
Conviron plant growth chamber was used to grow the N. benthamiana plants 
(Conviron, Canada) under regulated conditions. Transformation of Agrobacterium was 
performed using either a water bath system (Memmert, Germany) or Electroporator 
2510 (Eppendorf, Germany). Innova 42 incubator shaker (Eppendorf, Germany) was 
used to incubate bacterial broth culture while BINDER Microbiological Incubator 
(Binder, Germany) was used for bacterial plate incubation. Measurement of the bacterial 
optical density was performed using BioPhotometer Plus (Eppendorf, Germany). Most 
centrifugation works were performed using 5810R Refrigerated Centrifuge (Eppendorf, 
Germany). The ultraviolet (UV) observation of infiltrated N. benthamiana leaves was 
illuminated using Blak-Ray lamps (Ultra-Violet Product Ltd, USA). Besides, LSM 780 
confocal microscope (Zeiss, Germany) was also used to detect fluorescence emission. 
The homogenisation of plant extract could be performed using Omni Bead Ruptor 24 
homogenizer (Camlab, USA). Thermomixer (Eppendorf, Germany) was used to heat up 
loading sample for protein gel. Protein gel electrophoresis was performed using either 
NuPAGE® system (Invitrogen, USA) or Mini-PROTEAN® Tetra Cell system (Bio-Rad, 
USA). Subsequent electroblotting was conducted using either Mini Trans-Blot® Cell 
(Bio-Rad, USA) or XCell II™ Blot Module (Invitrogen, USA). Images of coomassie 
blue-stained protein gel and colorimetric development on Western blot membrane were 
recorded using GS-800™ calibrated densitometer (Bio-Rad, USA). Meanwhile, 
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ImageQuant LAS 500 (GE Healthcare, USA) was used as a chemiluminescence 
imaging system.  
 
4.2.3 Preparation and transformation of LBA4404 competent 
Agrobacterium tumefaciens 
The A. tumefaciens strain LBA4404 was used to deliver the recombinant vectors 
into N. benthamiana plant throughout the study. Competent cells of LBA4404 were 
prepared according to the method described in Section 3.2.11. 
The transformation of LBA4404 competent cells was performed via freeze-thaw 
method described by Hofgen and Willmitzer (1988). In brief, the competent cells were 
thawed on ice for 5 minutes before adding 100 ng of recombinant vector. After 30 
minutes, the bacterial cells were immersed in liquid nitrogen for 10 seconds, followed 
by 4-minute incubation in 37℃ water bath and another 2-minute incubation on ice. Then, 
super optimal broth with catabolite repressor (SOC) media was aseptically added and 
the cells were left to recover in 28℃ incubator shaker for 1 hour. Lastly, transformed 
cells were spread on Luria-Bertani (LB) agar plate containing 50 μg/ml of kanamycin 
and 50 μg/ml rifampicin, followed by incubation at 28℃ for 48 hours. 
Alternatively, the LBA4404 competent cells were also transformed via 
electroporation protocol stated by Main et al. (1995). Likewise, 100 ng of recombinant 
vector was added to the competent cells thawed on ice beforehand. Then, the mixture 
of LBA4404 cells and DNA was transferred to a pre-chilled cuvette (Eppendorf, 
Germany) and electroporated at 2500 V. SOC media was immediately added and the 
cells incubated in 28℃ incubator shaker for 1 hour. Transformed cells were then spread 
on LB agar plate containing 50 μg/ml of kanamycin and 50 μg/ml rifampicin, followed 
by incubation at 28℃ for 48 hours. Following the incubation, transformed colonies were 
picked from the selective plate for PCR screening (Section 3.2.13). 
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4.2.4 Inoculation of agrobacterial suspension 
Agroinfiltration of N. benthamiana was performed based on Sainsbury et al. 
(2012). Overnight A. tumefaciens culture was harvested and diluted to optical density at 
600 nm wavelength (OD600) of 0.4 with infiltration buffer containing 10 mM MES (pH 
5.6), 10 mM magnesium chloride and 100 μM acetosyringone. After that, the diluted 
agrobacterial suspension harbouring the recombinant vectors (Table 4.1) was infiltrated 
into 5 – 6 weeks old N. benthamiana plants.  
To perform the syringe infiltration, a 1 ml needless syringe (Terumo, Japan) was 
filled with agrobacterial suspension and pressed against the lower epidermis of a N. 
benthamiana leaf. By applying a counter-pressure to the other side of the leaf, the 
suspension was then injected into the airspaces of the leaf. Lastly, the infiltrated plants 
were placed back to their usual growth conditions. 
 
Table 4.1: Agrobacterial suspensions used for plant infiltration in this study. 
No. LBA4404 cells harbouring expression vector OD600 dilution 
1 pEAQ-HT::cEDIII-sGFP-KDEL-H 0.4 
2 pEAQ-HT::PR1a-cEDIII-sGFP-H-KDEL 0.4 
3 pEAQ-HT::CTB-cEDIII-KDEL-H 0.4 
4 pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL 0.4 
5 pEAQ-HT::PR1a-CTB-cEDIII-KDEL (xTH) 0.4 
6 pEAQ-HT::mHBcAg-cEDIII 0.4 
7 pEAQ-HT::mHBcAg-cEDIII (L) 0.4 
8 pEAQ-HT::tHBcAg-cEDIII 0.4 
9 pEAQ-HT 0.4 
10 pEAQ-HT::GFP 0.4 
11 pEAQ-HT::mEL 0.4 
12 pEAQ-HT::tEL 0.4 
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4.2.5 Ultraviolet (UV) observation and photography 
N. benthamiana plants that were infiltrated with recombinant cEDIII-sGFP 
vectors, namely pEAQ-HT::cEDIII-sGFP-KDEL-H and pEAQ-HT::PR1a-cEDIII-
sGFP-H-KDEL, were viewed using handheld Blak-Ray UV lamps. In addition, plants 
infiltrated with pEAQ-HT and pEAQ-HT::GFP vectors were used as negative and 
positive controls, correspondingly. Upon UV excitation in the dark room, photographs 
of green fluorescence emitted by cEDIII-sGFP-expressing leaves were taken by Mr. 
Andrew Davis (JIC, UK).  
 
4.2.6 Confocal microscopy 
LSM 780 confocal microscope was used to visualise the expression of 
recombinant cEDIII-sGFP in N. benthamiana leaves. Roughly 1 cm2 segment of 
infiltrated leaf was excised and mounted onto a coverslip, with the abaxial side facing 
upwards. Then, 40X/1.3 water lens was used and visualisation was conducted using 
GFP filter at 488 nm wavelength. 
 
4.2.7 Protein extraction 
A small-scale protein extraction was used to screen for the expression of cEDIII 
recombinant vector. Unless otherwise specified, the infiltrated leaves were harvested on 
6th dpi. Leaf discs corresponding to 100 mg of fresh weight tissue (FWT) were sampled. 
After adding 3X volume (w/v) of extraction buffer, leaf tissues were homogenised with 
a ¼-inch ceramic beads (MP Biomedicals, USA) using the Omni Bead Ruptor 24 
homogenizer. Or alternatively, infiltrated leaves were ground using liquid nitrogen in a 
pre-chilled mortar. The lysate was then centrifuged at 15,000 x g, 4℃ for 10 minutes 
and the supernatant was kept as soluble protein (SP). The SP extract was heated with 
lithium dodecyl sulphate sample buffer (141 mM Tris base; 106 mM Tris-hydrochloride; 
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2% (w/v) lithium dodecyl sulphate; 10% (v/v) glycerol; 0.51 mM EDTA; 0.22 mM 
SERVA Blue G; 0.175 mM phenol red) containing β-mercaptoethanol (LDS-βME) at 
99℃ for 10 – 20 minutes before used for analysis. Meanwhile, insoluble protein (INP) 
could be harvested from the pellet by heating with LDS-βME and subjected to another 
round of centrifugation. In specific, optimisation of buffer pH and compositions was 
done for the extraction of monomeric core and tandem core VLPs in order to increase 
recovery of SP. Details of the extraction buffer used and the estimated size of 
corresponding protein, in kilo-Dalton (kDa), are stated in Table 4.2. The specific 
composition for each extraction buffer can be found at Appendix A4.1. 
4-11 
 
Table 4.2: Details on the extraction of heterologous proteins expressed by corresponding recombinant vectors.  
No. Expressed protein Delivered recombinant vector Protein extraction buffer Estimated protein size 
1 cEDIII-sGFP-KDEL-H pEAQ-HT::cEDIII-sGFP-KDEL-H Tris extraction buffer ~ 40 kDa 
2 cEDIII-sGFP-H-KDEL pEAQ-HT::PR1a-cEDIII-sGFP-H-KDEL Tris extraction buffer ~ 40 kDa 
3 CTB-cEDIII-KDEL-H pEAQ-HT::CTB-cEDIII-KDEL-H Tris extraction buffer ~ 28 kDa 
4 CTB-cEDIII-H-KDEL pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL Tris extraction buffer ~ 28 kDa 
5 CTB-cEDIII-KDEL (xTH) pEAQ-HT::PR1a-CTB-cEDIII-KDEL (xTH) Tris extraction buffer ~ 26 kDa 
6 mHBcAg-cEDIII  pEAQ-HT::mHBcAg-cEDIII 
 VLPs extraction buffer A 
 
 VLPs extraction buffer B 
~ 34 kDa 
7 mHBcAg-cEDIII (L)  pEAQ-HT::mHBcAg-cEDIII (L) 
 VLPs extraction buffer A 
 
 VLPs extraction buffer B 
~ 36 kDa 
8 tHBcAg-cEDIII  pEAQ-HT::tHBcAg-cEDIII 
 Sodium phosphate 
extraction buffer 
 
 VLPs extraction buffer A 
~ 55 kDa 
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4.2.8 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
Same volume of sample was loaded into each protein well, and SeeBlue Plus2 
Pre-Stained Standard (Invitrogen, USA) was used as the protein marker throughout the 
study (Appendix A4.1). In specific, the two different SDS-PAGE systems used were 
described below.  
NuPAGE® Bis-Tris pre-cast gels (Invitrogen, USA), containing 12% (w/v) and 
4% – 12% (w/v) gradient acrylamide, were electrophoresed at 200 V for 50 minutes. 
Based on the desired molecular weight separation, NuPAGE® MOPS SDS Running 
Buffer (50 mM Tris base, pH 7.7; 50 mM MOPS; 0.1% (w/v) sodium dodecyl sulphate; 
1 mM ethylenediaminetetraacetic acid) or MES SDS Running Buffer (50 mM Tris base, 
pH 7.3; 50 mM MES; 0.1% (w/v) sodium dodecyl sulphate; 1 mM 
ethylenediaminetetraacetic acid) was selected accordingly.  
Alternatively, 12% (w/v) polyacrylamide gel was prepared using Mini-
PROTEAN® Tetra Cell system and electrophoresis was carried out at 150 V for 60 
minutes using Laemmli running buffer (Appendix A4.1).   
 
4.2.9 Coomassie blue gel staining 
Following electrophoresis, the protein gel was stained with InstantBlue 
(Expedeon, UK) for at least 1 hour. Then, the protein gel was destained with deionised 
water overnight before imaging. 
 
4.2.10 Western blotting 
For immunoblotting analysis, electrophoresed proteins were transferred onto a 
nitrocellulose membrane (Millipore, USA). The assembled blotting sandwich was 
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immersed in a transfer apparatus filled with Transfer Buffer, and wet-transfer was 
conducted using either system described as follows: 
Mini Trans-Blot® Cell set at 100 V for 60 minutes, with constant cooling by ice 
bath. Or alternatively, the XCell II™ Blot Module was used and voltage was set at 25 
V for 80 minutes. 
Blotted membrane was blocked with 5% milk (w/v) in phosphate-buffered saline 
(PBS) containing 0.05% (v/v) Tween-20 (PBST) for at least 1 hour. Membrane was 
subsequently incubated with either DENV 1-4, HBcAg, Tetra-His or cholera toxin (CT) 
primary antibody for 1 hour. Then, the membrane was washed three times with PBST 
at 5-minute intervals before incubation with mouse or rabbit immunoglobulin G (IgG) 
horseradish peroxidase (HRP)-conjugated secondary antibody for another hour. 
Washing steps were repeated for at least three times before detection. Details of the 
antibodies used are provided in Table 4.3.  
 
Table 4.3:  List of antibodies used for Western blotting in this study. 
 
Antibody name Species Dilution Source 
DENV 1-4 monoclonal antibody Mouse 1:2,000 
Thermo Scientific, 
USA 
HBcAg monoclonal antibody Mouse 1:4,000 Abcam, UK 
Tetra-histidine (His) monoclonal 
antibody 
Mouse 1:2,000 Qiagen, Germany 
CT polyclonal antibody Rabbit 1:8,000 Sigma, USA 
Mouse IgG (H+L) HRP-
conjugated polyclonal antibody 
Goat 1:10,000 Invitrogen, USA 
Rabbit IgG (H+L) HRP-
conjugated polyclonal antibody 
Goat 1:20,000 Agrisera, Sweden 
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To perform chemiluminescent detection, enhanced chemiluminescence (ECL) 
solution was added (Appendix A4.1) and developed signal was digitally captured using 
ImageQuant LAS 500. Meanwhile, colorimetric-based detection was done by adding 1 
ml of 3, 3’, 5, 5’-tetramethylbenzidine (TMB) substrate (KPL, USA) until a distinct 
purple colour was observed. The membrane was briefly rinsed with deionised water 
before images were captured by using GS-800™ calibrated densitometer. 
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4.3 Results 
4.3.1 Ultraviolet (UV) detection of recombinant cEDIII fused to green 
fluorescent protein (sGFP) 
Under UV light illumination, the green fluorescence emitted by cEDIII-sGFP 
recombinant proteins (expression vectors: pEAQ-HT::cEDIII-sGFP-KDEL-H and 
pEAQ-HT::PR1a-cEDIII-sGFP-H-KDEL) was observed (Figure 4.1). Notably, 
stronger signal was detected from the leaf infiltrated with the improved construct 
(expression vector: pEAQ-HT::PR1a-cEDIII-sGFP-H-KDEL) as compared to the leaf 
infiltrated with the initial construct (expression vector: pEAQ-HT::cEDIII-sGFP-
KDEL-H). Both healthy and pEAQ-HT-infiltrated leaves were included as negative 
controls, for which no green fluorescence was observed from these leaves. In fact, only 
autofluorescence of damaged tissue was detected from the leaf infiltrated with pEAQ-
HT (mock). Leaf infiltrated with pEAQ-HT::GFP vector was used as positive control, 
and it exhibited the strongest fluorescence as expected.  
Confocal microscopic observation of the localisation of recombinant cEDIII-
sGFP is shown in Figure 4.2. Panel A shows the trafficking of the recombinant cEDIII-
sGFP expressed by the initial construct (expression vector: pEAQ-HT::cEDIII-sGFP-
KDEL-H) to the cytosol region. Meanwhile, Panel B presents localisation of the 
recombinant cEDIII-sGFP to the intricate networks of ER, as mediated by the improved 
construct (expression vector: pEAQ-HT::PR1a-cEDIII-sGFP-H-KDEL). Such 
observation suggests that the improved construct had facilitated efficient protein 
trafficking to the ER. Panel C however, shows image of pEAQ-HT-infiltrated leaf to 
discriminate against background autofluorescence. Future improvement may consider 
the use of organelle marker antibody to confirm protein localisation to the ER. 
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Figure 4.1:  A comparative UV observation of green fluorescence emitted by 
N. benthamiana leaves infiltrated with different constructs. A 
scoring was made based on the intensity of fluorescence. 
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Panel A 
Infiltrated with pEAQ-HT::cEDIII-sGFP-KDEL-
H (initial construct) 
Panel B 
Infiltrated with pEAQ-HT::PR1a-cEDIII-sGFP-
H-KDEL (improved construct) 
Panel C 
Infiltrated with pEAQ-HT (mock) 
   
Green fluorescence detected in cytoplasm Green fluorescence detected in ER Only background autofluorescence detected 
 
Figure 4.2:  Confocal microscopic observation of N. benthamiana leaves expressing recombinant cEDIII-sGFP fusion proteins. Infiltration was conducted 
using the initial construct pEAQ-HT::cEDIII-sGFP-KDEL-H (Panel A), the improved construct pEAQ-HT::PR1a-cEDIII-sGFP-H-KDEL (Panel 
B) and the mock pEAQ-HT without gene insertion (Panel C).
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4.3.2 Expression of recombinant cEDIII in fusion to green fluorescent 
protein (sGFP) 
Successful expression of recombinant cEDIII-sGFP in N. benthamiana was 
achieved as shown in Figure 4.3. Immunoblot analysis was able to detect the soluble 
protein (SP) expressed by the two cEDIII-sGFP recombinant vectors, namely pEAQ-
HT::cEDIII-sGFP-KDEL-H and pEAQ-HT::PR1a-cEDIII-sGFP-H-KDEL. Denser 
bands were detected from the leaves infiltrated with improved construct (expression 
vector: pEAQ-HT::PR1a-cEDIII-sGFP-H-KDEL) as compared to the initial construct 
(expression vector: pEAQ-HT::cEDIII-sGFP-KDEL-H). This conformed to the 
speculation that inclusion of PR1a helped to mediate more efficient protein retention in 
the ER. Besides, degraded products were found in the SP extracts of pEAQ-HT::cEDIII-
sGFP-KDEL-H infiltrated leaves. Since no signal was obtained from the extract of 
pEAQ-HT-infiltrated leaf, this confirmed that the mock sample was free of gene insert 
and the expression of recombinant vectors in infiltrated plant is authentic. The pEAQ-
HT::PR1a-cEDIII-sGFP-H-KDEL vector was selected for further study based on the 
higher expression level. 
Following that, a time-course analysis was used to determine the peak 
accumulation of recombinant cEDIII-sGFP fusion protein (Figure 4.4). Panel A shows 
that chlorosis of pEAQ-HT::PR1a-cEDIII-sGFP-H-KDEL-infiltrated leaf was visible 
starting from 6th dpi, and necrosis was seen on 9th dpi. The Western blot profiles in Panel 
B indicate that the SP of recombinant cEDIII-sGFP had accumulated at persistently high 
level until 9th dpi. As different cells in host plant might exhibit unsynchronised state of 
protein expression, 6th dpi was selected as the optimal harvesting time to compromise 
for late responders while avoiding severe leaf distortions. 
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Lane Sample  Expression vector Estimated size 
L 
SeeBlue Plus2 Pre-
Stained Standard 
  
1-3 
SP extracted from leaf 
discs on 6th dpi 
pEAQ-HT::cEDIII-sGFP-
KDEL-H  
(initial construct) 
~ 40 kDa 
4-6 
SP extracted from leaf 
discs on 6th dpi 
pEAQ-HT::PR1a-cEDIII-
sGFP-H-KDEL 
(improved construct) 
~ 40 kDa 
7 
SP extracted from leaf 
discs on 6th dpi 
pEAQ-HT (mock)  
 
 
Figure 4.3:  Expression profiles of recombinant cEDIII-sGFP fusion proteins 
in N. benthamiana leaves. Immunoblot detection was performed 
using Tetra-His monoclonal antibody, to verify and compare the 
expressions mediated by pEAQ-HT::cEDIII-sGFP-KDEL-H and 
pEAQ-HT::PR1a-cEDIII-sGFP-H-KDEL vectors. Both vectors 
were able to express the recombinant cEDIII-sGFP fusion 
proteins by which pEAQ-HT::PR1a-cEDIII-sGFP-H-KDEL 
presented a higher level. 
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Panel A: Physical appearance of N. benthamiana infiltrated leaf 
 
 
 
Panel B: Western blot probed with Tetra-His monoclonal antibody 
 
 
 
Lane Sample  Expression vector Estimated size 
L 
SeeBlue Plus2 Pre-
Stained Standard 
  
1-9 
SP extracted from leaf 
discs from 1st – 9th dpi 
pEAQ-HT::PR1a-cEDIII-
sGFP-H-KDEL 
(improved construct) 
~ 40 kDa 
 
 
Figure 4.4:  Kinetic expression profiles of recombinant cEDIII-sGFP fusion protein 
in N. benthamiana. Panel A: Daily observations of infiltrated leaf; Panel 
B: Immunoblotting of cEDIII-sGFP fusion protein extracted from 1st – 
9th dpi, as detected using Tetra-His monoclonal antibody. The harvest 
time for cEDIII-sGFP-H-KDEL protein was determined as 6th dpi. 
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4.3.3 Expression of recombinant cEDIII in fusion to cholera toxin B 
subunit (CTB) 
The expressions of recombinant CTB-cEDIII fusion proteins were successfully 
achieved, as mediated by the pEAQ-HT::CTB-cEDIII-KDEL-H and pEAQ-HT::PR1a-
CTB-cEDIII-H-KDEL expression vectors (Figure 4.5). Based on the immunoblot 
profiles, greater signal strength was detected from the SP extract of leaves infiltrated 
with the improved construct (expression vector: pEAQ-HT::PR1a-CTB-cEDIII-H-
KDEL) in comparison to the initial construct (expression vector: pEAQ-HT::CTB-
cEDIII-KDEL-H). Once again, the higher protein accumulation has probably 
corresponded to the improved trafficking mediated by PR1a signal. No band was 
detected from the SP of leaves infiltrated with pEAQ-HT vector, as expected. The 
pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL expression vector was selected for further 
study. 
Time-course analysis of the expression of CTB-cEDIII fusion protein is shown 
in Figure 4.6. Panel A reveals that leaf chlorosis of N. benthamiana plant infiltrated 
with pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL could be spotted on 7th dpi as necrosis 
became progressively visible on 9th dpi. Besides, the Western blot profiles in Panel B 
suggests that satisfactory expression of recombinant CTB-cEDIII was detected between 
4th dpi to 7th dpi. Therefore, harvesting on 6th dpi would be ideal given to the milder leaf 
yellowing. 
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Lane Sample  Expression vector Estimated size 
L 
SeeBlue Plus2 Pre-
Stained Standard 
  
1-3 
SP extracted from leaf 
discs on 6th dpi 
pEAQ-HT::CTB-cEDIII-
KDEL-H  
(initial construct) 
~ 28 kDa 
4-6 
SP extracted from leaf 
discs on 6th dpi 
pEAQ-HT::PR1a-CTB-
cEDIII-H-KDEL 
(improved construct) 
~ 28 kDa 
7 
SP extracted from leaf 
discs on 6th dpi 
pEAQ-HT (mock)  
 
 
Figure 4.5:  Expression profiles of recombinant CTB-cEDIII fusion proteins in N. 
benthamiana leaves. Immunoblot detection was performed using Tetra-
His monoclonal antibody, to verify and compare the expressions 
mediated by pEAQ-HT::CTB-cEDIII-KDEL-H and pEAQ-HT::PR1a-
CTB-cEDIII-H-KDEL vectors. Both vectors were able to express the 
recombinant CTB-cEDIII fusion proteins by which pEAQ-HT::PR1a-
CTB-cEDIII-H-KDEL presented a higher level. 
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Panel A: Physical appearance of N. benthamiana infiltrated leaf 
 
 
 
Panel B: Western blot probed with Tetra-His monoclonal antibody 
 
 
 
Lane Sample  Expression vector Estimated size 
L 
SeeBlue Plus2 Pre-
Stained Standard 
  
1-9 
SP extracted from leaf 
discs from 1st – 9th dpi 
pEAQ-HT::PR1a-CTB-
cEDIII-H-KDEL 
(improved construct) 
~ 28 kDa 
 
 
Figure 4.6:  Kinetic expression profiles of recombinant CTB-cEDIII fusion protein in 
N. benthamiana. Panel A: Daily observations of infiltrated leaf; Panel B: 
Immunoblotting of CTB-cEDIII fusion protein extracted from 1st – 9th 
dpi, as detected using Tetra-His monoclonal antibody. The harvest time 
for CTB-cEDIII-H-KDEL protein was determined as 6th dpi. 
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Successful expression of the xTH version of recombinant CTB-cEDIII 
(expression vector: pEAQ-HT::PR1a-CTB-cEDIII-KDEL (xTH)) was verified from the 
detection of expected bands (Figure 4.7). In this case, the Western blot membrane was 
probed with DENV 1-4 monoclonal antibody (Panel A) due to the absence of 6X His 
tag in the expression cassette (see Table 3.2). Tetra-His monoclonal antibody was used 
for the detection of same set of protein samples. As expected, no signals were obtained 
from the CTB-cEDIII-KDEL (xTH) samples (expression vector: pEAQ-HT::PR1a-
CTB-cEDIII-KDEL (xTH)) when the blot was probed with Tetra-His antibody (Panel 
B). Meanwhile, the positive control CTB-cEDIII-H-KDEL fusion protein (expression 
vector: pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL) was detected in Panels A and B as it 
contained both cEDIII protein and 6X His tag. No signals were obtained from the SP of 
pEAQ-HT-infiltrated leaves. 
The kinetic expression profiles of CTB-cEDIII-KDEL (xTH) fusion protein are 
presented in Figure 4.8. Panel A shows that the leaf infiltrated with pEAQ-HT::PR1a-
CTB-cEDIII-KDEL (xTH) exhibited chlorosis starting from 5th dpi. Remarkably, no 
sign of leaf necrosis was recorded throughout the time-course study. Satisfactory 
accumulation of CTB-cEDIII-KDEL (xTH) fusion protein was detected between 3rd dpi 
– 7th dpi. After consideration, 6th dpi was chosen as the harvesting day for the reasons 
of milder leaf distortion and to accommodate for late responders of protein expression. 
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Panel A: Western blot probed with 
DENV 1-4 monoclonal 
antibody 
Panel B: Western blot probed with 
Tetra-His monoclonal 
antibody 
  
    
 
Lane Sample  Expression vector Estimated size 
L 
SeeBlue Plus2 Pre-
Stained Standard 
  
1-3, 
6-8 
SP extracted from leaf 
discs on 6th dpi 
pEAQ-HT::PR1a-CTB-
cEDIII-KDEL (xTH)  
~ 26 kDa 
4, 9 
SP extracted from leaf 
discs on 6th dpi 
pEAQ-HT::PR1a-CTB-
cEDIII-H-KDEL  
~ 28 kDa 
5, 10 
SP extracted from leaf 
discs on 6th dpi 
pEAQ-HT (mock)  
 
s 
Figure 4.7:  Expression profiles of CTB-cEDIII-KDEL (xTH) fusion protein in N. 
benthamiana leaves. Immunoblot detection was performed using two 
different primary antibodies (Panel A: DENV 1-4 monoclonal antibody; 
Panel B: Tetra-His monoclonal antibody) by which the expression of 
recombinant CTB-cEDIII-KDEL (xTH) protein mediated by pEAQ-
HT::PR1a-CTB-cEDIII-KDEL (xTH) vector had been verified. 
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Panel A: Physical appearance of N. benthamiana infiltrated leaf 
 
 
 
Panel B: Western blot probed with DENV 1-4 monoclonal antibody 
 
 
 
Lane Sample  Expression vector Estimated size 
L 
SeeBlue Plus2 Pre-
Stained Standard 
  
1-9 
SP extracted from leaf 
discs from 1st – 9th dpi 
pEAQ-HT::PR1a-CTB-
cEDIII-KDEL (xTH) 
~ 26 kDa 
 
 
Figure 4.8:  Kinetic expression profiles of CTB-cEDIII-KDEL (xTH) fusion protein 
in N. benthamiana. Panel A: Daily observations of infiltrated leaf; Panel 
B: Immunoblotting of CTB-cEDIII-KDEL (xTH) protein extracted on 1st 
– 9th dpi, detected with anti-DENV 1-4 antibody. The harvest time for 
CTB-cEDIII-KDEL (xTH) protein was determined as 6th dpi.  
4-27 
 
4.3.4 Expression of monomeric core virus-like particles (VLPs) with 
cEDIII epitopes display 
Based on Figure 4.9, the monomeric core HBcAg that was modified for cEDIII 
epitopes display had been produced in N. benthamiana (expression vector: pEAQ-
HT::mHBcAg-cEDIII). Panel A presents successful detection of mHBcAg-cEDIII SP 
using HBcAg monoclonal antibody with the estimated size around ~ 34 kDa. No signal 
was seen from the sample extracted from pEAQ-HT-infiltrated leaf. But given to the 
faint bands, the extraction buffer was re-formulated in order to increase the protein yield. 
Panel B indicates that the buffer optimisation was useful as a denser band of mHBcAg-
cEDIII SP was obtained following the change of buffer to VLPs extraction buffer B. 
The time-course analysis on mHBcAg-cEDIII protein was performed as shown 
in Figure 4.10. Based on Panel A observations, signs of leaf yellowing could be 
observed from pEAQ-HT::mHBcAg-cEDIII-infiltrated leaf from 6th dpi onwards. 
Immunoblotting assay showed the accumulation of mHBcAg-cEDIII SP (Panel B) at 
high expression level from 3rd to 6th dpi. Hence, the optimal harvest time was set as 4th 
dpi. 
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Panel A: Verification of expression Panel B: Buffer optimisation 
 
 
 
Lane Sample  Expression vector Estimated size 
L 
SeeBlue Plus2 Pre-Stained 
Standard 
  
1-3 
SP extracted from leaf 
discs on 6th dpi 
pEAQ-HT::mHBcAg-
cEDIII 
~ 34 kDa 
4 
SP extracted from leaf 
discs on 6th dpi 
pEAQ-HT (mock)  
5-7 
INP extracted from leaf 
discs on 6th dpi 
pEAQ-HT::mHBcAg-
cEDIII 
~ 34 kDa 
8 
Before optimisation  
VLPs extraction buffer A 
used to extract SP from 
leaf discs on 6th dpi 
pEAQ-HT::mHBcAg-
cEDIII 
~ 34 kDa 
9 
After optimisation  
VLPs extraction buffer B 
used to extract SP from 
leaf discs on 6th dpi 
pEAQ-HT::mHBcAg-
cEDIII 
~ 34 kDa 
 
 
Figure 4.9:  Expression profiles of mHBcAg-cEDIII protein in N. benthamiana host. 
Immunoblot detection was performed using HBcAg monoclonal 
antibody, to detect the expression mediated by pEAQ-HT::mHBcAg-
cEDIII vector (Panel A: Verification of mHBcAg-cEDIII expression; 
Panel B: Buffer optimisation). The recombinant vector was successfully 
shown to express mHBcAg-cEDIII protein. 
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Panel A: Physical appearance of N. benthamiana infiltrated leaf 
 
 
 
Panel B: Western blot probed with HBcAg monoclonal antibody 
 
 
 
Lane Sample  Expression vector Estimated size 
L 
SeeBlue Plus2 Pre-
Stained Standard 
  
1-9 
SP extracted from leaf 
discs from 1st – 9th dpi 
pEAQ-HT::mHBcAg-
cEDIII 
~ 34 kDa 
 
 
Figure 4.10:  Kinetic expression profiles of mHBcAg-cEDIII protein in N. 
benthamiana. Panel A: Daily observations of infiltrated leaf; Panel B: 
Immunoblotting of mHBcAg-cEDIII proteins extracted on 1st – 9th dpi, 
as detected using HBcAg monoclonal antibody. The harvest time for 
mHBcAg-cEDIII protein was determined as 4th dpi. 
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The production of a variant monomeric core HBcAg with cEDIII display, known 
as mHBcAg-cEDIII (L) (expression vector: pEAQ-HT::mHBcAg-cEDIII (L)) had been 
successfully achieved in N. benthamiana as well (Figure 4.11). Buffer optimisation was 
conducted to improve the extraction of mHBcAg-cEDIII (L) protein, by which higher 
yield was obtained using the optimised VLPs extraction buffer B. As a reminder, the 
only difference between the expression cassettes of mHBcAg-cEDIII and mHBcAg-
cEDIII (L) is the presence of (GGS)n linkers that flanked the cEDIII insert (described 
in Section 3.2.3). 
The kinetic expression profiles of mHBcAg-cEDIII (L) protein are presented in 
Figure 4.12. In this case, the pEAQ-HT::mHBcAg-cEDIII (L)-infiltrated leaf appeared 
to suffer from leaf crinkle and yellowing since 5th dpi (Panel A). The immunoblot 
profiles in Panel B imply that high mHBcAg-cEDIII (L) expression was achieved 
between 2nd to 4th dpi. With that, 4th dpi was chosen as the optimal time for large-scale 
harvest. 
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Panel A: Verification of expression Panel B: Buffer optimisation 
 
 
 
Lane Sample  Expression vector Estimated size 
L 
SeeBlue Plus2 Pre-Stained 
Standard 
  
1-3 
SP extracted from leaf 
discs on 6th dpi 
pEAQ-HT::mHBcAg-
cEDIII (L) 
~ 36 kDa 
4 
SP extracted from leaf 
discs on 6th dpi 
pEAQ-HT (mock)  
5-7 
INP extracted from leaf 
discs on 6th dpi 
pEAQ-HT::mHBcAg-
cEDIII (L) 
~ 36 kDa 
8 
Before optimisation  
VLPs extraction buffer A 
used to extract SP from 
leaf discs on 6th dpi 
pEAQ-HT::mHBcAg-
cEDIII (L) 
~ 36 kDa 
9 
After optimisation  
VLPs extraction buffer B 
used to extract SP from 
leaf discs on 6th dpi 
pEAQ-HT::mHBcAg-
cEDIII (L) 
~ 36 kDa 
 
 
Figure 4.11:  Expression profiles of mHBcAg-cEDIII (L) protein in N. benthamiana 
host. Immunoblot detection was performed using HBcAg monoclonal 
antibody, to verify the expression mediated by pEAQ-HT::mHBcAg-
cEDIII (L) vector. It is found that the vector was able to express 
mHBcAg-cEDIII (L) protein. 
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Panel A: Physical appearance of N. benthamiana infiltrated leaf 
 
 
 
Panel B: Western blot probed with HBcAg monoclonal antibody 
 
 
 
Lane Sample  Expression vector Estimated size 
L 
SeeBlue Plus2 Pre-
Stained Standard 
  
1-9 
SP extracted from leaf 
discs from 1st – 9th dpi 
pEAQ-HT::mHBcAg-
cEDIII (L) 
~ 36 kDa 
 
 
Figure 4.12:  Kinetic expression profiles of mHBcAg-cEDIII (L) protein in N. 
benthamiana. Panel A: Daily observations of infiltrated leaf; Panel B: 
Immunoblotting of mHBcAg-cEDIII (L) proteins extracted on 1st – 9th 
dpi, as detected using HBcAg monoclonal antibody. The harvest time for 
mHBcAg-cEDIII (L) protein was determined as 4th dpi. 
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4.3.5 Expression of tandem core virus-like particles (VLPs) displaying 
cEDIII epitopes  
Successful expression of the tandem core construct with cEDIII displays had been 
achieved using N. benthamiana (Figure 4.13). The yield of tHBcAg-cEDIII SP 
(expression vector: pEAQ-HT::tHBcAg-cEDIII) was enormously low that it was barely 
detectable (Panel A). In this case, the insoluble protein (INP) of pEAQ-HT::tHBcAg-
cEDIII-infiltrated leaf was also recovered for validation purpose. As anticipated, bands 
that corresponded to tHBcAg-cEDIII proteins were detected. Subsequently, buffer 
optimisation was done to increase the yield of tHBcAg-cEDIII protein (Panel B). With 
the use of new buffer labelled as VLPs extraction buffer A, a higher amount of SP for 
tHBcAg-cEDIII sample could be harvested. 
The kinetic expression profiles of tHBcAg-cEDIII protein (expression vector: 
pEAQ-HT::tHBcAg-cEDIII) can be found at Figure 4.14. Panel A shows that symptom 
of leaf chlorosis was observed from 7th dpi onwards, which led to visible necrosis on 9th 
dpi. Meanwhile, the immunoblot profiles in Panel B suggest that increasing 
accumulation of tHBcAg-cEDIII SP could be seen from 6th dpi onwards. As modest 
necrosis was observed on 9th dpi, it was more sensible to set 8th dpi as the optimal harvest 
time. 
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Panel A: Verification of expression Panel B: Buffer optimisation 
 
 
 
Lane Sample  Expression vector Estimated size 
L 
SeeBlue Plus2 Pre-Stained 
Standard 
  
1, 3, 5 
SP extracted from leaf 
discs on 6th dpi 
pEAQ-HT::tHBcAg-
cEDIII 
~ 55 kDa 
2, 4, 6 
INP extracted from leaf 
discs on 6th dpi 
pEAQ-HT::tHBcAg-
cEDIII 
~ 55 kDa 
7 
SP extracted from leaf 
discs on 6th dpi 
pEAQ-HT (mock)  
8 
Before optimisation  
Sodium phosphate 
extraction buffer used to 
extract SP from leaf discs 
on 6th dpi 
pEAQ-HT::tHBcAg-
cEDIII 
~ 55 kDa 
9 
After optimisation  
VLPs extraction buffer A 
used to extract SP from 
leaf discs on 6th dpi 
pEAQ-HT::tHBcAg-
cEDIII 
~ 55 kDa 
 
 
Figure 4.13:  Expression profiles of tHBcAg-cEDIII protein in N. benthamiana host. 
Immunoblot detection was performed using HBcAg monoclonal 
antibody, to verify the expression mediated by pEAQ-HT::tHBcAg-
cEDIII vector. The tHBcAg-cEDIII protein was successfully expressed, 
but was mostly in insoluble form. 
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Panel A: Physical appearance of N. benthamiana infiltrated leaf 
 
 
 
Panel B: Western blot probed with HBcAg monoclonal antibody 
 
 
 
Lane Sample  Expression vector Estimated size 
L 
SeeBlue Plus2 Pre-
Stained Standard 
  
1-9 
SP extracted from leaf 
discs from 1st – 9th dpi 
pEAQ-HT::tHBcAg-
cEDIII 
~ 55 kDa 
 
 
Figure 4.14:  Kinetic expression profiles of tHBcAg-cEDIII protein in N. benthamiana. 
Panel A: Daily observations of infiltrated leaf; Panel B: Immunoblotting 
of tHBcAg-cEDIII proteins extracted on 1st – 9th dpi, as detected using 
HBcAg monoclonal antibody. The harvest time for tHBcAg-cEDIII 
protein was determined as 8th dpi.  
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4.4 Discussion 
This chapter focuses on the delivery of cEDIII recombinant vectors into N. 
benthamiana via agroinfiltration. Subsequent expression profiling has allowed 
assessment of the stability of expressed proteins in order to select the most ideal 
candidates to proceed with downstream purification study. In this study, N. 
benthamiana is host species of choice given to its short life cycle and succulent 
vegetative growth. N. benthamiana plants are ready for infiltration in 5 – 6 weeks, and 
the succulent leaves make them easier to be infiltrated. Besides, its high biomass 
production is favoured for the potential to harvest high product yield. N. benthamiana 
plant is highly susceptible to Agrobacterium infection, which is useful to mediate the 
initial entry and delivery of expression vectors in achieving successful transformation 
(Klimyuk et al., 2014). As N. benthamiana is a non-food and non-feed crop, thereby 
eliminating the risk of contaminating the food chain. For these reasons, N. benthamiana 
is also preferably used by various biopharmaceutical companies such as Icon Genetics, 
Medicago Inc. and Kentucky Processing. Only N. benthamiana plants aged between 5 
– 6 weeks were used for agroinfiltration because flowering was observed 6 weeks after 
germination. According to Leuzinger et al. (2013), flower development is not desirable 
as the diversion of nutrients away from leaves could affect the accumulation of 
heterologous proteins. 
Syringe infiltration has been fully adopted as the transformation approach in this 
study. The syringe technique is exceptionally straightforward where it does not need 
dedicated equipment or special set-up. It is cost-effective and productive in the sense 
that different transgenes or expression strategies can be easily tested in parallel. For 
vaccine development, it is the method of choice for rapid screening of candidates in 
response to emerging pandemics such as dengue in this context. Arguably, manual 
inoculation may not be technically consistent, but variation can be compensated by 
harvesting leaf replica from same and different plants. Chen et al. (2013b) also agreed 
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that syringe infiltration is ideal for laboratory-scale expression, purification and pre-
clinical testing of plant-derived protein. The alternative vacuum infiltration however, is 
more suitable for industrial application by which the efficacy of a specific vaccine has 
been proven and is set for large-scale production. Moreover, application of vacuum 
demands for more stringent optimisation of parameters such as the pressure setting and 
treatment duration (Loh and Baranzan, 2014). This is crucial so that the mechanical 
injures experienced by the plant can be reduced to minimal while still able to acquire 
satisfactory protein expression. 
Apart from the design of expression cassettes (Chapter 3), the strain of 
Agrobacterium and the bacterial concentration used for infiltration can affect the protein 
expression as well. Various laboratory strains of Agrobacterium have been tested for 
transient expression including LBA4404, GV3101, EHA105 and C58C1. In this study, 
LBA4404 was chosen as it is the preferred strain used for transfer of pEAQ vector 
(Sainsbury et al., 2009), although strains like AGL1 and GV3101 have also been used 
with success (Dennis et al., 2018; Mardanova et al., 2015). In regard to the agrobacterial 
concentration, a constant OD600 of 0.4 was used throughout this study, which was in line 
with the recommended range of OD600 at 0.3 – 0.4 (Li, 2011; Shamloul et al., 2014; 
Wroblewski et al., 2005). This is because high bacterial density tends to trigger 
hypersensitive response that can lead to tissue necrosis, whereas low amount of 
Agrobacterium may result in insufficient gene delivery (Leuzinger et al., 2013). As 
presented in this study, reliable and high level of transient gene expression was achieved 
at the chosen OD400 of 0.4, without severely affected by hypersensitivity responses. 
In this study, all the cEDIII recombinant proteins were targeted to ER as the final 
cellular destination. To achieve this, two variants of expression cassettes were designed 
for recombinant cEDIII-sGFP, namely pEAQ-HT::cEDIII-sGFP-KDEL-H (initial 
construct) and pEAQ-HT::PR1a-cEDIII-H-KDEL (improved construct). Likewise, two 
variants were also designed for recombinant CTB-cEDIII, namely pEAQ-HT::CTB-
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cEDIII-KDEL-H (initial construct) and pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL 
(improved construct). A functional KDEL motif plays a key role in retaining the 
recombinant proteins in ER. However, the lack of PR1a signal from initial construct of 
cEDIII-sGFP seemed to have driven protein localisation to cytoplasm (Figure 4.2), 
whereas the improved construct with PR1a signal had directed the cEDIII-sGFP 
proteins to the ER compartment. Coherent to the expression profiles of cEDIII-sGFP 
(Figure 4.3) and CTB-cEDIII (Figure 4.5) proteins, the absence of PR1a in their initial 
constructs were indeed marked with poorer expressions. These show that the 
combinatory use of PR1a and KDEL signals is more effective in regulating protein 
localisation to ER, which mediates protein folding and accumulation in a more stable 
environment (Xu et al., 2002). Besides, previous studies claimed that KDEL signal must 
be positioned at the extreme C-terminus to render proper retention (Miesenbock and 
Rothman, 1995; Munro and Pelham, 1987. Consistent to that, efficient ER retention was 
achieved after shuffling the KDEL position, as shown in pEAQ-HT::PR1a-cEDIII-
sGFP-H-KDEL and pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL (Table 3.2). Overall, 
these efforts have fulfilled the objectives to increase the yield of cEDIII recombinant 
protein via gene cassettes improvement. Worthwhile to mention, the improved 
constructs of cEDIII-sGFP (expression vector: pEAQ-HT::PR1a-cEDIII-sGFP-H-
KDEL) and CTB-cEDIII (expression vector: pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL) 
had a Kozak sequence at their N-termini. The beneficial use of Kozak sequence is long 
known since Jones et al. (1988) reported that it could boost the expression of bacterial 
chitinase gene (chiA) by 8 folds in transgenic tobacco. To date, Kozak sequence is 
commonly used in several pEAQ-based expression vectors as demonstrated by 
Kanagarajan et al. (2012) and Peyret et al. (2015). Though the insertion of Kozak 
sequence may have contributed to the enhanced expression, but it should be noted that 
Kozak sequence does not regulate protein trafficking. 
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Reinstating the subcellular localisation effects, it was discovered that the N. 
benthamiana leaf infiltrated with initial constructs of recombinant cEDIII-sGFP 
(expression vector: pEAQ-HT::cEDIII-sGFP-KDEL-H) and CTB-cEDIII (expression 
vector: pEAQ-HT::CTB-cEDIII-KDEL-H) had suffered from much earlier necrosis on 
7th dpi (Appendix A4.2). It is believed that the cell death is correlated to the transient 
over-expression of recombinant proteins. This happens when the capacity of protein 
processing system is no longer able to cope with the translation event, thereby 
generating an abundance of unfolded or misfolded proteins (Fanata et al., 2013). To this 
end, the accumulation of unfolded proteins can impose ER stress which activates the 
unfolded protein response (UPR) to initiate protein repair. ER quality control (ERQC) 
system will monitor these processes and identifies misfolded conformations for ER 
associated degradation (ERAD) via ubiquitination (Schröder and Kaufman, 2005). 
Principally, ER houses molecular chaperones and enzymes that assist in protein folding 
and post-translational modifications. Subcellular localisation to ER can help to prolong 
the time in ER lumen to increase chance of proper protein folding and assembly. Yet, 
this was not mitigated for cytoplasm-localised constructs, namely pEAQ-HT::cEDIII-
sGFP-KDEL-H and pEAQ-HT::CTB-cEDIII-KDEL-H. Similar findings were reported 
by Hamorsky et al. (2015), suggesting that the massive tissue damage suffered by non-
ER-retained construct is associated with the overloaded ERQC and ERAD systems. The 
prolonged ER stress can cause severe damage to plant organelles that eventually leads 
to cell death. 
Upon translocation, a signal peptide is generally removed from the mature protein 
in the ER lumen, and this should apply to PR1a as well. The Signal-BLAST software 
was used to analyse the PR1a amino acid sequence and a cleavage site was predicted 
after the last residue of PR1a signal peptide (Appendix A4.3), which hereafter labelled 
as position -1. An early study done by von Heijne (1983) proposed that the small, neutral 
residues at positions -1 and -3 would fit into the pocket of signal peptidase before 
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cleavage takes place between positions -1 and +1 of the mature protein. Such patterns 
of amino acids conform to the PR1a sequence used in this study, where small alanine 
and cysteine residues are found at positions -1 and -3, respectively. In accordance with 
von Heijne (1983), it is speculated that the PR1a signal peptide would be post-
translationally removed, and hence PR1a is not included in the estimation of protein 
molecular weight (Table 4.2)  
While satisfactory amount of cEDIII-sGFP and CTB-cEDIII recombinant 
proteins could be harvested, problems were encountered with low recovery of chimeric 
HBcAg VLPs displaying cEDIII. The expression of HBcAg proteins in cytosol could in 
part explain for the low abundance. PR1a and KDEL signals were not incorporated into 
the expression cassettes of monomeric core and tandem core VLPs (Table 3.2) due to 
the concern that protein trafficking might disrupt VLPs assembly. Since the objective 
here was to develop chimeric VLPs that can display cEDIII epitopes, the localisation 
strategy was omitted with the primary hope that correctly assembled VLPs could be 
obtained. Apart from the low expression, most of these HBcAg-based proteins were 
detected in the insoluble pellet, possibly due to the macromolecular structures of VLPs 
which are hard to be solubilised. As protein solubility is dependent on the interactions 
of its surface residues with surrounding solution, new extraction buffers were 
formulated by considering the following aspects: (i) adding Triton X-100 detergent to 
assist the dissolution and release of VLPs from insoluble cell components, as stated by 
Gaik et al. (2008); (ii) use a low-salt condition (100 mM sodium chloride) to provide 
ionic strength that reduces formation of aggregates, of which was shown to be effective 
by Zahin et al. (2016); and (ii) adjusting the pH of extraction buffer away from the 
predicted isoelectric point (pI) to increase protein solubility (Abdalla et al., 2016). The 
pI of mHBcAg-cEDIII, mHBcAg-cEDIII (L) and tHBcAg-cEDIII proteins was 
predicted using the ExPASy ProtParam tool. Consequently, buffer optimisation proved 
to be useful as greater amount of SP extracts of mHBcAg-cEDIII (Figure 4.9), 
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mHBcAg-cEDIII (L) (Figure 4.11) and tHBcAg-cEDIII (Figure 4.13) proteins could 
be recovered. Though VLPs extraction buffer A can mediate satisfactory recovery of 
soluble mHBcAg-cEDIII and mHBcAg-cEDIII (L) proteins; yet, a further pH 
adjustment which gave rise to VLPs extraction buffer B produced more soluble 
monomeric core proteins. Given that each protein has its own unique properties, it could 
be better to determine the extraction conditions on case-to-case basis. This was 
rationalised from the observation that even the slightest change of the HBcAg sequence 
in monomeric core and tandem core can affect its overall solubility. Nonetheless, 
protease inhibitor cocktail was added in all the protein extraction buffers (Appendix 
A4.1) to reduce proteolytic degradation during extraction and purification procedures. 
In general, maximum protein expression is usually observed between 4th – 6th dpi 
(Joensuu et al., 2010; Kanagarajan et al., 2012; Nausch et al., 2012). Thus, the 
expression kinetics within this timeline were studied along with an allowance of ±3 
days to buffer for ‘exceptional’ case. The profiles were used to gauge the ideal harvest 
time which is assessed based on two aspects: (i) the peak accumulation of target protein; 
and (ii) the post-infiltration morphological distortions. Necrotic tissues should be 
avoided as they are flaccid and usually contain higher amount of phenolic and alkaloids 
that could be introduced into downstream purification. In fact, the antimicrobial exudate 
produced by necrotic tissues can inhibit efficient colonisation and gene delivery by the 
Agrobacterium (Pitzschke, 2013). Hence, it is projected that the protein yield in these 
leaf tissues could be drastically low. To minimise bias effects, the expression kinetics 
of each construct were analysed from at least 5 replicates of infiltrated N. benthamiana 
that were grown from the same batch. In summary, the optimal harvest time for each 
construct was determined as follows: (i) 6th dpi for pEAQ-HT::PR1a-cEDIII-sGFP-H-
KDEL, pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL and pEAQ-HT::PR1a-CTB-cEDIII-
KDEL (xTH); (ii) 4th dpi for pEAQ-HT::mHBcAg-cEDIII and pEAQ-HT::mHBcAg-
cEDIII (L); and lastly (iii) 8th dpi for pEAQ-HT::tHBcAg-cEDIII. Except for pEAQ-
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HT::tHBcAg-cEDIII, the expression of other constructs did fall within the 
recommended harvesting time of 4th – 6th dpi. The kinetic profiling was only conducted 
once since it was used for qualitative analyses. Nevertheless, yield quantification was 
performed after obtaining the purified products (Chapter 5). 
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4.5 Conclusion 
This chapter concludes with the successful in planta expression of cEDIII 
recombinant proteins and chimeric HBcAg VLPs displaying cEDIII, following gene 
delivery via syringe infiltration.  
The expression mediated by corresponding cEDIII-sGFP and CTB-cEDIII 
expression vectors had been evaluated in this study, in which the expression vectors 
named as pEAQ-HT::PR1a-cEDIII-sGFP-H-KDEL, pEAQ-HT::PR1a-CTB-cEDIII-H-
KDEL and pEAQ-HT::PR1a-CTB-cEDIII-KDEL (xTH) had been selected to proceed 
with large-scale purification (Chapter 5). On top of that, the improved ER localisation 
mediated by both PR1a and KDEL signals has been clearly addressed in this chapter.  
Meanwhile, successful expression of the monomeric core constructs (expressed 
by: pEAQ-HT::mHBcAg-cEDIII and pEAQ-HT::mHBcAg-cEDIII (L)) and tandem 
core construct (expressed by: pEAQ-HT::tHBcAg-cEDIII) was presented, even though 
most of these proteins were harvested in insoluble form. Hence, new extraction buffers 
were formulated to facilitate greater recovery of the SP. The proteins expressed by these 
constructs were then purified to assess their abilities to assemble into VLPs, by which 
are described in Chapter 5. 
Lastly, kinetic analyses had provided information on the accumulation of 
heterologous proteins and the post-infiltration symptoms. These findings were useful in 
order to determine the optimal harvest time to proceed with subsequent purification and 
quantification studies (Chapter 5).  
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5.1 Introduction 
Following expression studies in plant, protein purification is used to isolate pure 
product from a complex mixture of crude proteins in host cell. It engages a series of 
processes starting from cell lysis, clarification of soluble components to fractionation of 
desired proteins from host impurities. Besides, purification also facilitates the 
enrichment of a protein sample so that its structure and function can be characterised. 
The most challenging part however, is to recover heterologous protein with preserved 
functionality for downstream application. Hitherto, various methods have been 
developed for the purification of biological samples and a couple of them are discussed 
in relevant to the techniques applied in this study. 
Protein extraction from N. benthamiana leaves begins with physical cell lysis, as 
the rigid cellulose walls need to be sheared via homogeniser or manual grinding to 
release the cell contents. Unavoidably, some contaminants are also released during cell 
disruption including proteases, phenolics, photosynthetic pigments and Agrobacterium. 
Therefore, formulation of extraction buffer with appropriate pH, ionic strength and 
additives is crucial to maximise recovery of heterologous proteins (Laing and Christeller, 
2004), which has been discussed in Chapter 4. Other particulate materials or unbroken 
cells could be removed via clarification at high-speed centrifugation or syringe filters 
before proceeding to purification procedures. 
Principally, chromatography refers to an analytical technique where molecules in 
the applied mixture is separated from each other at the stationary phase as they move in 
a definite direction with the aid of mobile phase. Protein separation mainly relies on 
several principles such as affinity, charge, hydrophobicity and size difference. Among 
these, affinity chromatography is often chosen based on its high-throughput and specific 
binding properties. Technically, high affinity ligands are attached to the resin surface to 
capture target proteins prior eluted by changes in molecular interactions. Commonly 
used affinity tags to date include 6X histidine (His) tag, FLAG tag (with the sequence 
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motif, DYKDDDDK), glutathione S-transferase (GST) and maltose-binding protein 
(MBP) (Zhao et al., 2013). The immobilised metal affinity chromatography (IMAC) 
introduced by Porath et al. (1975), is one of the most popular affinity-based methods 
used to date. Hence, it was adopted as the main purification strategy to recover 
recombinant cEDIII fusion proteins in this study. 
Other chromatographic methods may be applied as further polishing step when 
the characteristics of a heterologous protein is more well-studied. For instance, size 
exclusion chromatography (SEC) is often used to fractionate protein according to 
molecular weight difference. As molecules pass through the sieving medium, those 
smaller than the pores inside the gels will penetrate through and take a longer path to be 
eluted as compared to larger molecules (Duong-Ly and Gabelli, 2014a).  In ion-
exchange chromatography (IEX), proteins are separated based on the electrostatic 
interactions between charged protein groups and the oppositely charged stationary 
phase matrix (Duong-Ly and Gabelli, 2014b). In contrast, purification via hydrophobic 
interaction chromatography (HIC) relies on the hydrophobic properties of protein 
molecules and adsorbents, as well as the salt concentration in mobile phase, which is 
particularly useful to separate aggregated species from monomeric form (McCue, 2014). 
Meanwhile, density gradient ultracentrifugation is a simpler procedure used to 
separate the virus-like particles (VLPs) in a suspension according to density. High 
centrifugal force is applied to pull the particles and plant constituents down through the 
density medium, which will eventually sediment at different rates. This type of 
ultracentrifugation is sub-divided into two types known as rate zonal and isopycnic. The 
main difference comes from the type of gradient medium, where rate zonal uses a lower 
density solution such as sucrose to separate particles based on their size and shape; while 
isopycnic relies on high-density solution like caesium chloride and nycodenz to separate 
particles until they reaches the equilibrium density (Dijkstra and de Jager, 1998). In rate 
zonal separation, sample is overlaid on a pre-formed, continuous gradient of sucrose 
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and centrifuged for 2 – 3 hours to avoid pelleting. For isopycnic separation, particles 
are also overlaid on pre-formed gradient, but they will never sediment regardless of 
centrifugation time as the gradient solution is much denser. The so-called sucrose 
cushion, is used as an initial step to concentrate VLPs from clarified lysate (Peyret, 
2015). This method is slightly different as it only uses a small volume of discontinuous 
density gradient for sample enrichment.  
In this chapter, large-scale harvest was carried out to recover high amount of 
recombinant cEDIII fused to green fluorescent protein (sGFP) and recombinant cEDIII 
fused to cholera toxin B subunit (CTB). On top of that, the chimeric hepatitis B core 
antigen (HBcAg) VLPs were also recovered, which comprised of monomeric core 
HBcAg (mHBcAg) VLPs-displaying cEDIII and tandem core HBcAg (tHBcAg) VLPs-
expressing cEDIII. These purified samples would then be used for immunogenicity 
testing in Chapter 6.  
With that, the specific objectives for this chapter are:  
(i) To purify recombinant cEDIII fusion proteins, namely cEDIII-sGFP-H-KDEL, 
CTB-cEDIII-H-KDEL and CTB-cEDIII-KDEL (xTH) with IMAC under native 
conditions; 
(ii) To perform subsequent removal of affinity tag via TEV protease cleavage; 
(iii) To prepare the recombinant cEDIII fusion protein that would be used for 
immunogenicity test; 
(iv) To study the pentameric folding of CTB-cEDIII-KDEL (xTH) protein; 
(v) To purify the mHBcAg-cEDIII, mHBcAg-cEDIII (L) and tHBcAg-cEDIII 
proteins via density gradient ultracentrifugation; 
(vi) To assess the ability of purified mHBcAg-cEDIII, mHBcAg-cEDIII (L) and 
tHBcAg-cEDIII proteins to assemble into VLPs; and 
(vii) To prepare the chimeric HBcAg VLPs samples that would be used for 
immunogenicity test.  
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5.2 Materials and methods 
5.2.1 Overview of the protein purification procedures  
Two distinct protein purification strategies were used to isolate the recombinant 
cEDIII fusion proteins and chimeric HBcAg VLPs-displaying cEDIII. 
An overview of the procedures involved in the purification of recombinant cEDIII 
fusion proteins is shown in Figure 5.1. Recombinant cEDIII fusion proteins that were 
purified in this study comprised of cEDIII-sGFP-H-KDEL fusion protein (expressed by 
pEAQ-HT::PR1a-cEDIII-sGFP-H-KDEL), CTB-cEDIII-H-KDEL fusion protein 
(expressed by pEAQ::HT::PR1a-CTB-cEDIII-H-KDEL) and CTB-cEDIII-KDEL (xTH) 
fusion protein (expressed by pEAQ-HT::PR1a-CTB-cEDIII-KDEL (xTH)). Procedure 
that was carried out for each cEDIII fusion protein is listed according to the numbered 
steps in Figure 5.1. Following sample lysis and clarification, first round IMAC was 
used to isolate His-tagged recombinant proteins in the eluted fraction, by which it was 
referred as IMAC purification_1. Next, TEV protease was used to digest the cEDIII-
sGFP-H-KDEL and CTB-cEDIII-H-KDEL fusion proteins at the designed cleavage site 
(refer to Table 3.2). A second round IMAC, referred as IMAC purification_2, was then 
conducted to isolate TEV protease-digested protein in the flow-through fraction. In fact, 
the AcTEVTM protease used in this study contained 6X His tag that would bind to Ni2+-
charged resin and hence, could be effectively separated from the target protein at the 
flow-through step. Lastly, the purified proteins were dialysed against phosphate-
buffered saline (PBS) and concentrated. 
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No. Expression vector 
Recombinant 
cEDIII fusion 
protein 
Purification 
procedure 
1 
pEAQ-HT::PR1a-cEDIII-
sGFP-H-KDEL 
cEDIII-sGFP-H-
KDEL  
2 
pEAQ-HT::PR1a-CTB-
cEDIII-H-KDEL 
CTB-cEDIII-H-
KDEL  
3 
pEAQ-HT::PR1a-cEDIII-
sGFP-KDEL (xTH) 
CTB-cEDIII-
KDEL (xTH)  
 
 
Figure 5.1:  An overview of the generic recombinant fusion protein purification 
procedures which were applied in this study. Note that IMAC 
purification_1 and IMAC purification_2 are used to differentiate first and 
second round IMAC, correspondingly. 
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Meanwhile, an overview of the steps involved in the purification of chimeric 
HBcAg VLPs-displaying cEDIII is illustrated in Figure 5.2. Chimeric VLPs that were 
purified in this chapter including mHBcAg-cEDIII (expressed by pEAQ-HT::mHBcAg-
cEDIII), mHBcAg-cEDIII (L) (expressed by pEAQ-HT::mHBcAg-cEDIII (L)) and 
tHBcAg-cEDIII (expressed by pEAQ-HT::tHBcAg-cEDIII). These chimeric VLPs 
were purified in the order of numbered steps in Figure 5.2. Following sample lysis and 
clarification, the plant lysate was subjected to sucrose cushion to isolate the chimeric 
VLPs. Next, sucrose fractions containing the desired VLPs were concentrated using 
vacuum concentrator and further purified via sucrose/nycodenz gradient. Lastly, the 
purified VLPs samples were dialysed against PBS and concentrated. 
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No. Expression vector 
Chimeric HBcAg 
VLPs 
Purification 
procedure 
1 
pEAQ-HT::mHBcAg-
cEDIII 
mHBcAg-cEDIII 
 
2 
pEAQ-HT::mHBcAg-
cEDIII (L) 
mHBcAg-cEDIII (L) 
 
3 
pEAQ-HT::tHBcAg-
cEDIII 
tHBcAg-cEDIII 
 
 
 
Figure 5.2:  An overview of the purification procedures used to isolate the chimeric 
HBcAg VLPs-displaying cEDIII. Note that sucrose cushion is used to 
obtain enriched sample before further purification by sucrose/nycodenz 
gradient. 
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5.2.2 Specialised equipment 
Clarification spin of homogenised leaf extract was performed using either 5810R 
Refrigerated Centrifuge (Eppendorf, Germany) or Sorvall Evolution RC Superspeed 
Centrifuge (Thermo Scientific, USA). Thermomixer comfort (Eppendorf, Germany) 
was used to incubate the TEV protease reaction at 30℃. BINDER Microbiological 
Incubator (Binder, Germany) was used to incubate the GM1-ELISA plate at 37℃.  SEC 
analysis was carried out using ÄKTA Avant (GE Healthcare, USA). High-speed 
ultracentrifugation was performed using either Optima XE Ultracentrifuge (Beckman 
Coulter, USA) or WX Ultra Ultracentrifuge (Thermo Scientific, USA). Transmission 
electron microscopy (TEM) was carried out using FEI Tecnai 20 transmission electron 
microscope (FEI, USA) and HT7700 Electron Microscope (Hitachi, Japan). Vacuum 
concentration was conducted using SpeedVac concentrator (Thermo Scientific, USA) 
and Concentrator Plus (Eppendorf, Germany). 
 
5.2.3 Large-scale sample harvest 
Large-scale extraction was conducted based on the optimal harvest time that had 
been determined for each construct (Chapter 4). Fresh N. benthamiana leaves were 
harvested in bulk, having the large veins and non-infiltrated areas removed. After 
weighing, the leaf tissues (~ 40 – 80 g) were homogenised with 3X (w/v) volume of 
extraction buffer (Table 4.2) using a blender. Crude lysate was filtered through one 
layer of Miracloth (Calbiochem, USA) before centrifugation at 15,000-20,000 x g for 
20 – 30 minutes at 4℃. To ensure complete removal of cell debris, the clarified extract 
was filtered with 0.45 μm and 0.2 μm syringe filters (Sartorius, Germany) prior to 
purification process. 
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5.2.4 Purification of recombinant cEDIII fusion proteins 
5.2.4.1 Immobilised metal affinity chromatography (IMAC) 
under native condition 
Agarose resin derivatized with nickel ion (Ni2+)-nitrilotriacetic acid, in short 
known as Ni-NTA Agarose (Qiagen, Germany) was used to purify His-tagged cEDIII 
fusion proteins: cEDIII-sGFP-H-KDEL (expressed by pEAQ-HT::PR1a-cEDIII-sGFP-
H-KDEL), CTB-cEDIII-H-KDEL (expressed by pEAQ-HT::PR1a-CTB-cEDIII-H-
KDEL) and CTB-cEDIII-KDEL (xTH) (expressed by pEAQ-HT::PR1a-CTB-cEDIII-
KDEL (xTH)). Firstly, 5 ml of Ni-NTA slurry was transferred to a 50-ml tube and 
briefly centrifuged at 1,000 x g, 4℃ for 5 minutes. The supernatant was removed and 
the Ni-NTA slurry was equilibrated with tris extraction buffer (Appendix A5.1) before 
another round of centrifugation. The equilibration step was repeated for 3 times before 
adding 20 ml of clarified plant lysate. For IMAC purification_2 (see Figure 5.1), the 
input sample was changed to TEV-digested protein (Section 5.2.4.2). 
After that, the mixture was gently mixed at 4℃ for 1 hour before loaded into 
gravity flow column (Thermo Scientific, USA). Upon loading, the flow-through fraction 
was immediately collected. The column was washed with 5-column volumes of tris 
extraction buffer, followed by three washes with 5-column volumes of IMAC washing 
buffers containing 5 – 20 mM of imidazole. These wash fractions were kept for analyses. 
Lastly, the His-tagged protein was eluted using 2-column volumes of IMAC elution 
buffer and subjected to SDS-PAGE (Section 4.2.8) and Western blotting analyses 
(Section 4.2.10) as previously described. Details of the buffer used can be found at 
Appendix A5.1. 
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5.2.4.2 Tobacco etch virus (TEV) protease digestion 
AcTEVTM (Thermo Fischer, USA) protease was used for the removal of 6X His 
tag from IMAC-purified cEDIII-sGFP-H-KDEL and CTB-cEDIII-H-KDEL fusion 
proteins. The cleavage reaction was modified from manufacturer’s protocol and set up 
as follows: 1X TEV Buffer (50 mM Tris-hydrochloride, pH 8.0; 0.5 mM 
ethylenediaminetetraacetic acid), 1 mM dithiothreitol, 100 units of TEV protease, 100 
mg of fusion protein and topped up to 500 µl of distilled water. The reaction tube was 
then incubated at 30℃ for 24 hours.  
 
5.2.5 Characterisation of CTB-cEDIII-KDEL (xTH) protein 
5.2.5.1 GM1 ganglioside enzyme-linked immunosorbent assay 
(GM1-ELISA) 
GM1 refers to monosialotetrahexosylganglioside, which are gangliosides present 
on antigen presenting cells (see Section 2.4.1.1). As the pentamers of CTB have high 
binding affinities for GM1 gangliosides, GM1-ELISA was used to characterise the 
pentameric folding of CTB-cEDIII-KDEL (xTH) fusion protein (Centers for Disease 
Control and Prevention (CDC), 2013). In brief, a 96-well microtitre plate (SPL, Korea) 
was coated with 2 μg/ml of GM1 (Sigma, USA) in sodium bicarbonate buffer 
(Appendix A5.1) overnight at 4℃. Another plate was coated with 2 μg/ml of bovine 
serum albumin (BSA) (Sigma, USA) to serve as assay control. 
On the next day, the wells were washed with PBS containing 0.05% (v/v) Tween-
20 (PBST) for three times before blocking with 1% (w/v) BSA in PBST for 1 hour at 
room temperature (RT). Then, CTB-cEDIII-KDEL (xTH) protein was added in 
duplicates, along with purified cEDIII and mHBcAg-cEDIII proteins to serve as sample 
controls All the proteins were serially-diluted in two-fold starting from the 
concentration of 100 ng/ml. After 1 hour-incubation at 37℃, the wells were washed 
with PBST for five times. Next, cholera toxin (CT) polyclonal antibody produced in 
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rabbit (Sigma, USA) was added at 1:8,000 dilution and incubated at 37℃ for 1 hour. 
Washing steps were repeated before adding goat anti-rabbit immunoglobulin G (IgG), 
horseradish peroxidase (HRP)-conjugate (Agrisera, Sweden) at 1:20,000 dilution for 
another hour of incubation at 37℃. After final washes, 3, 3', 5, 5'-tetramethylbenzidine 
(TMB) substrate (BD, USA) was added. The absorbance at 450 nm wavelength (A450) 
was measured using Epoch microplate reader (Biotek, USA), with the correction 
wavelength at 570 nm. The results were presented as means ± standard deviation (SD) 
of the A450 readings obtained from three independent experiments.  
 
5.2.5.2 Size exclusion chromatography (SEC) 
For further characterisation of the pentameric folding of CTB-cEDIII-KDEL 
(xTH) fusion protein, the IMAC-purified sample was sent to Malaysia Genome Institute 
(Bangi, Malaysia) for SEC analysis. Approximately 500 µl of the protein sample was 
loaded onto Superdex 200 10/300 GL column (GE Healthcare, USA) and separated by 
ÄKTA Avant at flow rate of 0.5 ml min-1. Besides, the following protein standards (GE 
Healthcare, USA) with different molecular mass (Mr) were analysed under the same 
conditions: ribonuclease A (13.7 kDa), ovalbumin (43 kDa) and conalbumin (75 kDa). 
The chromatogram of protein standards was then used to estimate the molecular weight 
of fractionated CTB-cEDIII-KDEL (xTH) sample. Eluted fractions were analysed by 
Western blotting as described in Section 4.2.10.   
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5.2.6 Purification of chimeric virus-like particles (VLPs)-displaying 
cEDIII 
5.2.6.1 Sucrose cushion 
Sucrose cushion was used to remove cell debris and organelles from the clarified 
lysates of mHBcAg-cEDIII (expressed by pEAQ-HT::mHBcAg-cEDIII), mHBcAg-
cEDIII (L) (expressed by pEAQ-HT::mHBcAg-cEDIII (L)) and tHBcAg-cEDIII 
(expressed by pEAQ-HT::tHBcAg-cEDIII). Firstly, the lysate was overlaid onto 25% 
and 70% (w/v) sucrose solutions in an Ultra-Clear® tube (Beckman Coulter, USA). The 
sample was centrifuged at 30,000 rpm (167,000 x g), 4℃ for 2.5 hours using either SW 
32 Ti rotor (Beckman Coulter, USA) or SureSpin 630/36 (Thermo Scientific, USA) 
rotor. Upon completion, the sample was fractionated by piercing through the bottom of 
the Ultra-Clear® tube using 25 G needle (Terumo, USA). Subsequently, collected 
fractions were analysed via SDS-PAGE (Section 4.2.8) and Western blotting (Section 
4.2.10). At this point, the presence of partially-purified VLPs could be verified via TEM 
(Section 5.2.7.1). 
 
5.2.6.2 Sucrose/nycodenz gradient 
After identifying the sucrose cushion fractions that contained assembled VLPs, 
these fractions could be further purified using gradient made from 20% – 60% (w/v) of 
sucrose/nycodenz solutions. Ultracentrifugation was then carried out at 40,000 rpm 
(274,000 x g), 4℃ using either SW 41 Ti rotor (Beckman Coulter, USA) or TH-641 
rotor (Thermo Scientific, USA). The rate-zonal separation in sucrose solution was 
performed for 2.5 hours, while isopycnic separation in nycodenz solution could be 
extended up to 24 hours. Likewise, fractionated samples were analysed via SDS-PAGE 
(Section 4.2.8) and Western blotting (Section 4.2.10). VLPs-containing fractions were 
then pooled and visualised using TEM (Section 5.2.7.1). 
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5.2.7 Characterisation of chimeric virus-like particles (VLPs)-displaying 
cEDIII 
5.2.7.1 Transmission electron microscopy (TEM) 
Approximately 10 µl of the purified VLPs sample was adsorbed onto a copper-
palladium grid, and washed with sterile distilled water before negatively stained with 
2% (w/v) of uranyl acetate. Particles were viewed using FEI Tecnai 20 TEM at 50,000X 
magnification unless otherwise stated. Most of the TEM imaging procedures were 
carried out with assistance from Dr. Hadrien Peyret (JIC, UK). 
 
5.2.7.2 Immunogold labelling 
Based on the protocol described by Chua et al. (2013), immunogold labelling was 
performed for chimeric mHBcAg VLPs samples, namely mHBcAg-cEDIII and 
mHBcAg-cEDIII (L). In brief, purified sample was diluted in tris-buffered saline (TBS) 
(Appendix A5.1) and adsorbed onto formvar-carbon coated nickel grid (Electron 
Microscopy Sciences, USA). The grid was briefly rinsed with a few drops of distilled 
water before incubating with 100 μl of solution containing: 1% (w/v) BSA for 30 
minutes at RT, followed by DENV 1-4 monoclonal antibody (see Table 4.3) at 1:100 
dilution for 1 hour at RT. The grid was then washed with TBS for three times at every 
5-minute intervals. Next, 10-nm colloidal gold-tagged goat anti-mouse IgG polyclonal 
antibody (Sigma, USA) was added at 1:100 dilution and incubated at RT for 1 hour. 
Five washing steps were repeated as above before rinsing with distilled water. Lastly, 
the grid was negatively-stained with 2% (w/v) of uranyl acetate, air-dried and examined 
under HT7700 Electron Microscope. 
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5.2.8 Dialysing protein 
In general, Float-A-Lyzer device (Sigma, USA) was used for the dialysis of small 
volume sample. Dialysis device with molecular weight cut-off (MWCO) of 3.5-5 kDa 
was used for dialysis of recombinant cEDIII fusion proteins; whereas device with 100 
kDa MWCO was used to dialyse chimeric HBcAg VLPs-displaying cEDIII samples. 
For larger volume sample, SnakeSkinTM 7.5 kDa MWCO dialysis tubing (Thermo 
Scientific, USA) was generally used. The dialysis was carried out in 5 litres beaker 
containing desired buffer, with a total of three buffer changes over 24 hours.  
 
5.2.9 Concentrating protein 
To perform vacuum concentration, VLPs fractions were buffer-exchanged into 
20 mM ammonium bicarbonate buffer (Section 5.2.8) and then centrifuged in the 
vacuum concentrator. 
To prepare samples for immunogenicity test, Macrosep Advance 3K Omega 
Centrifugal Device (Pall, USA) was used to concentrate the following vaccine 
candidates: cEDIII protein, CTB-cEDIII-KDEL (xTH) fusion protein, mHBcAg-cEDIII 
VLPs, mHBcAg-cEDIII (L) VLPs and tHBcAg-cEDIII VLPs. Based on manufacturer’s 
recommendation, the purified protein was concentrated to at least 10 folds before 
reconstituting with PBS to desired volume.  
 
5.2.10 Yield quantification 
Quick quantification of a protein concentration could be determined using a 
Nanodrop spectrophotometer (Thermo Scientific, USA). To obtain a more precise 
quantification, either Modified Lowry Protein Assay Reagent Kit (Thermo Scientific, 
USA) or Pierce BCA Protein Assay Kit (Thermo Scientific, USA) was used.  
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The protocol for Modified Lowry kit was performed as follows: (i) Protein 
sample and BSA standards were transferred in triplicates to a microplate; (ii) Modified 
Lowry Reagent was added and the plate was incubated at RT for 10 minutes; (iii) 1X 
Folin-Ciocalteu Reagent was added and incubated at RT for another 30 minutes; and 
lastly (iv) the absorbance at 750 nm was measured using CLARIOstar microplate reader 
(BMG LABTECH, Germany). The average 750 nm absorbance values were subtracted 
from average blank values, and the protein concentration was determined based on the 
BSA standard curve.  
Meanwhile, the protocol for Pierce BSA kit was performed in the following order: 
(i) Protein sample and BSA standards were transferred in triplicates to a microplate; (ii) 
BCA Working Reagent was added and the plate incubated at 37℃ for 30 minutes; and 
lastly (iii) the absorbance at 562 nm was measured using VersaMax microplate reader 
(Molecular Devices, USA). The average 562 nm absorbance values were subtracted 
from average blank values, and protein concentration was determined based on the BSA 
standard curve.   
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5.3 Results 
5.3.1 Step-by-step isolation of cEDIII protein 
Following the large-scale extraction on 6th dpi, IMAC purification_1 (Figure 5.1) 
was used to harvest the recombinant cEDIII fused with sGFP (expressed by pEAQ-
HT::PR1a-cEDIII-sGFP-H-KDEL vector) from clarified plant lysate (Figure 5.3). As 
shown in Panels A and B, the washing steps with low concentrations of imidazole had 
removed some of the weakly bound proteins and non-specific binding of endogenous 
proteins. The eluted fraction harbouring the desired products at ~ 40 kDa was collected 
and is referred as IMAC-purified cEDIII-sGFP-H-KDEL fusion protein thereafter. 
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Panel A: Coomassie blue-stained gel 
 
 
 
Panel B: Western blot probed with Tetra-His monoclonal antibody 
 
 
 
Lane Sample  Estimated protein size 
L SeeBlue Plus2 Pre-Stained Standard  
1 Clarified plant lysate 
cEDIII-sGFP-H-KDEL: ~ 
40 kDa 
2 Flow-through fraction 
3-6 
Washing steps with 0 mM, 5 mM, 10 
mM and 20 mM imidazole 
7 Eluted fraction 
 
 
Figure 5.3:  IMAC purification_1 profiles of recombinant cEDIII fused with sGFP. 
Panel A: SDS-PAGE profiles of coomassie blue-stained IMAC fractions; 
Panel B: Western blot profiles of sample fractions detected with Tetra-
His monoclonal antibody. The cEDIII-sGFP-H-KDEL fusion protein 
was harvested from the eluted fraction. 
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IMAC-purified cEDIII-sGFP fusion protein was then subjected to TEV protease 
cleavage in order to isolate cEDIII protein. SWISS modelling was used to check the 
accessibility of the cleavage site as depicted in Appendix A5.2. Following cleavage, the 
cEDIII protein that was detached from its sGFP partner and 6X His tag, was harvested 
from the flow-through fraction of IMAC purification_2, by which the results are 
depicted in Figure 5.4. With ultraviolet (UV) illumination, green fluorescence was not 
seen in the flow-through fraction that harboured purified cEDIII only (Panels A and B). 
In contrast, fluorescence was detected from the eluted fraction containing the sGFP 
protein. Both coomassie blue-stained gel (Panel C) and Western blot profiles (Panel D) 
confirmed the presence of cEDIII protein with Mr of ~11 kDa. The TEV protease that 
could bind to Ni2+-charged resin column would remain in the eluted fraction as well. 
Future study may consider the use of antibody against sGFP to differentiate the sGFP-
H-KDEL fragment and TEV protease in eluted fraction since both have similar band 
size of ~ 28 kDa. 
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Panel A: Schematic illustration of TEV protease reaction 
 
 
 
Panel B: Ultraviolet (UV) detection of green fluorescence 
 
 
 
Panel C: Coomassie-blue stained gel 
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Panel D: Western blot probed with DENV 1-4 monoclonal antibody 
 
 
 
Lane Sample Estimated protein size Panel C Panel D 
L 
SeeBlue Plus2 Pre-
Stained Standard 
   
1 
IMAC-purified 
cEDIII-sGFP-H-
KDEL protein 
cEDIII-sGFP-H-KDEL: ~ 
40 kDa 
+ + 
2 
TEV protease-
digested cEDIII-
sGFP-H-KDEL 
protein 
cEDIII:  
~ 11 kDa 
+ + 
sGFP-H-KDEL:  
~ 28 kDa 
+ − 
cEDIII-sGFP-H-KDEL: ~ 
40 kDa 
+ + 
TEV protease: 
~ 28 kDa 
+ − 
3 
Flow through 
fraction 
cEDIII:  
~ 11 kDa 
+ + 
sGFP-H-KDEL:  
~ 28 kDa 
− − 
cEDIII-sGFP-H-KDEL: ~ 
40 kDa 
− + 
4 
Washing steps with 
0 mM imidazole 
cEDIII:  
~ 11 kDa 
+ + 
sGFP-H-KDEL:  
~ 28 kDa 
− − 
cEDIII-sGFP-H-KDEL: ~ 
40 kDa 
− + 
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5-7 
Washing steps with 
5 mM, 10 mM and 
20 mM imidazole 
cEDIII:  
~ 11 kDa 
− − 
sGFP-H-KDEL:  
~ 28 kDa 
− − 
cEDIII-sGFP-H-KDEL: ~ 
40 kDa 
− + 
8 Eluted fraction 
cEDIII:  
~ 11 kDa 
− − 
sGFP-H-KDEL:  
~ 28 kDa 
+ − 
cEDIII-sGFP-H-KDEL: ~ 
40 kDa 
+ + 
TEV protease: 
~ 28 kDa 
+ − 
 
 
Figure 5.4:  IMAC purification_2 profiles of TEV protease-digested cEDIII-sGFP-H-
KDEL protein. Panel A: Schematic illustration of the digestion reaction; 
Panel B: Detection of green fluorescence under UV light; Panel C: 
Coomassie blue-stained gel profiles of IMAC fractions; Panel D: 
Western blot profiles of sample fractions detected with DENV 1-4 
monoclonal antibody. The cEDIII protein had been successfully obtained 
as evident from the loss of green fluorescence (yellow circle in Panel B) 
and presence of ~11 kDa bands in Panels C and D. 
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5.3.2 Purification of CTB-cEDIII fusion protein 
After large-scale harvesting on 6th dpi, the IMAC purification_1 profiles of CTB-
cEDIII-H-KDEL protein (expressed by pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL vector) 
are shown in Figure 5.5. Panels A and B indicate that the protein of interest of ~ 28 kDa 
was successfully captured in the eluted fraction, which was designated as IMAC-
purified CTB-cEDIII-H-KDEL protein thereafter. On top of that, multimerisation 
patterns of dimer and trimer could be seen around ~ 56 kDa and ~ 84 kDa, respectively. 
The bands resolved between 30 kDa – 40 kDa could be deciphered as interactions 
between the multimeric proteins. 
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Panel A: Coomassie blue-stained gel 
 
 
Panel B: Western blot probed with Tetra-His monoclonal antibody 
 
 
 
Lane Sample  Estimated protein size 
L SeeBlue Plus2 Pre-Stained Standard  
1 Clarified plant lysate 
CTB-cEDIII-H-KDEL: ~ 
28 kDa 
2 Flow-through fraction 
3-6 
Washing steps with 0 mM, 5 mM, 10 
mM and 20 mM imidazole 
7 Eluted fraction 
 
 
Figure 5.5:  IMAC purification_1 profiles of recombinant cEDIII fused with CTB. 
Panel A: SDS-PAGE profiles of coomassie blue-stained IMAC fractions; 
Panel B: Western blot profiles of sample fractions detected with Tetra-
His monoclonal antibody. The CTB-cEDIII-H-KDEL fusion protein was 
successfully isolated from the eluted fraction. 
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Likewise, TEV protease digestion was set up to remove the C-terminal 6X His 
tag from IMAC-purified CTB-cEDIII-H-KDEL protein (Figure 5.6, Panel A). SWISS 
modelling predicted that the TEV cleavage site was not structurally buried (Appendix 
A5.2). However, the IMAC purification_2 profiles of digested-CTB-cEDIII-H-KDEL 
indicate that protease cleavage might not be successful. This is because the expected 
CTB-cEDIII protein could not be detected in the flow-through fraction of both Panels 
B and C. Thus, it was speculated that the digested protein had retained similar binding 
efficiency to the Ni2+-charged resin, and the CTB-cEDIII protein was recovered along 
with the CTB-cEDIII-H-KDEL protein during elution step. Meanwhile, the digested 
fragment of H-KDEL may have run off the gel due to the small molecular size. 
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Panel A: Schematic illustration of TEV protease reaction 
 
 
 
Panel B: Coomassie blue-stained gel 
 
 
 
Panel C: Western blot probed with DENV 1-4 monoclonal antibody 
 
 
 
Lane Sample Estimated protein size Panel C Panel D 
L 
SeeBlue Plus2 Pre-
Stained Standard 
   
1 
IMAC-purified 
CTB-cEDIII-H-
KDEL protein 
CTB-cEDIII-H-KDEL: ~ 
28 kDa 
+ + 
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2 
TEV protease-
digested CTB-
cEDIII-H-KDEL 
protein 
CTB-cEDIII:  
~ 27 kDa 
+ + 
H-KDEL:  
~ 1 kDa 
− − 
CTB-cEDIII-H-KDEL: ~ 
28 kDa 
+ + 
TEV protease: 
~ 28 kDa 
+ − 
3 
Flow through 
fraction 
CTB-cEDIII:  
~ 27 kDa 
− − 
H-KDEL:  
~ 1 kDa 
− − 
CTB-cEDIII-H-KDEL: ~ 
28 kDa 
− − 
4-6 
Washing steps with 
0 mM, 5 mM and 10 
mM imidazole 
CTB-cEDIII:  
~ 27 kDa 
− − 
H-KDEL:  
~ 1 kDa 
− − 
CTB-cEDIII-H-KDEL: ~ 
28 kDa 
− − 
7 
Washing steps with 
20 mM imidazole 
CTB-cEDIII:  
~ 27 kDa 
+ + 
H-KDEL:  
~ 1 kDa 
− − 
CTB-cEDIII-H-KDEL: ~ 
28 kDa 
+ + 
8 Eluted fraction 
CTB-cEDIII:  
~ 27 kDa 
+ + 
H-KDEL:  
~ 1 kDa 
− − 
CTB-cEDIII-H-KDEL: ~ 
28 kDa 
+ + 
TEV protease: 
~ 28 kDa 
+ − 
 
 
Figure 5.6:  IMAC purification_2 profiles of TEV protease-digested CTB-cEDIII-H-
KDEL protein. Panel A: Schematic illustration of the digestion reaction; 
Panel B: Coomassie blue-stained gel profiles of IMAC fractions; Panel 
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C: Western blot profiles of sample fractions detected with DENV 1-4 
monoclonal antibody. The CTB-cEDIII protein could still bind to Ni2+-
charged resin despite after TEV cleavage, and hence was detected in the 
eluted fraction of Panels B and C. 
 
Following that, an alternative purification approach was attempted using the 
expression vector pEAQ-HT::PR1a-CTB-cEDIII-KDEL (xTH). The expressed protein, 
named as CTB-cEDIII-KDEL (xTH), represents a variant of CTB-cEDIII-H-KDEL 
protein but without the TEV protease cleavage site and 6X His tag. Based on Figure 
5.7, the IMAC purification_1 results indicate that omitting the 6X His tag in cassette 
design did not alter the binding of CTB-cEDIII-KDEL (xTH) protein to Ni2+-charged 
resin. Hence, the desired protein could be harvested from the eluted fraction as verified 
by SDS-PAGE (Panel A) and Western blotting (Panel B). It was postulated that the 
increase of protein size of Mr ~ 2 kDa may be attributed to protein glycosylation. 
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Panel A: Coomassie blue-stained gel 
 
 
 
Panel B: Western blot probed with DENV 1-4 monoclonal antibody 
 
 
 
Lane Sample  Estimated protein size 
L SeeBlue Plus2 Pre-Stained Standard  
1, 8 Clarified plant lysate 
CTB-cEDIII-KDEL (xTH): ~ 
26 kDa 
2, 9 Flow-through fraction 
3-6 
Washing steps with 0 mM, 5 mM, 10 
mM and 20 mM imidazole 
7, 10 Eluted fraction 
 
 
Figure 5.7:  IMAC purification_1 profiles of the variant CTB-cEDIII-KDEL (xTH) 
protein. Panel A: SDS-PAGE profiles of coomassie blue-stained IMAC 
fractions; Panel B: Western blot profiles of sample fractions detected 
with Tetra-His monoclonal antibody. The CTB-cEDIII-KDEL (xTH) 
fusion protein was successfully harvested from the eluted fraction. 
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With the successful isolation of CTB-cEDIII-KDEL (xTH) fusion protein that 
does not have the 6X His tag, this protein was used for characterisation study in order 
to determine its functional binding to GM1 gangliosides. Based on the GM1-ELISA 
analysis (Figure 5.8), it was revealed that the purified CTB-cEDIII-KDEL (xTH) 
protein interacted with the coated GM1. This result was consolidated by negative 
controls, whereby the cEDIII and mHBcAg-cEDIII did not demonstrate binding to GM1 
gangliosides. Furthermore, none of these protein samples gave signals when BSA was 
used as the coating agent.  
 
 
Figure 5.8:  Evaluation of the binding affinities between pentameric CTB and GM1 
gangliosides (+ GM1) via ELISA. Alternative plate was coated with BSA 
(+ BSA) to serve as negative control. The proteins used for testing were 
serially-diluted in two-fold starting from 100 ng/ml. The data are 
expressed as mean ± SD of the A450 readings of three independent 
experiments. Overall, CTB-cEDIII-KDEL (xTH) fusion protein showed 
high binding affinity to GM1 ganglioside, but not the cEDIII and 
mHBcAg-cEDIII proteins. 
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Besides, SEC was also conducted to examine the pentameric folding of CTB-
cEDIII-KDEL (xTH) protein. Protein standards that were separated under the same 
conditions (Appendix A5.3) were used to determine the molecular mass (Mr) of peaks 
resolved from CTB-cEDIII-KDEL (xTH) sample. Based on the analysed SEC 
chromatogram (Figure 5.8, Panel A), several peaks which probably represent the 
pentamers (fractions A8 and A9), dimers (fractions A10 and A11) and monomers 
(fractions A12 to B3) had been annotated. These fractions containing the monomers, 
dimers and pentamers were individually pooled and analysed via Western blotting; and 
as expected, the predicted monomer in Lane 5 detected only a single band at ~ 26 kDa. 
On top of that, aggregates of CTB-cEDIII-KDEL (xTH) were identified in fractions A4 
to A7, with the Mr estimated at ~ 301 kDa and ~ 460 kDa. Nonetheless, multiple bands 
of oligomers were seen from the Western blot profiles due to partial denaturation of 
protein samples. To prevent this, future improvement may omit the use of reducing 
agent for better differentiation of proteins that migrate on the basis of Mr. 
 
Panel A: SEC standard curve 
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Panel B: SEC chromatogram of CTB-cEDIII-KDEL (xTH) protein 
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Panel C: Western blot probed with cholera toxin (CT) polyclonal antibody 
 
 
 
Lane Sample  Estimated band size 
L SeeBlue Plus2 Pre-Stained Standard  
1 Purified CTB-cEDIII-KDEL (xTH) protein 
Monomer: ~ 26 kDa 
Dimer: ~ 52 kDa 
Pentamer: ~ 130 kDa 
Aggregates: > 130 kDa 
2 Pooled fractions A4 – A7 (  a  and  b  )  
3 Pooled fractions A8 – A9 (  c  )  
4 Pooled fractions A10 – A11 (  d  )  
5 Pooled fractions A12 – B3 (  e  ) 
 
 
Figure 5.9: SEC profiling of CTB-cEDIII-KDEL (xTH) fusion protein. Panel A: The 
standard curve used to define Mr; Panel B: SEC chromatogram results; 
Panel C: Western blot profiles of the different pooled fractions, as 
detected with CT polyclonal antibody. SEC yielded several fractions that 
might correspond to different oligomeric states of this CTB fusion protein. 
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5.3.3 Purification of monomeric core virus-like particles (VLPs) 
displaying cEDIII 
N. benthamiana leaves infiltrated with the recombinant vector pEAQ-
HT::mHBcAg-cEDIII were harvested on 4th dpi, clarified and partially-purified via 
sucrose cushion. The profiles of fractionated samples are shown in Figure 5.10, in 
which the 70% sucrose fraction appeared to be ‘cleaner’ than the interface fraction 
(Panel A). The presence of mHBcAg-cEDIII VLPs in both 70% sucrose and interface 
fractions were confirmed via Western blotting (Panel B). These VLPs-containing 
fractions were pooled and subjected to sucrose gradient for further purification. 
 
Panel A:  Coomassie blue-
stained gel 
Panel B:  Western blot probed with HBcAg 
monoclonal antibody 
 
 
 
Lane Sample  Estimated protein size 
L SeeBlue Plus2 Pre-Stained Standard  
1 Clarified plant lysate mHBcAg-cEDIII: ~ 34 kDa 
2 70% sucrose fraction mHBcAg-cEDIII: ~ 34 kDa 
3 Interface fraction mHBcAg-cEDIII: ~ 34 kDa 
 
 
Figure 5.10:  Sucrose cushion purification and detection of mHBcAg-cEDIII VLPs. 
Panel A: SDS-PAGE analysis of fractionated samples; Panel B: Western 
blot profiles showing that the VLPs were successfully detected in the 
70% sucrose and interface fractions using HBcAg monoclonal antibody. 
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Following sucrose gradient ultracentrifugation, the mHBcAg-cEDIII VLPs 
sample was fractionated (Figure 5.11, Panel A) before examination via SDS-PAGE 
(Panel B) and Western blotting (Panel C) techniques. The coomassie blue-stained gel 
revealed that a significant amount of plant endogenous proteins was present in fractions 
4 – 9. The desired VLPs, however were detected in fractions 4 – 6, corresponding to 
sedimentation between 40% – 50% concentration of sucrose. With that, the mHBcAg-
cEDIII VLPs in fraction 4 were harvested and subjected to protein dialysis. Similar 
procedure was employed to purify the monomeric core without gene insert (mEL) as 
control. 
 
 
Panel A: Sample fractionation 
 
 
 
Panel B: Coomassie-blue stained gel 
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Panel C: Western blotting 
 
(i)  DENV 1-4 monoclonal antibody used 
to detect mHBcAg-cEDIII VLPs 
(ii) HBcAg monoclonal antibody 
used to detect mEL VLPs 
 
 
 
Lane Sample  Estimated protein size 
L SeeBlue Plus2 Pre-Stained Standard  
1-2 Fractions 1-2  mHBcAg-cEDIII: ~ 34 kDa 
3-4 Fractions 3-4  mHBcAg-cEDIII: ~ 34 kDa 
5-6 Fractions 5-6  mHBcAg-cEDIII: ~ 34 kDa 
7-8 Fractions 7-8  mHBcAg-cEDIII: ~ 34 kDa 
9 Fraction 9  mHBcAg-cEDIII: ~ 34 kDa 
10 Purified mEL VLPs control mEL: ~23 kDa 
 
 
Figure 5.11:  Sucrose gradient purification and detection of mHBcAg-cEDIII VLPs. 
Panel A: A schematic illustration of the fractionation of VLPs sample 
after ultracentrifugation; Panel B: SDS-PAGE profiles of the recovered 
fractions; Panel C: Western blot profiles of fractionated mHBcAg-cEDIII 
VLPs as detected using DENV 1-4 monoclonal antibody. Fraction 4 was 
harvested and used for downstream application. 
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Purification of mHBcAg-cEDIII (L) VLPs expressed by recombinant vector 
pEAQ-HT::mHBcAg-cEDIII (L) was conducted on 4th dpi following large extraction 
and clarification. The separation on a sucrose cushion yielded several fractions as shown 
in Figure 5.12.  Similarly, the 70% sucrose fraction resolved a cleaner fraction on SDS-
PAGE gel (Panel A) with lesser background proteins as compared to the interface 
fraction. Western blotting (Panel B) confirmed the presence of mHBcAg-cEDIII (L) 
VLPs in 70% and interface fractions, which were harvested for further purification step 
by using sucrose gradient. 
 
Panel A:  Coomassie blue-
stained gel 
Panel B:  Western blot probed with HBcAg 
monoclonal antibody 
 
 
 
Lane Sample  Estimated protein size 
L 
SeeBlue Plus2 Pre-Stained 
Standard 
 
1 Clarified plant lysate mHBcAg-cEDIII (L): ~ 36 kDa 
2 70% sucrose fraction mHBcAg-cEDIII (L): ~ 36 kDa 
3 Interface fraction mHBcAg-cEDIII (L): ~ 36 kDa 
 
 
Figure 5.12:  Sucrose cushion purification and detection of mHBcAg-cEDIII (L) VLPs. 
Panel A: SDS-PAGE profiles of fractionated samples; Panel B: Western 
blot profiles showing that the VLPs were successfully detected in the 
70% sucrose and interface fractions using HBcAg monoclonal antibody. 
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Sucrose gradient analysis of partially-purified mHBcAg-cEDIII (L) is presented 
in Figure 5.13. After ultracentrifugation, the sample was fractionated from bottom of 
the tube (Panel A). The SDS-PAGE profiles (Panel B) indicate that increasing amount 
of background proteins could be detected from fraction 5 onwards, and the presence of 
mHBcAg-cEDIII (L) VLPs could not be clearly differentiated. Only upon Western 
blotting (Panel C), the presence of mHBcAg-cEDIII (L) VLPs was found in fractions 4 
– 6 which implies their sedimentations around 40% – 50% of sucrose concentrations. 
Following that, fraction 4 was collected for protein dialysis before downstream testing. 
The mEL VLPs were purified in similar manner as assay control. 
 
Panel A: Sample fractionation 
 
 
 
Panel B: Coomassie-blue stained gel 
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Panel C: Western blotting 
 
(i)  DENV 1-4 monoclonal antibody used 
to detect mHBcAg-cEDIII (L) VLPs 
(ii) HBcAg monoclonal antibody 
used to detect mEL VLPs 
 
 
 
Lane Sample  Estimated protein size 
L 
SeeBlue Plus2 Pre-Stained 
Standard 
 
1-2 Fractions 1-2  mHBcAg-cEDIII (L): ~ 36 kDa 
3-4 Fractions 3-4  mHBcAg-cEDIII (L): ~ 36 kDa 
5-6 Fractions 5-6  mHBcAg-cEDIII (L): ~ 36 kDa 
7-8 Fractions 7-8  mHBcAg-cEDIII (L): ~ 36 kDa 
9 Fraction 9  mHBcAg-cEDIII (L): ~ 36 kDa 
10 Purified mEL VLPs control mEL: ~ 23 kDa 
 
 
Figure 5.13: Sucrose gradient purification and detection of mHBcAg-cEDIII (L) 
VLPs. Panel A: A schematic illustration of the fractionation of VLPs 
sample after ultracentrifugation; Panel B: SDS-PAGE profiles of the 
recovered fractions; Panel C: Western blot profiles of fractionated 
mHBcAg-cEDIII (L) VLPs sample as detected using DENV 1-4 
monoclonal antibody. Fraction 4 was harvested and used for 
downstream application. 
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In order to conclusively characterise the assembly of purified VLPs, TEM was 
used to check the particles conformation. As illustrated in Figure 5.14, both mHBcAg-
cEDIII VLPs (Panel A) and mHBcAg-cEDIII (L) VLPs (Panel B) did assemble into 
particles with the characteristics spikes on surface. A majority of these VLPs appeared 
with large symmetry, though the smaller symmetry could be spotted as well. The mean 
particle size for mHBcAg-cEDIII VLPs measured is approximately 38 nm whereas 
mHBcAg-cEDIII (L) VLPs have a mean diameter of 36 nm. These measurements with 
TEM are used as rough approximations. Besides, aggregation of particles was noted and 
this could affect the precision in measurement. As compared to the uniformly-shaped 
mEL VLPs (Panel C), the chimeric mHBcAg VLPs with cEDIII epitopes seemed to 
exhibit an uneven surface layer which is hereafter termed as ‘knobbly’ appearance. 
Meanwhile, the spiky appearance was more prominent in mEL VLPs. Insertion of 
cEDIII has contributed to an increase of 9 – 11 nm in particle’s size. 
 
 
Panel A: Electron micrograph of mHBcAg-cEDIII VLPs 
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Panel B: Electron micrograph of mHBcAg-cEDIII (L) VLPs 
 
 
 
Panel C: Electron micrographs of mEL VLPs 
 
 
 
Figure 5.14:  Electron micrographs showing the purified monomeric core VLPs. The 
VLPs were negatively stained with 2% (v/v) uranyl acetate and visualised 
at 50,000X magnification. Panel A: mHBcAg-cEDIII VLPs; Panel B: 
mHBcAg-cEDIII (L) VLPs; Panel C: mEL VLPs control. Scale bar = 100 
nm. Red arrow is used to indicate VLPs with large symmetry and orange 
arrow refers to those with smaller symmetry. Successful assembly of the 
chimeric mHBcAg VLPs with cEDIII epitopes were shown.  
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In addition, immunogold labelling was specifically used to locate the cEDIII 
antigens displayed on assembled VLPs. Based on Figure 5.15, both mHBcAg-cEDIII 
VLPs (Panel A) and mHBcAg-cEDIII (L) VLPs (Panel B) were successfully labelled 
with the 10-nm colloidal gold as indicated by white arrows. To a certain extent, the 
aggregation of particles might have hindered optimal labelling as not every particle was 
tagged with the gold antibody. Nonetheless, it was significant that the mHBcAg-cEDIII 
VLPs and mHBcAg-cEDIII (L) VLPs still preserved the expected antigenicity to react 
with DENV 1-4 monoclonal antibody. 
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Panel A: Electron micrograph of mHBcAg-cEDIII VLPs 
 
 
 
 
Panel B: Electron micrograph of mHBcAg-cEDIII (L) VLPs 
 
 
 
Figure 5.15: Electron micrographs showing the chimeric mHBcAg VLPs reacted with 
immunogold of DENV 1-4 monoclonal antibody. Purified VLPs were 
subjected to immunogold labelling and imaged at 100,000X 
magnification. Scale bar = 200 nm. Panel A: mHBcAg-cEDIII VLPs; 
Panel B: mHBcAg-cEDIII (L) VLPs. 
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5.3.4 Purification of tandem core virus-like particles (VLPs) displaying 
cEDIII 
Leaves infiltrated with the recombinant vector pEAQ-HT::tHBcAg-cEDIII were 
harvested on 8th dpi for large-scale purification. The first-step isolation of tHBcAg-
cEDIII VLPs from plant contaminants was achieved by sucrose cushion (Figure 5.16). 
As seen from the SDS-PAGE profiles (Panel A), the 70% sucrose fraction gave a cleaner 
separation as compared to the interface fraction. However, the signal strength of this 
70% sucrose fraction appeared to be very weak on the immunoblot membrane (Panel 
B). The tHBcAg-cEDIII VLPs were mostly detected in the interface fraction, around 
the expected size of ~ 55 kDa. Nonetheless, the 70% sucrose and interface fractions 
were collected to include all the VLPs present in the sample and further purified by 
nycodenz gradient. 
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Panel A:  Coomassie blue-
stained gel 
Panel B:  Western blot probed with HBcAg 
monoclonal antibody 
 
 
 
Lane Sample  Estimated protein size 
L SeeBlue Plus2 Pre-Stained Standard  
1 Clarified plant lysate tHBcAg-cEDIII: ~ 55 kDa 
2 70% sucrose fraction tHBcAg-cEDIII: ~ 55 kDa 
3 Interface fraction tHBcAg-cEDIII: ~ 55 kDa 
 
 
Figure 5.16: Sucrose cushion purification and detection of tHBcAg-cEDIII VLPs. 
Panel A: SDS-PAGE profiles of fractionated samples; Panel B: Western 
blot profiles showing that the VLPs were successfully detected in the 
70% sucrose and interface fractions using HBcAg monoclonal antibody. 
 
With the use of nycodenz gradient, the presence of VLPs can be visualised due 
to their light-scattering properties (Figure 5.17). As revealed in Panel A, two greyish 
bands were observed upon illumination, with the sedimentation of green contaminants 
towards the top of the gradient. These grey bands were collected from the side of tube, 
followed by fractionation of the remaining gradient from the bottom of the tube (Panel 
B). The collected fractions were then analysed with SDS-PAGE (Panel C) and Western 
blotting (Panel D) techniques. Following immunoblotting, those grey bands were 
confirmed to be tHBcAg-cEDIII VLPs, and the sedimentation point of tHBcAg-cEDIII 
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VLPs was estimated at 40% nycodenz concentration. Similar purification procedures 
were used to isolate the tandem core particles without gene insert (tEL) as control. 
 
Panel A: Visible bands of VLPs 
 
 
 
Panel B: Sample fractionation 
 
 
 
Panel C: Coomassie blue-stained gel 
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Panel D: Western blotting 
 
(i)  DENV 1-4 monoclonal antibody used 
to detect tHBcAg-cEDIII VLPs 
(ii) HBcAg monoclonal antibody 
used to detect tEL VLPs 
 
 
 
Lane Sample  Estimated protein size 
L SeeBlue Plus2 Pre-Stained Standard  
1-2 Fractions 1-2  tHBcAg-cEDIII: ~ 55 kDa 
3-4 Fractions 3-4  tHBcAg-cEDIII: ~ 55 kDa 
5-6 Fractions 5-6  tHBcAg-cEDIII: ~ 55 kDa 
7-8 Fractions 7-8  tHBcAg-cEDIII: ~ 55 kDa 
9-10 Fraction 9-10 tHBcAg-cEDIII: ~ 55 kDa 
11 Top band tHBcAg-cEDIII: ~ 55 kDa 
12 Bottom band tHBcAg-cEDIII: ~ 55 kDa 
13 Purified tEL VLPs control tEL: ~ 42 kDa 
 
 
Figure 5.17: Nycodenz gradient fractionation and detection profiles of tHBcAg-
cEDIII VLPs. Panel A: Visualisation of VLPs band in nycodenz gradient; 
Panel B: Fractionation of VLPs sample after ultracentrifugation; Panel C: 
SDS-PAGE profiles of the recovered fractions; Panel D: Western blot 
detection of fractionated VLPs using DENV 1-4 monoclonal antibody. 
The tHBcAg-cEDIII VLPs could be harvested from the visible grey 
bands. 
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Following sample purification, TEM imaging revealed that plant-produced 
tHBcAg-cEDIII did assemble into VLPs (Figure 5.18, Panel A), which were visualised 
as a mixture of large and small aggregated particles. These particles exhibit the ‘knobbly’ 
morphology and constitute an average particle size of 30 nm in diameter. In contrast, 
the tEL appeared to be smaller and more regular in shape with prominent spikes on their 
surface (Panel B). Purified tEL sample constituted mostly T=4 particles, with an average 
size of 27 nm in diameter. The tHBcAg-cEDIII particles had an increase of 3 nm in 
diameter when compared to tEL control.  
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Panel A: Electron micrographs of tHBcAg-cEDIII VLPs 
 
 
 
Panel B: Electron micrographs of tEL VLPs control  
 
 
 
Figure 5.18: Electron micrograph showing the purified tandem core VLPs that were 
negatively stained with 2% (v/v) uranyl acetate. Panel A: tHBcAg-cEDIII 
VLPs visualised at 80,000X magnification; Panel B: tEL VLPs control 
visualised at 100,000X magnification. Scale bar = 20 nm. Red arrow is 
used to specify particle with large symmetry, while orange arrow denotes 
those with smaller symmetry. The chimeric tHBcAg VLPs with cEDIII 
epitopes had successfully assembled into viral particles. 
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Nonetheless, efforts were made in resolving particles aggregation and significant 
success was obtained for the purification of tHBcAg-cEDIII sample (Figure 5.19). 
Stringent handling during the vacuum concentration step yielded only a single iridescent 
band on the nycodenz gradient after ultracentrifugation (Panel A). Subsequent TEM 
imaging also confirmed that the grey band harboured less aggregated VLPs (Panel B), 
with a mixture of large and small particles. 
 
Panel A:  Visible band of VLPs Panel B:  Electron micrograph 
 
   
 
Figure 5.19: Nycodenz gradient fractionation and detection of tHBcAg-cEDIII VLPs, 
following deliberate handling of vacuum concentration step. Panel A: 
Single band of VLPs observed from nycodenz gradient; Panel B: TEM 
imaging of the collected single band. Scale bar = 100 nm. Red and orange 
arrows are used to indicate large and small particles, correspondingly. 
Stringent sample processing led to less aggregated tHBcAg-cEDIII 
particles. 
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5.3.5 Quantification of purified protein sample 
After purification procedures, recovered protein samples were dialysed against 
PBS buffer and subjected to quantification (Table 5.1). The yield was expressed as 
protein content per unit of fresh weight tissue (FWT). Overall, it was noted that 
recombinant fusion proteins could be harvested at higher level than the chimeric VLPs 
in N. benthamiana. Among the fusion proteins, the yield of CTB-cEDIII-KDEL (xTH) 
protein were doubled of cEDIII-sGFP-H-KDEL protein. Meanwhile, almost equivalent 
yield levels were obtained for all the chimeric HBcAg VLPs (monomeric core: 
mHBcAg-cEDIII and mHBcAg-cEDIII (L); tandem core: tHBcAg-cEDIII).  
 
Table 5.1:  List of quantified protein yield after the final purification procedures. 
No. Purified protein sample Yield  
1 Fusion protein: cEDIII-sGFP-H-KDEL 130 – 170 mg/kg 
2 Protein: cEDIII  13 – 14 mg/kg 
3 Fusion protein: CTB-cEDIII-KDEL (xTH) 310 – 340 mg/kg 
4 Monomeric core VLPs: mHBcAg-cEDIII 13 – 15 mg/kg 
5 Monomeric core VLPs: mHBcAg-cEDIII (L) 16 – 17 mg/kg 
6 Tandem core VLPs: tHBcAg-cEDIII 12 – 16 mg/kg 
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5.4 Discussion 
In this study, cEDIII as the antigen of interest has been designed to express either 
as recombinant fusion protein or as epitope display on chimeric HBcAg VLPs. 
Therefore, two different purification approaches had been used to recover proteins for 
downstream immunogenicity testing.  
During vector construction, 6X His tag was added to the C-terminal ends of 
recombinant cEDIII fusion protein to enable purification via IMAC. In this technique, 
His-tagged protein is chelated based on the high affinity for transition metal ions such 
as Ni2+, Co2+, Cu2+ and Zn2+. His residue exhibits the strongest interaction with metal 
ions because it has electron donor groups on the imidazole ring that can readily form 
coordination bond (Bornhorst and Falke, 2000). To date, NTA is the preferred chelating 
agent used to fix metal ions on agarose, as other ligands like iminodiacetic acid (IDA) 
and tris(carboxymethyl)ethylene diamine (TED), suffer from low purity and/or high 
metal leaching issue (Block et al., 2009). This is associated with the coordination sites 
available on Ni2+; and NTA turns out to have the most effective ratio for interaction with 
the ligand and protein imidazole ring. With that, effective isolation of His-tagged 
recombinant cEDIII protein had been achieved with Ni-NTA in this chapter. Stringent 
washes with 5 mM to 20 mM imidazole had been employed to prevent high background 
binding to the metal ions. 
To isolate cEDIII protein, TEV protease was used to cleave its translationally-
fused sGFP and C-terminal 6X His tag. Removal of the affinity tag was justified by 
reports that His tag can negatively affect the folding or activity of certain proteins 
(Amor-Mahjoub et al., 2006; Chant et al., 2005; Horchani et al., 2009). Figure 5.4 
shows that the IMAC-purified cEDIII-sGFP-H-KDEL fusion protein was successfully 
cleaved into two parts, comprising ~ 28 kDa sGFP-H-KDEL and ~ 11 kDa cEDIII. 
Though the protease digestion was successful, but cleavage efficiency was considerably 
low. For every 100 µg of digested cEDIII-sGFP-H-KDEL protein, only 13 – 14 µg of 
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cEDIII protein could be recovered. Assuming that the protease cleavage is 100% 
efficient, the digestion should yield ~ 28 µg of cEDIII protein and ~ 72 µg of separated 
sGFP-H-KDEL. However, this assumption was arbitrarily made based on the ratio of 
the size difference of cEDIII and sGFP-H-KDEL proteins, at 11 kDa and 28 kDa, 
respectively. The two-fold loss of cEDIII protein could explain for the low yield, even 
though IMAC-purified cEDIII-sGFP-H-KDEL could be harvested at 130 – 170 mg/kg 
FWT (Table 5.1). The protein modelling of cEDIII-sGFP-H-KDEL suggests that the 
TEV recognition site is not sterically hindered (Appendix A5.2). Thus, optimisation of 
the TEV digestion reaction was performed. The best condition was hence set at long 
incubation time of 24 hours, along with doubled TEV enzyme concentration as 
compared to manufacturer’s recommendation.  
Since cEDIII is generated from multiple sequence alignment, little is known 
regarding the novel protein. Other than His tag isolation, the use of other 
chromatographic methods could be fairly challenging since cEDIII has not been well-
characterised. It is presumed that cEDIII also folds into a β barrel configuration, with 
the nine β strands typically found on dengue EDIII (Huang et al., 2007; Volk et al., 
2007). However,  a thermodynamic study revealed that cEDIII exhibited greater 
stability than the serotype-specific EDIII when exposed to heat or chemical denaturants 
(Zidane et al., 2013). As current strategy involved multi-step processing that can cause 
gradual protein losses, there is a need to devise an alternative approach to isolate cEDIII 
in future. Immuno-affinity chromatography may be opted to achieve high yield and 
purity, but it requires greater investment on antibodies to set up the stationary phase. 
Similar strategy was adopted for the purification of CTB-cEDIII-H-KDEL 
protein. Despite initial protein isolation via IMAC purification_1 was successful, but 
the subsequent TEV protease cleavage did not yield expected results. Figure 5.6 reveals 
that the digested protein was still firmly bound to the Ni2+-charged resin despite 
expected removal of 6X His tag. Protein modelling did indicate that the TEV cleavage 
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site was not structurally hidden (Appendix A5.2), and increased amount of  TEV 
enzyme was not able to rectify the problem as well. Soon after, the root cause was 
identified as the inherent binding affinity of CTB to Ni2+ ions. In specific, the binding 
was mediated by three His residues at positions 13, 57 and 94, as discovered by 
Dertzbaugh and Cox (1998). Analysis of the CTB-cEDIII-H-KDEL protein sequence 
conforms to the findings, whereby the three His residues could be identified (Figure 
5.20). Therefore, the new CTB-cEDIII-KDEL (xTH) variant was designed to obviate 
the protease cleavage step for affinity tag removal. A significant finding was achieved 
when the CTB-cEDIII-KDEL (xTH) fusion protein could be retrieved via IMAC 
purification_1 (Figure 5.7). This also reduces the need for tedious purification process 
and associated costs. Novelty stands out here as the first report on single step isolation 
of recombinant cEDIII protein fused to CTB.   
 
 
Figure 5.20: Identification of the three His residues (in red box) responsible for the 
CTB-cEDIII-H-KDEL protein binding to Ni2+ ion, as reported by 
Dertzbaugh and Cox (1998). 
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In the event of cholera infection, CTB-GM1 binding occurs at the apical 
membrane of polarised cell before the toxin is internalised into vesicles and disocciates 
into A and B subunits in the ER (Lencer et al., 1999). Structural configuration of CTB 
is crucial as its adjuvant effect depends on the binding of pentameric form to GM1 
gangliosides on cellular surfaces (Merritt et al., 1994). Hence, GM1-ELISA was 
performed to characterise the resemblance of plant-derived protein to its native 
conformation. Commercial CTB is often added as a positive control, so that it can gauge 
the expression level of recombinant protein as well. However, Malaysia government 
has classified it under the Dangerous Drugs and Psychotropic Substances; and hence 
could not be obtained due to permit restriction. With no option, cEDIII and mHBcAg-
cEDIII purified proteins were included as negative controls to differentiate any false-
positive binding. Based on Figure 5.8, molecular recognition of the CTB-cEDIII-KDEL 
(xTH) protein to GM1 receptor could be detected at concentration as low as 10 ng/ml. 
So, it is presumed that the fusion protein can bind to GM1 to the same extent as native 
CTB. Nonetheless, this speculation still needs to be validated with inclusion of 
commercial CTB in future. For cEDIII and mHBcAg-cEDIII proteins, despite being 
expressed from the same expression vector and/or purified using similar strategy, both 
proteins could not interact with GM1 at all. This proved that plant-produced CTB-
cEDIII-KDEL (xTH) protein did fold into biologically active pentamers via specific 
recognition to the GM1 gangliosides. 
In addition to GM1-ELISA, SEC was used to study the pentamerisation of CTB-
cEDIII-KDEL (xTH) protein and several peaks that corresponded to various oligomeric 
states were obtained (Figure 5.9). According to Lesieur et al. (2002), hydrogen network 
is responsible for the assembly of CTB pentameric complexes, that can occur either via 
(i) interaction of dimer with trimer or (ii) coupling of monomer with tetramer. The 
presence of high molecular mass (Mr) molecules, designated as Aggregates A and B, 
could be deciphered as pentamer-pentamer interaction. According to Merritt et al. 
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(1995), CTB pentamers tend to interact with each other via reciprocal insertion of the 
His13 imidazole ring from one subunit of each pentamer into another pentamer, when 
they are not bound to GM1 receptor (Figure 5.21). Successive pairs of interacting 
pentamers thus, can give rise to an inifinite chains of linked pentamers. The Aggregate 
B may represent shorter intermediates of Aggregate A. Collectively, it seems that the 
CTB-cEDIII-KDEL (xTH) fusion protein has not only preserved the ability to assemble 
into pentamer, but also demonstrates an inclined propensity to associate into high Mr 
molecules. The formation of pentamer and aggregates has most likely protected the 
fusion protein from proteolytic degradation (Kwon et al., 2013), where no significant 
yield loss was noted after 1.5 years of storage. Nonetheless, the aggregates have not 
hindered binding to GM1 gangliosides as validated from GM1-ELISA. With the 
knowledge of protein oligomerisation, it is possible to integrate SEC as a polishing step 
to achieve enhanced purity. Technically, the flow rate can be reduced to acquire better-
resolved peaks. As Lee et al. (2014) observed that the different linker designs between 
CTB and the fused antigen could affect the oligomeric states of fusion protein, this may 
be an interesting subject for future follow-up.  
 
 
Figure 5.21:  Crystal structure of CTB pentamer-pentamer association, with the His13 
imidazole ring coloured in red. Image obtained from Merritt et al. (1995). 
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In terms of VLPs purification, the procedures begin with sucrose cushion to 
isolate and concentrate VLPs from plant lysate, which then leaves density gradient to 
further purify the particles. A gentle purification procedure was preferred as Fuscaldo 
et al. (1971) claimed that pelleting was liable to cause particles damage. In fact, the use 
of sucrose gradient has been reported in various purification works (Mathew et al., 2014; 
Shoji et al., 2015; Yang et al., 2017; Zahmanova et al., 2014). Despite being the most 
economical material, sucrose forms very viscous solution that can exert high osmotic 
effects at concentration as low as 10% (w/v) (Griffiths, 2000). Furthermore, soluble 
proteins which have similar sizes but disparate densities could not be effectively 
separated using rate zonal centrifugation. Hence, nycodenz gradient was adopted as an 
alternative measure for purification of tandem core VLPs. Nycodenz is an inert aromatic 
compound that can form isopycnic gradient, which is particularly useful for VLPs that 
can react with caesium chloride (Gugerli, 1984). Isopycnic generally means ‘of the same 
density’, where VLPs will migrate until the equilibrium sedimentation is reached 
despite of running hours (Luttmann et al., 2006). Swing-bucket rotors were used in all 
ultracentrifugation works to prevent mixing of layers. 
With sucrose cushion, the VLPs within plant lysate would travel through the 25% 
sucrose layer and eventually rested at the interface with 70% sucrose solution. However, 
a thick green band was visible at the interface region as well. According to Peyret (2015), 
this band is likely to overlap with migrating VLPs that co-sediment slightly below. 
Coherent to that, tandem core VLPs-displaying GFP were found to accumulate 
predominantly in the 40% fraction (Peyret et al., 2015). Ideally, harvesting only the 
70% fraction will yield a clean isolated sample. But, due to the low expression of all 
chimeric HBcAg VLPs constructs in this study, the interface fraction was collected 
along with the 70% fraction to recover all the VLPs present in the sample. Some of the 
green impurities were removed by clarification after vacuum concentration. Further 
purification via density gradient serves to facilitate cleaner separation with more 
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consistent fractions. Based on Appendix A5.4, an inference is drawn whereby nycodenz 
can offer better separation of plant impurities than sucrose. In fact, the visible light-
scattering bands in nycodenz gradient can facilitate rapid identification of particles 
aggregation (Sathananthan et al., 1997); which was seen from the denser band of the 
two VLPs sub-populations shown in Figure 5.17.  
Next, TEM was used to validate the presence of correctly assembled VLPs. 
Looking at the monomeric core VLPs, both mHBcAg-cEDIII and mHBcAg-cEDIII (L) 
VLPs (Figure 5.14) were imaged as larger and ‘knobbly’ particles as compared to the 
empty VLPs without cEDIII, namely mEL. The increase in particle diameter strongly 
indicates epitope projections on the VLPs surface. However, subsequent immunogold 
labelling (Figure 5.15) showed that not every particle was tagged with the 10-nm 
colloidal gold. There are two possibilities that can lead to this: (i) too high concentration 
of primary antibody causes steric hindrance that hinders gold probe attachment 
(Dopping-Hepenstal and Beesley, 1993); or (ii) some of the cEDIII epitopes might have 
been masked from antibody recognition due to VLPs aggregation.  
Meanwhile, tHBcAg-cEDIII particle also had the ‘knobbly’ morphology (Figure 
5.18) and were relatively larger than its empty counterpart, namely tEL. Such 
observation also proves that cEDIII epitopes were presented on the particle surface. 
Besides, measurement of particle diameter reveals that tHBcAg-cEDIII particles were 
roughly 6 – 8 nm smaller than the monomeric core VLPs with similar cEDIII displays. 
The size difference was expected because cEDIII was inserted to the Core II of tandem 
core HBcAg cassette (see Table 3.2), and hence only half of the chimeric VLPs were 
decorated with cEDIII epitopes.  
Several factors might have caused VLPs aggregation, and the first aspect is 
speculated from accidental heat-shock of sample during vacuum concentration. Peyret 
(2015) also found that a sample could rapidly heat up if it was not kept on ice 
immediately after vacuum evaporation, leading to aggregation or sample loss. In fact, 
5-60 
 
some heat-labile particles can aggregate following tube transfer from 4℃ to RT (Shi et 
al., 2005). Secondly, the choice of density gradient material might not be ideal. Gias et 
al. (2008) believed that sucrose can cause severe hyperosmotic damage and hamper 
recovery of VLPs. Thirdly, the properties of antigenic epitope might have contributed 
to particles aggregation. It was found that the chimeric VLPs-displaying cEDIII 
(monomeric core: mHBcAg-cEDIII and mHBcAg-cEDIII (L); tandem core: tHBcAg-
cEDIII) tend to exhibit more prominent aggregation as compared to their empty 
counterparts, namely mEL and tEL correspondingly. The insertion of cEDIII could have 
altered the particles surface hydrophobicity; which was in line with Shi et al. (2005) 
finding that the hydrophobic surface exposed on human papillomavirus (HPV) VLPs 
was partially responsible for aggregation.  
A major concern with particles aggregation is the possible obstruction of 
immunogenic display which can affect vaccine potency. Hence, rectification was 
focused on stringent handling of sample particularly during vacuum evaporation. A 
centrifugal concentrator was not opted in early concentration step as the plant debris in 
interface fraction could clog the filter unit. With the deliberate efforts, aggregation of 
tHBcAg-cEDIII particles were no longer detected after ultracentrifugation on a 
nycodenz gradient (Figure 5.19). These results have indirectly provided an insight to 
the VLPs properties, deciphering them as heat-sensitive molecules. However, similar 
efforts did not yield positive results for the purification of monomeric core VLPs via 
sucrose gradient. So following the discussions above, it seems likely that the use of 
sucrose has caused osmolarity damage to the particles (Zeddam et al., 2008). Due to 
limitations, this issue has not been addressed and remained to be verified in future study. 
Paradoxically, a research team had focused on producing VLPs in highly aggregated 
forms as they claimed that aggregates could induce stronger cell-mediated immunity 
(Suzarte et al., 2014; Valdés et al., 2009). Despite so, induction of aggregates may not 
be ideal as the immunogenic properties can vary from batch-to-batch. 
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In general, protein quantification showed that the yields obtained for fusion 
proteins were at least 10 folds higher than the chimeric HBcAg VLPs (Table 5.1). Two 
aspects may have attributed to the yield difference. The first aspect was due to 
expression efficiency: the entire gene sequence of cEDIII fusion proteins were codon-
optimised according to N. benthamiana usage and they were sequestered in the 
endoplasmic reticulum (ER); meanwhile, only the cEDIII gene in chimeric HBcAg 
VLPs constructs was codon-optimised for N. benthamiana expression and no 
subcellular targeting was involved (as discussed in Chapter 4).The second aspect may 
be attributed to purification efficiency: enrichment of His-tagged fusion proteins were 
easily achieved via chelating metal ions; while harvesting of chimeric HBcAg VLPs 
was achieved via step-wise fractionation of density gradient. Comparing between the 
cEDIII fusion to sGFP and CTB, it seems that fusion with CTB has led to higher yield 
possibly due to its ability to enhance solubility and stability of fusion protein (Harakuni, 
et al., 2005). Between the mHBcAg and tHBcAg chimeric VLPs, it was deduced that 
tHBcAg-cEDIII VLPs were expressed at higher level. This was because tHBcAg-
cEDIII VLPs were recovered with higher purity using nycodenz gradient, even though 
protein quantification (Table 5.1) showed that both mHBcAg and tHBcAg chimeric 
VLPs samples were purified at almost equivalent yields. This speculation is also made 
based on the rationale of tandem core development, which aims to reduce steric clashes 
and boost accumulation of assembled VLPs (Peyret et al., 2015). 
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5.5 Conclusion 
Following successful protein expression, purification procedures were performed 
to isolate and characterise the target proteins that would be used for immunogenicity 
testing. Two different approaches had been strategized here for the purification of 
recombinant fusion proteins, namely cEDIII and CTB-cEDIII-KDEL (xTH) as well as 
the chimeric HBcAg VLPs, namely mHBcAg-cEDIII, mHBcAg-cEDIII (L) and 
tHBcAg-cEDIII.  
Despite the purification efficiency of cEDIII protein was rather low, yet a 
satisfactory amount of sample could still be obtained. Purification of CTB-cEDIII-
KDEL (xTH) protein however, could be easily achieved via a single IMAC procedure 
due to its inherent affinity for Ni2+ ions. Besides, oligomerisation of CTB-cEDIII-KDEL 
(xTH) fusion protein had been characterised via SEC which was valuable for better 
understanding of the protein organisation. 
On the other hand, ultracentrifugal separation of VLPs was successful and the 
assembly of chimeric VLPs also had been identified via TEM imaging. It was proposed 
that isopycnic density gradient would serve as a better choice for future recovery of 
VLPs with higher purity. 
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6.1 Introduction 
The development of a protective and durable dengue vaccine has been longed for 
prevention against the deadly disease. After decades of research, it is now understood 
that pre-existing antibodies can lead to severe dengue due to antibody-dependent 
enhancement (ADE). Such complication imposes a major hiccup for vaccine 
development as secondary encounter of a different serotype can jeopardise the efficacy 
of a vaccine if tetravalent protection is not observed at the first place. Hence, one of the 
key requirements for a dengue vaccine is the ability to neutralise all four dengue 
serotypes (DENV 1-4) simultaneously. Up to date, no such vaccine is available yet 
including the pioneer Dengvaxia®. Despite there are several vaccine candidates in the 
pipeline (reviewed in Section 2.2.5), the call for a reliable vaccine has continued to 
intensify as the disease is progressing at a pace faster than it can be coped. 
Following the purification of vaccine candidates, immunogenicity testing is 
needed to assess the product safety and efficacy. This is to comply with the Food and 
Drug Administration (FDA) regulation, where pharmaceutics intended for human use 
should observe a proof of protective response in animal subjects. Thereby, the 
immunogenicity data are crucial in determining whether the product will progress to 
human clinical trials. Animal models that are routinely used for testing include rodents 
and non-human primates. Although wild-type mice are known to be inherently resistant 
to dengue infection, but BALB/c mice are immuno-competent and are commonly used 
for the evaluation of immunogenicity of vaccine candidate. Besides, Leng et al. (2009) 
had successfully tested the E. coli-produced cEDIII in 6 – 8 weeks old BALB/c mice. 
After vaccine administration, several responses can be assessed including the 
antigen-specific antibody titre, differentiation of antibody isotypes, type of immunity 
and duration of responses. A long-term immunity is anticipated as it defines the ability 
to rapidly reactivate memory cells into immune effectors upon exposure to the same 
antigen. Principally, humoral immunity and cell-mediated immunity (CMI) are the two 
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arms of the immune system. Humoral immune response is mediated by antibody 
molecules produced by B cells to prevent the spread of pathogens in body fluid. In this 
study, the neutralisation potency of antibodies is vital to inhibit DENV infection, either 
by blocking the attachment of virus to host cell or by blocking the post-attachment steps 
(Dowd and Pierson, 2011). 
Meanwhile, the CMI relies on T cells to respond to aberrant markers that are 
displayed by the major histocompatibility complex (MHC) on antigen-presenting cells 
(APCs). Two distinct T cells can be activated, namely: (i) T helper (Th) cells, of Th1 
and Th2 subtypes that express cluster of differentiation (CD)4 and (ii) T cytotoxic (Tc) 
cells that express CD8. Upon antigen presentation to naïve T cells, differentiation into 
immune effectors of Th1/Th2 subtype will ensue. Th1 response mainly activates the Tc 
and natural killer cells to help in removing virus-infected cells that are shielded from 
circulating antibodies; while Th2 cells assist in the growth and differentiation of 
antibody-secreting B cells (Lydyard et al. 2011). Hence, the development of both Th1 
and Th2 immune responses are crucial to help in combating the deadly viral disease. As 
cytokines are the signalling molecules that mediate intercellular communication, 
profiling studies could help to identify the type of immune effectors that are 
predominantly elicited. 
In this chapter, the humoral response in BALB/c mice was analysed based on 
cEDIII-specific antibodies production and most importantly, the neutralisation potency 
of these antibodies to inhibit DENV infection. Since the consensus sequence is used, a 
state of protective immunisation against DENV 1-4 is anticipated. Meanwhile, the T 
cell responses were assessed in several aspects including the lymphoproliferative 
responses of splenocytes to cEDIII stimulation, immunophenotyping of cells according 
to CD markers and secretory cytokines production. Since the cEDIII antigen was 
expressed in two different forms, as recombinant proteins and epitope display on 
chimeric hepatitis B core antigen (HBcAg) virus-like particles (VLPs), their 
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immunogenic potential could be evaluated based on the corresponding humoral and 
cell-mediated immune responses. In addition, the presentation of the immunogenicity 
results of chimeric tHBcAg displaying cEDIII (vaccine candidate: tHBcAg-cEDIII 
VLPs) was made in this chapter as well, as previously tested by iQur Ltd. (UK). 
Overall, the specific objectives for this chapter are set as follows:  
(i) To immunise female BALB/c mice with the purified recombinant proteins 
(vaccine candidates: recombinant cEDIII and recombinant CTB-cEDIII-KDEL 
(xTH) fusion protein) and chimeric mHBcAg VLPs-displaying cEDIII (vaccine 
candidates: mHBcAg-cEDIII VLPs and mHBcAg-cEDIII (L) VLPs); 
(ii) To collect mouse serum and check for cEDIII-specific immunoglobulin G (IgG) 
production; 
(iii) To examine the ability of raised antibodies to recognise native DENV 1-4; 
(iv) To determine the neutralising potential of vaccine candidates; 
(v) To assess the lymphoproliferative response of cultured splenocytes to cEDIII 
stimulation; 
(vi) To perform immunophenotyping via fluorescence-activated cell sorting (FACS) 
analysis; 
(vii) To evaluate the cytokine secretion profiles; and 
(viii) To compare the efficacy of the afore-mentioned vaccine candidates.  
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6.2 Materials and methods 
6.2.1 Overview of vaccination schedule 
The animal experiment was conducted in the animal facility located at Monash 
University Malaysia, with a total of 122 female BALB/c mice permitted for testing. 
Protocols were approved by the Animal Ethics Committee of Monash University 
(reference number: MARP/2016/018) as well as the Animal Welfare and Ethical 
Review Body of Nottingham University (reference number: UNMC10). 
In general, a dosage of 20 µg (unless otherwise stated) of purified vaccine 
construct was prepared in a volume of 200 µl phosphate-buffered saline (PBS) for each 
individual mouse, either with or without 1 mg of alum adjuvant (Sigma, Germany). In 
this study, two independent mouse experiments were designed for immunisation against 
recombinant cEDIII proteins (Table 6.1). Likewise, two mouse experiments also had 
been conducted for immunisation against chimeric mHBcAg VLPs-displaying cEDIII. 
In this case, two different experimental designs had been strategised, referred as VLPs 
(a) (Table 6.2a) and VLPs (b) (Table 6.2b). In specific, VLPs (b) represents an 
improvement of VLPs (a), whereby two amendments had been made, including: (i) 
adding two new vaccine constructs namely G7-V and G8-V; and (ii) changing the 
antigen dosage of G5-V to G8-V to 30 µg. 
Each immunisation test was scheduled for 6 weeks starting from the day when 
the 7 – 8 weeks old mice were obtained until the end of vaccination. A step-by-step 
methodology is illustrated in Figure 6.1.  
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Table 6.1:  A summary of the experimental design for mouse immunisation against 
recombinant cEDIII proteins. 
Grouping Purified vaccine construct 
Group 1 (G1-R) PBS control 
Group 2 (G2-R) Alum (1 mg) control 
Group 3 (G3-R) cEDIII (20 µg) 
Group 4 (G4-R) cEDIII (20 µg) + Alum (1 mg) 
Group 5 (G5-R) CTB-cEDIII-KDEL (xTH) (20 µg) 
Group 6 (G6-R) CTB-cEDIII-KDEL (xTH) (20 µg) + Alum (1 mg) 
 
 
Table 6.2a: A summary of the experimental design for mouse immunisation against 
chimeric mHBcAg VLPs-displaying cEDIII, referred as VLPs (a) 
experiment. 
Grouping Purified vaccine construct 
Group 1 (G1-V) PBS control 
Group 2 (G2-V) Alum (1 mg) control 
Group 3 (G3-V) mEL (20 µg) 
Group 4 (G4-V) mEL (20 µg) + Alum (1 mg) 
Group 5 (G5-V) mHBcAg-cEDIII (L) (20 µg) 
Group 6 (G6-V) mHBcAg-cEDIII (L) (20 µg) + Alum (1 mg) 
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Table 6.2b: A summary of the experimental design for mouse immunisation against 
chimeric mHBcAg VLPs-displaying cEDIII, referred as VLPs (b) 
experiment.  
Grouping Purified vaccine construct 
Group 1 (G1-V) PBS control 
Group 2 (G2-V) Alum (1 mg) control 
Group 3 (G3-V) mEL (20 µg) 
Group 4 (G4-V) mEL (20 µg) + Alum (1 mg) 
Group 5 (G5-V) mHBcAg-cEDIII (L) (30 µg) 
Group 6 (G6-V) mHBcAg-cEDIII (L) (30 µg) + Alum (1 mg) 
Group 7 (G7-V) mHBcAg-cEDIII (30 µg) 
Group 8 (G8-V) mHBcAg-cEDIII (30 µg) + Alum (1 mg) 
 
 
Panel A: An overview of immunisation schedule 
 
 
Panel B: Stepwise methodology 
 
6-10 
 
 
Figure 6.1: A schematic illustration of the animal experiment plan. Panel A: 
Immunisation schedule. Mice were primed on day 0 and received 
boosters on day 14 and day 21. Blood samples were collected on day -1, 
day 13, day 27 and day 42. Splenocytes were cultured after cardiac 
puncture. Panel B: A step-by-step description of the methodology 
involved. 
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6.2.2 Housing of mice 
BALB/c mice were held in individual ventilation cage (IVC) to provide clean air 
circulation through high-efficiency particulate air (HEPA) filter. Housing temperature 
was set at 22℃ with relative humidity of 55%. For hygienic purpose, the corncob 
bedding and absorbent papers were changed weekly. Each individual mouse was 
identified based on indelible mark on tail. 
 
 
Figure 6.2: Images of BALB/c mice held in IVC cages. Panel A: Housing of mice 
within the animal facility; Panel B: An example of 4 – 5 BALB/c mice 
grouped in one cage.  
 
6.2.3 Intraperitoneal (IP) injection 
To perform IP injection, the mouse was first manually restrained using one hand 
and held in supine position with its posterior end slightly elevated. Prepared antigen was 
then injected into the mouse’s peritoneal cavities using a 25 G needle (BD, USA). These 
mice were monitored daily for abnormal behaviours such as ruffling of fur, slowing of 
activity, soft stool and weight loss.  
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6.2.4 Serum collection 
6.2.4.1 Through saphenous vein 
The mouse was manually restrained and the fur on the back of hind leg was 
removed using hair-removal cream (Veet, UK). Once the saphenous vein was visible, 
it was punctured with a 27 G needle (BD, USA) and roughly 50 μl of blood was 
collected. Lastly, the punctured site was compressed with sterile cotton wool to stop 
bleeding. After centrifugation at 1,000 x g, 4℃  for 10 minutes, the serum was 
harvested from the supernatant and kept at -80 ℃. 
 
6.2.4.2 Through cardiac puncture 
Two weeks after the final immunisation, the mouse was deeply anesthetized with 
10 mg/kg of xylazine (Ilium, Australia) and 100 of mg/kg ketamine (Ilium, Australia) 
to perform cardiac puncture. The IP injection volume of the drug was prepared 
according to individual body weight, with the formula obtained from (Pennsylvania 
Institutional Animal Care and Use Committee (IACUC), 2016). Once the heart was 
located, a 27 G needle (BD, USA) was inserted and slight negative pressure was 
applied to the syringe plunger. About 700 µl of blood was collected from each mouse. 
Confirmation of euthanasia was performed by placing the mice in carbon dioxide 
chamber. 
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6.2.5 Specialised equipment  
Incubation of Vero cell line and splenocytes culture was carried out using Forma 
380 Steri Cycle CO2 Incubator (Thermo Scientific, USA) and BINDER CB 150 CO2 
Incubator (Binder, Germany). Centrifugation of samples was conducted using 
Microfuge 22R Refrigerated Microcentrifuge (Beckman Coulter, USA) and Eppendorf 
5810R Refrigerated Centrifuge (Eppendorf, Germany). Olympus IX-81 inverted 
fluorescence microscope (Olympus, Japan) was used for microscopic imaging of 
immunofluorescence samples. Accuri C6 Cytometer (BD, USA) was used for 
fluorescence-activated cell sorting (FACS) analyses. Absorbance measurement for 
enzyme-linked immunosorbent assay (ELISA) was performed using either Benchmark 
Plus Microplate Reader (Bio-Rad, USA) or Epoch Microplate Reader (Biotek, USA), 
as stated.  
 
6.2.6 Propagation Vero cell line 
Vero cell line (ATCC® CCL-81™) (American Type Cell Collection (ATCC), 
USA) was used throughout the study as this cell line had been widely used to study 
dengue infection. Vero cells were maintained in minimum essential media (MEM)-10 
medium (Appendix A6.1) and grown at 37℃ incubator with 5% carbon dioxide (CO2) 
until 80% cell confluency was reached. To passage confluent cells, MEM-10 medium 
was removed and the cells were washed with 1X Dulbecco's phosphate-buffered saline 
(DPBS) (Nacalai Tesque, Japan). TrypLE Express (Thermo Scientific, USA) was then 
added and the flask was incubated at 37℃  for 10 minutes. Subsequently, an equal 
volume of MEM-10 medium was added to inactivate the trypsin. Desired cell dilution 
was prepared and the culture flask was placed back to 37℃/5% CO2 incubator. 
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6.2.7 Dengue virus stock preparation 
All the virus samples used in this study were obtained from Dr. Sharifah Syed 
Hassan (Monash University Malaysia), which were isolated from DENV-infected 
patient sera and the specific serotypes DENV 1-4 had been confirmed by multiplex 
reverse transcriptase-polymerase chain reaction (RT-PCR) (Yong et al., 2007) or whole 
genome sequencing. 
To propagate DENV, 70 – 80% confluent Vero cells were washed and re- fed 
with MEM-2 medium (Appendix A6.1) before adding the virus sample at multiplicity 
of infection (MOI) of 0.1. Then, infected cells were incubated for 5 – 6 days and were 
monitored daily for cytopathogenic effect (CPE) using an inverted microscope. To 
harvest the virus, the flask was freeze-thawed for three times before centrifuged at 200 
x g, 4℃ for 10 minutes. 
Virus titre was then determined via focus-forming assay (FFA). In brief, Vero 
cells were seeded at 1 x 105 cells/well in a 24-well culture plate and grown overnight. 
After removing the MEM-10 medium, 10-fold serially diluted virus samples were added 
to the wells in duplicate. Then, the plate was incubated at 37℃ for 1 hour, with gentle 
swirling at every 15-minute intervals. Lastly, the virus inoculum was removed and 4% 
(v/v) carboxymethylcellulose (CMC) in 2X plaque medium (Appendix A6.1) was 
added to each well. The plate was then incubated in 37℃/5% CO2 incubator for 4 days. 
On the 4th day, the formed virus foci were detected via immunostaining technique. 
In brief, the MEM-2 medium was removed and cells were washed with tris-buffered 
saline (TBS) (Appendix A6.1). Fixation was done by adding 80% (v/v) ice-cold acetone 
for 10 minutes. The monolayer was washed twice prior blocking with 1% (w/v) 
BSA/TBS containing 0.5% (v/v) Triton X-100. After 1-hour incubation at 37℃ , 
blocking buffer was aspirated and DENV 1-4 monoclonal antibody (Thermo Scientific, 
USA) was added at 1:2,000 dilution. The plate was incubated at 37℃ for 1 hour, 
followed by three washes with TBS supplemented with 0.1 % (v/v) Tween-20 (TBST) 
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at 5-minute intervals. Next, goat anti-mouse IgG alkaline phosphatase (AP)-labelled 
antibody (Santa Cruz Biotechnology, USA) was added at 1:2,000 dilution and incubated 
at 37℃ for another hour. Washing steps were repeated and residual liquid was removed 
by tapping on paper towel. Lastly, AP-based substrate (Appendix A6.1) was added until 
optimal development was acquired. The focus-forming units (FFU) were manually 
counted and virus titre was calculated based on the average number of FFU in duplicate 
wells. 
 
6.2.8 Serological analyses 
6.2.8.1 Immunoglobulin G (IgG) enzyme-linked 
immunosorbent assay (ELISA) 
A 96-well immuno-plate (SPL, Korea) was coated with 2 µg/ml of purified CTB-
cEDIII-KDEL (xTH) protein in sodium bicarbonate buffer (Appendix A6.1) at 4℃. On 
the next day, the wells were washed with PBS supplemented with 0.05% (v/v) Tween-
20 (PBST) for five times before blocking with 5% (w/v) low-fat milk/PBS at room 
temperature (RT). After 1 hour, the washing steps were repeated. To determine the IgG 
titre of individual mouse, 100 μl of serum sample was applied to the wells in duplicate 
along with PBS diluent as negative control. The pooled sera of G4-R (Table 6.1) was 
used as the reference standard for all ELISA. The plate was incubated at 37℃ for 1 hour, 
followed by five washes with PBST. Next, goat anti-mouse IgG horseradish peroxidase 
(HRP)-conjugated secondary antibody (Invitrogen, USA) was added at 1:5,000 dilution 
and incubation was set at 37℃ for another hour. Washing steps were repeated prior 
adding 3, 3’, 5, 5’-tetramethylbenzidine (TMB) substrate (BD, USA). After 15 minutes, 
the colorimetric reaction was terminated with 0.1 M phosphoric acid and the absorbance 
at 450 nm wavelength (A450) was measured using Benchmark Plus Microplate Reader, 
at a correction wavelength at 570 nm. Data were plotted as the mean of ELISA unit 
(E.U.) ± standard deviation (SD) against different time points of serum collection. 
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6.2.8.2 Immunofluorescence assay (IFA) 
Vero cells were seeded at 1 x 105 cells/ml into each well of a 24-well culture plate. 
After overnight plating, monolayer was washed with 1X DPBS, re-fed with MEM-2 
medium and the virus inoculum was added at MOI = 0.1. After further incubation for 4 
days, the infection medium was removed and monolayer was washed with 1X DPBS. 
Cells were fixed with 80% (v/v) ice-cold acetone for 10 minutes. Blocking was done 
with 1% (w/v) BSA/PBS supplemented with 0.5% Triton X-100 for 1 hour at 37℃. 
Next, heat-inactivated mouse sera were pooled in group and added at 1:25 dilution. 
DENV 1-4 antibody (Thermo Scientific, USA) at 1:100 dilution was included as 
positive control. Meanwhile, wells with pre-immune sera and Vero cells only were used 
as negative controls. Plate incubation was set at 37℃ for 1 hour, followed by three 
washes with PBST at 5-minute intervals. Next, AlexaFluor®488-conjugated goat anti-
mouse IgG secondary antibody (Thermo Scientific, USA) was added at 1:2,500 dilution 
and incubated for another hour at 37℃. Washing steps were repeated and Hoechst 33342 
Solution (Thermo Scientific, USA) was added into each well at 1:2,000 dilution. After 
10-minute incubation at RT, wells were washed with PBS before examination under 
Olympus IX-81 inverted fluorescence microscope. 
 
6.2.8.3 Focus reduction neutralisation test (FRNT) 
Approximately 1 x 105 cells/ml of Vero cells were seeded into each well of the 
24-well plate and incubated at 37℃/5% CO2 for 24 hours. Heat-inactivated mouse sera 
used for IFA were serially diluted in three-fold in MEM-2 medium starting from 1:25 
dilution. Serum was then mixed with virus inoculum at 1:1 ratio, and allowed to incubate 
at 37℃/5% CO2 for 1 hour. Next, the serum-virus mixture was transferred to the culture 
plate containing pre-formed Vero cell monolayer. Virus adsorption was performed at 
37℃/5% CO2 for 1 hour. Each serum-virus mixture was tested in duplicate with three 
experimental controls: Vero-cell control, virus-only control and a positive control of 
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DENV-infected patient serum. Lastly, mixtures were removed before overlaying each 
well with 4% (v/v) CMC in 2X plaque medium, and the plate was incubated for another 
4 days. All the subsequent steps involved in foci development were performed as 
described in Section 6.2.7. Developed virus foci were manually counted and the 
neutralizing antibody titre was determined based on the highest dilution yielding 50% 
reduction of FFU (FRNT50) as compared to the virus-only control. Each FRNT 
experiment was repeated at least two times. Data were expressed as the mean FRNT50 
obtained from different immunisation groups. 
 
6.2.9 Spleen collection 
After euthanasia (Section 6.2.4.2), the mouse was dissected to harvest the spleen 
organ.  In brief, the body was wiped with 70% (v/v) ethanol and incised with a sterile 
scissor. Once the spleen was located, sterile forceps was used to remove the organ and 
immediately transferred to cold RPMI-10 medium (Appendix A6.1). 
 
6.2.10 Lymphocytes screening assays 
6.2.10.1 Splenocytes culture and stimulation 
The mouse spleens were pooled in group and single cell suspensions were 
prepared by gently mashing them between two sterile frosted microscope slides. The 
cell suspension was then spun at 200 x g for 5 minutes at 4℃, followed by incubation 
with ACK lysing buffer (Appendix A6.1) to remove the erythrocytes. The supernatant 
was filtered through 30 μm nylon cell strainer (SPL, Korea) prior cell counting. 
Splenocytes from each group were seeded at 8 x 106 cells/well in a 6-well plate and 
stimulated with 5 μg/ml of CTB-cEDIII-KDEL (xTH) protein for 72 hours at 37℃/5% 
CO2 incubator. Wells with RPMI-10 medium and 5 μg/ml concanavalin A (ConA) 
(Sigma, Germany) were included as negative and positive controls, respectively.  
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6.2.10.2 Lymphocytes proliferation test 
After 72 hours, 100 μl of the splenocytes from Section 6.2.10.1 were transferred 
in triplicate into a 96-well plate, and subsequent steps were conducted based on 
bromodeoxyuridine (BrdU) cell proliferation assay protocol (Roche, Switzerland). In 
brief, BrdU labelling reagent was added at 1:100 dilution into each well and incubated 
for another 24 hours. Then, the labelling solution was removed and the cells were dried 
in 60℃ oven for 1 hour. FixDenat solution was added into each well for 30 minutes, 
followed by anti-BrdU-POD working solution at 1:100 dilution for 90 minutes. The 
wells were rinsed three times with 1X Washing Solution before adding the Substrate 
Solution. After 30 minutes, absorbance at 370 nm wavelength (A370) was measured 
using Epoch Microplate Reader, with a correction wavelength of 492 nm. With 
reference to Heo et al. (2015), the stimulation index (SI) was then calculated as: 
 
 
6.2.10.3 Fluorescence-activated cell sorting (FACS)  
The splenocytes from Section 6.2.10.1 were collected after 72 hours and 
centrifuged at 200 x g for 10 minutes at 4℃ to harvest the pellet for FACS analyses. 
Pellet was re-suspended with staining buffer (Appendix A6.1) and cell counting was 
done using haemocytometer. About 2.5 x 106 of cells were aliquoted from 
corresponding splenocytes group and re-suspended in staining buffer containing 10% 
(v/v) normal rat serum (Invitrogen, USA). These cells were blocked with 1 µg of 
purified rat anti-mouse CD16/CD32 antibody (BD, USA) on ice for 30 minutes in dark. 
Then, 1 x 106 cells were aliquoted into microcentrifuge tube for antibodies staining 
(Table 6.3). A single tube was prepared for each splenocytes group for each marker 
combination. After the antibodies were added, tubes were incubated on ice for 30 
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minutes. Cells were washed with staining buffer and spun down at 200 x g, at 4℃ for 5 
minutes. Next, 2% (v/v) paraformaldehyde/PBS was added and allowed to incubate at 
RT for 10 minutes. Stained cells were centrifuged at 200 x g for 5 minutes, re-suspended 
in 1X PBS and stored at 4℃ away from light. On the day of analysis, 50,000 of events 
were collected using the fast fluidics setting of Accuri C6 cytometer. Data were then 
analysed using Accuri C6 software, where gating and fluorescence compensation could 
be done. With this, immunophenotyping allowed a qualitative assessment of the 
different lymphocyte populations present in the splenocytes. 
 
Table 6.3: The combination of antibodies used in FACS analyses. 
No. Marker combination 
1 
CD19PE (Thermo Scientific, USA) at 1:400 dilution 
CD3APC (Thermo Scientific, USA) at 1:200 dilution 
 
Remarks: To differentiate B and T lymphocytes  
2 
CD3APC (Thermo Scientific, USA) at 1:200 dilution 
CD4PE (Thermo Scientific, USA) at 1:400 dilution 
CD8FITC (Thermo Scientific, USA) at 1:400 dilution 
 
Remarks: To differentiate T cells into Th and Tc 
 
 
 
6.2.10.4 Secretory cytokines profiling 
The supernatants of mouse splenocytes obtained from the centrifugation in 
Section 6.2.10.3 were kept for secretory cytokines analyses. In specific, OptEIA ELISA 
kits (BD, USA) were used to determine the levels of following cytokines: interferon-
gamma (IFN-γ), interleukin-2 (IL-2), IL-4, IL-10 and IL-12. In brief, a 96-well immuno-
plate (SPL, Korea) was coated with corresponding capture antibody (Table 6.4) 
overnight. The wells were washed three times with PBST before blocking with assay 
diluent (Appendix A6.1) at RT for 1 hour. The washing steps were repeated, followed 
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by adding 100 µl of the sample and ELISA standard to duplicate wells. The plate was 
sealed and incubated at RT for 2 hours. After five washes with PBST, corresponding 
working detector solution (Table 6.4) was added and incubated for another hour at RT. 
TMB substrate solution (BD, USA) was added after final washes and incubated in dark 
for 30 minutes. Lastly, 0.1 M phosphoric acid was added to stop the reaction and the 
A450 reading was measured using Epoch Microplate Reader, at a correction wavelength 
at 570 nm. The results were then expressed as the mean cytokine concentration (pg/ml) 
± SD of different vaccine groups. 
 
Table 6.4: List of reagents used for corresponding OptEIA ELISA kit. 
No. OptEIA ELISA kit Capture antibody Working detector 
1 IFN-γ (BD, USA) 
Anti-mouse IFN-γ at 
1:250 dilution in 
sodium bicarbonate 
buffer 
Biotinylated anti-mouse 
IFN-γ at 1:500 dilution + 
Streptavidin-horseradish 
peroxidase (SAv-HRP) 
conjugate at 1:250 dilution 
2 IL-2 (BD, USA) 
Anti-mouse IL-2 at 
1:250 dilution in 
sodium bicarbonate 
buffer 
Biotinylated anti-mouse 
IL-2 at 1:500 dilution +  
SAv-HRP at 1:250 dilution 
3 IL-4 (BD, USA) 
Anti-mouse IL-4 at 
1:250 dilution in 
sodium bicarbonate 
buffer 
Biotinylated anti-mouse 
IL-4 at 1:1,000 dilution +  
SAv-HRP at 1:250 dilution 
4 IL-10 (BD, USA) 
Anti-mouse IL-10 at 
1:250 dilution in 
sodium phosphate 
buffer 
Biotinylated anti-mouse 
IL-10 at 1:250 dilution +  
SAv-HRP at 1:250 dilution 
5 IL-12 (BD, USA) 
Anti-mouse IL-12 at 
1:250 dilution in 
sodium phosphate 
buffer 
Biotinylated anti-mouse 
IL-12 at 1:250 dilution +  
SAv-HRP at 1:250 dilution 
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6.2.11 Statistical analyses 
GraphPad Prism 7 was used for all statistical analyses in this study. In Section 
6.2.8.1, two-way analysis of variance (ANOVA) was performed followed by a Tukey 
multiple comparisons test to calculate the degree of significance of IgG titre produced 
by different immunisation groups. In Section 6.2.8.3, two-way ANOVA was done 
followed by a Tukey multiple comparisons test to determine the degree of significance 
of FRNT50 induced by different immunisation groups. In Section 6.2.10.2, two-way 
ANOVA was used to assess the lymphoproliferative responses of splenocytes 
stimulated with CTB-cEDIII-KDEL (xTH) antigen and ConA mitogen, followed by a 
Tukey multiple comparisons test to compare the responses between different vaccine 
groups. In Section 6.2.10.4, two-way ANOVA was performed followed by a Sidak 
multiple comparisons test to calculate the degree of significance of secretory cytokines 
production among different vaccine groups. Ultimately, the significance levels were 
denoted at P ≤ 0.05 with *, P ≤ 0.01 with **, P ≤ 0.001 with ***, and P ≤ 0.0001 with 
**** in the charts.   
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6.3 Results 
6.3.1 Measurement of anti-dengue immunoglobulin G (IgG) 
6.3.1.1 Recombinant cEDIII proteins 
To study the immunogenicity of vaccinated proteins, mouse sera were collected 
at four different time points to analyse for anti-cEDIII IgG antibody responses. Figure 
6.3 presents the IgG production of BALB/ mice immunised with recombinant cEDIII 
proteins (Table 6.1). Overall, high levels of antibodies were obtained when the mice 
were vaccinated with proteins formulated with alum. The production of antibodies could 
be ranked in a descending order of G6-R > G4-R > G5-R > G3-R. The highest anti-
cEDIII production was observed from mice immunised with alum-adjuvanted CTB-
cEDIII-KDEL (xTH) while cEDIII protein alone gave the weakest response. Comparing 
the adjuvant efficacy, CTB fusion to cEDIII had significantly boosted the 
immunogenicity by 63.3 folds while alum-adjuvanted cEDIII had contributed to 77.4-
fold increase in anti-cEDIII production by the end of immunisation. A further 3.7-fold 
boost was obtained when the CTB-cEDIII-KDEL (xTH) protein was formulated with 
alum. Nonetheless, discernible antibodies production could be observed 2 weeks after 
priming, particularly for mice immunised with G4-R, G5-R and G6-R. No ELISA 
signals were seen from day 0 pre-immune samples, as well as the control groups G1-R 
and G2-R; which thereby validated the specificity of anti-cEDIII IgG response. Similar 
trend was generally obtained from the two independent experiments. 
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Annotation  
G1-R: PBS control G2-R: Alum control 
G3-R: cEDIII G4-R: cEDIII + Alum 
G5-R: CTB-cEDIII-KDEL (xTH) G6-R: CTB-cEDIII-KDEL (xTH) + Alum 
 
Figure 6.3:  cEDIII-specific IgG responses in mice injected with recombinant cEDIII 
proteins (Table 6.1). The BALB/c mice were immunised 
intraperitoneally with 20 µg of recombinant proteins at every 14-day 
intervals over a period of 42 days. The results were shown as mean of 
E.U. ± SD of two independent experiments (n = 10) against different 
serum collection time points. Tukey multiple comparisons test was used 
to calculate the degree of significance between the vaccine groups, by 
which **** represented P ≤ 0.0001. Note that a indicates a degree of 
significance of P ≤ 0.0001 as compared to G1-R control group, while b 
denotes a degree of significance of P ≤ 0.0001 as compared to G2-R 
control group. Successful anti-cEDIII antibodies production was 
observed from all vaccinated groups. 
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6.3.1.2 Chimeric mHBcAg VLPs-displaying cEDIII 
(i) VLPs (a) experiment 
During the first immunisation with chimeric mHBcAg VLPs-displaying cEDIII, 
the presence of cEDIII-specific antibodies could not be detected. Thus, this led to an 
investigation study to examine whether the administered VLPs were recognised by the 
mouse immune system (Figure 6.4). For that purpose, two purified proteins were used 
to coat the immuno-plates, namely mEL (Panel A) and mHBcAg-cEDIII (L) (Panel B), 
by which they were used for injection in VLPs (a) experiment (see Table 6.2a). As 
anticipated, successful antiserum binding was demonstrated as shown in both Panels A 
and B. This thereby signified that antibodies were successfully generated against the 
particle. As the responses for G5-V and G6-V were noticeably lower in Panel A, this 
led to the speculation that the administered dosage of G5-V and G6-V may be 
insufficient. G3-V and G4-V refers to mEL VLPs, which also harbour the same 
mHBcAg backbone except that they are smaller in size due to the absence of cEDIII 
insert in the c/e1 loop. Because of the molecular size difference, a concentration of 20 
µg may not reflect an equivalent number of particles in the injection dose. 
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Annotation  
G1-V: PBS control G2-V: Alum control 
G3-V: mEL G4-V: mEL + Alum 
G5-V: mHBcAg-cEDIII (L) G6-V: mHBcAg-cEDIII (L) + Alum 
 
Figure 6.4: Examination of the mEL-specific (Panel A) and mHBcAg-cEDIII (L)-
specific (Panel B) IgG titres in BALB/c mice. The serum samples (n = 5) 
were pooled in group and assayed in duplicate wells. Results were 
expressed as the average of A450 readings of corresponding groups. 
Antiserum binding of G5-V and G6-V was demonstrated in both panels. 
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(ii) VLPs (b) experiment 
The anti-cEDIII IgG response induced by chimeric mHBcAg VLPs-displaying 
cEDIII from VLPs (b) experiment (Table 6.2b) was presented in Figure 6.5. In fact, 
this result presents a successful modification to the first experiment, referred as VLPs 
(a), which did not produce cEDIII-specific antibodies but showed response against mEL 
and mHBcAg-cEDIII (L). To this end, the BALB/c mice were injected with an increase 
dosage of 30 µg for G5-V, G6-V, G7-V and G8-V. ELISA results revealed that anti-
cEDIII IgG could be found from G6-V and G8-V. Apparently, formulation with alum 
had boosted the immunogenicity of chimeric mHBcAg VLPs-displaying cEDIII. 
Slightly higher anti-cEDIII response was provided by mHBcAg-cEDIII VLPs as 
compared to mHBcAg-cEDIII (L) VLPs. No signals were seen from the control groups 
G1-V to G4-V, as well as the day 0 pre-immune samples (Figure 6.5).  
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Annotation  
G1-V: PBS control G2-V: Alum control 
G3-V: mEL G4-V: mEL + Alum 
G5-V: mHBcAg-cEDIII (L) G6-V: mHBcAg-cEDIII (L) + Alum 
G7-V: mHBcAg-cEDIII G8-V: mHBcAg-cEDIII + Alum 
 
Figure 6.5: cEDIII-specific IgG antibody titres in BALB/c mice vaccinated with 
chimeric mHBcAg VLPs displaying cEDIII (VLPs (b) experiment; 
Table 6.2b). The mice (n = 4) were injected intraperitoneally with 30 µg 
of chimeric VLPs at every 14-day intervals over a period of 42 days. The 
results were presented as mean of E.U. ± SD against different time points 
of serum collection. Tukey multiple comparisons test was used to 
calculate the degree of significance between the vaccine groups, whereby 
**** signified P ≤ 0.0001. Note that the symbols a, b, c, d indicate the 
degree of significance of P ≤ 0.0001 as compared to G1-V, G2-V, G3-V 
and G4-V, correspondingly. Production of anti-cEDIII antibodies could 
be detected from G6-V and G8-V. 
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6.3.2 Immunofluorescence detection of serum antibodies binding to 
native dengue virus 
6.3.2.1 Recombinant cEDIII proteins 
Following the successful detection of anti-cEDIII IgG, mouse sera were pooled 
in each group to test for recognition of native DENV 1-4 serotypes via IFA. Figure 6.6 
presents the immunofluorescence results for antibodies raised against recombinant 
cEDIII protein. After applying the heat-inactivated sera on DENV-infected and non-
infected Vero cells, green fluorescence was detected from all the infected cells treated 
with G4-R, G5-R and G6-R serum samples. Correspondingly, their pre-immune sera 
(Pre) did not bind to any of the native dengue viruses. Meanwhile, green fluorescence 
was not seen from the Vero cells incubated with G3-R sera, despite of the modest IgG 
production. Control groups, G1-R and G2-R, did not recognise the native viruses as 
expected. For validation purpose, DENV 1-4 monoclonal antibody (mAb) was 
incorporated as a positive control which showed intense green fluorescence. Hoechst 
dye was used to stain the nuclei of Vero cells with blue fluorescence. Similar 
observations were recorded from the two independent experiments.
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Figure 6.6: Immunofluorescence profiles of cross-reactivity between sera of mice immunised with recombinant cEDIII proteins and DENV 1-4 serotypes. 
Visualisation was made at 200X magnification, with successful recognition of viruses portrayed by green dye emission.
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6.3.2.2 Chimeric mHBcAg VLPs-displaying cEDIII 
After assessing the cEDIII-specific response in mice, IFA was used to test the 
ability of antibodies raised against mHBcAg VLPs-displaying cEDIII to recognise 
native DENV 1-4 serotypes. The immunofluorescence results for mouse sera collected 
from VLPs (a) experiment and VLPs (b) experiment are presented in Figure 6.7 and 
Figure 6.8, respectively. For both VLPs (a) and VLPs (b), none of the groups had 
reacted with the native DENV 1-4 except for mAb that served as the positive control. 
No green fluorescence was detected from the samples G5-V and G6-V as shown in 
Figure 6.7, as well as samples G5-V, G6-V, G7-V and G8-V as shown in Figure 6.8, 
which made them indistinguishable to the G1-V and G2-V control groups. In fact, only 
Hoechst-stained cell nuclei were visible in all samples.  
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Figure 6.7: Immunofluorescence profiles of interactions between mouse sera collected from VLPs (a) experiment and DENV 1-4 serotypes. Images were 
captured at the magnification of 200X. All the mouse sera failed to react with the native viruses.   
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Figure 6.8: Immunofluorescence profiles of cross-reactivity between mouse sera collected from VLPs (b) experiment and DENV 1-4 serotypes. Observation 
was made at 200X magnification, with which all the serum samples failed to bind with the native viruses.
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6.3.3 Evaluation of virus neutralising antibody production 
6.3.3.1 Recombinant cEDIII proteins 
Following the immunofluorescence recognition of native dengue viruses, the 
neutralisation potential of raised antibodies was further evaluated via FRNT. Figure 6.9 
illustrates the neutralisation activities of the sera collected from mice immunised with 
recombinant cEDIII proteins. Notably, the mouse sera of G4-R, G5-R and G6-R 
demonstrated high reduction of virus FFU as compared to G1-R and G2-R control 
groups. In specific, G4-R and G6-R showed significant neutralising activities against 
DENV serotypes 2, 3 and 4. Albeit their responses against DENV 1 was not statistically 
significant, but their neutralising ability was evidenced. Meanwhile, G5-R exhibited an 
equivalent inhibition of all four serotypes. A sample of DENV-infected patient serum 
was included as positive control, by which could neutralise all the four DENV serotypes 
at the highest dilution (1:675) tested. Overall, the results imply that both recombinant 
cEDIII and CTB-cEDIII-KDEL (xTH) proteins could simultaneously neutralise DENV 
serotypes 1-4, and stronger response is acquired with the use of alum adjuvant. 
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Figure 6.9: Virus neutralising antibody responses of recombinant cEDIII proteins 
against DENV 1-4 serotypes. Mouse sera from day 42 were pooled in 
each group and serially-diluted in three-fold magnitude starting from 
1:25 dilution. The neutralising antibody titre was determined based on 
the reciprocal of the highest serum dilution that neutralised ≥ 50% of the 
DENV (FRNT50), as compared to virus-only control. Results (n = 8) 
were expressed as the mean FRNT50 of two independent mouse 
experiments. Tukey multiple comparisons test was used to calculate the 
degree of significance between the vaccine groups where; *P ≤ 0.05, **P 
≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001. Significant neutralisation 
activities were observed from G4-R and G6-R. A DENV-infected patient 
serum was used as a positive control, which could neutralise DENV 1-4 
serotypes at the highest dilution tested. 
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6.3.3.2 Chimeric mHBcAg VLPs-displaying cEDIII 
(i) VLPs (a) experiment 
The FRNT results for antibodies raised against mHBcAg VLPs-displaying 
cEDIII from VLPs (a) experiment are shown in Figure 6.10. However, no neutralising 
response was obtained in mice vaccinated with G5-V and G6-V, by which correspond 
to the mHBcAg-cEDIII (L) VLPs. The assay was shown to be valid as the positive 
control could neutralise the DENV at the highest dilution of 1:675. In line with the IFA 
results (Figure 6.7), the antiserum was not able to bind with the native dengue viruses, 
and therefore did not show an inhibition of virus infectivity. 
 
 
Figure 6.10: Virus neutralising antibody responses of chimeric mHBcAg VLPs-
displaying cEDIII against four serotypes of DENV (VLPs (a) 
experiment). Mouse sera from day 42 were pooled in each group and 
serially-diluted in three-fold magnitude starting from 1:25 dilution. 
Neutralising antibody titre (FRNT50) was determined based on the 
reciprocal of the highest serum dilution that neutralised ≥ 50% of the 
DENV as compared to virus-only control. The results (n = 4) are 
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expressed as the mean FRNT50 of two independent FRNT experiments. 
No significant neutralising activities were detected from all the 
immunisation groups. The positive control represents a DENV-infected 
patient serum which can neutralise all four serotypes and hence is used 
to validate the assay. 
 
(ii) VLPs (b) experiment 
Meanwhile, Figure 6.11 presents the neutralising ability of the antiserum raised 
against the chimeric mHBcAg VLPs in VLPs (b) experiment. Although cEDIII-specific 
IgG production could be detected following the change of antigen dose for G5-V to G8-
V (Figure 6.5), however no neutralising activities against DENV 1-4 were noted except 
for the positive control. In fact, the serum sample of DENV-infected patient had 
demonstrated strong neutralising responses at dilution up to 1:675. Since the antiserum 
failed to interact with native dengue viruses (Figure 6.8), it made sense that no reduction 
in virus FFU was obtained.          
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Figure 6.11: Virus neutralising antibody responses of chimeric mHBcAg VLPs-
displaying cEDIII against DENV 1-4 serotypes (VLPs (b) experiment). 
Mouse sera from day 42 were pooled in each group and serially-diluted 
in three-fold magnitude starting from 1:25 dilution. The neutralising 
antibody titre (FRNT50) was calculated as the reciprocal of highest 
dilution that yielded 50% reduction of FFU as compared to the virus-only 
control. Results (n = 4) are expressed as the mean FRNT50 of two 
independent FRNT experiments. Apart from the positive control, 
neutralising antibody activities were not observed from mice immunised 
with the vaccine groups.   
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6.3.4 Assessing lymphocytes proliferation following antigen stimulation 
6.3.4.1 Recombinant cEDIII proteins 
Cell-mediated immune responses were assessed based on the ability of mouse 
splenocytes to proliferate upon antigen stimulation. Figure 6.12 shows the cEDIII-
specific lymphoproliferative response of BALB/c mice immunised with recombinant 
cEDIII proteins. A cut-off line was drawn at SI = 1, and only value above 1 was 
perceived as positive cell proliferation. ConA was used as a non-specific stimulus, in 
which splenocytes from all the groups had responded non-specifically to this mitogen. 
Although no significant differences were obtained among the antigen-stimulated G1-R 
to G6-R, however a relative comparison could be made to gauge the efficacy of different 
vaccine groups. In comparison to G3-R, the splenocytes of G4-R, G5-R and G6-R had 
showed higher cell proliferation. The SI of G3-R splenocytes however were somewhat 
comparable to the G1-R and G2-R control groups. The results are expressed as an 
average of two independent experiments.  
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Figure 6.12: Lymphoproliferative responses of the splenocytes of BALB/c mice 
vaccinated with recombinant cEDIII proteins. Mouse spleens were 
pooled in group for splenocytes culture, and co-treated with ConA 
mitogen at 5 μg/ml and CTB-cEDIII-KDEL (xTH) antigen at 5 μg/ml. 
The SI was calculated as the triplicate A370 readings of stimulated 
splenocytes over unstimulated splenocytes. Value of 1 (dashed line) 
indicates that there is no difference in proliferation between stimulated 
and unstimulated. The graph was plotted as the mean of SI ± SD from 
two independent mouse experiments. Two-way ANOVA indicates that a 
degree of significance of **** P ≤ 0.0001 is obtained between ConA-
stimulated and antigen-stimulated splenocytes. 
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6.3.4.2 Chimeric mHBcAg VLPs-displaying cEDIII 
(i) VLPs (a) experiment 
To study the lymphoproliferative responses of BALB/c mice vaccinated with 
chimeric mHBcAg VLPs from VLPs (a) experiment, BrdU assay was performed as 
shown in Figure 6.13. A cut-off line at SI = 1 was used to differentiate those with 
positive cell proliferation at value above 1. As expected, all the splenocytes groups had 
responded non-specifically to ConA stimulus. However, no sign of cell proliferation 
was detected from G5-V and G6-V, which were comparable to the G1-V to G4-V 
control groups. Taken together, these results have demonstrated that the mouse 
splenocytes are not responsive to cEDIII antigen and would not be used for further 
analyses. 
 
 
Figure 6.13: Lymphocyte proliferation activities of splenocytes of mice immunised 
with chimeric mHBcAg VLPs-displaying cEDIII (VLPs (a) experiment). 
The mouse spleens were pooled in group for splenocytes culture, and 
treated with 5 μg/ml of CTB-cEDIII-KDEL (xTH) antigen and 5 μg/ml 
of ConA mitogen for 72 hours. The SI was calculated based on the 
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triplicate A370 readings of stimulated splenocytes over unstimulated 
splenocytes. Value at 1 (dashed line) indicates that there is no discernible 
proliferation between stimulated and unstimulated splenocytes. The 
graph was expressed as the mean of SI ± SD of triplicate wells. Two-way 
ANOVA shows a degree of significance of **** P ≤ 0.0001 between 
ConA-stimulated and antigen-stimulated splenocytes. The splenocytes of 
mice immunised with G5-V and G6-V did not respond to cEDIII antigen. 
 
(ii) VLPs (b) experiment 
Meanwhile, Figure 6.14 presents the proliferation of splenocytes of mice 
immunised with chimeric mHBcAg VLPs of VLPs (b) experiment. As anticipated, the 
optimisation approach with VLPs (b) experiment had yielded positive outcome as cell 
proliferation could now be detected. The cut-off line at SI = 1 was used to identify 
positive cell proliferation activity. ConA mitogen generally had induced high 
proliferative response across all the splenocytes groups. Although the responses 
between antigen-stimulated groups were not statistically significant, but modest cell 
proliferation could be detected from G6-V and G8-V. In comparison to G2-V control 
group, the magnitude of lymphoproliferative response was determined as 1.5 folds 
higher for G6-V and 1.2 folds higher for G8-V. 
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Figure 6.14: Lymphoproliferative responses of splenocytes of mice injected with 
chimeric mHBcAg VLPs-displaying cEDIII (VLPs (b) experiment). 
Mouse spleens were pooled in group for splenocytes culture, and cultured 
with CTB-cEDIII-KDEL (xTH) antigen as well as ConA mitogen at the 
same concentration of 5 μg/ml for 72 hours. The SI was then determined 
based on the ratio of A370 readings of stimulated splenocytes over 
unstimulated splenocytes. The graph was expressed as the mean of SI ± 
SD of triplicate wells. The degree of significance between ConA-
stimulated and antigen-stimulated splenocytes was determined by two-
way ANOVA, and **** indicates P ≤ 0.0001. Proliferative responses 
were detected from G6-V and G8-V. 
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6.3.5 Flow cytometric immunophenotyping  
6.3.5.1 Recombinant cEDIII proteins 
Following antigen stimulation, immunophenotyping was used to identify the 
lymphocyte populations based on the markers expressed on cell surface. A summary of 
the FACS analyses on splenocytes of mice immunised with recombinant cEDIII 
proteins is provided in Figure 6.15. Panel A shows that no obvious change in the B cell 
population was observed between unstimulated and antigen-stimulated splenocytes. 
Meanwhile, changes in the memory T cell populations could be reflected from the CD4+ 
T cells profile (Panel B) and CD8+ T cells profile (Panel C). In specific, G4-R, G5-R 
and G6-R were observed with notable increment of CD4+ and CD8+ T cells as compared 
to the G1-R and G2-R control groups.  
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Figure 6.15: Immunophenotyping of lymphocyte populations in splenocytes of mice 
vaccinated with recombinant cEDIII proteins. Changes in B lymphocytes 
(Panel A), CD4+ T lymphocytes (Panel B) and CD8+ T lymphocytes 
(Panel C) populations were measured via flow cytometry following 
stimulation with CTB-cEDIII-KDEL (xTH) antigen. The results were 
expressed as the average of percentage of cells (%) from two independent 
experiments. 
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6.3.5.2 Chimeric mHBcAg VLPs-displaying cEDIII 
Immunophenotyping of the lymphocyte populations in mice immunised with 
chimeric mHBcAg VLPs from VLPs (b) experiment is presented in Figure 6.16. Panel 
A suggests that no stimulatory effect on B cell population was observed following 
antigen stimulation. Analyses on the T cell responses indicate that the percentage of 
CD4+ T cells (Panel B) in G5-V and G8-V had shown discernible increment after 
stimulation. Peculiarly, the percentage of CD4+ T cells in G3-V was seen to rise as well. 
Meanwhile, the changes of CD8+ T cell population was apparent among the groups of 
G3-V, G4-V, G5-V, G6-V, G7-V and G8-V. 
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Figure 6.16: Immunophenotyping of cell populations in splenocytes of mice 
immunised with chimeric mHBcAg VLPs-displaying cEDIII. The 
changes in B lymphocytes (Panel A), CD4+ T lymphocytes (Panel B) and 
CD8+ T lymphocytes (Panel C) populations were measured via flow 
cytometry after stimulated with CTB-cEDIII-KDEL (xTH) antigen. 
Results were presented as the percentage of cells (%) from VLPs (b) 
experiment. 
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6.3.6 Measurement of secretory cytokines levels 
6.3.6.1 Recombinant cEDIII proteins 
Following the observed changes in CD4+ and CD8+ T cell populations, cytokines 
profiling was used to differentiate the cell-mediated response into Th1 and Th2 subtypes. 
In specific, IFN-γ, IL-2 and IL-12 are signatures of Th1 response whereas IL-4 and IL-
10 are representatives of Th2 response. The cytokines secretion profiles of splenocytes 
of BALB/c mice immunised with recombinant cEDIII proteins are summarised in 
Figure 6.17. Mouse splenocytes of G4-R, G5-R and G6-R were observed with 
significant secretion of IFN-γ and IL-2 following antigen stimulation (Panels A and B). 
Increased level of IL-4 was only significant in G6-R (Panel C) while production of IL-
10 could be seen from both G5-R and G6-R (Panel D). Meanwhile, not much changes 
were noted for IL-12 levels after antigen stimulation (Panel E). These results suggest 
that cEDIII is potent in mediating the secretion of Th1 cytokines, and production of Th2 
cytokines is only prominent when cEDIII was fused with CTB partner.  
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Figure 6.17: Cytokines secretion profiles of mice vaccinated with recombinant cEDIII 
proteins. Five panels were used to determine the concentrations of IFN-γ 
(Panel A), IL-2 (Panel B), IL-4 (Panel C), IL-10 (Panel D) and IL-12 
(Panel E), correspondingly. The graphs showed mean of two independent 
experiments and were expressed as cytokine concentration (pg/ml) ± SD. 
Sidak multiple comparisons test was used to calculate the degree of 
significance as compared to unstimulated controls where; *P ≤ 0.05, **P 
≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001. 
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6.3.6.2 Chimeric mHBcAg VLPs-displaying cEDIII 
Cytokines profiling of BALB/c mice immunised with vaccine constructs of VLPs 
(b) experiment is presented in Figure 6.18. Significant production of IFN-γ was noted 
among G4-V, G5-V G6-V, G7-V and G8-V (Panel A) while secretion of IL-2 was 
detected from G3-V, G4-V, G5-V, G6-V, G7-V and G8-V (Panel B). On top of that, 
increased production of IL-4 was seen among G4-V, G6-V, G7-V and G8-V (Panel C). 
Despite of the repeated analyses on IL-10 and IL-12, however no measurable level was 
obtained for all the splenocytes groups. Overall, the results suggest that the chimeric 
mHBcAg VLPs-displaying cEDIII could mediate a mixed Th1/Th2 cytokine response. 
However, the cytokine production in G3-V and G4-V is not expected since they do not 
carry the cEDIII antigen. 
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Figure 6.18: Cytokines profiling of mice immunised with chimeric mHBcAg VLPs-
displaying cEDIII. Three profiles were presented, namely IFN-γ (Panel 
A), IL-2 (Panel B) and IL-4 (Panel C). Graphs were plotted as the average 
cytokine levels (pg/ml) ± SD of triplicate wells. The graph represents data 
from VLPs (b) experimental design and similar trend was acquired from 
two repeats. Sidak multiple comparisons test was used to calculate the 
degree of significance as compared to unstimulated controls where; ***P 
≤ 0.001 and ****P ≤ 0.0001. 
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6.3.7 Comparative evaluation of the immunogenicity of different vaccine 
constructs 
The capacity of plant-based recombinant cEDIII proteins to elicit humoral and 
cell-mediated immune responses is summarised in Table 6.5. cEDIII as the antigen of 
interest (vaccine group: G3-R), has demonstrated its ability to induce antigen-specific 
IgG production that can cross-neutralise all four DENV serotypes, along with the 
stimulatory production of Th1 cytokines. In comparison, stronger response was 
acquired when cEDIII was formulated with alum (vaccine group: G4-R), including: (i) 
77.4-fold increment of cEDIII-specific antibodies production (Figure 6.3); (ii) 
significantly stronger virus binding (Figure 6.6) and neutralisation activities (Figure 
6.9); (iii) 1.8 folds higher lymphoproliferative response to cEDIII antigen re-call 
(Figure 6.12); and (iv) higher levels of Th1 secretory cytokines production (Figure 
6.17). Meanwhile, CTB-cEDIII-KDEL (xTH) protein (vaccine group: G5-R) has also 
demonstrated strong humoral and cell mediated immune responses than cEDIII alone 
where: (i) 63.3-fold increase in anti-cEDIII antibodies production (Figure 6.3); (ii) 
robust virus recognition with the capacity to neutralise all four DENV serotypes (Figure 
6.9); (iii) 1.5-fold increment in the splenocytes proliferative response to cEDIII antigen 
(Figure 6.12); and (iv) the ability to mediate a balanced Th1/Th2 cytokines production 
(Figure 6.17). Nonetheless, the co-delivery of CTB-cEDIII-KDEL (xTH) with alum 
adjuvant had provided even stronger immune responses. 
  On the other hand, a summary of the immunogenicity test of chimeric mHBcAg 
VLPs-displaying cEDIII is provided in Table 6.6. It is useful to clarify that G5-V and 
G6-V were the vaccine candidates tested in VLPs (a) experiment, of which no cEDIII-
specific humoral or cell-mediated response was detected. Therefore, a second 
experiment with VLPs (b) was attempted with an increased dosage of G5-V and G6-V, 
along with addition of G7-V and G8-V vaccine groups (see Table 6.2b). In general, the 
results shown that the alum-adjuvanted mHBcAg-cEDIII VLPs (vaccine construct: G8-
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V) has stimulated slightly higher cEDIII-specific antibody response (Figure 6.5) with 
notable lymphocytes proliferation (Figure 6.14) and Th1 cytokines production (Figure 
6.18) after antigen stimulation. Nonetheless, not much difference was noted between 
the immunogenicity of mHBcAg-cEDIII (L) VLPs (vaccine group: G6-V) and 
mHBcAg-cEDIII VLPs (vaccine group: G8-V); and both require co-delivery with alum 
in order to achieve a satisfactory immune stimulation. 
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Table 6.5: A comparison of the immunogenicity mediated by recombinant cEDIII proteins. 
Immuno-assay G3-R G4-R G5-R G6-R 
Antigen-specific IgG production Yes (++) Yes (++++) Yes (+++) Yes (+++++) 
Recognition of native DENV No  Yes, against DENV 1-4 Yes, against DENV 1-4 Yes, against DENV 1-4 
Neutralisation of DENV serotypes No neutralisation Yes, against DENV 1-4 Yes, against DENV 1-4 Yes, against DENV 1-4 
Lymphocytes proliferation No Yes Yes Yes 
Secretory cytokines production IL-2 IFN-γ, IL-2 IFN-γ, IL-2, IL-10 IFN-γ, IL-2, IL-4, IL-10 
 
 
Table 6.6: A comparison of the immunogenicity mediated by chimeric mHBcAg VLPs-displaying cEDIII (VLPs (b) experiment). 
Immuno-assay G5-V G6-V G7-V G8-V 
Antigen-specific IgG production No Yes (+) No Yes (++) 
Recognition of native DENV No  No No No 
Neutralisation of DENV serotypes No neutralisation No neutralisation No neutralisation No neutralisation 
Lymphocytes proliferation No Yes No Yes 
Secretory cytokines production IFN-γ, IL-2 IFN-γ, IL-2, IL-4 IFN-γ, IL-2, IL-4 IFN-γ, IL-2, IL-4 
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6.4 Discussion 
Development of a dengue vaccine has been a challenging goal due to the need to 
provide solid and durable protection against four DENV serotypes. Thereby, this 
chapter aimed to evaluate the immunogenicity of purified cEDIII antigens and most 
importantly, the ability of raised antibodies to neutralise DENV 1-4 simultaneously. 
Since cEDIII is claimed to be a poorly immunogenic small molecule (Chen et al., 2013a; 
Chiang et al., 2011) alum adjuvant is incorporated as a stimulus to potentiate an 
effective immune response. Alum specifically refers to aluminium potassium sulphate, 
an insoluble salt particle which has been used in human vaccines since it is inexpensive 
and has a long-standing safety record (Paneque-Quevedo, 2013). Though oil emulsions 
like Freund’s adjuvant and Montanide have been routinely used in animal testing, but 
these are clinically less useful as most are too toxic for human prophylactic vaccine use 
(Aguilar and Rodríguez, 2007). 
In this study, BALB/c mouse was used as this albino, inbred strain is known to 
be a good responder to immunisation (Potter and Boyce, 1962). Female BALB/c mouse 
was chosen considering the calmer behaviour that would allow easier handling. The 
male however, tends to fight aggressively which causes physiological stress that may 
lead to discrepancy of results. Moreover, a study found that young adult female BALB/c 
exhibited better B and T cells-mediated immune responsiveness than the male (Belisle 
and Strausser, 1981). For a more accurate representation of data, mice of the same sex 
were used to minimise variation too. Worthwhile to mention, barbering of furs were 
intermittently observed throughout the animal experiment (Appendix A6.2). Ironically, 
such behavioural pattern is not commonly seen among BALB/c mice (Canavello et al., 
2013), and female is in fact less aggressive. According to Garner et al. (2004), barbering 
is not a dominance behaviour, but rather an abnormal repetitive action affected by 
husbandry and social factors. If this reflects an underlying distress experienced by the 
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mice, it is therefore prudent to respond with pre-emptive improvements such as cage 
enrichment in future (Burkholder et al., 2012). 
Based on Figure 6.3, BALB/c mice were seropositive after receiving three doses 
of recombinant cEDIII proteins, namely G3-R, G4-R, G5-R and G6-R. In fact, anti-
cEDIII IgG could be detected two weeks after primary immunisation with G5-R and 
G6-R. This thereby suggests that CTB-cEDIII-KDEL (xTH) may have the advantage to 
be developed as a vaccine that can accommodate shorter immunisation schedule. On 
top of that, the successful antiserum binding of G4-R, G5-R and G6-R to DENV 1-4 
(Figure 6.6) implies the recombinant cEDIII proteins harboured epitopes that resembled 
native viruses. The failed interaction between G3-R sera and DENV was coherent to the 
neutralisation result (Figure 6.9) as no inhibition of virus infection was detected. In 
terms of the neutralising efficacy, G6-R seemed to confer almost equivalent potency as 
G4-R. The reason for lower neutralisation response against DENV 1 may be related to 
the accessibility of epitope, as the physical properties of virus particles could be affected 
by (i) the state of virion maturity, (ii) conformation flexibility of E proteins, and (iii) the 
structural heterogeneity resulted from 37°C incubation as seen from the expanded 
“bumpy” conformation of DENV 2 virion (Diamond and Pierson, 2015). Another 
plausible reason of lower neutralisation could be due to genotypic variation of DENV 
strains that were used to align the cEDIII sequence (Appendix A3.10) as this may lead 
to differences in antibody affinity (Wahala et al., 2010). Nonetheless, successful 
neutralisation of four DENV serotypes was achieved in this study and future study may 
consider a more in-depth design of a global consensus sequence with a better 
understanding of the antibodies binding to the dynamic populations of DENV virions. 
As an emphasis, the serum samples used for virology test in this study had been heat-
inactivated at 56°C for 30 minutes in order to eliminate potential complement 
interference in cell lysis assays. Hence, this would not lead to false positive 
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interpretations and the results obtained in this study are true representatives of the 
antiserum interactions with native dengue viruses.  
The immunogenicity results for cEDIII conformed to Leng et al. (2009) findings, 
where no significant neutralising antibody titre could be detected when cEDIII was 
administered alone. The poor inhibition of viral infection might be attributed to the low 
antibody production, since virus neutralisation could be seen when cEDIII was 
adjuvanted. Pierson and Diamond (2009) explained that the neutralisation of flavivirus 
followed a ‘multiple-hit’ model, whereby the number of antibodies bound to a virion 
must surpass a required stoichiometric threshold in order to inhibit virus infection. For 
instance, a study with West Nile virus indicated that ~ 30 antibody molecules were 
needed to bind to the EDIII site for effective neutralisation (Pierson et al., 2009). In 
general, it can be perceived that cEDIII is poorly immunogenic and thereby rationalises 
the objective of this study in terms of improving the immunogenicity of cEDIII via 
genetic fusion with CTB or being displayed as epitopes on VLPs carrier.  
The VLPs (a) experiment for chimeric mHBcAg VLPs-displaying cEDIII did not 
work as anticipated, as the cEDIII-specific humoral and cell-mediated responses were 
not obtained. From a troubleshooting attempt however, IgG production against the 
mHBcAg carrier could be detected via ELISA (Figure 6.4). Therefore, it was 
hypothesised that the chimeric mHBcAg VLPs-displaying cEDIII were indeed 
presented to the mouse immune system, but the actual amount of cEDIII presented may 
be significantly lower than the recombinant proteins. It is obvious that the protein 
sequence of mHBcAg-cEDIII (L) composes mainly of mHBcAg carrier. Out of the 324 
amino acids in mHBcAg-cEDIII (L) protein sequence, cEDIII only contributes to 103 
amino acids. Hence, it is of no surprise that the mEL control (vaccine groups: G3-V and 
G4-V) would yield higher E.U. since an injection dosage of 20 µg does not correspond 
to an equal number of particles. In specific, mEL was short of 136 amino acids that were 
inserted into the c/e1 loop of mHBcAg-cEDIII (L). To verify the hypothesis, a second 
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experiment with VLPs (b) was repeated with an increased dosage of mHBcAg-cEDIII 
(L) to account for the 56.9% molecular size difference. An arbitrary calculation was 
made as shown below. In addition, mHBcAg-cEDIII VLPs were also included to see if 
the linker-less variant can induce better immune response. The mHBcAg-cEDIII did not 
have extra 29 amino acids from (GGS)n linkers that flanked the cEDIII (see Table 3.2). 
 
 
During VLPs (b) immunisation test, the dosage for the chimeric mHBcAg VLPs-
displaying cEDIII (vaccine groups: G5-V to G8-V) was raised to 30 µg, based on the 
estimated size difference from mEL (vaccine groups: G3-V and G4-V). As anticipated, 
induction of cEDIII-specific IgG could be detected after the adjustment (Figure 6.5). In 
fact, the linker-less mHBcAg-cEDIII (vaccine groups: G8-V) developed higher 
antibody titres than the mHBcAg-cEDIII (L) variant (vaccine groups: G6-V). This 
therefore conforms to the hypothesis of molecular size difference, and this should be 
considered when calculating the amount of inserted cEDIII sequence in relevant to the 
entire chimeric particle (Whitacre et al., 2016). Despite that, further analyses indicate 
that no virus binding or neutralisation activities were observed. Such outcome mostly 
likely corroborates to the low antibody level as previously discussed. Hence, future 
study may take the molecular size into consideration, in order to gauge the optimal dose 
needed. For instance, Chua et al. (2013) did an explicit calculation to determine the 
specific number of EDIII copies available on the VLP per injection dose.    
In relation to cell-mediated immune response, a cell is expected to undergo clonal 
expansion to mediate effector function upon recognition of the cEDIII antigen. CTB-
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cEDIII-KDEL (xTH) was used for antigenic stimulation as this fusion protein was 
highly stable, expressed at higher yield and most importantly, it also harboured the 
cEDIII antigen. Since CTB is not a mitogen, it is presumed not to mediate any direct 
proliferative effect. In fact, a previous study showed that antigen-primed splenocytes 
that were incubated with CTB did not undergo cell proliferation (Wang et al., 2003). In 
this study, bromodeoxyuridine (BrdU) labelling was used to identify dividing cells as 
BrdU could be incorporated into replicating DNA as an analogue of thymine. Following 
antigen stimulation, subsets of B and T lymphocytes were sorted based on the markers 
on cell surface known as cluster of differentiation (CD). This FACS results were 
complemented with secretory cytokines profiling in order to differentiate the cell-
mediated immunity into Th1 or Th2 subtypes. For Th1 response, IL-2 is required for T 
cells proliferation while IL-12 induces differentiation of Th1 cells and produces IFN-γ 
that has direct killing effect on intracellular pathogens; whereas IL-4 and IL-10 
represent Th2 response that induces B cell activation (Lydyard et al., 2011). A general 
overview on the cellular responses mediated by T cells and their cytokines is illustrated 
in Figure 6.19. 
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Figure 6.19:  A schematic diagram of the aspects of cellular-mediated immune 
responses studied in this context. Note that Th1 and Th2 subtypes activate 
different arms of the immune system. 
 
 For mice immunised with recombinant cEDIII proteins, splenocytes of G4-R, 
G5-R and G6-R were seen to exhibit cEDIII-stimulated proliferation (Figure 6.12). In 
specific, the second mouse experiment in general had observed a lower stimulation 
index (SI) which could explain for the high error bar. The discrepancy might be 
attributed to the formation of proliferative clusters upon antigen stimulation, which 
thereby could affect anti-BrdU recognition and led to underestimated values. This can 
be prevented in future by thorough resuspension of cells after BrdU labelling to ensure 
optimal accessibility of antibodies. FACS analyses showed that increase of CD8+ T cells 
was substantial in G4-R, G5-R and G6-R (Figure 6.15), and in line with the robust 
stimulation of IFN-γ and IL-2 (Figure 6.17) to indicate a Th1 type immunity. The fact 
that G3-R also showed secretion of IL-2 suggests that the dengue envelope glycoprotein 
domain III (EDIII) may harbour a T cell epitope that stimulates a predominant Th1 type 
response  (Li et al., 2011). Moreover, significant levels of IL-4 and IL-10 in splenocytes 
of G6-R, and in G5-R to lesser extent, indicate the CTB partner had skewed the immune 
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response towards a mixed of Th1/Th2 type. It is hence believed that cEDIII fusion with 
CTB could impart a Th2 immune response, as agreed by Eriksson et al. (2003).  
 Meanwhile, the BrdU assay with mice immunised with the chimeric mHBcAg 
VLPs-displaying cEDIII also showed that dosage adjustment was effective as cell 
proliferation could now be seen from splenocytes of G6-V and G8-V (Figure 6.14). 
Next, FACS analyses showed that increment of CD8+ cells was noted for the six groups, 
from G3-V to G8-V (Figure 6.16), and in line with the production of IL-2 (Figure 6.18) 
to suggest a Th1-biased response. Besides, cEDIII-primed IFN-γ secretion was also 
prominent in G4-V, G5-V, G6-V, G7-V and G8-V. The rise of IL-4, a Th2 cytokine, 
however was significant in G4-V, G6-V, G7-V and G8-V. In fact, increased IFN-γ, IL-
2 and IL-4 levels were observed from G3-V and G4-V that served as experimental 
controls without cEDIII epitopes presentation. Hence, the protein Basic Local 
Alignment Search Tool (BLAST) analysis was used to check the sequence similarity 
between the mHBcAg and CTB-cEDIII-KDEL (xTH) used for splenocytes stimulation. 
Peculiarly, a 35% sequence similarity was mapped at the N-terminus of mHBcAg 3’core 
segment (Appendix A6.3). One possible explanation could be that this region harboured 
one of the T cell peptide determinants that had been identified by Ferrari et al. (1991). 
Using G3-V and G4-V as the benchmarks, the extent of elevated cytokines production 
was still higher in G6-V, G7-V and G8-V. The results imply that though cEDIII and 
mHBcAg are serologically distinct but they may be cross-reactive at the T cell level. 
This may in part, due to the nature of T cells that can only recognise linear peptide while 
antibodies recognise the three-dimensional shape of VLPs (Lydyard et al., 2011). From 
a different perspective, this may be beneficial in terms of priming for robust T-cell 
activation. This could be an interesting subject for future study as no information is 
available on the cross-reactivity. It could be that most studies have been focusing on the 
efficacy of chimeric VLPs-displaying desired epitope and may have overlooked other 
effects driven by the carrier molecule itself.  
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With the efforts to improve the immunogenicity of cEDIII, the vaccine constructs 
have been designed to harbour intrinsic adjuvants. As shown in Table 6.5, the adjuvant 
efficacy of CTB was well-demonstrated based on the superior performance of the 
cEDIII-fused CTB as compared to cEDIII alone. This is mediated by the capacity of 
CTB to bind with monosialotetrahexosylganglioside (GM1) on antigen-presenting cells 
(APCs) to promote antigen uptake that leads to more abundant peptides presentation on 
major histocompatibility complex (MHC) II, together with the increased levels of CD40 
and CD86 costimulatory molecules on APCs and upregulated IL-12 and IFN-γ 
secretions to augment the T-cell activating potential of APCs (George-Chandy et al., 
2001). Besides, the assembly of pentameric CTB-cEDIII-KDEL (xTH) molecules may 
have served as a stabiliser for defined organisation of cEDIII and promotes antigen 
presentation to the dendritic cells. Studies had proven that conjugation with CTB could 
elicit > 10 folds stronger antibody response (Miyata, et al., 2012; Miyata et al., 2010). 
In this study, > 65 folds higher IgG titre was obtained when comparing cEDIII to CTB-
cEDIII-KDEL (xTH). G3-R had an average IgG titre at 3590 E.U. in comparison to G5-
R with an average 236090 E.U. by the end of immunisation. This signifies that a lower 
dosage is required to achieve immune stimulation if CTB-cEDIII-KDEL (xTH) fusion 
protein is harnessed for vaccine design. Immunisation with CTB alone was not 
attempted due to limited number of BALB/c mice permitted for use in this study and 
findings already showed that the response of CTB control would be similar to PBS (Lee 
et al., 2015b).    
Meanwhile, VLPs-based vaccine is known to prime immune response in a Th1-
biased fashion (Guillén et al., 2010). In this study, the uptake of HBcAg VLPs carrier 
is expected to deliver 180 – 240 copies of the cEDIII antigens from each particle to the 
APCs, following disruption in the lysosomal compartment (Cooper and Shaul, 2006). 
Such high-density of antigen presentation is hence greatly valued for the robust immune 
stimulation. In line with Milich et al. (1997b) findings, immunisation with chimeric 
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mHBcAg VLPs-displaying cEDIII (Table 6.6) induced high productions of IL-2 and 
IFN-γ, and lower of IL-4 levels, which preferentially primed for Th1 type response. 
Besides, the chimeric mHBcAg VLPs-displaying cEDIII still retained the C-terminal 
nucleic acid binding domain (see Table 3.2). Thus, it is speculated that the trace amount 
of encapsidated plant RNA in the VLPs might be responsible for the strong Th1 
response (Riedl et al., 2002), thereby reproducing the same effect as a CpG 
oligodeoxynucleotides (ODNs) adjuvant. Albeit the production of antigen-specific 
antibodies has been testified in this study, the dosage might still be sub-optimum. For 
instance, Yang et al. (2017) administrated at least 50 µg of HBcAg-zDIII VLPs to 
ensure that 15 µg of the Zika virus (ZIKV) EDIII was presented for immune activation. 
As ZIKV EDIII shares similar size as the cEDIII, future study may consider optimising 
the dose to 50 – 60 µg of chimeric mHBcAg VLPs-displaying cEDIII. Besides, since 
the efficacy of mHBcAg-cEDIII VLPs and mHBcAg-cEDIII (L) VLPs was comparable, 
further study may focus on either one of the constructs. In favour of the molecular 
weight theory, the linker-less mHBcAg-cEDIII may be a better option. Theoretically, a 
preceding hepatitis B infection might seem to limit the use of HBcAg as an antigenic 
carrier. However, it should not be a concern as evidences showed that pre-existing 
immunity will not interfere with antigen presentation (Ruedl et al., 2005; Schödel et al., 
1994), and most importantly, the major B cell epitope of HBcAg lies on the c/e1 loop 
where cEDIII antigen is inserted.  
Worthwhile to mention, a preliminary study on the immunogenicity of tandem 
core HBcAg (tHBcAg) particles displaying cEDIII had been conducted in collaboration 
with iQur Ltd. (UK) (see Appendix A6.4). The results showed that successful 
production of cEDIII-specific IgG antibody is achieved following injection with 
tHBcAg-cEDIII VLPs; which thereby confirms that the cEDIII epitopes have been 
displayed in immunogenic context on the tandem core particles. Besides, immunisation 
with tHBcAg-cEDIII VLPs leads to higher CD8+ degranulation response and this is 
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favoured for the release of perforin and granzyme from CD8+ T cells lysosome that can 
mediate killing of DENV-infected cells (Yauch et al., 2009). Although the tandem core 
approach is still relatively new, a recent publication had shown the feasibility of this 
technology whereby the mice immunised with a tandem core based influenza A vaccine 
had obtained 100% protection in a lethal challenge study (Ramirez et al., 2018). This 
signifies that the tHBcAg-cEDIII VLPs also has the potential to be translated into an 
improved protective dengue vaccine, which warrants for further investigation. 
Taken together, the co-delivery of vaccine construct with alum has boosted the 
immunogenicity of recombinant cEDIII, recombinant CTB-cEDIII-KDEL (xTH) fusion 
protein, mHBcAg-cEDIII VLPs and mHBcAg-cEDIII (L) VLPs. Albeit it is 
conventionally accepted that alum can mediate sustained release of antigen from the 
depot formed at inoculation site, but current findings prefer the theory of alum’s abilities 
to activate the APCs and inflammasome (Wen and Shi, 2016). Although alum is known 
to generate strong Th2 response, but this effect is not discernibly reflected from the 
secretory cytokine profiles in this study. According to Marrack et al. (2009), it could be 
that alum had modulated the Th2 responses indirectly via Th1 suppression. Comparing 
the adjuvant efficacy, alum has seemed to perform better than CTB in terms of boosting 
the immunogenicity of cEDIII in this study. Although a marginal 1.2-fold difference in 
the anti-cEDIII antibodies production was observed between G4-R and G5-R (Figure 
6.3), discernible neutralisation potencies were obtained from FRNT (Figure 6.9). This 
may correlate to the action of CTB that tends to skew the immune response towards B 
cell activation instead of mediating the intracellular killing activity via Tc lymphocytes. 
Nonetheless, the production of Th2 cytokines has the benefit of inducing sterilising 
immunity which can completely prevent virus invasion into host. In fact, the lack of this 
immune status would allow wild-type pathogens to circulate within vaccinated host, 
probe for the weakness of vaccine-induced immunity, and eventually evolve to revert 
to virulence. A significant example was shown from the abandoned vaccine used for 
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Marek’s disease due to the ‘leaky’ infection resulted from virus mutation (Read et al., 
2015). In this context, the CTB-cEDIII-KDEL (xTH) vaccine candidate might have the 
added benefit to induce sterilising immunity and clear DENV-infected cells. 
Momentously, this study represents the first in the field of plant-based dengue 
vaccine research (reviewed in Section 2.5) to demonstrate the abilities to neutralise four 
DENV serotypes simultaneously. So far, only two studies had tested the 
immunogenicity of non-adjuvanted, plant-produced cEDIII, by which both failed to 
show induction of antigen-specific antibodies production (Huy and Kim, 2017; Kim et 
al., 2016a). In contrast to Kim et al. (2016a), the disparity may have come from the 
transgenic rice system used to produce the cEDIII. But when compared to Huy and Kim 
(2017), it is interesting to know that the cEDIII produced via pEAQ-HT vector in this 
study has outperformed the cEDIII derived from a tobacco mosaic virus (TMV)-based 
pro-vector of Icon Genetics. This has most likely corroborated to the benefit of using 
the non-replicative pEAQ-HT system to omit mutation issue. On top of that, Kim et al. 
(2017) had tried to boost the immunogenicity of cEDIII by fusing it to polymeric 
immunoglobulin G scaffold (PIGS). Although the delivery of cEDIII-PIGS with alum 
did induce high IgG titre at 1:1,000,000, but the vaccine construct only produced weak 
neutralisation titre against DENV 2, by which was not more than 1:100 dilution. 
Although the authors argued that this could be due to the lack of neutralising epitopes 
in cEDIII, but this study has solidly proven that cEDIII is capable of neutralising DENV 
1-4 at satisfactory levels.   
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6.5 Conclusion 
In summary, the immunogenicity of cEDIII in the form of recombinant proteins 
(vaccine candidates: recombinant cEDIII and recombinant CTB-cEDIII-KDEL (xTH) 
fusion protein) and as epitope display on chimeric mHBcAg VLPs (vaccine candidates: 
mHBcAg-cEDIII VLPs and mHBcAg-cEDIII (L) VLPs) had been studied. 
Recombinant cEDIII protein has shown neutralising potencies against four 
DENV serotypes, with a predominant Th1 immune response. On the other hand, 
recombinant CTB-cEDIII-KDEL (xTH) fusion protein also has the capability to elicit 
cEDIII-specific antibodies production that inhibit DENV 1-4. Apart from Th1 immunity, 
fusion with CTB seems to skew the response towards a mixed of Th1 and Th2 that may 
be superior in terms of providing sterilising immunity while clearing virus-infected cells. 
During the testing of chimeric mHBcAg VLPs-displaying cEDIII vaccine 
candidates, the adjustment of dosage based on molecular size has shed lights on the 
importance of sufficient presentation of cEDIII epitopes. Albeit successful production 
of cEDIII-specific antibodies had been achieved, further optimisation may be useful for 
better utilisation of these VLPs-based vaccines that were shown to confer a predominant 
Th1 immune response.  
 Based on Malaysian context, this study represents a significant step forward in 
realising the potential of developing an affordable local vaccine that can benefit all 
communities. To the best of my knowledge, this study is the first to demonstrate that a 
plant-based dengue vaccine candidate has the potency to neutralise all four DENV 
serotypes.  
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7 General discussion 
The primary aim of this research was to explore the feasibility of using plant 
system to produce a viable dengue vaccine candidate to address the alarming rise of 
dengue epidemics. With close to 400 million global cases per annum, dengue is now 
regarded as a mosquito-borne disease of global importance (Bhatt et al., 2013). Over 
the past 50 years, transmission of the disease has massively expanded by 30 folds 
(World Health Organization (WHO), 2014), which reflects that vector control 
programmes have been futile. Besides, the lack of anti-viral medications has driven sole 
reliance on fluid therapy. As experts believe that dengue cases will continue to escalate 
(Murray et al., 2013), the development of a dengue vaccine is foreseen as a more 
sustainable approach to achieve disease control. Hitherto, Dengvaxia® has only been 
used in 11 out of 130 countries that are affected by dengue. Low adoption is held back 
by concerns like low efficacy, high cost, limited use for flavivirus-naïve population and 
risk of adverse events (see Section 2.2.5.1). In fact, Philippines has recently suspended 
its use after the dengue vaccine is found to cause severe illness and death (Antiporda, 
2018). Such scenario signifies a typical problem of live-attenuated vaccine where it is 
hard to balance immunogenicity with safety. Hence, the development of subunit vaccine 
would be a better option based on its safe and precise immune targeting.  
The domain III of dengue envelope glycoprotein (EDIII) has been primarily used 
for vaccine development as EDIII is characterised with potent serotype-specific 
neutralising determinants (Guzman et al., 2010). Notably, this specificity is crucial to 
evade pathological effects from antibody-dependent enhancement (ADE). Several 
approaches have been used to generate a tetravalent vaccine based on EDIII, such as 
stoichiometrically mixing four monovalent EDIII (Block et al., 2010), recombinant 
fusion of four EDIII in a single protein (Etemad et al., 2008) or the use of a consensus 
EDIII (cEDIII) (Leng et al., 2009). In this study, the expression of cEDIII was favoured 
because: (i) it obviates the need to produce and adjust doses of four individual 
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monovalent proteins; (ii) cEDIII is proven to be highly stable than individual EDIII; (iii) 
it comprises a single domain and hence is not subjected to structural hindrance as in 
linked EDIII domains; (iv) the consensus sequence would still be useful despite with 
evolution of new virus strain; and lastly (v) the small insert has allowed easier 
manipulation to be tagged with fusion partner or displayed on virus-like particles (VLPs) 
(Chapter 3).  
As stated previously, EDIII possesses a single disulphide bond which is critical 
for its antigenic integrity. The structural antigenicity is so crucial that a single mutation 
in this region can alter the neutralisation outcome (Zhou et al., 2013). Hence, expression 
in plant would be ideal due to its capability of post-translational modifications. In this 
study, the immunogenicity of plant-derived cEDIII in this study clearly outweighs 
bacteria-derived cEDIII (Chiang et al., 2011; Leng et al., 2009) in terms of higher 
neutralisation titres. To clarify, this study calculated the neutralising titres based on 50% 
reduction of DENV (FRNT50) while Chiang et al. (2011) and Leng et al. (2009) 
determined the titres at 40% reduction (FRNT40). So comparatively, stronger response 
was obtained in this study with FRNT50 at 1:119 – 1:356 while the bacterial studies 
reported FRNT40 at 1:8 – 128. Apart from the benefits of eukaryotic system, plant offers 
added safety advantage and is easy to scale-up which can revolutionise the accessibility 
of dengue vaccines to provide rapid yet affordable medical relief to affected regions. 
Making use of current advances in transient expression technology, speedy production 
of vaccine is now achievable via agroinfiltration. As applied in this study, syringe 
infiltration has facilitated rapid screening of different dengue vaccine constructs 
(Chapters 4 and 5) before proceeding with immunogenicity test to select the best 
candidate (Chapter 6). Only then, it would be useful to switch to vacuum infiltration 
for automated delivery of uniform products at industrial scale. N. benthamiana plant, as 
a non-food and non-feed crop, has been widely used for transient expression due to its 
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amenability to Agrobacterium infection and the large amount of leaf biomass that can 
be harvested (Goodin et al., 2008). 
To increase the chance of developing a strong vaccine, cEDIII as the antigenic 
determinant was designed to express in several forms: (i) recombinant protein; (ii) 
recombinant fusion to cholera toxin B subunit (CTB) and (iii) epitope display on 
hepatitis B core antigen (HBcAg) VLPs (Chapter 3). Worthwhile to mention, cEDIII 
was only obtained after tobacco etch virus (TEV) protease cleavage of recombinant 
cEDIII fused with green fluorescent protein (sGFP). Fusion to sGFP mainly served to 
facilitate better monitoring of the spatial and temporal expression of cEDIII 
recombinant protein. Meanwhile, fusion with CTB is rationalised based on its 
immunostimulatory properties that could be imparted to bystander cEDIII antigen. 
Besides, new information was elucidated from size exclusion chromatography (SEC) as 
CTB-cEDIII-KDEL (xTH) fusion protein was prone to fold into pentamer and to 
interact with neighbouring pentamers to strengthen overall lattice. The outstanding 
stability of CTB-cEDIII fusion further suggests that the protein may have the potential 
to be developed as a diagnostic agent other than vaccine. For VLPs production, HBcAg 
was chosen as the vaccine carrier for the high-density presentation of foreign epitopes 
on surface and direct activation of B and T cells. In fact, it is long known that strong 
immunogenicity of HBcAg is conferred by its dual functions as T cell-dependent and T 
cell-independent antigen (Francis et al., 1990). Although the expression of chimeric 
VLPs with cEDIII epitopes had been achieved for monomeric core HBcAg (mHBcAg) 
and tandem core HBcAg (tHBcAg) constructs, it is speculated that insertion of cEDIII 
may have altered the surface properties and led to aggregation. But, aggregation could 
have been exacerbated by extrinsic factors such as heat-shock or hyperosmotic damage. 
This implies that the VLPs derived from either mHBcAg or tHBcAg construct are very 
fragile and require deliberate downstream processing to maximise sample recovery. 
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Practically speaking, expression of a heterologous protein is unlikely to be as 
straightforward as in its native milieu. For that reason, several improvement strategies 
had been applied in this study to boost the expression yield (Chapter 3). At the 
transcriptional and translation levels, codon usage, design of Kozak sequence and co-
expression of gene silencing suppressor were considered. Firstly, all the expression 
cassettes containing cEDIII were synthesised with optimised N. benthamiana codons. 
Fine tuning the codon adaptation index (CAI) to ≥ 0.85 was likely to promote optimal 
and accurate translation by adapting to the codon usage of N. benthamiana host. 
Removal of mRNA secondary structure also helped in getting rid of elements that could 
inhibit expression. A Kozak context, on the other hand, was presumed to mediate 
efficient protein translation by promoting ribosomal recognition of the start codon. The 
use of tombusvirus P19 RNA silencing suppressor was favoured for the capacity to 
block activation of gene silencing complexes while boosting transgene expression 
(Zheng et al., 2009). A significant advantage with pEAQ-HT vector is the ability to 
express P19 in cis; and hence eliminates the need to co-infiltrate another Agrobacterium 
clone that could have negative impact on plant due to the increased density of inoculated 
bacteria. 
Besides, two strategies were used to modulate protein stability at the post-
translational level, including subcellular localisation and design of protein linker. For 
the sequestration of heterologous protein in endoplasmic reticulum (ER), a proper 
design of targeting signals is imperative to ascertain precise targeting. Firstly, the ER 
retention signal (KDEL) should be positioned at the C-terminal tail to render efficient 
recognition for retrograde transport. Then, a combinatory use with the signal peptide of 
tobacco pathogenesis-related 1a protein (PR1a) was needed to ensure passage across the 
endomembrane system. This was verified via confocal imaging (Chapter 4), as the 
recombinant protein expressed by pEAQ-HT::PR1a-cEDIII-H-KDEL was stably 
retained at higher level in the ER, in contrast to the protein expressed by pEAQ-
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HT::cEDIII-sGFP-KDEL-H which accumulated in the cytosol. Besides, kinetic studies 
unveiled rapid leaf necrosis after a progressive accumulation of cytosol-localised 
recombinant protein. Corresponding to the ER stress induced by transient 
overexpression, it is likely that proteolytic activities in cytoplasm had resulted in high 
amount of degraded products that no longer could be rescued by unfolded protein 
response (UPR). Thus, retention in ER is beneficial in the sense it prolongs the residence 
time of recombinant protein to achieve proper folding, as monitored by chaperones and 
molecular enzymes. Besides, the controversial disparity of plant and mammalian N-
linked glycosylation could be avoided via ER localisation. On other hand, protein linker 
plays a key role to provide flexibility to connecting domains. The glycine-proline-
glycine-proline (GPGP) linker between CTB and cEDIII proved to be useful as majority 
of the fusion proteins could fold into the pentameric form (Chapter 5). Lee et al. (2014) 
had attempted a linker-less fusion of antigen with CTB and found that majority of the 
proteins existed in an unstable oligomeric state. Meanwhile, the addition of glycine-rich 
(GGS) linker did not seem to yield discernible difference between the expression yield 
and particles assembly of mHBcAg-cEDIII and mHBcAg-cEDIII (L) constructs. This 
may be contributed by the intrinsic property of cEDIII which was claimed to have a 
defined fold relative to serotype-specific EDIII (Zidane et al., 2013). 
Preceding protein purification, it is noteworthy to emphasise that the PR1a signal 
peptide could be recognised by host signal peptidase for post-translational removal. 
Albeit the knowledge on KDEL signal processing is still obscure, but arguably it should 
not cause any deleterious effect since a vast majority of endogenous proteins in animal 
cells also harbour the KDEL motif, such as the binding immunoglobulin protein (BiP), 
protein disulphide isomerase and calreticulin (Pelham, 1989). Different purification 
procedures were designed to tailor for different forms of cEDIII antigens, namely 
recombinant fusion proteins and VLPs (Chapter 5). The recovery of cEDIII 
recombinant fusion proteins was primarily achieved via immobilised metal affinity 
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chromatography (IMAC), based on the binding affinity of C-terminal 6X histidine (His) 
tag for nickel ions (Ni2+). Subsequent TEV cleavage of 6X His tag was attempted to 
minimise non-native sequence that may affect protein folding or activity. Though pure 
cEDIII could be harvested after digesting cEDIII-sGFP-H-KDEL protein, but the yield 
was relatively low at 13 – 14 mg/kg. Since the cleavage was not as effective as expected, 
future investment on immuno-affinity chromatography may be opted. Meanwhile, the 
cleavage of His tag from CTB-cEDIII-H-KDEL did not yield expected product 
separation, in which was found to be attributed to peculiarity of CTB pentamer to bind 
with metal-affinity resin (Dertzbaugh and Cox, 1998). Such distinguished property, was 
later utilised as means to achieve single step isolation of its variant, CTB-cEDIII-KDEL 
(xTH) fusion protein. On top of that, the purified CTB-cEDIII-KDEL (xTH) was proven 
to preserve the conformation of biological-active pentamers via binding with its native 
receptor known as monosialotetrahexosylganglioside (GM1). 
Purification of VLPs, on the other hand, relies on the density gradient 
sedimentation to separate assembled VLPs from host proteins. Sucrose cushion was 
meant to concentrate all the VLPs in the clarified extract and relayed them to further 
purification by density gradient. Electron microscopy revealed that production of 
cEDIII in the form of mHBcAg and tHBcAg VLPs were successful. In comparison, 
nycodenz gradient was found to perform better owing to the clear fractionation from 
plant endogenous proteins. This suggests that a combinatory use of rate-zonal and 
isopycnic sedimentation may be more optimal for VLPs purification. Notably, 
immunogold labelling provided the first evidence that the cEDIII epitopes were 
correctly displayed on mHBcAg-cEDIII and mHBcAg-cEDIII (L) VLPs, as evident 
from the successful attachment of DENV 1-4 antibody to the surface of chimeric VLPs.  
The immunogenicity results of cEDIII recombinant proteins revealed that both 
cEDIII and CTB-cEDIII-KDEL (xTH) elicited potent anti-cEDIII humoral response 
(Chapter 6). Conformed to Leng et al. (2009) findings, the immunisation with cEDIII 
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alone also induced low anti-cEDIII IgG titres without significant neutralising activities. 
This agrees to the notion that cEDIII is poorly immunogenic and hence requires co-
delivery with alum adjuvant to potentiate the immune responses. Current study on the 
cellular-mediated immunity (CMI) revealed that cEDIII is likely to induce a 
predominant T helper (Th) type 1 response based on interferon-gamma (IFN-γ) and 
interleukin-2 (IL-2) secretions. In fact, a cohort study in Thailand found that the pre-
existing IFN-γ-producing memory T cells was associated with lower risk of secondary 
infection (Hatch et al., 2011). This thereby rationalises the use of cEDIII for vaccine 
development owing to the protective role of Th1-mediated virus clearance. On the other 
hand, the potency of CTB adjuvant was evident from the 63.3-fold increase in anti-
cEDIII immunoglobulin G (IgG) titre, and that recombinant CTB-cEDIII-KDEL (xTH) 
itself was able to evoke neutralising protection against DENV 1-4 without alum. 
Complementary to the GM1-ELISA data, the active binding of CTB-cEDIII-KDEL 
(xTH) to GM1 gangliosides on antigen-presenting (ACPs) has potentially led to 
enhanced antigen uptake that stimulates robust CD4+ and CD8+ responses. In specific, 
cEDIII fusion with CTB has skewed the response towards a mixed Th1/Th2. This is in 
part mediated by the CTB partner that generates a default Th2 response, as shown from 
the productions of IL-4 and IL-10. This would be ideal for a virus vaccine development 
in terms of the ability to provide sterilising immunity while clearing DENV-infected 
cells in the host. In fact, immunisation with Dengvaxia® does not generate Th2 response 
(Guy, 2009); and this maybe one of the reasons that correlates with increased risk of 
ADE due to the lack of memory B cells to produce neutralising antibodies. Instead of 
eradicating virus-infected cells, sterilising immunity is able to block virus infection into 
the host and thereby prevent the evolution of virulence strain from ‘leaky’ infection 
(Read et al., 2015). 
For the immunogenicity studies of chimeric mHBcAg VLPs-displaying cEDIII, 
the first VLPs (a) experiment had failed to induce immune responses. Hence, VLPs (b) 
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experiment was designed as an improvement to VLPs (a), whereby the antigen dosage 
was increased to account for the molecular size difference as discussed in Chapter 6. 
This approach was also justified from the successful immunogold experiment, by which 
presentation of cEDIII epitopes in immunogenic context was convincingly shown. As 
anticipated, successful proof-of-concept was attained as cEDIII-specific humoral and 
cell-mediated responses could be detected by the end of VLPs (b) experiment. A 
predominant Th1 response was acquired after vaccination with mHBcAg-cEDIII VLPs 
and mHBcAg-cEDIII (L) VLPs, based on the high levels of IFN-γ and IL-2. Overall, it 
is noted that most of these chimeric VLPs require co-delivery with adjuvant to increase 
the stimulation of immune system. This is likely to correlate with the concept of 
molecular size difference, where adequate presentation of cEDIII epitopes may 
correspond to more efficient immune stimulation. Besides, it may be possible that 
aggregation of the VLPs has hindered effective display of cEDIII epitopes. However, 
this may be rather subjective as some researches claimed that aggregated VLPs can 
mediate stronger cytotoxic T cell responses with significant level of protection in mice, 
as compared to the non-aggregated form (Valdés et al., 2009). Although the cross-
presentation of aggregated species may be more effective, production of non-aggregated 
VLPs is still preferred considering the factor of product consistency.  
Worthwhile to mention, this is the first study that reports on the successful 
production of chimeric HBcAg VLPs with dengue protein epitopes in plant system. In 
fact, the production of the monomeric core particles is proven to feasible and is able to 
induce cEDIII-specific response (vaccine candidates: mHBcAg-cEDIII and mHBcAg-
cEDIII (L)). This contradicts to the perception made by previous studies (Peyret et al., 
2015; Walker et al., 2011a), which claim that the chance of successful VLPs production 
can be perilously low and hence requires the use of new technology such as SplitCore 
and ‘Tandem Core’. However, this does not defy the usefulness of the tandem core 
approach, as preliminary evidence (Appendix A6.4) shown that the tHBcAg-cEDIII 
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particles could induce cEDIII-specific response with strong cytolytic activity. Thus, it 
seems promising to further explore the potential of tHBcAg-cEDIII VLPs as a dengue 
vaccine candidate, which may also address the low immunogenicity of the monomeric 
core particles. 
Thus far, it is safe to say that cEDIII fusion with CTB performs better than 
chimeric VLPs with cEDIII display, at least at the equivalent dosage of 20 µg. Although 
the cEDIII formulated with alum seems to generate slightly stronger humoral response 
than the cEDIII fused with CTB, but latter is preferred due to the following reasons: (i) 
CTB has high T cell activating potential (ii) the built-in CTB enables easier vaccine 
preparation and reduces associated cost; and (iii) the potential use as multivalent vaccine 
against dengue and cholera diseases. In addition, it is believed that the pentamerisation 
of CTB-cEDIII-KDEL (xTH) fusion protein would impart added benefit for the 
development a highly stable vaccine with defined presentation of cEDIII on the 
oligomeric structure. Not to forget, CTB is a well-known mucosal adjuvant. Future 
prospect may consider developing the CTB-cEDIII-KDEL (xTH) fusion protein into an 
oral vaccine. For that, an in vitro antigen uptake assay can be performed using Peyer’s 
patches to assess the binding ability to mucosal lymphoid tissues. Considering dengue 
often thrives in tropical developing nations, oral vaccination may be more amenable to 
mass immunisation without requiring specialised medical settings and assistance (Pang 
and Loh, 2017). 
Comparing to other plant-based dengue vaccine researches (Table 2.3), one of 
the primary aspects in this study is the use of cEDIII antigen that simplifies the vaccine 
design that can offer tetravalent neutralisation with a considerably lower production cost. 
In fact, this is the first report which shows that non-adjuvanted, plant-produced cEDIII 
can elicit antigen-specific IgG production. It is greatly believed that the strategised ER 
localisation has preserved the correct folding of neutralising epitopes on EDIII. To 
enhance the immunogenicity of cEDIII, CTB-cEDIII-KDEL (xTH) protein was 
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developed in this study. The robustness of the fusion protein to be delivered in a self-
adjuvanting manner is evidently shown, which can minimise the reliance on exogenous 
adjuvant. Likewise, Kim et al. (2017) had also attempted to engineer a self-adjuvanting 
molecule that features cEDIII fusion to polymeric immunoglobulin G scaffold (PIGS). 
However, its final yield at 17 mg/kg fresh weight tissue (FWT) was nearly 20 folds 
lower than CTB-cEDIII-KDEL (xTH). This may be explained from the use of N. 
tabacum optimised gene for expression in N. benthamiana system and the lack of 
subcellular localisation to improve protein stability. Although immunisation with 
adjuvanted cEDIII-PIGS yielded a remarkably high IgG titre at 1:1,000,000, but the 
poor neutralisation response against DENV 2 could be a demerit for the vaccine 
candidate. Following that, it is noteworthy to mention that this study is the first in the 
field of plant-based dengue vaccine research to demonstrate the ability of vaccine 
candidates to neutralise four DENV serotypes simultaneously. Besides, this study 
utilised the non-replicative system of pEAQ-HT vector by which there is no issue of 
sequence mutation as compared to the use of infectious RNA transcripts by Saejung et 
al. (2007). 
Based on Malaysian context, local vaccine development would have a 
momentous impact as up to date, there are (i) no universal dengue vaccine is available 
yet; (ii) no effective containment of disease-carrying Aedes mosquitoes; and (iii) no 
specific anti-viral treatment to alleviate the potentially fatal illness. Particularly for 
nations with emerging economics, cost is the major determinant that affect the vaccine 
uptake and utilisation. A survey among policy-makers in South East Asia indicated that 
governments could afford to pay a price of $0.50 – $1.00 per dose of dengue vaccine 
given to the urgent need (DeRoeck et al., 2003). However, this was not the case for 
Dengvaxia® as the price had been marked to approximately $80 per shot for a national 
vaccination programme in Philippines (Afinidad-Bernardo, 2017). In fact, a survey 
indicated that only 17% of the Brazilian population would be willing to pay for this 
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vaccine (Godói et al., 2017). Besides, an annual manufacturing capacity of 100 million 
doses of Dengvaxia® is insufficient to meet the demand of 3 billion people who are 
living in dengue-endemic areas (Dow and Mora, 2012). Following these reasons, it 
seems sensible to establish a local production system to deliver timely medical support. 
In addition, the production of dengue vaccine may bring added value to the nation’s 
economy as the market is projected to capture an astounding value of USD $4 billion – 
21 billion (Kanagaraj et al., 2011). Based on all the perspectives above, this study is 
viable and has shown the potential to make a significant impact in battling dengue 
disease which can benefit the global communities.  
 
Limitations of current study and suggestions for improvements 
Although the general objectives of the study had been achieved, some limitations 
were unavoidable and could be addressed in future for improvement. The first aspect is 
discussed in terms of the cassette designs of chimeric VLPs-displaying cEDIII 
(expressed by pEAQ-HT::mHBcAg-cEDIII, pEAQ-HT::mHBcAg-cEDIII (L) and 
pEAQ-HT::tHBcAg-cEDIII). Based on Chapter 4, the high expression of fusion 
proteins has spurred an interest of targeting the VLPs to cellular compartment to boost 
expression. Initially, there was a concern that the distinct pH conditions in different 
plant organelle can abolish VLPs assembly as shown by van Zyl et al. (2016). 
Nevertheless, there is exception as the hepatitis B virus surface antigen (HBsAg) VLPs 
could still assemble despite localisation to ER (Richter et al., 2000; Sojikul et al., 2003). 
Hence, it may be worthwhile to attempt subcellular localisation as a strategy to improve 
the expression yield of chimeric VLPs. 
Apart from gene targeting, optimisation of coding sequence of HBcAg VLPs 
carrier could be considered as an improvement of cassette designs. To clarify, the 
cEDIII genes inserted into the c/el loop of the mHBcAg and tHBcAg VLPs carriers 
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were optimised with N. benthamiana codons (Section 3.2.3). But, the cloning vectors 
used for construction, namely pEAQ-HT::mEL for mHBcAg VLPs and pEAQ-
HT::tHBcAg-VHH2 for tHBcAg VLPs, were previously codon-optimised for E. coli 
expression. Knowing that there might be a risk of low expression, codon optimisation 
of the VLPs carriers was not attempted as it was thought to be safer to continue working 
with the E. coli-optimised construct. This was because codon optimisation may not be 
always beneficial as some studies had observed a failed particle production when the 
plant codon-optimised gene was used (Maclean et al., 2007; Šmídková et al., 2010). 
Likewise, this strategy could be considered in future to explore the feasibility of 
improving the VLPs expression using N. benthamiana codon-optimised mHBcAg and 
tHBcAg sequences. 
The second aspect is related to the improvement of agroinfiltration. In this study, 
only the agrobacterial stain LBA4404 was used for transgene delivery as this was the 
preferred strain. Future work may consider the employment of strain GV3101, as Shah 
et al. (2013) claimed that higher GFP expression could be obtained following the 
delivery of pEAQ-HT vector using GV3101. Other improvements may include 
optimisation of the bacterial inoculation density and adding additives in the infiltration 
medium to enhance transformation efficiency. Zhao et al. (2017) found that a 
combinative supplement of 0.56 mM ascorbate acid, 20 µM 5-azacytidine and 0.03% 
(v/v) Tween-20 could boost the transgene expression by up to 6 folds. 
Thirdly, the purification procedures for cEDIII recombinant proteins could be 
improved with polishing step via ion exchange chromatography or SEC. This part was 
not focused in this study as the main objective was to recover satisfactory amount of 
recombinant proteins for immunogenicity test, which was primarily achieved via IMAC. 
Immuno-affinity chromatography may be used as a substitute of IMAC since low yield 
of cEDIII was obtained following TEV cleavage. Besides, future X-ray crystallographic 
study of cEDIII protein could be considered as this has not been studied yet, and this 
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information would help in understanding the protein structure and function for better 
utilisation of cEDIII in vaccine development. Meanwhile, the purification procedures 
for VLPs sample are rather well-established and future work may focus on standardising 
the use of nycodenz density gradient for isolation of chimeric VLPs. 
The last aspect is considered in relevant to the immunogenicity analyses. For the 
immunisation with chimeric mHBcAg VLPs displaying cEDIII, it is now understood 
that the formulation of antigen dose should account for the molecular size of chimeric 
VLPs so that sufficient cEDIII epitopes could be presented to the mouse immune system. 
Although the VLPs (b) experiment is proven to be a successful modification, further 
optimisation of the injection dosage may serve valuable to determine the threshold 
needed to achieve a strong immune stimulation.  
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Conclusions and future perspectives 
The work presented in this study provides a significant step in paving way 
towards plant-based dengue vaccine development. This is particularly important to 
address the alarming burden of dengue disease that has yet to meet a promising 
resolution. Establishment of the plant production system can solve a vast of the 
intriguing concerns of vaccine cost and accessibility faced by the poorer people in 
dengue-endemic areas. It is of no doubt that cEDIII is able to confer neutralising 
protection against four DENV serotypes along with stimulation of Th1 response. The 
antigen fusion with CTB, namely CTB-cEDIII-KDEL (xTH) has not only preserved its 
biologically-active pentameric structure, but also potentiates the immune responses with 
high neutralising antibody titres and robust activation of balanced Th1/Th2 responses. 
Meanwhile, the presentation of cEDIII epitopes on VLPs carrier is proven to be feasible, 
which also has been displayed in immunogenic context in mHBcAg-cEDIII VLPs, 
mHBcAg-cEDIII (L) VLPs and tHBcAg-cEDIII VLPs. In fact, the preliminary study 
on tHBcAg-cEDIII VLPs shows that it can elicit robust immunogenicity with high 
cytolytic activity that warrants for future investigation as a better VLPs-based vaccine.  
Prevention is always better than cure. Considering that dengue outbreaks 
predominantly occur in developing nations including Malaysia, the development of an 
affordable and effective vaccine that can benefit all communities is highly desired. This 
also complements to the government’s efforts in combating disease transmission and 
makes a significant impact in dengue control. It is believed that the findings reported in 
this study would deliver a substantial impact to the field of plant-based dengue vaccine 
development and make a leap to clinical trials in the nearest future. 
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9 Appendices 
Appendices for Chapter 3 
A3.1 Nucleotide and amino acid sequences of the mEL expression cassette in 
pEAQ-HT::mEL vector 
 
Nucleotide sequence 
ATG GAT ATC GAC CCA TAT AAA GAA TTT GGC GCG ACG GTT GAG CTG 
CTG AGC TTT CTG CCA AGC GAT TTC TTT CCG AGC GTC CGC GAC CTG 
CTG GAT ACC GCC AGC GCA CTG TAT CGT GAA GCC CTG GAG AGC CCG 
GAA CAT TGC AGC CCG CAT CAT ACG GCC CTG CGT CAG GCA ATC CTG 
TGC TGG GGC GAA CTG ATG ACC CTG GCA ACC TGG GTC GGC AAT AAT 
CTG GTC GAC GCT GGT GGA GGT CCT AGG GGT GGG TCT GGT ATT AAT 
GAC CCA GCA AGC CGT GAT CTG GTT GTT AAT TAC GTG AAC ACC AAC 
ATG GGC CTG AAG ATC CGC CAA CTG CTG TGG TTT CAT ATC AGC TGT 
CTG ACG TTT GGC CGC GAG ACG GTG CTG GAA TAC CTG GTT AGC TTT 
GGC GTT TGG ATT CGT ACG CCA CCG GCC TAC CGC CCA CCA AAC GCA 
CCG ATT CTG AGC ACG CTG CCG GAA ACG ACG GTT GTT CGT CGC CGT 
GAT CGC GGC CGT AGC CCG CGC CGC CGT ACG CCG AGC CCA CGT CGT 
CGC CGC AGC CAG AGC CCG CGC CGC CGT CGC AGC CAG AGC CGT GAA 
AGC CAA TGT TAG 
 
Amino acid sequence 
M D I D P Y K E F G A T V E L L S F L P S D F F P S V R D L L D T A S A L Y R 
E A L E S P E H C S P H H T A L R Q A I L C W G E L M T L A T W V G N N L V 
D A G G G P R G G S G I N D P A S R D L V V N Y V N T N M G L K I R Q L L W 
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F H I S C L T F G R E T V L E Y L V S F G V W I R T P P A Y R P P N A P I L S T 
L P E T T V V R R R D R G R S P R R R T P S P R R R R S Q S P R R R R S Q S R 
E S Q C * 
 
Feature 
5’ core I : Nucleotide (1…228) : Amino acid (1…76) 
SalI RE site : Nucleotide (229…234) : Amino acid (77…78) 
c/e1 loop : Nucleotide (235…264) : Amino acid (79…88) 
AseI RE site : Nucleotide (265…270) : Amino acid (89…90) 
3’ core : Nucleotide (271…597) : Amino acid (91…199) 
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A3.2 Nucleotide and amino acid sequences of the tHBcAg-VHH2 expression 
cassette in pEAQ-HT::tHBcAg-VHH2 vector 
 
Nucleotide acid sequence 
ATG GAC ATT GAT CCG TAC AAA GAA TTT GGC GCG ACC GTC GAG CTG 
CTG AGC TTC CTG CCG AGC GAT TTT TTC CCA AGC GTG CGT GAC CTG 
CTG GAC ACC GCG AGC GCA CTG TAT CGT GAA GCA CTG GAA AGC CCA 
GAG CAC TGT AGC CCG CAC CAC ACC GCC CTG CGC CAG GCG ATT CTG 
TGC TGG GGT GAA CTG ATG ACC CTG GCC ACC TGG GTG GGT AAT AAT 
CTG GAA CCC GGG GCT GGT GGA AGT TCT GGT CAA TTG GAC CCG GCG 
AGC CGT GAT CTG GTC GTC AAC TAT GTG AAT ACC AAC ATG GGT CTG 
AAA ATT CGT CAG CTG CTG TGG TTT CAT ATT AGC TGC CTG ACC TTC 
GGT CGT GAA ACC GTG CTG GAG TAT CTG GTG AGC TTC GGT GTG TGG 
ATT CGC ACC CCG CCA GCG TAT CGT CCG CCG AAC GCG CCA ATT CTG 
AGC ACG CTG CCG GAG ACC ACC GTG GTT GGT GGA AGT TCT GGT GGT 
AGT GGA GGA AGT GGT GGT TCT GGT GGA AGC GGT GGT AGT GGT GGG 
ACT GGT ACA ATG GAT ATC GAC CCA TAT AAA GAA TTT GGC GCG ACG 
GTT GAG CTG CTG AGC TTT CTG CCA AGC GAT TTC TTT CCG AGC GTC 
CGC GAC CTG CTG GAT ACC GCC AGC GCA CTG TAT CGT GAA GCC CTG 
GAG AGC CCG GAA CAT TGC AGC CCG CAT CAT ACG GCC CTG CGT CAG 
GCA ATC CTG TGC TGG GGC GAA CTG ATG ACC CTG GCA ACC TGG GTC 
GGC AAT AAT CTG GTC GAC GGT GGT GGT GGA AGC GGA GGT GGT GGT 
TCT GGT GGT GGT GGT TCA CCT AGG ATG GCT GTT CAG CTT CAA GAA 
AGC GGT GGT GGA CTT GTT CAA GCT GGT GGA TCT CTT AGG CTT AGC 
TGC ACT GCT AGC GGT AGG ATC TCC AGC TCT TAT GAT ATG GGA TGG 
TTC AGG CAG GCT CCT GGT AAA GAG AGA GAG TTC GTT GCT GCT ATC 
AGC TGG TCT GGT GGT ACT ACC GAT TAC GCT GAT TCT GTG AAG GGA 
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AGG TTC GCT ATC AGC AAG GAT AAC GCT AAG AAC GCT GTG TAC CTG 
CAG ATG AAC TCT CTG AAG CCT GAG GAT ACC GCA GTT TAC TAC TGT 
GCT GCT AAG TGG AGG CCT CTG AGG TAC TCT GAT TAC CCT AGC AAC 
AGC GAT TAC TAC GAT TGG GGT CAG GGT ACT CAG GTG ACC GTT TCA 
TCT CCT GCA GGT GGT GGT GGT AGT GGT GGT GGT GGA TCA GGT GGT 
GGT GGA TCT ATT AAT GAC CCA GCA AGC CGT GAT CTG GTT GTT AAT 
TAC GTG AAC ACC AAC ATG GGC CTG AAG ATC CGC CAA CTG CTG TGG 
TTT CAT ATC AGC TGT CTG ACG TTT GGC CGC GAG ACG GTG CTG GAA 
TAC CTG GTT AGC TTT GGC GTT TGG ATT CGT ACG CCA CCG GCC TAC 
CGC CCA CCA AAC GCA CCG ATT CTG AGC ACG CTG CCG GAA ACG ACG 
GTT GTT CGT CGC CGT GAT CGC GGC CGT AGC CCG CGC CGC CGT ACG 
CCG AGC CCA CGT CGT CGC CGC AGC CAG AGC CCG CGC CGC CGT CGC 
AGC CAG AGC CGT GAA AGC CAA TGT TAG 
 
Amino acid sequence 
M D I D P Y K E F G A T V E L L S F L P S D F F P S V R D L L D T A S A L Y R 
E A L E S P E H C S P H H T A L R Q A I L C W G E L M T L A T W V G N N L E 
P G A G G S S G Q L D P A S R D L V V N Y V N T N M G L K I R Q L L W F H I 
S C L T F G R E T V L E Y L V S F G V W I R T P P A Y R P P N A P I L S T L P E 
T T V V G G S S G G S G G S G G S G G S G G S G G T G T M D I D P Y K E F G 
A T V E L L S F L P S D F F P S V R D L L D T A S A L Y R E A L E S P E H C S P 
H H T A L R Q A I L C W G E L M T L A T W V G N N L V D G G G G S G G G G 
S G G G G S P R M A V Q L Q E S G G G L V Q A G G S L R L S C T A S G R I S S 
S Y D M G W F R Q A P G K E R E F V A A I S W S G G T T D Y A D S V K G R F 
A I S K D N A K N A V Y L Q M N S L K P E D T A V Y Y C A A K W R P L R Y 
S D Y P S N S D Y Y D W G Q G T Q V T V S S P A G G G G S G G G G S G G G 
G S I N D P A S R D L V V N Y V N T N M G L K I R Q L L W F H I S C L T F G R 
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E T V L E Y L V S F G V W I R T P P A Y R P P N A P I L S T L P E T T V V R R R 
D R G R S P R R R T P S P R R R R S Q S P R R R R S Q S R E S Q C * 
 
Feature 
5’ Core I : Nucleotide (1…231) : Amino acid (1…77) 
XmaI RE site : Nucleotide (232…237) : Amino acid (78…79) 
Core I c/e1 loop : Nucleotide (238…255) : Amino acid (80…85) 
MfeI RE site : Nucleotide (256…261) : Amino acid (86…87) 
3’ Core I : Nucleotide (262…477) : Amino acid (88…159) 
(GGS)n linker : Nucleotide (478…549) : Amino acid (160…183) 
5’ Core II : Nucleotide (550…777) : Amino acid (184…259) 
SalI RE site : Nucleotide (778…783) : Amino acid (260…261) 
(GGS)n linker : Nucleotide (784…828) : Amino acid (262…276) 
AvrII RE site : Nucleotide (829…834) : Amino acid (277…278) 
VHH2 : Nucleotide (835…1218) : Amino acid (279…406) 
SbfI RE site : Nucleotide (1219…1226#) : Amino acid (407…409#) 
(GGS)n linker : Nucleotide (1225#…1269) : Amino acid (409#…423) 
AseI RE site : Nucleotide (1270…1275) : Amino acid (424…425) 
3’ Core II : Nucleotide (1276…1602) : Amino acid (410…534) 
  
Annotation: # Indicates that part of the (GGS)n linker overlaps with SbfI RE site.  
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A3.3 Nucleotide and amino acid sequences of synthesised cEDIII-sGFP-KDEL  
 
Nucleotide sequence 
AAG GGA ATG TCA TAC GCT ATG TGT ACT GGA AAG TTC AAG TTG GAG 
AAG GAG GTG GCA GAG ACT CAG CAC GGA ACC ATC TTA ATC AAA GTT 
AAA TAT GAA GGT GAT GGT GCT CCT TGT AAG ATT CCT TTC GAA ATC 
CAA GAT GTT GAG AAG AAA CAT GTG AAT GGA AGG TTG ATT ACC GCT 
AAC CCA ATC GTT ACT GAT AAG GAG TCA CCT GTG AAT ATT GAA GCA 
GAG CCT CCA TTT GGT GAT AGT TAT ATT GTT ATC GGT GTG GGA GAT 
AAG GCA CTT AAA TTG AAC TGG TTC AAG AAG GGA TCT TCA GAA AAC 
CTT TAC TTC CAG GGA ATG GTT TCA AAA GGT GAA GAG CTT TTT ACT 
GGT GTT GTG CCA ATT CTT GTT GAG TTG GAT GGA GAT GTG AAT GGT 
CAC AAG TTC AGT GTT TCT GGT GAA GGA GAG GGT GAT GCT ACA TAC 
GGA AAG TTA ACC CTC AAA TTT ATC TGT ACT ACT GGA AAG TTG CCT 
GTT CCT TGG CCT ACA TTG GTG ACC ACT TTT ACC TAT GGA GTG CAA 
TGC TTT TCT AGG TAT CCT GAT CAC ATG AAG CAG CAC GAT TTC TTT 
AAA TCA GCT ATG CCT GAA GGA TAC GTT CAA GAG AGA ACA ATT TTC 
TTT AAG GAT GAT GGT AAC TAC AAA ACT AGG GCA GAG GTT AAG TTT 
GAG GGA GAT ACA CTT GTG AAC AGA ATC GAA TTG AAG GGT ATC GAT 
TTC AAA GAG GAT GGA AAC ATC CTC GGT CAT AAG CTC GAA TAC AAC 
TAC AAC AGT CAC AAC GTT TAC ATC ATG GCT GAT AAG CAA AAG AAT 
GGA ATC AAG GTG AAC TTC AAA ATT AGG CAT AAC ATC GAG GAT GGT 
TCT GTT CAG CTT GCA GAT CAC TAT CAA CAG AAT ACC CCA ATT GGA 
GAT GGT CCA GTT CTT TTG CCT GAT AAC CAT TAC TTA TCA ACA CAG 
AGT GCT CTC TCT AAA GAT CCT AAC GAA AAG AGA GAT CAC ATG GTT 
CTT CTT GAA TTT GTG ACT GCT GCT GGT ATT ACA CAC GGT ATG GAT 
GAA TTA TAC AAG CCT AAA GAT GAG TTG 
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Amino acid sequence 
K G M S Y A M C T G K F K L E K E V A E T Q H G T I L I K V K Y E G D G A P 
C K I P F E I Q D V E K K H V N G R L I T A N P I V T D K E S P V N I E A E P P 
F G D S Y I V I G V G D K A L K L N W F K K G S S E N L Y F Q G M V S K G E 
E L F T G V V P I L V E L D G D V N G H K F S V S G E G E G D A T Y G K L T 
L K F I C T T G K L P V P W P T L V T T F T Y G V Q C F S R Y P D H M K Q H 
D F F K S A M P E G Y V Q E R T I F F K D D G N Y K T R A E V K F E G D T L 
V N R I E L K G I D F K E D G N I L G H K L E Y N Y N S H N V Y I M A D K Q 
K N G I K V N F K I R H N I E D G S V Q L A D H Y Q Q N T P I G D G P V L L P 
D N H Y L S T Q S A L S K D P N E K R D H M V L L E F V T A A G I T H G M D 
E L Y K P K D E L  
 
Feature 
cEDIII : Nucleotide (1…309) : Amino acid (1…103) 
TEV cleavage site : Nucleotide (310…330) : Amino acid (104…110) 
sGFP : Nucleotide (331…1050) : Amino acid (111…350) 
KDEL signal : Nucleotide (1051…1062) : Amino acid (351…354) 
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A3.4 Nucleotide and amino acid sequences of synthesised PR1a-cEDIII-sGFP-
H-KDEL  
 
Nucleotide sequence 
AAC AAT GGG ATT CGT TTT ATT CTC TCA ACT TCC TTC ATT TCT CCT TGT 
GTC AAC TCT TTT GCT CTT CCT CGT TAT TAG TCA TTC TTG TAG AGC TAA 
AGG AAT GTC TTA TGC TAT GTG TAC TGG AAA GTT CAA ATT GGA AAA 
GGA GGT TGC TGA AAC ACA ACA TGG AAC CAT TCT TAT CAA GGT GAA 
ATA CGA GGG TGA TGG AGC ACC ATG CAA AAT TCC TTT TGA AAT CCA 
GGA TGT TGA GAA GAA ACA TGT GAA TGG AAG GCT TAT TAC AGC TAA 
CCC AAT CGT TAC CGA TAA GGA ATC ACC TGT GAA TAT TGA AGC AGA 
GCC TCC ATT TGG TGA TAG TTA TAT TGT TAT CGG TGT GGG AGA TAA 
GGC TCT TAA ATT GAA CTG GTT CAA GAA GGG ATC TTC AGA AAA CCT 
CTA CTT CCA AGG AAT GGT TTC TAA AGG TGA AGA GTT GTT TAC TGG 
TGT TGT GCC AAT TCT TGT TGA GTT GGA TGG AGA TGT GAA TGG TCA 
TAA GTT CAG TGT TTC TGG TGA AGG AGA GGG TGA TGC AAC TTA TGG 
AAA GTT AAC ACT CAA GTT TAT CTG TAC TAC TGG AAA GTT GCC TGT 
TCC TTG GCC TAC TTT GGT GAC CAC TTT TAC TTA TGG TGT TCA ATG CTT 
TTC TAG GTA TCC TGA TCA CAT GAA GCA GCA CGA TTT CTT TAA ATC 
AGC TAT GCC TGA AGG ATA CGT TCA GGA GAG AAC AAT TTT CTT TAA 
GGA TGA TGG TAA CTA CAA AAC CAG GGC AGA GGT TAA GTT TGA GGG 
AGA TAC ACT TGT GAA CAG AAT CGA ATT GAA GGG TAT CGA TTT CAA 
AGA GGA TGG AAA CAT CCT CGG TCA TAA GCT CGA ATA CAA CTA CAA 
CAG TCA CAA CGT TTA CAT CAT GGC TGA TAA GCA AAA GAA TGG AAT 
CAA GGT GAA CTT CAA AAT TAG GCA TAA CAT CGA GGA TGG TTC TGT 
TCA GTT GGC AGA TCA CTA TCA ACA GAA TAC TCC AAT TGG AGA TGG 
TCC AGT TCT TTT GCC TGA TAA CCA TTA CTT ATC AAC ACA AAG TGC 
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TCT CTC TAA AGA TCC TAA CGA AAA GAG AGA TCA CAT GGT TCT TCT 
TGA ATT TGT GAC TGC TGC TGG TAT TAC TCA CGG TAT GGA TGA ACT 
TTA CAA ACA TCA CCA TCA CCA TCA CAA GGA TGA GCT TTG A 
 
Amino acid sequence 
M G F V L F S Q L P S F L L V S T L L L F L V I S H S C R A K G M S Y A M C T 
G K F K L E K E V A E T Q H G T I L I K V K Y E G D G A P C K I P F E I Q D V 
E K K H V N G R L I T A N P I V T D K E S P V N I E A E P P F G D S Y I V I G V 
G D K A L K L N W F K K G S S E N L Y F Q G M V S K G E E L F T G V V P I L 
V E L D G D V N G H K F S V S G E G E G D A T Y G K L T L K F I C T T G K L 
P V P W P T L V T T F T Y G V Q C F S R Y P D H M K Q H D F F K S A M P E G 
Y V Q E R T I F F K D D G N Y K T R A E V K F E G D T L V N R I E L K G I D F 
K E D G N I L G H K L E Y N Y N S H N V Y I M A D K Q K N G I K V N F K I R 
H N I E D G S V Q L A D H Y Q Q N T P I G D G P V L L P D N H Y L S T Q S A L 
S K D P N E K R D H M V L L E F V T A A G I T H G M D E L Y K H H H H H H 
K D E L * 
 
Feature 
Kozak sequence : Nucleotide (1…4)  
PR1a signal : Nucleotide (5…94) : Amino acid (1…30) 
cEDIII : Nucleotide (95…403) : Amino acid (31…133) 
TEV cleavage site : Nucleotide (404…424) : Amino acid (134…140) 
sGFP : Nucleotide (425…1144) : Amino acid (141…380) 
6X His tag : Nucleotide (1145…1162) : Amino acid (381…386) 
KDEL signal : Nucleotide (1163…1174) : Amino acid (387…390) 
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A3.5 Nucleotide and amino acid sequences of synthesised CTB-cEDIII-KDEL 
 
Nucleotide sequence 
ATG ATT AAG CTC AAG TTT GGT GTT TTC TTT ACC GTG TTA CTC TCT TCA 
GCA TAC GCA CAT GGA ACC CCT CAG AAT ATT ACA GAT TTG TGT GCT 
GAA TAC CAT AAC ACT CAA ATC CAC ACA CTC AAC GAT AAG ATT TTC 
TCT TAC ACT GAA TCT CTC GCT GGA AAG AGA GAG ATG GCA ATC ATC 
ACA TTC AAG AAC GGT GCT ACC TTC CAG GTT GAA GTG CCT GGA TCA 
CAA CAT ATT GAT AGT CAG AAG AAA GCA ATT GAG AGA ATG AAG GAT 
ACC TTA AGG ATT GCT TAT CTC ACT GAA GCA AAG GTT GAG AAG TTG 
TGT GTG TGG AAT AAC AAA ACA CCA CAC GCT ATT GCT GCA ATC TCT 
ATG GCA AAC GGT CCT GGA CCA AAG GGA ATG TCT TAT GCT ATG TGC 
ACC GGA AAG TTT AAA CTT GAA AAA GAG GTT GCA GAA ACC CAA CAT 
GGA ACT ATC TTG ATC AAG GTT AAG TAC GAG GGT GAT GGT GCT CCT 
TGC AAG ATT CCA TTC GAA ATC CAG GAT GTT GAG AAG AAA CAC GTG 
AAT GGT AGG CTT ATT ACT GCT AAC CCT ATC GTT ACA GAT AAA GAG 
AGT CCA GTG AAT ATT GAA GCA GAG CCT CCA TTC GGA GAT TCA TAT 
ATT GTT ATC GGT GTG GGA GAT AAG GCA CTT AAA TTG AAC TGG TTC 
AAG AAG GGT TCT TCA GAA AAC CTT TAC TTC CAA GGA AAG GAT GAG 
TTG 
 
Amino acid sequence 
M I K L K F G V F F T V L L S S A Y A H G T P Q N I T D L C A E Y H N T Q I H 
T L N D K I F S Y T E S L A G K R E M A I I T F K N G A T F Q V E V P G S Q H 
I D S Q K K A I E R M K D T L R I A Y L T E A K V E K L C V W N N K T P H A 
I A A I S M A N G P G P K G M S Y A M C T G K F K L E K E V A E T Q H G T I 
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L I K V K Y E G D G A P C K I P F E I Q D V E K K H V N G R L I T A N P I V T 
D K E S P V N I E A E P P F G D S Y I V I G V G D K A L K L N W F K K G S S E 
N L Y F Q G K D E L  
 
Feature 
CTB : Nucleotide (1…372) : Amino acid (1…124) 
GPGP linker : Nucleotide (373…384) : Amino acid (125…128) 
cEDIII : Nucleotide (385…693) : Amino acid (129…231) 
TEV cleavage site : Nucleotide (694…714) : Amino acid (232…238) 
KDEL signal : Nucleotide (715…726) : Amino acid (239…242) 
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A3.6 Nucleotide and amino acid sequences of synthesised PR1a-CTB-cEDIII-H-
KDEL  
 
Nucleotide sequence 
AAC AAT GGG ATT CGT GCT CTT CAG TCA ACT TCC TTC ATT CTT GCT 
CGT TTC AAC TTT GCT CTT ATT CCT CGT GAT TTC TCA TTC TTG TAG GGC 
TAT GAT CAA GTT GAA GTT CGG TGT TTT CTT TAC TGT GCT TTT GTC TTC 
AGC TTA TGC ACA TGG AAC ACC TCA AAA TAT TAC CGA TTT GTG TGC 
AGA ATA CCA TAA CAC TCA GAT CCA CAC ACT CAA CGA TAA GAT TTT 
CTC TTA CAC AGA AAG TCT CGC TGG AAA GAG AGA GAT GGC AAT CAT 
CAC TTT CAA GAA CGG TGC TAC ATT CCA AGT TGA AGT GCC TGG ATC 
TCA ACA TAT TGA TTC ACA GAA GAA AGC AAT TGA GAG AAT GAA GGA 
TAC ACT TAG GAT TGC TTA CTT GAC CGA AGC AAA GGT TGA GAA ACT 
TTG TGT GTG GAA TAA CAA AAC TCC ACA CGC TAT TGC TGC AAT CAG 
TAT GGC AAA TGG TCC TGG ACC AAA GGG AAT GTC TTA CGC TAT GTG 
CAC TGG AAA GTT TAA ACT TGA AAA AGA GGT TGC AGA AAC CCA ACA 
TGG AAC TAT CTT GAT CAA GGT TAA GTA TGA GGG TGA TGG TGC TCC 
TTG CAA GAT TCC ATT CGA AAT CCA GGA TGT TGA GAA GAA ACA CGT 
GAA TGG TAG GCT TAT TAC CGC TAA CCC TAT CGT TAC TGA TAA AGA 
GTC ACC AGT GAA TAT TGA AGC AGA GCC TCC ATT TGG AGA TTC TTA 
CAT TGT TAT CGG TGT GGG AGA TAA GGC TTT AAA ACT CAA CTG GTT 
CAA GAA GGG TAG TTC TGA AAA CCT CTA CTT CCA GGG ACA TCA CCA 
TCA CCA TCA CAA GGA TGA GCT TTG A 
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Amino acid sequence 
M G F V L F S Q L P S F L L V S T L L L F L V I S H S C R A M I K L K F G V F F 
T V L L S S A Y A H G T P Q N I T D L C A E Y H N T Q I H T L N D K I F S Y T 
E S L A G K R E M A I I T F K N G A T F Q V E V P G S Q H I D S Q K K A I E R 
M K D T L R I A Y L T E A K V E K L C V W N N K T P H A I A A I S M A N G P 
G P K G M S Y A M C T G K F K L E K E V A E T Q H G T I L I K V K Y E G D G 
A P C K I P F E I Q D V E K K H V N G R L I T A N P I V T D K E S P V N I E A E 
P P F G D S Y I V I G V G D K A L K L N W F K K G S S E N L Y F Q G H H H H 
H H K D E L * 
 
Feature 
Kozak : Nucleotide (1…4)  
PR1a signal : Nucleotide (5…94) : Amino acid (1…30) 
CTB : Nucleotide (95…466) : Amino acid (31…154) 
GPGP linker : Nucleotide (467…478) : Amino acid (155…158) 
cEDIII : Nucleotide (479…787) : Amino acid (159…261) 
TEV cleavage site : Nucleotide (788…808) : Amino acid (262…268) 
6X His tag : Nucleotide (809…826) : Amino acid (269…274) 
KDEL signal : Nucleotide (827…838) : Amino acid (275…278) 
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A3.7 Nucleotide and amino acid sequences of synthesised cEDIII (L)  
 
Nucleotide sequence 
GGT GGT GGA AGC GGA GGT GGT GGT TCT GGT GGT GGT GGT TCA ACG 
CGT AAG GGA ATG TCA TAC GCT ATG TGT ACT GGA AAG TTC AAG TTG 
GAG AAG GAG GTG GCA GAG ACT CAG CAC GGA ACC ATC TTA ATC AAA 
GTT AAA TAT GAA GGT GAT GGT GCT CCT TGT AAG ATT CCT TTC GAA 
ATC CAA GAT GTT GAG AAG AAA CAT GTG AAT GGA AGG TTG ATT ACC 
GCT AAC CCA ATC GTT ACT GAT AAG GAG TCA CCT GTG AAT ATT GAA 
GCA GAG CCT CCA TTT GGT GAT AGT TAT ATT GTT ATC GGT GTG GGA 
GAT AAG GCA CTT AAA TTG AAC TGG TTC AAG AAG GGA TCT TCA TCC 
GGA GGT GGT GGT GGT AGT GGT GGT GGT GGA TCA GGT GGT GGT GGA 
TCT  
 
Amino acid sequence 
G G G S G G G G S G G G G S T R K G M S Y A M C T G K F K L E K E V A E T 
Q H G T I L I K V K Y E G D G A P C K I P F E I Q D V E K K H V N G R L I T A 
N P I V T D K E S P V N I E A E P P F G D S Y I V I G V G D K A L K L N W F K 
K G S S S G G G G G S G G G G S G G G G S 
 
Feature 
(GGS)n linker : Nucleotide (1…42) : Amino acid (1…14) 
MluI RE site : Nucleotide (43…48) : Amino acid (15…16) 
cEDIII : Nucleotide (49…357) : Amino acid (17…119) 
BspEl RE site : Nucleotide (358…363) : Amino acid (120…121) 
(GGS)n linker : Nucleotide (364…408) : Amino acid (122…136) 
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A3.8 List of primers used in this study 
 
Primer Sequence  
PFGS (sGFP) GTG ATC GCG ACC GGT AAG G 
PFGS (CTB) GTG ATC GCG ACC GGT ATG ATT AAG C 
PRGS AGA AGA CCC GGG CAA CTC ATC 
CTBcED3F CAA GGA CCG GTA ACA ATG GGA TTC GTG CT 
CTBcED3R (1st) 
AGA ACT ACC CTT CTT GAA CCA GTT GAG TTT 
TAA AGC C 
CTBcED3R (2nd) 
GCT GAC TCG AGT TAC AAT TCG TCT TTA GAA 
CTA CCC TTC TTG 
cED3F (mono) 
CAT TAG TCG ACA AGG GAA TGT CAT ACG CTA 
TG 
cED3R (mono) CGC AGC ATT AAT TGA AGA TCC CTT 
cED3F (monoL) CAT AGT CGA CGG TGG TGG AAG CGG A 
cED3R (monoL) CGC TAC GCA TTA ATA GAT CCA CCA CCA 
cED3F  
GAA TAC CTA GGA AGG GAA TGT CAT ACG CTA 
TGT GTA CTG GAA AG 
cED3R  
CAT TGC CTG CAG GTG AAG ATC CCT TCT TGA 
AC 
C1 AAC GTT GTC AGA TCG TGC TTC GGC ACC 
C3 CTG AAG GGA CGA CCT GCT AAA CAG GAG 
5’ MCS GTT TTC CCG TGG TTT TCG AAC TTG 
3’ MCS 
CTT TAG TTT GAA TTT ACT GTT ATT CGG TGT 
GC 
5’ core c/e1 GAA CTG ATG ACC CTG GCA ACC TG 
3’ core c/e1 GTG ATC TGG TTG TTA ATT ACG TGA ACA CC 
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A3.9 An example of the alignment of sequencing results with expected DNA sequence 
 
Panel A:  First alignment of PR1a-cEDIII-sGFP-H-KDEL sequence to the DNA sequenced by C1 primer 
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Panel B:  Second alignment of PR1a-cEDIII-sGFP-H-KDEL sequence to the DNA sequenced by C1 and C3 primers 
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Panel C:  Third alignment of PR1a-cEDIII-sGFP-H-KDEL sequence to the DNA sequenced by C1, C3 and cED3F primers 
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Panel D:  Fourth alignment of PR1a-cEDIII-sGFP-H-KDEL sequence to the DNA sequenced by C1, C3, cED3F and cED3R primers 
 
Figure A3.9: A step-wise alignment of the DNA sequencing results for PR1a-cEDIII-sGFP-H-KDEL expression cassette. A total of four sequencing primers 
were used, namely C1 (Panel A), C3 (Panel B), cED3F (Panel C) and cED3R (Panel D).
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A3.10 Sequence alignment of cEDIII from isolates of four dengue serotypes (DENV 1-4) 
 
The consensus sequence of each dengue virus serotype, namely DENV 1-consensus, DENV 2-consensus, DENV 3-consensus and DENV 4-consensus, was first obtained before 
aligning the four consensus sequences to generate an ultimate cEDIII sequence.  
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Figure A3.10:  The alignment of cEDIII sequence, which is representative of the EDIII sequence of DENV serotypes 1 to 4.  Source: Leng et al. (2009).
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Appendices for Chapter 4 
A4.1 List of buffers and consumables used in Chapter 4 
 
(i) Buffers used for protein extraction (Section 4.2.7) 
Buffer  Recipe 
Tris extraction buffer 
50 mM Tris base, pH 7.25; 300 mM sodium 
chloride; 0.1% (v/v) Triton X-100; Complete 
Protease Inhibitor Cocktail tablet (Roche, 
Switzerland) 
Sodium phosphate extraction 
buffer  
100 mM Sodium phosphate, pH 7.5; Complete 
Protease Inhibitor Cocktail tablet (Roche, 
Switzerland)  
VLPs extraction buffer A 
100 mM Sodium phosphate, pH 6.8; 150 mM 
sodium chloride; 0.1% (v/v) Triton X-100; 
Complete Protease Inhibitor Cocktail tablet (Roche, 
Switzerland) 
VLPs extraction buffer B 
100 mM Sodium phosphate, pH 8.0; 150 mM 
sodium chloride; 0.1% Triton (v/v) X-100; Halt 
Protease Inhibitor Cocktail (Thermo Scientific, 
USA) 
 
 
(ii) Buffers used for SDS-PAGE (Section 4.2.8) 
Buffer  Recipe 
Laemmli running buffer 
25 mM Tris base, pH 8.3; 192 mM glycine; 0.1% 
(w/v) sodium dodecyl sulphate 
Lithium dodecyl sulphate 
sample buffer containing β-
mercaptoethanol  
(LDS-βME)  
4X LDS sample buffer (Invitrogen, USA) and β-
mercaptoethanol in 3:1 ratio 
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(iii) Buffers used for Western blotting (Section 4.2.10) 
Buffer  Recipe 
Phosphate-buffered saline 
(PBS)  
137 mM Sodium chloride; 3.7 mM potassium 
chloride; 10 mM disodium phosphate; 1.8 mM 
monopotassium phosphate, pH 7.4 
Western blot transfer buffer 
25 mM Tris base, pH 8.3; 192 mM glycine; 0.1% 
(w/v) sodium dodecyl sulphate; 20% (v/v) methanol 
Enhanced 
chemiluminescence (ECL) 
solution 
1.25 mM luminol; 200 mM paracoumaric acid; 27 
mM hydrogen peroxide; 100 mM Tris-
hydrochloride, pH 8.5 
 
 
 
(iv) SeeBlue Plus2 Pre-Stained Standard (Invitrogen, USA) was used as the protein 
marker in this study. Distinct separation range is obtained when different 
running buffer is used for SDS-PAGE (Figure A4.1). 
 
 
Figure A4.1: The separation range of SeeBlue Plus2 Pre-Stained Standard in 
different types of buffer systems.  
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A4.2 Illustrations of the early necrosis suffered by Nicotiana benthamiana leaves 
infiltrated with pEAQ-HT::cEDIII-sGFP-KDEL-H and pEAQ-HT::CTB-
cEDIII-KDEL-H vectors 
 
Panel A:  Physical appearance of N. benthamiana leaf infiltrated with pEAQ-
HT::cEDIII-sGFP-KDEL-H  
Following agroinfiltration with pEAQ-HT::cEDIII-sGFP-KDEL-H vector, the leaf was 
monitored daily from 1st – 9th dpi for sign of morphological distortions. Leaf chlorosis 
was detected around 7th dpi, which rapidly led to cell death on 8th dpi. 
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Panel B:  Physical appearance of N. benthamiana leaf infiltrated with pEAQ-
HT::CTB-cEDIII-KDEL-H  
Infiltrated leaf was monitored daily from 1st – 9th dpi for sign of morphological 
distortions. Following the use of pEAQ-HT::CTB-cEDIII-KDEL-H vector, leaf 
chlorosis started to appear on 6th dpi and modest necrosis was observed by the end of 
the time course study. 
 
 
Figure A4.2:  Daily observations of the infiltrated N. benthamiana leaf. Panel A: Leaf 
infiltrated with pEAQ-HT::cEDIII-sGFP-KDEL-H; Panel B: Leaf 
infiltrated with pEAQ-HT::CTB-cEDIII-KDEL-H. These leaves were 
found to suffer from severe necrotic symptoms during the kinetic assays. 
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A4.3 Post translational removal of PR1a signal peptide was predicted using 
Signal-BLAST 
 
The protein sequence of PR1a signal peptide was analysed with Signal-BLAST and the 
result indicated that a cleavage site was found at the end of the PR1a sequence, 
specifically after residue 30 (Figure A4.3). Hence, PR1a was not included in the 
estimation of expressed protein size (expression vectors: pEAQ-HT::PR1a-cEDIII-
sGFP-H-KDEL, pEAQ-HT::PR1a-CTB-cEDIII-H-KDEL and pEAQ-HT::PR1a-CTB-
cEDIII-KDEL (xTH)). 
  
  
Figure A4.3: A Signal-BLAST profile that shows the predicted cleavage site of PR1a 
signal peptide.  
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Appendices for Chapter 5 
A5.1 Details of buffers used in Chapter 5 
 
(i) Buffers used for IMAC purification (Section 5.2.4.1) 
Buffer Recipe 
Tris extraction buffer 
50 mM Tris base, pH 7.25; 300 mM sodium 
chloride; 0.1% (v/v) Triton X-100, Complete 
Protease Inhibitor Cocktail tablet (Roche, 
Switzerland) 
IMAC washing buffer with 5 
mM imidazole 
Tris extraction buffer supplemented with 5 mM 
imidazole 
IMAC washing buffer with 
10 mM imidazole 
Tris extraction buffer supplemented with 10 mM 
imidazole 
IMAC washing buffer with 
20 mM imidazole 
Tris extraction buffer supplemented with 20 mM 
imidazole 
IMAC elution buffer 
50 mM Tris base, pH 7.25; 300 mM sodium 
chloride; 250 mM imidazole 
 
 
(ii) Buffers used for GM1-ELISA (Section 5.2.5.1) 
Buffer Recipe 
Sodium bicarbonate buffer 
15 mM Sodium carbonate; 35 mM sodium 
bicarbonate, pH 9.6 
Phosphate-buffered saline 
(PBS)  
137 mM Sodium chloride; 2.7 mM potassium 
chloride; 80 µM disodium phosphate; 1.5 mM 
monopotassium phosphate, pH 7.0 
 
 
(iii) Buffers used for immunogold labelling (Section 5.2.7.2) 
Buffer Recipe 
Tris-buffered saline (TBS)  20 mM Tris base, pH 8.0; 500 mM sodium chloride  
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A5.2 SWISS modelling used to predict the tobacco etch virus (TEV) protease cleavage site in recombinant cEDIII fusion proteins 
 
Panel A:  A predictive modelling of cEDIII-sGFP-H-KDEL fusion protein  
The blue colour ribbon represents cEDIII protein that is fused to its sGFP partner in green. A closed-up view of the TEV cleavage site is shown in the grey box. 
The cleavage site (ENLYFQG) should be accessible for protease digestion. 
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Panel B:  A predictive modelling of CTB-cEDIII-H-KDEL fusion protein  
The blue colour ribbon represents cEDIII protein that is fused to its CTB partner in red. A closed-up view of the TEV cleavage site is shown in the grey box. 
The cleavage site (ENLYFQG) should be accessible for protease digestion. 
 
Figure A5.2:  Predictive models of recombinant cEDIII fusion proteins. Panel A: cEDIII-sGFP-H-KDEL fusion protein; Panel B: CTB-cEDIII-H-KDEL 
fusion protein.   
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A5.3 Chromatograms of protein standard used to analyse the different fractions 
of CTB-cEDIII-KDEL (xTH) protein separated via size exclusion 
chromatography (SEC) 
 
Ribonuclease A, ovalbumin and conalbumin were used to estimate the range of 
molecular mass (Mr) between 10,000 to 80,000.  
 
Figure A5.3:  SEC chromatogram of protein standards separated under the same 
conditions as CTB-cEDIII-KDEL (xTH) protein.  
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A5.4 Relative comparison of the purification efficiency achieved by different 
density gradient media 
 
As shown in Figure A5.4, the use of sucrose and nycodenz as density gradient media 
had observed a discernible separation outcome. The sedimentation point of the chimeric 
VLPs was matched based on the corresponding Western blot profiles of fractionated 
samples. When sucrose gradient was used, the VLPs were found to co-sediment with 
some green contaminants around the 45% –  55% sucrose fraction. Meanwhile, 
nycodenz gradient offered a cleaner separation with the VLPs deposited below the plant 
debris. 
 
mHBcAg-cEDIII VLPs tHBcAg-cEDIII VLPs 
Sucrose gradient: 20% – 60% (w/v) Nycodenz gradient: 20% – 60% (w/v) 
  
 
Figure A5.4: A comparison of different density gradient media used in VLPs 
purification process. VLPs could be more effectively separated 
from the green impurities when nycodenz gradient was used.  
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Appendices for Chapter 6 
A6.1 Details of buffers used in Chapter 6 
 
(i) Buffers used for cell culture work (Section 6.2.6; Section 6.27; Section 6.2.8.2; 
Section 6.2.8.3; Section 6.2.10.1) 
Buffer  Recipe 
MEM-10 medium 
Minimum essential media (MEM) (Thermo 
Scientific, USA); 10% (v/v) fetal bovine serum 
(FBS) (Thermo Scientific, USA); 1% (v/v) HEPES 
buffer (Thermo Scientific, USA); 1% (v/v) 
penicillin-streptomycin (Thermo Scientific, USA) 
MEM-2 medium 
MEM (Thermo Scientific, USA); 2% FBS (Thermo 
Scientific, USA); 1% (v/v) HEPES buffer (Thermo 
Scientific, USA); 1% (v/v) penicillin-streptomycin 
(Thermo Scientific, USA) 
2X Plaque medium 
MEM (Thermo Scientific, USA); 4% FBS (Thermo 
Scientific, USA); 2% (v/v) HEPES buffer (Thermo 
Scientific, USA); 2% (v/v) penicillin-streptomycin 
(Thermo Scientific, USA) 
RPMI-10 medium 
RPMI 1640 medium (Corning, USA); 10% FBS 
(Thermo Scientific, USA); 1% (v/v) penicillin-
streptomycin (Thermo Scientific, USA) 
ACK lysing buffer 
150 mM Ammonium chloride; 10 mM potassium 
bicarbonate; 0.1 mM disodium 
ethylenediaminetetraacetate dehydrate, pH 7.4 
 
 
 
(ii) Buffers used for ELISA work (Sections 6.2.8.1; Section 6.2.10.4) 
Buffer  Recipe 
Sodium bicarbonate buffer 
15 mM Sodium carbonate; 35 mM sodium 
bicarbonate, pH 9.6 
Sodium phosphate buffer 
130 mM Monosodium phosphate; 88 mM disodium 
phosphate, pH 6.5 
Phosphate-buffered saline 
(PBS)  
137 mM Sodium chloride; 3.7 mM potassium 
chloride; 10 mM disodium phosphate; 1.8 mM 
monopotassium phosphate, pH 7.4 
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Assay diluent PBS supplemented with 10% (v/v) FBS 
 
 
 
(iii) Buffers used for FFA work (Sections 6.2.7; Section 6.2.8.3) 
Buffer  Recipe 
Tris-buffered saline (TBS) 50 mM Tris base, pH 7.5; 150 mM sodium chloride 
Alkaline phosphatase (AP)-
based substrate 
66 µl Nitro-blue tetrazolium (50 mg/ml) and 33 µl 
5-bromo-4-chloro-3'-indolyphosphate (50 mg/ml) 
in 10 ml AP substrate buffer (100 mM Tris base, 
pH 9.5; 100 mM sodium chloride; 5 mM 
magnesium chloride) 
 
 
 
(iv) Buffers used for FACS work (Section 6.2.10.3) 
Buffer  Recipe 
Staining buffer 
0.5% (v/v) Bovine serum albumin (BSA) and 2 mM 
ethylenediaminetetraacetic acid dissolved in 1X 
Dulbecco's phosphate-buffered saline (DPBS) 
(Nacalai Tesque, Japan) 
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A6.2 Mouse barbering behaviour was intermittently observed throughout the 
animal experiment 
 
Barbering behaviour was intermittently observed among the female BALB/c mice that 
led to significant hair loss (Figure A6.2). It is speculated that the physiological stress 
induced by husbandry factors may have caused the abnormal behaviour. 
 
 
Figure A6.2:  An illustration of the barbering behaviour among female BALB/c mice 
used in this study. Panel A: BALB/c mice housed within the same 
individual ventilation cage (IVC); Panel B: A closed-up view of a single 
mouse.   
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A6.3 Protein Basic Local Alignment Search Tool (BLAST) analysis 
 
A protein BLAST analysis was used to identify region of local similarity between two 
protein sequences, namely mEL VLPs and the CTB-cEDIII-KDEL (xTH) protein used 
for antigenic stimulation. This was due to the non-specific stimulatory responses 
observed from splenocytes of mice immunised with G3-V and G4-V (see Figure 6.19). 
As a result, a 35% sequence similarity was found at the N-terminal region of mHBcAg 
3’core sequence (Figure A6.3). Note that this similarity region only came from 8% of 
the CTB-cEDIII-KDEL (xTH) sequence, which comprised of 235 amino acids in length. 
 
 
Figure A6.3:  A protein sequence alignment results of mEL and CTB-cEDIII-KDEL 
(xTH), as generated from protein BLAST analysis.  
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A6.4 A case study on the immunogenicity evaluation of tandem core virus-like 
particles (VLPs)-displaying cEDIII 
 
A preliminary study of the immunogenicity of tHBcAg-cEDIII VLPs was 
conducted by iQur Ltd. (UK) as part of collaboration. Immunisation was performed 
using 8 – 10 weeks old female BALB/c mice. The mice (n = 5) were intraperitoneally 
injected with 10 µg of the purified VLPs for three times at one-week intervals. 
Two findings had been summarised from the preliminary study (Figure A6.4), 
including: (i) successful production of cEDIII-specific IgG antibody (Panel A); and (ii) 
positive CD8+ T cell-mediated killing activity in response to cEDIII antigen (Panel B). 
Based on the results obtained, it was confirmed that the cEDIII antigen inserted into the 
c/e1 loop of tandem core particles was displayed in an immunogenic context. 
Nevertheless, the IgG titre elicited by the recombinant cEDIII alone seemed to be 
stronger than tHBcAg-cEDIII VLPs; by which has most likely conformed to the 
molecular size difference as discussed in Chapter 6. However, a key aspect was 
discovered whereby vaccination with tHBcAg-cEDIII VLPs led to higher CD8+ 
degranulation response in comparison to recombinant cEDIII protein. As the high 
degranulation activity is correlated to efficient Tc cells killing activity, it is foreseen that 
the tHBcAg-cEDIII VLPs has the potential to be developed into a protective dengue 
vaccine. 
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Panel A: Analyses of mouse sera anti-cEDIII humoral response 
 
Panel B: Detection of T cell degranulation activity  
 
Figure A6.4:  A summary of the immunogenicity assessment of tHBcAg-cEDIII 
VLPs. Panel A: cEDIII-specific IgG responses in mice. Mouse sera (n 
= 5) were pooled and assayed in duplicate. The results are expressed as 
an average of A450 readings for respective group. Panel B: 
Degranulation activity of activated CD8+ T cell in immunised mice. 
Mouse spleens were pooled in group (n = 5) and subjected to cEDIII 
antigenic stimulation. The bars were expressed as an average of 
triplicate staining. 
